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ABSTRACT
AMBER MARIE KING: Synthesis and Pharmacological Evaluation of  
Primary Amino Acid Derivatives (PAADs):  
Novel Neurological Agents for the Treatment of Epilepsy and Neuropathic Pain 
(Under the direction of Dr. Harold Kohn) 
 
Epilepsy and neuropathic pain (NP) are chronic neurological disorders that result 
from dysregulations in neuronal function. Currently, there is a lack of adequate therapeutic 
agents available to treat these disorders and the need remains to develop compounds that 
possess a novel mechanism of action to address the shortcomings of current medications. 
Recently, the role of voltage-gated sodium channels (VGSCs) has been implicated in the 
pathophysiological mechanisms of NP, while their role in epilepsy has been known for some 
time. The functionalized amino acid (FAA) (R)-lacosamide is an emerging antiepileptic drug 
(AED) that has been shown to selectively promote VGSCs into the slow inactivated state 
and has recently been approved by the EMEA and the US FDA under the trademark 
Vimpat® for the adjuvant treatment of partial-onset seizures in adults. (R)-Lacosamide has 
also demonstrated clinical efficacy in treating painful diabetic neuropathy, but has yet to gain 
regulatory approval for this indication.  
The pharmaceutical industry has made advances in developing peripheral nervous 
system (PNS)-specific agents that target specific isoforms of VGSCs for the treatment of 
NP. We combined the concept of PNS-selectivity with our knowledge of FAAs and proposed 
that primary amino acid derivatives (PAADs) may selectively target PNS receptor sites, 
thereby avoiding potential CNS side effects that makes adherence to pain therapy difficult. 
Additionally, we examined the effect of PAADs on CNS function due to the excellent 
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anticonvulsant activity of FAAs. We synthesized and evaluated over 50 PAADs in whole 
animal models of epilepsy and NP, and developed a structure-activity relationship (SAR) 
that defined the structural requirements for PAAD activity. The SAR revealed excellent 
anticonvulsant activity and pain attenuation for a novel class of compounds, the C(2)-
hydrocarbon PAADs. Then, we synthesized over 40 additional PAADs to optimize 
anticonvulsant activity and pain attenuation. From our optimization studies, we discovered 
two PAADs that displayed superior anticonvulsant activity and may rival the therapeutic 
capabilities of (R)-lacosamide. Finally, we evaluated the most active PAADs in a series of 
binding and enzymatic assays but we did not reveal any new binding targets of therapeutic 
relevance. 
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To my youngest sisters, Hailey and Zoe Smith: 
You can achieve any goal with confidence and perseverance. 
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PREFACE 
 
As a young child, I possessed the gift of gab and a sense of confidence that often 
resulted in borderline inappropriate conservations with strangers when my parents dared to 
venture into public with me. As I grew older, I retained those qualities but learned the value 
of modesty, which can be misinterpreted as shyness. My family and friends know better. 
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 Chapter 1. Introduction
 
1. Central nervous system disorders 
Central nervous system (CNS) disorders, including but not limited to epilepsy and 
neuropathic pain (NP), are some of the most poorly treated illnesses in modern medicine. 
The lack of new chemical entities (NCEs) for CNS disorders is a multifaceted problem 
involving the complexity of the brain, blood-brain barrier (BBB) penetration, CNS side 
effects, and a lack of validated biomarkers.1 Not only are CNS therapies less likely to reach 
the market compared to other therapeutic areas, such as cardiovascular disease (CVD) 
(clinical success rates: CNS, 8%; CVD, 20%), their time in development can be significantly 
longer (years in development: CNS, 12.6; CVD, 6.3).1,2 A shift in the drug discovery 
paradigm over the last several decades to design high-specificity compounds could be one 
of the largest contributing factors to the current unmet medical need of CNS disorders, and 
perhaps another shift is necessary to adequately address these issues. 
The birth of synthetic organic chemistry in the 19th century altered the identification of 
therapeutic agents from empirical methods, which are blind to mechanism, to a more 
“rational” hypothesis-driven approach. Post-19th century drug discovery has become 
increasing more sophisticated, first incorporating cellular analysis (biochemistry), followed by 
target analysis (molecular biology), with the overarching goal of creating a therapeutic 
agent, or “magic bullet,” that can selectively target and treat a single disease state.3,4 While 
the magic bullet approach has experienced limited success in areas such as oncology 
(monoclonal antibodies, kinase inhibitors),5,6 it presents a challenge when addressing 
2 
 
disorders that are multifactorial in origin, such as CNS disorders. Treatment of these 
complex processes may benefit from a multitargeted or “magic shotgun” approach, rather 
than a high-specificity, magic bullet approach.7,8 Analysis of currently marketed 
anticonvulsants7 and antipsychotics8 revealed that interaction with multiple molecular targets 
are responsible for their pharmacological effects. We agree that the magic shotgun 
approach may be the more appropriate choice for the treatment of CNS disorders and, 
accordingly, we have developed several possible lead compounds based on structure-
activity relationships (SAR) in whole animal models of epilepsy and neuropathic pain, 
independent of mechanism.  
 
1.1. Epilepsy 
Epilepsy is a serious neurological disorder affecting up to 1% of the world‟s 
population, including more than two million Americans.9-12 Currently, the estimated annual 
medical cost of epilepsy exceeds $15 billion and it is estimated that 140,000 new cases of 
epilepsy will be diagnosed in the US in 2010.12  It is a common misconception to define 
epilepsy as a singular disease, but it is more appropriate to refer to epilepsy as a 
heterogeneous mixture of disorders with the commonality of neuronal dysregulations as a 
result of varying external, brain developmental, or genetic causes.10,11,13-16 Broadly defined, 
epilepsy is characterized by reoccurring, unprovoked seizures, which results from neuronal 
hyperexcitability and hypersynchronous neuronal firing, and is classified as either partial-
onset (localized within one hemisphere of the brain) or generalized-onset (involving both 
brain hemispheres).11,17 Treatment of epilepsy is limited to antiepileptic drugs (AEDs), 
dietary regulations (ketogenic diet), or surgery. Although newer generation AEDs have 
made improvements (reviewed in Section 1.3), it is estimated that 30% of epilepsy patients 
fail at least two first-line AED treatments, deeming these patients pharmacoresistant, while 
~40% of the patients that respond to AEDs experience adverse side effects.9-11,18,19 
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Pharmacoresistant patients represent a substantial market with an important unmet medical 
need. Therefore, the need remains for highly potent AEDs with improved efficacy, 
decreased toxicity, and favorable pharmacokinetic (PK) properties with the hope of not only 
suppressing seizures, but also reducing the patient‟s susceptibility to future seizures.  
 
1.2. Neuropathic pain 
Neuropathic pain (NP) is caused by damage, disease, or dysfunction in the nervous 
system.20 However, this is an oversimplification due to the sheer complexity of 
pathophysiological events that occur during the development of NP, and this complexity 
often results in poorly diagnosed and improperly managed therapy.21,22 The source of 
nervous system damage can range from genetic factors to traumatic factors, but symptoms 
commonly include spontaneous, unpleasant burning sensations (dysesthesia), exaggerated 
pain sensations (hyperalgesia), and/or hypersensitivity to normally non-painful stimuli 
(allodynia).20,22,23 Currently, treatment options rely on pharmacological management and/or 
surgical management, but both options fail to adequately relieve pain in the majority of 
patients.24 First line medications include nonsteroid anti-inflammatory drugs (NSAIDs), 
opioids, antidepressants, and anticonvulsants, but nonspecific mechanisms of CNS 
depression cause a range of inconsistent and unwanted side effects, which often limits their 
use.23-26 Recently, the role of voltage-gated ion channels (VGICs) and downstream effectors 
of neurotrophins in NP have been investigated.20,26,27 Ultimately, inadequate pain control can 
be attributed to the combination of ill-defined pathophysiological mechanisms and limited 
treatment options, but large efforts are underway to clearly define and specifically disrupt the 
development of neuropathies with therapeutic agents that possess a novel mechanism of 
action.28-33 
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1.3. Antiepileptic drugs 
Presently, AEDs are classified into three groups based on the timeframe in which 
they were discovered: established (Figure 1), recent (Figure 2), or emerging (Figure 3). 
Established or traditional AEDs span until ~1978, after which there was a period of inactivity 
(~15 years) before a resurgence of AED research in the early 1990s. The pathophysiological 
processes of most AEDs fall into one of four categories: increase of inhibitory 
neurotransmission, decrease of excitatory neurotransmission, blocking VGICs, and 
interference with intracellular signaling pathways.13,16,18,34-38 
 
1.3.1. Established AEDs: 1800s–1978 
Antiepileptic drugs have a relative short history in the grand scheme of medicinally 
relevant agents. Bromide salts were the principle AED throughout the 19th century until the 
anticonvulsant properties of phenobarbital (5) were discovered serendipitously at the turn of 
the 20th century.39 Then, the development of electrically-induced40 and chemically-induced41 
animal seizure models aided the discovery of phenytoin (6), primidone (7), and 
ethosuximide (4) in the 1930s–1950s. In 1962, the anticonvulsant activity of valproic acid (8) 
was also discovered serendipitously when it was used as a solvent for compounds that were 
screened for seizure protection. The 1970s saw a re-purposing of known CNS agents, such 
as the antipsychotic carbamazepine (1), and the anxiolytics clobazam (2) and clonazepam 
(3), as they began to be recognized for their anti-seizure activities.39  
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Figure 1. Established AEDs 
 
1.3.2. Recent AEDs: 1993–Early 2000s 
The Epilepsy Branch of the National Institute of Neurological Disorders and Stroke 
(NINDS) started the Antiepileptic Drug Development (ADD) program in 1975 to facilitate the 
development of new therapeutics for the treatment of seizure disorders as a response to the 
decline in novel anticonvulsant agents. Within the ADD program, the Anticonvulsant 
Screening Project (ASP) served as the preclinical component to identify lead compounds.42 
Several novel compounds, including felbamate (10) and topiramate (18), were identified 
through the collaborative efforts of pharmaceutical companies and the ADD. Felbamate (10) 
was the first anticonvulsant to be approved by the United States Food and Drug 
Administration (US FDA) since the 1978, and topiramate (18) followed suit a few years 
later.42  
Among the recent AEDs, several are second generation anticonvulsants that have 
tried to improve efficacy/safety or circumvent unfavorable side effects/PK properties 
compared with the established parent AEDs, while others are novel chemical structures. 
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Some second generation AEDs include fosphenytoin (9) and oxacarbazepine (14). 
Fosphenytoin (9) was developed as a phosphate ester prodrug of phenytoin (6) and, unlike 
phenytoin (6), it is freely soluble in aqueous solutions,18,43,44 while oxacarbazepine (14) 
avoids the inducible cytochrome CYP3A4-mediated oxidative metabolism of carbamazepine 
(1).45 Many new chemical structures that possess anticonvulsant activity are gabapentin 
(11), lamotrigine (12), levetiracetam (13), rufinamide (16), tiagabine (17), vigabatrin (19), 
and zonisamide (20).  Pregabalin (15) is a follow up to gabapentin (11) and has 
demonstrated higher efficacy than gabapentin (11) in preclinical models of epilepsy, 
neuropathic pain, and anxiety.45 
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Figure 2. Recent AEDs 
 
1.3.3. Emerging AEDs: Early 2000s–2010  
Several emerging AED candidates are second generation to recent AEDs, but many 
are novel in structure. Second generation emerging AED candidates include brivaracetam 
(21), carisbamate (22), eslicarbazepine (24), JZP-4 (27), propylisopropyl acetamide (29), 
and valrocemide (31). Brivaracetam (21) has ~10-fold higher affinity than levetiracetam (13) 
for synaptic vesicle protein 2 (SVP2) and it expands upon the mechanism of action (MOA) to 
include neuronal voltage-gated sodium channels (VGSCs).37,45-47 Carisbamate (22) was 
developed to avoid the toxic metabolites of felbamate (10), and also displays a broader 
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spectrum of activity.37,47 Eslicarbazepine (24), second generation to oxacarbazepine (14) 
and third generation carbamazepine (1), was designed as a prodrug to obtain patent rights. 
The active, non-patentable metabolite of eslicarbazepine (licarbazepine, 25) displayed 
higher bioavailability than oxacarbazepine (14) and still avoids the inducible cytochrome 
CYP3A4-mediated oxidative metabolism associated with carbamazepine (1).45-47 JZP-4 (27) 
has better efficacy in the 6 Hz seizure model than lamotrigine (12), and has demonstrated a 
greater selectivity for neuronal VGSCs over peripheral tetrodotoxin-resistant (TTX) 
VGSCs.46 Propylisopropyl acetamide (29) and valrocemide (31) are just two of the many 
valproic acid (8) derivatives in development, and these compounds decrease the 
teratogenicity and hepatotoxicity associated with valproic acid (8).45-47 New scaffolds with 
seizure protection are neuroactive sugars (2-deoxy-D-glucose, 23), neuroactive steroids 
(ganaxolone, 26), functionalized amino acids (lacosamide, 28), and α-aminoamides 
(safinamide, 30).47,48 
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Figure 3. Emerging AEDs 
 
1.3.3.1. Lacosamide  
Of the emerging AEDs with anticonvulsant activity, we have a particular connection 
with lacosamide (28) because the inception of functionalized amino acids (FAAs), and the 
subsequent discovery of lacosamide (28), occurred in the Kohn laboratory (Figure 4). Before 
FAAs, the Kohn laboratory examined the pharmacological activity of substituted 
imidazolidinethiones and thioimidazolines,49 followed by the effect of structural modification 
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of the hydantoin ring on anticonvulsant activity.50 Concurrent analysis of the literature of 
emerging anticonvulsants51 led the Kohn laboratory to examine the pharmacological 
activities of protected amino acid derivatives (33), which were conceptually open-chain 
analogs of hydantoins (i.e., 32). These compounds were termed Functionalized Amino Acids 
(FAAs), and racemic FAA 33 (R = CH3) displayed significant anticonvulsant activity in mice 
(<100 mg/kg).50,52 Next, the Kohn laboratory demonstrated that the seizure protection of 
FAAs were associated with the D-amino acid configuration (typically (R)-stereoisomer) of 
FAAs ((R)-33).53 Then, a series of studies were published probing the 2-position of FAAs,54-
58 and the 2-furanyl FAA (R)-34 was identified as a lead compound (ED50 = 3.3 mg/kg in 
mice).56 However, toxicity in preclinical assessment at the Eli Lilly Laboratories (Indianapolis, 
IN) halted further advancement into phase I clinical trial.59 Further studies of heteroatom-
containing 2-substituents in FAAs revealed the potent anticonvulsant properties of (R)-
lacosamide ((R)-28) (ED50 = 4.5 mg/kg in mice),
60 which attracted the interest of Harris FRC 
Corporation (Holmdel, NJ), and subsequently Schwarz Pharma (Monheim, Germany; 
acquired by UCB Pharma (Brussels, Belgium) in 2006). 
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Figure 4. Highlights on the path to discovering (R)-lacosamide ((R)-28) 
 
(R)-Lacosamide ((R)-28) has recently been approved by the European Medicines 
Agency (EMEA) and the US FDA under the trademark Vimpat® for the adjuvant treatment of 
partial-onset seizures in adult patients with epilepsy.61 (R)-28 is a new generation AED due 
to its unique structure and in vivo pharmacological profile. The molecular mode of action is 
currently unknown, but recent research indicates that (R)-28 promotes selective 
enhancement of sodium channel slow inactivation (reviewed in Section 2.1.2). Recent 
studies have also shown that (R)-28 binds to the collaspin-response mediator protein 2 
(CRMP-2)62-64 and carbonic anhydrase,65 but the functional significance of these interactions 
have not been determined. While (R)-28 has demonstrated clinical efficacy in treating 
painful diabetic neuropathy in two out of three phase III clinical trials and was determined 
suitable for long-term use with a desirable safety profile, additional testing is needed for 
approval for this indication.66  
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1.4. Pain attenuating drugs 
First line treatment of NP relies heavily on therapeutic agents that were originally 
developed for other medical conditions, such as inflammation, acute pain, depression, and 
seizures.23 These include, but are not limited to, the nonsteroid anti-inflammatory drugs 
(NSAIDs) acetaminophen (35), diclofenac sodium (36), ibuprofen (37), and indomethacin 
(38); the opioids codeine (39), morphine (40), and oxycodone (41); the antidepressants 
amitriptyline (42), despiramine (43), duloxetine (44), and nortryptyline (45); and the 
anticonvulsants carbamazepine (1), clonazepam (3), gabapentin (11), and pregabalin (15) 
(Figure 5).27 There are limited US FDA approved drugs specifically for NP, but those that 
have received approval include carbamazepine (1, facial pain),67 duloxetine (44, painful 
diabetic peripheral neuropathy and fibromyalgia),68 gabapentin (11, post-herpetic 
neuralgia),69 and pregabalin (15, post-herpetic neuralgia, painful diabetic peripheral 
neuropathy, and fibromyalgia).70 Current pharmacological management of NP usually 
consists of a combination of agents from several of the listed drug classes, but it provides 
only 30–50% pain reduction in ~50% of patients.23 Therefore, the need remains to identify 
and validate new targets that are involved in NP and design novel therapeutic agents to 
address those targets.  
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Figure 5. Drugs used for the management of neuropathic pain 
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2. Communication methods of the nervous system 
Communication between the central and peripheral nervous systems (CNS and 
PNS, respectively) and the brain is a highly regulated process involving the sending, 
receiving, and integration of electrical and chemical impulses. Neurons are responsible for 
sending these signals over considerable distances by the propagation of action potentials 
(electrical transmission) or through the release of endogenous chemicals (chemical 
transmission). 
 
2.1. Electrical transmission  
2.1.1. The action potential 
The intracellular and extracellular sides of the neuronal cell plasma membrane are 
surrounded by ions (K+, Na+, Ca2+, Cl-). The differential distribution in ionic concentration 
(intracellular relative to extracellular) defines an equilibrium potential (Eion) for each ion 
(Table 1) and the differential distribution in ionic concentrations and the relative 
permeabilities of each ion under normal physiological conditions create the resting 
membrane potential.71 When neurons are stimulated, voltage-, ligand-, or stretch-activated 
ion channels open or close, causing a change in ionic permeabilities and, consequently, a 
change in the membrane potential. The constant flux of ions across the plasma membrane 
requires active transport mechanisms that use the hydrolysis of ATP (i.e., Na+/K+ ATPase, 
H+/K+ ATPase, Ca2+ ATPase, Mg2+ ATPase) and co-transport mechanisms (symport and 
antiport transporters) to maintain ionic homeostasis. An action potential (AP) is generated if 
the change in membrane potential reaches a particular value (threshold) before ionic 
homeostasis can be restored by ionic pumps and transporters.  
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Table 1. Physiological mammalian ion gradients and equilibrium potentials 
Ion  [Outside]
a
 (mM)  [Inside]
b
 (mM)  Eion (mV) 
K
+ 
 3  135  -102 
Na
+ 
 150  18  +56 
Ca
2+ 
 1.2  0.0001  +125 
Cl
- 
 120  7  -76 
a
 Concentration of extracellular ions. Fundamental Neuroscience. Academic Press: 
Boston, 2003, p. 140. 
 b
 Concentration of intracellular ions. Fundamental Neuroscience. 
Academic Press: Boston, 2003, p. 140. 
 
In the generation of an AP as depicted in Figure 6, the membrane potential slowly 
becomes less negative compared with the resting potential (1) due to extrinsic stimulation or 
intrinsic pacemaker depolarization until the membrane potential reaches its threshold (2). At 
this point, the neuron is committed to the generation of the AP, and the membrane potential 
rapidly becomes less negative than the resting potential (depolarization, 3) due to the 
activity of VGSCs. As the membrane potential depolarizes, inactivation of VGSCs and 
activation of voltage-gated potassium channels (VGPCs) causes repolarization (4), and 
often becomes more negative than the original resting potential (afterhyperpolarization, 5), 
before equilibrating back to the resting potential (1). A hypothetical voltage-clamp analysis of 
the ionic current that underlies an AP (Figure 7) shows that the total membrane current (3) is 
a combination of the outward conductance of K+ (1) through VGPCs and the inward 
conductance of Na+ (2) through VGSCs.71  
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Figure 6. Hypothetical action potential 
 
 
 
Figure 7. Hypothetical voltage-clamp analysis of ionic currents underlying an action 
potential71 
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2.1.2. VGSCs 
Many mutated genes that encode for VGICs have been identified in idiopathic 
epilepsies72-74 and pain disorders75,76 (Table 2). Therefore, it is not surprising that VGICs 
have become potential targets for AEDs.77 Specifically, the Kohn laboratory is focused on 
the role of VGSCs in epilepsy and neuropathic pain since reports indicate that lacosamide 
((R)-28) promotes selective enhancement of sodium channel slow inactivation.63,64  
 
Table 2. Mutated genes that encode for VGICs that are associated with idiopathic 
epilepsies and pain disorders 
 
Gene  Ion Channel  Syndrome 
KCNQ2  K
+ 
 Benign familial neonatal seizures 
KCNQ3  K
+ 
 Benign familial neonatal seizures 
SCN1A  Na
+
  Generalized epilepsy with febrile seizures 
SCN1B  Na
+ 
 Generalized epilepsy with febrile seizures 
SCN2A  Na
+
  Benign familial neonatal seizures 
SCN9A  Na
+
  Paroxysmal extreme pain disorder 
SCN9A  Na
+
  Erythromelalgia 
CACNB4  Ca
2+ 
 Juvenile myoclonic epilepsy 
CLCN2  Cl
-
  Idiopathic generalized epilepsy 
 
 
2.1.2.1. Structural properties of VGSCs 
VGSCs are transmembrane proteins, comprised of an α-subunit (~260 kDa) (Figure 
8A) and an accessory β-subunit, that allow the influx of sodium during cell depolarization 
and have been implicated in nociception, hyperexcitability, and increased pain sensitivity.75 
The α-subunit consists of four internally homologous domains (DI–DIV) (Figure 8C) that are 
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further divided into six transmembrane segments (S1–S6) (Figure 8B). The S4 segment 
contains a positively charged residue at every third position and creates the voltage-sensing 
mechanism.78-85 Nine isoforms (Nav1.1–1.9) are involved in physiological processes such as 
cognition, locomotion, and nociception. Generally, Nav1.1–Nav1.3, and Nav1.6 are 
extensively found in the CNS, Nav1.4 is present in muscle tissue, Nav1.5 is present is 
cardiac tissue, and Nav1.7–Nav1.9 are distributed in the PNS.
78,83-87 However, expression 
can change significantly under pathological conditions such as NP and multiple 
sclerosis.75,83 In conjunction with tissue distribution, sodium channel classification is also 
based on sensitivity to TTX, a powerful neurotoxin that selectivity binds to sodium channels 
with nanomolar affinity. Nav1.1–1.4, 1.6, and 1.7 are TTX-sensitive while Nav1.5, 1.8, and 
1.9 are TTX-resistant.85,86 Each subtype exhibits different voltage and kinetic profiles and is 
responsible for the rapid upstroke of the AP in neurons, and consequently leads to the 
initiation and propagation of electrical signals in the CNS and PNS.83  
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Figure 8. Topology of the VGSC 
 
2.1.2.2. Functional states of the VGSC 
The voltage-dependence of sodium channels mediates the opening, closing, and 
inactivation of the channel in response to cell depolarization (Figure 9). Upon depolarization, 
the sodium channel transitions from the closed (resting) state to the opened state, and 
allows the influx of sodium into the cell. Local anesthetics (e.g., lidocaine) have been shown 
block the open state by interacting with the cytoplasmic region of the inner pore.64,88 Next, 
the channel transitions into the inactivated state to terminate the influx of sodium before 
returning back to the closed state. Inactivation serves as a biophysical mechanism that 
essentially makes the channel unavailable, thereby regulating the firing frequency of the AP 
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and controlling the excitability of tissues.62,80,85 Two distinct kinetic classes of inactivation 
have been characterized: fast inactivation and slow inactivation, appropriately described by 
the time scale on which they occur (5–20 milliseconds and 500–1000 milliseconds, 
respectively).62,80,85 Fast inactivation is well characterized and arises when the channel pore 
is physically blocked by a cytoplasmic region located between DIII and DIV of the sodium 
channel (Figure 8A and Figure 9D). This cytoplasmic region is distinguished by a specific 
amino acid sequence (IFM motif) and obstructs the pore in a „ball-and-chain‟ or „hinged lid‟ 
mechanism.78,80,84,85 Several established anticonvulsants (e.g., carbamazepine) have been 
shown to selectively bind and enhance fast inactivation.62,63 Slow inactivation is functionally 
and structurally distinct and much less understood. It is thought to occur via a 
conformational rearrangement experienced during repeated neuronal firing or sustained 
depolarization that impedes ionic flow through the channel.62,80,85 In Figure 9C, slow 
inactivation is depicted as obstructing sodium flow on the extracellular side of the channel 
but the precise structural mechanism for sodium impedance remains elusive. (R)-28 has 
been shown to promote the entry of sodium channels into the slow inactivated state.63,64  
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Figure 9. Functional states of the VGSC 
 
Recently, Lees et al. demonstrated that (R)-28 inhibits sodium channel activation by 
shifting the slow inactivation voltage-dependence in the hyperpolarizing direction in primary 
neuronal cultures. Significantly, use of the (S)-stereoisomer of 28 did not show any 
modulation of the slow inactivation process.63 Cummins et al. demonstrated that (R)-28 
enhances inactivation of rat Nav1.3 and human Nav1.7 in stably expressed HEK293 cells, as 
well as Nav1.8-type TTX-R currents from dorsal root ganglion (DRG) neurons, with IC50 
values of 415, 182, and 16 μM, respectively, without altering steady-state fast inactivation. It 
was also demonstrated that carbamazepine affects the fast inactivated state, while lidocaine 
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shows evidence of affecting both the fast and slow inactivated states. When comparing the 
resting state IC50 values of cells expressing Nav1.3, Nav1.7, and Nav1.8 channels to the IC50 
values of chronically depolarized cells expressing Nav1.3, Nav1.7, and Nav1.8 channels, (R)-
28 was 123-250 times more selective for the chronically depolarized state, while 
carbamazepine and lidocaine were only 3-16 times more selective for the chronically 
depolarized state. This indicates that (R)-28 can selectively block the activity of nociceptive 
neurons (Nav1.3, Nav1.7, and Nav1.8) that are chronically depolarized, a pathological 
phenomenon that may characterize NP.64  
 
2.1.2.3. The role of VGSCs in nociception 
Recently, several sodium channel isoforms have been demonstrated to play a role in 
peripheral nociception and NP.64,75,76,83,86 Gain-of-function mutations of the peripheral Nav1.7 
channel results in extremely painful disorders, such as erythromelalgia and paroxysmal 
extreme pain disorder (PEPD). Conversely, deletion of the Nav1.7 channel results in an 
inability to experience pain without affecting non-nociceptive sensory functions.33,75 Along 
with Nav1.7, Nav1.3 and Nav1.8 are thought to be involved in NP and recent studies reported 
promising PNS-specific agents that target these sodium channel isoforms.28-33,75 Among 
these, researchers at Merck Research Laboratories (Whitehouse Station, NJ) have 
characterized a novel class of benzazepinones as potent inhibitors of hNav1.7 channels for 
the potential treatment of NP.29,30,33 Extensive SAR studies, with a focus on PK-enhancing 
properties, led to the discovery of 46 (IC50 = 30 nM).
29,30,33 Merck also developed CDA54 
(47) to selectively inhibit injury-induced nerve signaling by blocking the inactivated state of 
hNav1.7 and hNav1.8 channels (IC50 = 0.25 μM and 0.18 μM, respectively).
28 Similarly, 
investigators at Abbott Laboratories (Abbott Park, IL) have developed and evaluated a 
series of 5-aryl-2-furfuramides, which led to the discovery of A-803467 (48) as a selective 
hNav1.8 channel blocker (IC50 = 140 nM) that reduced mechanical allodynia.
31,32 As 
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demonstrated by Merck Research Laboratories and Abbott Laboratories, preferential binding 
of small molecules to specific sodium channel isoforms could lead to therapeutically relevant 
molecules for NP with improved efficacy and safety. We will revisit the importance of 48 as it 
relates to this project in Chapter 3.  
 
 
 
2.2. Chemical transmission 
Neuronal communication consists not only of electrically-mediated transmission, but 
also chemically-mediated transmission. The chemical messengers can be broadly defined 
as classic neurotransmitters (small molecules) and non-classical neurotransmitters 
(peptides). Classic neurotransmitters include the biogenic monoamines dopamine (49), 
epinephrine (50), norepinephrine (51), and serotonin (52); the amino acids aspartate (53), 
GABA (54), glutamate (55), glycine (56), and serine (57); as well as acetylcholine (58) 
(Figure 10).  
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Figure 10. Classic neurotransmitters 
 
 As the AP propagates along the axon of a neuron, the abrupt changes in the plasma 
membrane potential signals the release of neurotransmitters from the presynaptic nerve 
terminal into the synaptic cleft (Figure 11). Once released into the synapse, the 
neurotransmitters interact with receptors embedded within the plasma membrane of the 
postsynaptic nerve terminal. This interaction can be excitatory (i.e., causes a depolarization 
of the membrane potential) or inhibitory (i.e., causes a hyperpolarization of the membrane 
potential) in nature, but both result in changes of the postsynaptic membrane potential, 
which affects the AP. Equally important as the release of neurotransmitters is the 
termination of the neurotransmission by active mechanisms (i.e., reuptake through specific 
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transporter proteins, enzymatic degradation) or passive mechanisms (diffusion). Failure to 
terminate neurotransmission results in continual stimulation of the postsynaptic nerve 
terminal and can lead to neuronal disorders, such as epilepsy and neuropathic pain.71 
 
 
Figure 11. Neurotransmission 
 
3. Primary amino acid derivatives as a treatment for CNS 
disorders 
The extensive work on FAAs (33) by the Kohn laboratory,49-58,60,89-105 and the 
approval of (R)-28 for the adjuvant treatment of partial-onset seizures by the US FDA and 
EMEA, has led us to hypothesize that primary amino acid derivatives (PAADs, 59) may be 
useful agents for the treatment of CNS disorders due to their close structural similarities with 
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FAAs (33). To provide proof-of-concept, a literature search revealed that PAADs 60–63 
have shown moderate-to-excellent anticonvulsant activity in maximal electroshock seizure 
(MES) tests (Table 3).55,56,89,92 With few known literature examples, much of the PAAD 
chemical space is largely unexplored.1 
 
 
 
Lacosamide ((R)-28) has shown significant protection in NP models for inflammatory 
pain, osteoarthritis pain, and diabetic neuropathy, but it is unclear if the site of action occurs 
in the CNS, PNS, or both.66,106-111 With the reported efficacy of FAA (R)-28 in several NP 
models and the recent emergence of PNS-selective agents,28-33 we proposed that the amino 
structural counterpart of FAAs, the PAADs, after adsorption through the gastrointestinal tract 
(GI) would be less likely to cross the blood-brain barrier (BBB) due to their expected 
increased water solubility compared with the corresponding FAA (Figure 12). Significantly, at 
physiological pH, the primary amine (59) is protonated to give the corresponding ammonium 
salt (64), thus possibly hindering its ability to cross the anionic surface of the BBB. We 
recognize from the onset that targeting the PNS was a challenge and selectivity would 
depend on the hydrophilicity of the PAAD and the possible role of drug transporters. Indeed, 
the fact that PAADs 60–63 showed pronounced seizure protection in the MES test 
documents that these PAADs can access the CNS. Finally, the presence of the protonated 
primary amine also allows greater diversity of substitution at the C(2) and N-benzylamide 
                                               
1
 In Chapter 3, we briefly review earlier reports on the pharmacological activity of secondary amino 
acid derivatives (SAADs) and tertiary amino acid derivatives (TAADs). 
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sites, while still maintaining a high degree of water solubility. This permits the synthesis and 
evaluation of hydrophilic PAADs where the FAA counterpart may not have been extensively 
transported into systemic circulation because of poor water solubility. Thus, PAADs may 
represent an ideal class of compounds that can be tailored at the C(2) and N-benzylamide 
sites to selectively target PNS sites and reduce neurological toxicities typically associated 
with CNS active drugs. 
 
Table 3. Previously reported MES activity of PAADs in mice and rats 
 
    Mice (ip)
a
  Rat (po)
b
 
Cmpd No.  R  MES,
c
 ED50  MES,
c
 ED50 
(R)-60
d
  CH3  >10, <30  
19 [2.0] 
(13-25) 
(R)-61
d,e
  CH2OCH3  
48 [0.25] 
(40-61) 
 18 [4.0] 
(R,S)-62
d
  Ph  >100, <300  >30, <100 
(R,S)-63
f
  N(H)C(O)CH3  
65 [0.5] 
(56-75) 
 ND
g
 
phenytoin
h
    
9.5 [2.0] 
(8.1–10) 
 
30 [4.0] 
(22-39) 
phenobarbital
h
    
22 [1.0] 
(15–23) 
 
9.1 [5.0] 
(7.6-12) 
valproate
h
    
270 [0.25] 
(250–340) 
 
490 [0.5] 
(350-730) 
a 
The compounds were administered intraperitoneally to adult male albino CF-1 mice 
under the auspices of the NINDS ASP. ED50 values are in mg/kg.
 b 
The compounds 
were administered orally to adult male albino Sprague Dawley rats. ED50 values are in 
mg/kg. A dose-response curve was generated for all compounds that displayed 
sufficient activity and the dose-effect data for these compounds was obtained at the 
“time of peak effect” (indicated in hours in the brackets). Numbers in parentheses are 
95% confidence intervals. 
c 
MES = maximal electroshock seizure test. 
d
 Béguin, C. et al. 
Bioorg. Med. Chem. 2004, 12, 3079–3096. 
e
 Andurkar, S. et al. Tetrahedron: 
Asymmetry, 1998, 9, 3841–3854. 
f
 Kohn, H. et al. J. Med. Chem. 1991, 34, 2444–2452. 
g 
ND = not determined. 
h
 Porter, R.J. et al. Cleveland Clin. Q. 1984, 51, 293–305. 
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Figure 12. Proposed distribution of PAADs 
 
Although our primary objective was to synthesize and then evaluate PAADs to 
determine if their site of action was restricted to the PNS, thereby avoiding potential CNS 
side effects that makes adherence to pain therapy difficult, we also examined the effect of 
PAADs on CNS function. Specifically, we aimed to (1) use the pharmacological data 
generated from whole animal models of epilepsy and NP to develop a SAR that defined the 
C(2)-structural requirements for PAAD activity; (2) optimize PAADs that displayed 
anticonvulsant activity and/or pain attenuation by functionalization of either the N-terminal 
amine or N-benzylamide sites; and (3) subject the most active PAADs to in vitro binding and 
enzymatic assays to explore their mechanism of action. Two2 whole animal models of 
epilepsy (MES test and 6 Hz test) were used to identify PAADs that could prevent seizures 
in mice, and one whole animal model of NP (formalin test) was used to identify PAADs that 
could attenuate pain in mice. Many PAADs were also evaluated using the MES test in rats. 
                                               
2
 Subcutaneous pentylenetetrazol (Metrazol
®
) (scMET) screening was also performed at the NINDS 
ASP as a method to identify seizure protection, but PAADs were generally inactive in this test 
(Chapter 2 and Chapter 3). 
29 
 
Neurotoxicity was determined by the rotorod test in mice, while behavioral toxicity was 
monitored in rats. 
We synthesized over 50 C(2)-substituted PAADs that were evaluated in whole 
animal models of epilepsy and NP (Chapter 2). A subset of PAADs displayed excellent 
anticonvulsant activity and pain attenuation and surpassed the activity of several established 
AEDs. Next, we synthesized over 40 PAADs to determine the affect of functionalization of 
both the N-terminal amine and the N-benzylamide moiety of PAADs on anticonvulsant 
activity and pain attenuation (Chapter 3). Anticonvulsant data suggests that several of the 
optimized PAADs can arguably rival the therapeutic value of lacosamide ((R)-28). Then, we 
initiated studies on the MOA of the most active PAADs through a series of binding and 
enzymatic assays (Chapter 4). Finally, we comment on the therapeutic significance of 
PAADs for the treatment of epilepsy and NP and suggest further studies that could prove 
beneficial for the development of PAADs (Chapter 5). 
 CHAPTER 2. Defining the Structural Requirements for 
PAADs
 
1. Introduction 
Over the past 25 years, the Kohn laboratory has synthesized more than 300 FAAs 
that have been evaluated for anticonvulsant activity.50,52-58,60,89-93,96-105,112,113 With the clinical 
success of lacosamide ((R)-28), we have proposed that PAADs may serve as useful 
neurological agents for the treatment of epilepsy and NP. Our choice of compounds in this 
study was driven by the in vivo behavioral tests that were conducted by UCB Pharma and 
the NINDS ASP for anticonvulsant activity, pain attenuation, and neurotoxicity.  
 
2. Results and discussion 
The SAR of the comprehensively studied FAAs (33) revealed excellent 
anticonvulsant activities in the MES test and, accordingly, the FAA structural blueprint was 
the foundation for the development of PAADs (59) due to their similar pharmacophores. 
Hallmarks of the FAA SAR include: (1) the N-acetyl; (2) the diamine backbone; (3) the 
carbonyl group within the diamine backbone; (4) the N’-benzylamide; (5) the heteroatom one 
atom removed from the chiral C(2) center; (6) the substitution of the heteroatom; and (7) the 
stereochemistry corresponding to the D-amino acid at the chiral C(2) center.50,52-58,60 Building 
the SAR of primary amino acid derivatives inherently precludes hallmark one. Hallmarks 
two, three, and four are retained in the structural blueprint of PAADs, thereby directing the 
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majority of the initial SAR exploration at hallmarks five, six, and seven. Therefore, our 
studies began by simultaneously examining the requirement for a heteroatom one carbon 
removed from the C(2) center, the heteroatom substitution, and the stereochemistry at the 
C(2) position. After examining the FAA hallmarks in the context of PAADs, we investigated 
C(2)-hydrocarbon substituents that deviated from the traditional FAA SAR.  
 
 
 
2.1. Choice of compounds: PAADs 
Using lacosamide ((R)-28) as the prototypical FAA structural template, we 
systematically modified the C(2) position of the PAADs according to three categories: (1) 
C(2)-(CH2)nXR PAADs (61, 65–76), where n equals the number of methylene carbons, X is 
an oxygen, nitrogen, or sulfur, and R is an alkyl group; (2) C(2)-6-membered and 5-
membered aromatic and heteroaromatic PAADs (62, 77–94); and (3) C(2)-hydrocarbon 
PAADs (60, 95–102).  
 
2.1.1. C(2)-(CH2)nX(R)y PAADs 
The C(2)-(CH2)nX(R)y PAADs simultaneously examined the heteroatom one-to-two 
carbons removed from the C(2) center, the heteroatom substitution, and in select cases, the 
stereochemistry at the C(2) position. The (CH2)nX(R)y PAADs are further classified 
according to three sub-categories: (1) C(3)-alkoxy PAADs (61, 65–69); (2) C(3)-amino 
PAADs (70–73); and (3) C(4)-substituted PAADs (74–76). In the C(3)-alkoxy series, n 
equals one, X is oxygen, and R (y = 1) was successively replaced with a methyl, ethyl, 
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propyl, allyl, and propargyl group. All of the C(3)-alkoxy PAADs were synthesized in the 
(R,S)-configuration with the exception of the hydroxy PAAD (65) and the methoxy PAAD 
(61), which were synthesized in the (R)-, (S)-, and (R,S)-configurations. In the C(3)-amino 
series, n equals one, X is nitrogen, and R was successively replaced with either one methyl 
group (y = 1) or two methyl groups (y = 2), or the C(3)-amino group was embedded within a 
morpholino moiety. All C(3)-amino PAADs were synthesized in the (R,S)-configuration. In 
the C(4)-substituted series, n equals two, X is oxygen or sulfur, and R (y = 1) is either a 
hydrogen or methyl group. All C(4)-substituted PAADs were synthesized in the (R)-
configuration. Inspiration for the C(3)-alkoxy and C(4)-substituted PAADs was directly 
obtained from the structure of lacosamide ((R)-28), the prototypical FAA where n equals 
one, X is oxygen, and R (y = 1) is a methyl group. Like lacosamide ((R)-28), excellent 
anticonvulsant activity was also observed for other oxygen-substituted FAA analogs, 
provided the oxygen was one atom removed from the C(2) center. Our interest in C(3)-
amino PAADs was increased by the notion that these compounds might exhibit decreased 
penetration into the CNS. We expected that under physiological condition that the C(3)-
amino groups would be protonated, thus hindering passive diffusion across the blood-brain 
barrier. 
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2.1.2. 6-Membered and 5-membered aromatic and heteroaromatic PAADs 
Excellent anticonvulsant activity in the MES test has been observed for 6-membered 
and 5-membered aromatic and heteroaromatic compounds in the FAA series, and activity 
typically increased when a heteroatom was located one atom removed from the C(2) chiral 
carbon (e.g., 2-furanyl, 2-pyrrolyl, 1-pyrazolyl, 2-oxazolyl, 2-thiazolyl, 2-pyridyl, 2-pyrimidyl, 
2-pyrazinyl).53-57,60 Utilizing the knowledge of the heteroaromatic FAAs, we synthesized 6-
membered aromatic and heteroaromatic PAADs 62, 77–88 and 5-membered heteroaromatic 
PAADs 89–94. Except where R equals phenyl (62), all 6-membered and 5-membered 
aromatic and heteroaromatic PAADs (77–94) were synthesized by Drs. Pranjal Baruah, 
Jason Dinsmore, and Christophe Salomé. PAAD 62 served as a reference compound and 
was synthesized in the (R)-, (S)-, and (R,S)- configurations, while compounds 77–94 were 
synthesized as the (R,S)-configuration only.  
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2.1.3. C(2)-Hydrocarbon PAADs 
Initially, we synthesized the hydrocarbon equivalent of PAAD 61 (O→CH2, 96) in the 
(R)-, (S)-, and (R,S)-configurations to further examine the requirement for a heteroatom one 
atom removed from the C(2) center in conjunction with the need for stereochemical 
specificity at the C(2) position. Modest anticonvulsant activity and NP protection was 
observed for (R)- and (R,S)-96 (reviewed in Section 2.3.3), which prompted the synthesis of 
an expanded series of C(2)-hydrocarbon PAADs (60, 95, 97–102). Therefore, we prepared 
C(2)-hydrocarbon PAADs where R is a linear alkyl group (methyl, ethyl, and n-butyl), a 
branched alkyl group (isopropyl, t-butyl, and 2-methyl-propyl), or a cyclic group (cyclohexyl 
and benzyl). PAADs 97 and 101 were synthesized by Drs. Jason Dinsmore and Christophe 
Salomé, respectively. Since the C(2)-(CH2)nXR PAADs revealed a preference for 
stereochemistry in the D-amino acid configuration, all of the hydrocarbon PAADs were 
synthesized in the (R)-configuration, except PAAD 100, which contained two chiral centers 
and was a mixture of stereoisomers. The excellent anticonvulsant activity of PAADs (R)-98 
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and (R)-99 prompted the synthesis of the corresponding (S)-stereoisomers to determine if 
pharmacological activity paralleled the C(2)-(CH2)nX(R)y PAADs, where activity preferentially 
resided in the C(2)-D-amino acid configuration. 
 
 
 
2.2. Synthesis 
2.2.1. C(2)-(CH2)nX(R)y PAADs 
2.2.1.1. C(3)-Hydroxy and C(3)-alkoxy PAADs 
PAADs 61, 65–69 were synthesized in three to four steps using commercially 
available reagents and established synthetic procedures (Scheme 1). Treatment of (R)-, (S)-
, and (R,S)-serine (103) with benzyl chloroformate under basic conditions gave (R)-, (S)-, 
and (R,S)-104,89,98 which was then converted to the amides (R)-, (S)-, and (R,S)-105 using 
the mixed anhydride coupling (MAC) procedure,89,98 followed by subsequent hydrogenolysis 
to obtain the corresponding PAADs (R)-, (S)-, and (R,S)-65.89,98 Alkylation of (R)-, (S)-, and 
(R,S)-105 using methyl iodide (106) and Ag2O gave (R)-, (S)-, and (R,S)-109 before 
hydrogenolysis to the corresponding PAADs (R)-, (S)-, and (R,S)-61.92 Similarly, treatment 
of (R,S)-105 with either ethyl iodide (107) or propyl iodide (108) and Ag2O gave (R,S)-110 
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and (R,S)-111, respectively, followed by hydrogenolysis to their respective PAADs (R,S)-67 
and (R,S)-68. We observed an increase in reaction time and temperature, as well as a 
decrease in yield as the alkyl iodide went from methyl to ethyl to propyl. However, this was 
not unexpected as work on the corresponding FAAs by Choi et al. resulted in similar 
trends.60 
 
Scheme 1. Synthesis of C(3)-hydroxy PAAD 65 and C(3)-alkoxy PAADs 61, 67, and 68 
 
 
We attempted to synthesize (R,S)-114 and (R,S)-115 using the alkylation conditions 
from Scheme 1, but no reaction was observed (Scheme 2).  
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Scheme 2. Attempted alkylation of (R,S)-105 using allyl iodide (112) and propargyl 
iodide (113) 
 
 
 
 Therefore, we attempted to synthesize PAADs (R,S)-68 and (R,S)-69 via an aziridine 
intermediate (Scheme 3). Aziridines are important intermediates in the derivatization of 
amino acids due to their highly strained three-membered rings that are readily opened by a 
nucleophile under Lewis-acid catalyzed conditions.114-118 A highly desirable trait of aziridine 
chemistry is the retention of stereochemistry of the aziridine precursor in the ring-opened 
product. The Kohn group utilizes two methods for aziridine formation: a one-step 
cyclodehydration using 2-amino alcohols and diethoxytriphenylphosphorane 
(DTPP),100,119,120 and a three-step N-trityl protection of methyl ester followed by 
cyclodehydration.94-97 We successfully converted (R,S)-65 to the corresponding aziridine 
(R,S)-116 using DTPP on gram scale, but we were unable to N-protect the aziridine using 
trifluoroacetic anhydride. In each attempt, the 1H NMR displayed signs of ring opening and 
the trifluoroacetyl-protection route was abandoned.  
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Scheme 3. Attempted synthesis of PAADs (R,S)-68 and (R,S)-69 
 
 
 
 An alternative route to synthesize PAADs (R,S)-68 and (R,S)-69 was based on a 
study by Koenig and coworkers (Scheme 4).121 In this report, the researchers illustrate how 
imidoyl chlorides, generated from secondary acetamides and oxalyl chloride in the presence 
of base, can be selectively deprotected to give the primary amine, without racemization of 
the chiral center. Encouraged by the scope of the results, we attempted three model 
reactions to convert FAAs (R)-122, (R)-123, and (R)-124, generously provided by Drs. Ki 
Duk Park and Christophe Salomé, to PAADs (R)-125, (R)-126, and (R)-127, respectively. 
Ideally, the secondary acetyl is converted to the imidoyl chloride in the presence of base and 
releases a mixture of carbon monoxide and carbon dioxide. The reaction is quenched at 0 
ºC with 1,2-propanediol, converting the imidoyl chloride to an imidoyl ester. Finally, warming 
the reaction to room temperature releases the carboxylic ester and amine salt. However, we 
were unable to generate PAADs using this method. 
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Scheme 4. Attempted synthesis of C(3)-alkoxy PAADs by acetyl deprotection 
 
 
Reverting back to the aziridine chemistry, we decided to modify our approach using a 
different protecting group based on chemistry that was familiar to the Kohn laboratory 
(Scheme 5).101 We successfully executed a three-step procedure beginning with the N-
tritylation protection of commercially available (R,S)-128, followed by cyclodehydration to 
give (R,S)-130.122-127 Optimization of the remaining steps to obtain PAADs (R,S)-68 and 
(R,S)-69 required consideration of (1) the sensitivity of the N-protecting group to BF3•Et2O; 
and (2) the sensitivity of the unsaturated alkenyl or alkynyl group to the final deprotection 
conditions.  
Generally, aziridines exhibit only modest reactivity toward ring opening by oxygen 
nucleophiles.128 Therefore, we considered replacing the bulky electron-donating trityl group 
with an electron-withdrawing group that could coordinate with a Lewis acid to enhance ring 
opening. Protecting groups considered were tert-butyloxycarbonyl (tBoc), 2,2,2-trichloro-tert-
butyloxycarbonyl (TcBoc), 2,2,2-trichloroethoxycarbonyl (Troc), and an azidomethyl carbonyl 
(Azoc). tBoc is a classic protecting group that undergoes cleavage in acidic media and has 
been widely used in aziridine chemistry.125,129-134 TcBoc and Troc are stable against acids 
and bases, making them orthogonal to classic protecting groups (e.g., Cbz, tBoc, Fmoc, and 
Alloc) and are removed by freshly activated zinc dust in acetic acid at room temperature.135-
141 Cases of TcBoc removal in the presence of an allyl functionality have been 
reported,138,139 however we found literature evidence that zinc could possibly reduce the 
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terminal alkynyl group.142-144 Azoc is a more recent alternative that is stable against acids 
and bases, providing control over neighboring functional groups, and undergoes fast 
deprotection (<2 min) using phosphines.145,146  
Immediate accessibility and familiarity with Boc2O led us to choose tBoc as the 
protecting group. In a model reaction, propargyl ether was exposed to the acidic tBoc 
deprotection conditions (TFA/CH2Cl2) and did not show signs of decomposition after several 
hours (TLC and 1H NMR analysis). Further support for pursuing the tBoc aziridine came 
from the reported preparation of (S)-131 by Wei and coworkers.133 Hence, we felt confident 
that PAADs (R,S)-68 and (R,S)-69 could be synthesized under our optimized conditions 
using tBoc as the protecting group.  
Deprotection of (R,S)-130 under acidic conditions was followed by reprotection with 
Boc2O under basic conditions to give aziridine (R,S)-131.
129-131  Ring-opening with allyl 
alcohol (118) or propargyl alcohol (119) in the presence of BF3•Et2O gave (R,S)-132 and 
(R,S)-133, respectively, which were hydrolyzed to give (R,S)-134 and (R,S)-135, 
respectively, and then directly used for the MAC coupling to give amides (R,S)-136 and 
(R,S)-137, respectively. Finally, amides (R,S)-136 and (R,S)-137 were deprotected under 
acidic conditions (TFA) to the corresponding PAADs (R,S)-68 and (R,S)-69, respectively. 
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Scheme 5. Synthesis of unsaturated C(3)-alkoxy PAADs (R,S)-68 and (R,S)-69 
 
 
2.2.1.2. C(3)-Amino PAADs 
Previously, the Kohn laboratory has reported the expedient synthesis of racemic 2,3-
diaminopropionic acid derivatives by the addition of amines to dehydroalanine derivatives.147 
Similarly, we attempted a two-step, one-pot reaction to form the dehydroalanine, followed by 
the Michael addition of various amines to obtain the desired C(3)-amino intermediates. First, 
we attempted to O-Cbz protect commercially available (R,S)-138 using benzyl chloroformate 
in the presence of base at low temperature to give the carbonate (R,S)-139, but reaction 
completion and purification from the starting material posed some difficulties (Scheme 6).148  
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Scheme 6. Attempted synthesis of Cbz-protected dehydroalanine methyl ester 
intermediate 140 
 
 
 
Next, alcohol (R,S)-105 was converted to a mesylate that was expected to quickly 
undergo elimination upon the addition of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 
(Scheme 7). We were unable to isolate (R,S)-142 and instead isolated a mixture of products 
with unique 1H NMR spectra (Scheme 8).  
 
Scheme 7. Attempted synthesis of Cbz-protected dehydroalanine N-benzylamide 
intermediate 142 
 
 
 
 
A total of four compounds (143–146) were isolated and characterized from the 
reaction conditions indicated in Scheme 8. In order of elution from a flash column using an 
increasing gradient of EtOAc in hexanes, benzyl alcohol (143) was isolated in the highest 
yield (37%), followed by hydantoins 144–146 (3%, 27%, and 11%, respectively). The first 
indication of an unexpected reaction was the absence of the α-proton in all four of the 1H 
NMR spectra. The second indication was the dramatic change in the coupling constant for 
the N-benzyl methylene protons. Typically, we observe a doublet of doublets for these 
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protons with a coupling constant of ~6 Hz, but under the current reaction conditions we 
generated compounds that showed a doublet of doublets with a coupling constant of ~11 
Hz. Unable to unequivocally identify the compounds by NMR techniques, we submitted 
compound 144 for crystallographic x-ray analysis, which was identified as the functionalized 
hydantoin 144. From there, we were able to suggest a structure for the remaining two 
compounds 145 and 146, and proposed a mechanism to account for the formation of each 
compound (Scheme 9).  
 
Scheme 8. Isolated products from the attempted synthesis of 142  
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Based on literature precedent,149 we expect that formation of mesylate (R,S)-141 
from (R,S)-105 allowed the subsequent DBU-mediated elimination to give dehydroalanine 
142 (Scheme 9). Deprotonation of 142 generated isocyanate 147 and benzyl alcohol (143). 
Cyclization of 147 by a 5-exo-dig ring closure process gave hydantoin 145. Subsequent 
tautomerization of 145 to 148 permitted the Michael addition of 143 (route A) or 145 (route 
B) to give 144 or 149, respectively, and 149‟s tautomer 146. 
A more in depth search of the literature revealed the same mesylation-elimination-
cyclization sequence was reported by Cernak and coworkers.149 These researchers showed 
that the desired N-protected dehydroalanine intermediate was isolated with DBU when the 
protecting group was tBoc but when the protecting group was Cbz (105), elimination was 
accompanied by cyclization to the hydantoin 145. They prevented unwanted cyclization by 
transforming mesylate 141 to the corresponding iodide followed by elimination under milder 
conditions (Et3N in acetone).  
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Scheme 9. Proposed mechanism for the formation of hydantoin products 144–146 
 
 
 We continued in our effort to develop a general synthetic method that could utilize a 
two-step, one-pot reaction that entailed Michael addition of amines to a suitable 
dehydroalanine intermediate to obtain the desired C(3)-amino intermediates. We 
successfully generated dehydroalanine 140149 via the mesylation and elimination of (R,S)-
138 using Et3N (Scheme 10). Michael addition of dimethylamine (152) or morpholine (153) 
to 140 gave (R,S)-156 and (R,S)-157, respectively, which were subsequently hydrolyzed 
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and directly used for the MAC coupling to give the corresponding amides (R,S)-158 and 
(R,S)-159, respectively. Deprotection of amides (R,S)-158 and (R,S)-159 by hydrogenolysis 
gave the corresponding PAADs (R,S)-72 and (R,S)-73, respectively. Use of ammonia (150) 
and methylamine (151) in this protocol were unsuccessful and in the case of methylamine, 
we observed a competing side reaction.  
 
Scheme 10. General pathway for the synthesis of C(3)-amino PAADs utilizing Cbz-
protected dehydroalanine methyl ester 140 
 
 
 47 
 
Therefore, we modified our approach and treated commercially available diamine 
(R,S)-160 with Boc2O under basic conditions to give (R,S)-161.
150-153 (R,S)-161 was coupled 
with benzylamine using the MAC method to give amide (R,S)-162, followed by acid 
deprotection to give PAAD (R,S)-70 (Scheme 11). 
 
Scheme 11. Synthesis of (R,S)-N-benzyl 2,3-diaminopropionamide (R,S)-70 
 
 
 Attempted Michael addition of methylamine (151) to 140 (generated from (R,S)-138) 
gave a mixture of products: the desired methyl ester (R,S)-155 as the minor product and the 
N-methyl amide (R,S)-163 as the major product (Scheme 12). We scaled up the reaction in 
an attempt to accumulate enough (R,S)-155 to continue with the remaining synthetic 
procedure, but the percentage of (R,S)-163 generated increased as we scaled up. However, 
we viewed the competing side reaction as a possible opportunity to evaluate the importance 
of the N-benzylamide unit to the PAAD pharmacological activity. Therefore, hydrogenolysis 
of (R,S)-163 gave PAAD (R,S)-164, but stability and purification issues prompted us to 
convert the free amine ((R,S)-164) to the maleic salt ((R,S)-165). An attempt was made to 
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complete the proposed synthesis of PAAD (R,S)-71 using the limited amount of (R,S)-155. 
We successfully generated the double N-Cbz-protected methyl ester (R,S)-166 from (R,S)-
155 using benzyl chloroformate under basic conditions,154 followed by hydrolysis and MAC 
coupling with benzylamine to give the amide (R,S)-167. However, at this point we did not 
have enough material to continue with the deprotection. 
 
Scheme 12. Attempted synthesis of (R,S)-N-benzyl 3-N’-(methyl)aminopropionamide 
(R,S)-71 (Method A) 
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 In Scheme 13, we outline a similar Michael addition route that used tBoc as the 
amine protecting group and 1,1-dimethylethyl methyl carbamate as the nucleophile.155,156 
Accordingly, (R,S)-168 was readily synthesized from commercially available (R,S)-128 using 
Boc2O under basic conditions. Subsequent treatment of (R,S)-168 with MsCl and Et3N 
followed by 1,1-dimethylethyl methylcarbamate gave a complex mixture (TLC, 1H NMR 
analysis). The 1H NMR spectrum supported the formation of (R,S)-169, but purification and 
low yield limited the utility of this method. 
 
Scheme 13. Attempted synthesis of (R,S)-N-benzyl 3-N’-(methyl)aminopropionamide 
(R,S)-71 (Method B) 
 
 
 In a final attempt to synthesize PAAD (R,S)-71, we adapted a protocol reported by 
Ratemi and Vederas (Scheme 14).157 They reported the stereoselective and regioselective 
synthesis of several N-alkyl derivatives upon ring opening of N-Cbz-L-serine β-lactone. Like 
dehydroalanine derivatives, β-lactones can serve as a powerful intermediate for the 
functionalization of amino acids that are not easily accessible by other methods.157-160 
However, the inherent ring strain of β-lactones results in a highly reactive species that can 
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generate a mixture of two products upon the addition of a nitrogen nucleophile: (1) the 
amide arising from acyl-oxygen cleavage; and (2) the amino acid arising from alkyl-oxygen 
cleavage. Ratemi and Vederas demonstrated that alkyl regioselectivity can be achieved by 
using a weaker nucleophile (N-trimethylsilylamine)161 and a more polar solvent (ACN) to 
afford the highest acid:amide ratio.157  
 We successfully synthesized lactone (R,S)-171 from (R,S)-104,158,162 however 
several attempts to ring open (R,S)-171 with N-methyl-N-(trimethylsilyl)amine gave the 
undesired amide (acyl-oxygen cleavage) (data not shown).163,164 At this point in time, initial 
pharmacological data from the other C(3)-amino PAADs did not warrant further efforts to 
prepare PAAD (R,S)-71.  
 
 51 
 
Scheme 14. Attempted synthesis of (R,S)-N-benzyl 3-N’-(methyl)aminopropionamide 
(R,S)-71 (Method C) 
 
 
2.2.1.3. C(4)-Substituted PAADs 
To conclude the C(2)-(CH)nX(R)y series, we explored the effect of the heteroatom 
two atoms removed from the chiral C(2) center. Evaluation of (R)-, (S)-, and (R,S)-61 
indicated that the pharmacological activity resided largely in the D-amino acid configuration 
(See Section 2.3.1.1). Therefore, all C(4)-substituted PAADs were synthesized in the (R)-
configuration. Synthesis of (R)-76 was achieved without complications starting from 
commercially available D-methionine (174). (R)-174 was N-tBoc protected following 
standard procedures, coupled with benzylamine using the MAC method, and deprotected to 
give (R)-76 (Scheme 15).97,165-167  
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Scheme 15. Synthesis of (R)-N-benzyl 2-amino-4-(methylthio)butanamide ((R)-76) 
 
 
To synthesize the oxygen equivalent of (R)-76 (S → O, (R)-75), we initially planned 
to follow the synthetic route depicted in Scheme 1, using commercially available D-
homoserine ((R)-177) to obtain the C(4)-hydroxy PAAD ((R)-74) and the C(4)-methoxy 
PAAD ((R)-75). However, lactonization during N-Cbz protection of (R)-177 gave (R)-179, 
and accordingly, we modified our route to take advantage of (R)-179 (Scheme 16).168,169 
Treatment of (R)-179 under basic conditions with benzylamine gave amide (R)-180,170 
followed by hydrogenolysis to obtain the corresponding PAAD (R)-74 (Scheme 16). Several 
attempts were made to obtain (R)-75, but efforts to methylate (R)-180 were unsuccessful 
and prompted us to switch the N-protecting group. 
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Scheme 16. Synthesis of (R)-N-benzyl 2-amino-4-hydroxybutanamide ((R)-74) and 
attempted synthesis of (R)-N-benzyl 2-amino-4-methoxybutanamide ((R)-75) 
 
 
 
Accordingly, we proposed to use a N-trityl protecting group (Scheme 17). Following 
literature procedure, treatment of commercially available (R)-177 with thionyl chloride in 
MeOH, followed by subsequent treatment with trityl chloride in the presence of base, gave a 
5:1 mixture of N-trityl protected γ-lactone (major) and methyl ester (minor) ((R)-183).171,172  
The mixture was treated with benzylamine in MeOH to give amide (R)-184. We successfully 
alkylated (R)-184 on small scale using CH3I and Ag2O to give (R)-185, which was 
deprotected under acidic conditions to the corresponding PAAD ((R)-75). However, scale up 
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attempts of the methylation resulted in a mixture of (R)-185 and the dimethylated analog 
(R)-186, where amide methylation had occurred. 1D and 2D (COSY) NMR experiments 
supported the assignment of methylation at the amide nitrogen, however a degree of 
ambiguity leaves the possibility of methylation at the tritylated nitrogen. We attempted to 
purify (R)-185 from (R)-186 by flash column chromatography, but their similar 
chromatographic properties prevented their separation. In a final effort to recover the 
desired PAAD, we deprotected the mixture of (R)-185 and (R)-186 under acidic conditions, 
and then reprotected with Boc2O under basic conditions, to give (R)-188 and (R)-189. Once 
again, attempts to purify sufficient amounts of (R)-188 by flash column chromatography 
were unsuccessful. 
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Scheme 17. Attempted synthesis of (R)-N-benzyl 2-amino-4-methoxybutanamide ((R)-
75) 
 
 
 
2.2.2. C(2)-6-Membered and 5-membered aromatic and heteroaromatic PAADs 
C(2)-6-Membered and 5-membered aromatic and heteroaromatic PAADs 77–94 
were synthesized by Drs. Jason Dinsmore, Pranjal Baruah, and Christophe Salomé. (R)-, 
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(S)-, and (R,S)-62 were synthesized according to Scheme 18, and in the case of the (R)- 
and (S)-62, we were mindful of the potential for C(2) racemization during the amide coupling 
and the N-Cbz protection steps. Therefore, commercially available (R)-, (S)-, and (R,S)-190 
was treated at low temperature with benzyl chloroformate under basic conditions in two 
portions to give (R)-, (S)-, and (R,S)-191.173-175 Optical rotations of (R)- and (S)-191 were 
consistent with previously reported values,173 and (R)-, (S)-, and (R,S)-191 were converted 
to the amides (R)-, (S)-, and (R,S)-192176 using the MAC procedure. Finally, deprotection 
using 10% Pd-C and H2 gave the corresponding PAADs (R)-, (S)-, and (R,S)-62.
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Scheme 18. Synthesis of N-benzyl 2-amino-2-phenylacetamide (R)-, (S)-, and (R,S)-62 
 
 
2.2.3. C(2)-Hydrocarbon PAADs 
As previously stated, we synthesized the hydrocarbon equivalent of 61 (O→CH2, 96) 
in the (R)-, (S)-, and (R,S)- configurations to examine the requirement for a heteroatom one 
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atom removed from the C(2) center, as well as the need for stereochemical specificity at the 
C(2) position. Modest anticonvulsant activity and NP protection was observed for (R)- and 
(R,S)-96, and prompted the synthesis of an expanded series of C(2)-hydrocarbon PAADs 
(95, 97–102) (Scheme 19). Commercially available amino acids (R)-193, -195, -196, -199, 
(S)-195, -196 and (R,S)-197 were N-tBoc protected following standard procedures, coupled 
with benzylamine using the MAC method, and then deprotected to give PAADs (R)-95, -98, -
99, -102, (S)-98, -99, and (R,S)-100, respectively. (R)-97 and (R)-101 were synthesized by 
Drs. Jason Dinsmore and Christophe Salomé, respectively, in the same manner as depicted 
in Scheme 19. 
 
Scheme 19. Synthesis of C(2)-hydrocarbon PAADs 95–102 
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2.2.4. Assessment of PAAD optical purity 
We determined the enantiomeric purity of select PAADs to assess the 
pharmacological data. Accordingly, we confirmed that (R)-61, (R)-62, and (S)-62 were 
prepared without racemization. (R)-61 was selected based on the central role of lacosamide 
((R)-28) and its PAAD equivalent ((R)-61) in this study. (R)- and (S)-62 were selected based 
on their presumed higher tendency to racemize during synthesis due to the acidity of the α-
proton. Unfortunately, comparing the optical rotation or melting point of enantiomeric PAADs 
is not sufficient due to the possibility of equal racemization. The selected PAADs also have 
poor solubility in CDCl3, making it impossible to verify enantiomeric purity by the addition of 
the chiral resolving agent mandelic acid.177 Therefore, each isomer was coupled with (R)-2-
phenylpropionic acid (214) using the MAC procedure to give (R)-215, (R)-216, and (S)-216. 
Each derivative contained two stereocenters that were analyzed for racemization by 1H 
NMR prior to extensive purification and shown to be enantiomerically pure (>95%).  
 
Scheme 20. Synthesis of (R)-N-benzyl 2-N’-((R)-2-phenylpropionyl)amino-3-
methoxypropionamide ((R,R)-215), (R)-N-benzyl 2-N’-((R)-2-phenylpropionyl)amino-2-
phenylacetamide ((R,R)-216), and (S)-N-benzyl 2-N’-((R)-2-phenylpropionyl)amino-2-
phenylacetamide ((R,S)-216) 
 
 
 
2.3. Pharmacological evaluation 
PAADs 61, 62, and 65–94 were evaluated for anticonvulsant activity using the MES 
test at either UCB Pharma, following the procedures described by Klitgaard,178 or at the 
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NINDS ASP, following the procedures described by Stables and Kupferberg,42 or both. 
Anticonvulsant activity using the 6 Hz test was performed either at UCB Pharma following 
the procedures described by Kaminski and coworkers (44 mA),179 or at the NINDS ASP, 
following the procedures described by Stables and Kupferberg (32 mA),42 or both. PAADs 
evaluated at UCB Pharma were also tested for NP protection (formalin test).180 Recently, 
Visser and coworkers demonstrated a good correlation between findings in the second 
phase of the formalin test and results for cold allodynia in the chronic constriction injury 
(CCI) model for both rats (r = 0.72) and gerbils (r = 0.68) using drugs with proven pain 
attenuating effects in humans.181 Therefore, the formalin model of NP is advantageous 
compared to other well-characterized models of NP (CCI) due to the ease of administration 
and standardization, and is an effective tool to prescreen compounds for NP protection. All 
compounds were administered intraperitoneally (ip) to mice at UCB Pharma or ip to mice 
and orally (po) to rats at the NINDS ASP. The pharmacological data from the MES, 6 Hz, 
and formalin tests are summarized in Tables 5, 7, 9–11, 13, and 14. The MES activities of 
PAADs are compared with the MES activities of their corresponding FAAs in Tables 6, 8, 12, 
15, and 16. The pharmacological data from PAADs synthesized as individual isomers ((R), 
(S), and (R,S)) are summarized in Table 17. Several compounds were evaluated at both 
UCB Pharma and the NINDS ASP and displayed comparable activities. Therefore, we 
conclude the initial PAAD SAR by comparing the MES activities of PAADs that were 
obtained at UCB Pharma and the NINDS ASP (Table 18). The tables list the results 
obtained from qualitative (dose range) or quantitative (ED50) testing in mice (ip) and rats 
(po). We also include qualitative (dose range) or median neurological impairing dose (TD50) 
values in mice (ip) using the rotorod test in mice, and the behavioral toxicity effects 
observed in rats (po). The protective indices (PI = TD50/ED50) are provided, when applicable. 
PAADs tested at the NINDS ASP were evaluated in the subcutaneous Metrazol® (scMET) 
seizure model but protection was not observed at the doses (30, 100, 300 mg/kg) and times 
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(0.5 and 4 h) tested (data not shown), with two exceptions. (R)-98 displayed protection in 
the scMET seizure model for one out of eight mice treated with 62 mg/kg of compound and 
the remaining seven mice displayed continuous seizure activity. Similarly, (R)-99 protected 
one out of eight mice treat with 63 mg/kg and the remaining seven mice displayed 
continuous seizure activity, while three out of eight mice treated with 75 mg/kg were 
protected and the remaining five mice displayed continuous seizure activity.  
Early evaluation of (R)-61, (R)-65, and (R,S)-77 surprisingly revealed good brain-to-
plasma (B:P) ratios in mice (Table 4). (R)-61 and (R)-65 were detected in a B:P ratio of 1.2:1 
and (R,S)-77 was detected in a B:P ratio of 2.7:1. We had hypothesized (Chapter 1, Figure 
12) that protonation of the amino group in PAADs at physiological pH, to give the 
corresponding ammonium ion, would hinder penetration of the predominately negatively 
charged phospholipid head groups of the BBB. Good penetration of the BBB indicated that 
these hydrophilic PAADs do not selectively target the PNS, but rather possibly exert their 
mechanism of action through a combination of interactions within the CNS and PNS.  
 
Table 4. Plasma and brain levels of PAADs in mice 
 
Cmpd No.
a 
 R  
Plasma 
level (µM)
b
 
 
Brain 
level (µM)
b
 
 
Brain:Plasma 
Ratio 
(R)-65  CH2OH  5.5  6.6  1.2:1 
(R)-61  CH2OCH3  8.2  10  1.2:1 
(R,S)-77  2-pyridyl  12  32  2.7:1 
a 
The compounds were administered intraperitoneally (10 mg/kg) to adult male NMRI 
mice (n = 3) under the auspices of UCB. 
b
 Plasma and brain levels are in µM and were 
determined 30 min after ip administration.   
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2.3.1. C(2)-(CH2)nX(R)y PAADs 
2.3.1.1. C(3)-Hydroxy and C(3)-alkoxy PAADs 
Table 5 lists the neurological activities for C(3)-oxy N-benzylamide PAADs (R)- and 
(S)-61, (R)-, (S)-, and (R,S)-65 and (R,S)-66–69 in mice, where we systematically evaluated 
the effect of a hydrogen, methyl, ethyl, propyl, allyl, and propargyl group placed at the C(3)-
oxy terminus (R) on anticonvulsant activity and pain attenuation. Throughout this study, we 
used ((R)-28) and the clinical AEDs, phenytoin, phenobarbital, and valproate, as reference 
compounds. The MES values for (R)-, (S)-, and (R,S)-65 were not determined due to (1) the 
MES test was implemented after the initial testing; (2) the absence of activity in the 6 Hz and 
formalin tests; and (3) the FAA counterpart ((R)-217) was inactive in the MES test (Table 6). 
The MES activities of PAADs (R)-, (S)-, and (R,S)-61, and (R,S)-66–69 remained relatively 
constant throughout the series, but we observed a slight increase in activity as we went from 
a saturated alkyl group ((R,S)-67, ED50 = 69 mg/kg) to unsaturated hydrocarbon groups 
(ED50 (mg/kg): (R,S)-68; 45; (R,S)-69, 46). (R)-61 displayed the highest anticonvulsant 
activity in this series (ED50 = 34 mg/kg) but it was a ~10-fold drop in activity from the 
corresponding FAA (R)-28 (ED50 = 3.3 mg/kg). PAAD 61 also showed a ~2-fold preference 
in regard to MES activity for the (R)-isomer. This selectivity was considerably lower than that 
exerted for (R)-28, where there was ~22-fold difference in activity between the (R)- and (S)-
isomers in mice. In all instances, the MES activity was greater than the 6 Hz activity (44 mA 
and 32 mA) and no significant pain attenuation was observed. Comparison of the MES 
activities of PAADs 61, 65, 66, 68, and 69 with their corresponding FAAs (Table 6) revealed 
a consistent drop in activity (3–10-fold) as we went from the FAA to the PAAD. Therefore, 
we conclude that the C(3)-hydroxy and C(3)-alkoxy PAADs do not provide any significant 
advantage for the prevention of seizures or NP.  
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Table 5. Pharmacological activities of C(3)-oxy N-benzylamide PAADs in mice (mg/kg) at UCB and the NINDS ASP 
 
      Mice (ip)
a 
Cmpd No.  
Test 
Site 
 R  
MES,
b
 
ED50 
 
6 Hz,
c
 
ED50 
 
Formalin, 
ED50 
 
Tox,
d
 
TD50
  
Com-
ments
e
 
 
PI,
f
 
MES 
 
PI,
f
 
Form 
(R)-28  UCB  LCM  3.3  10  15  19  Ref  5.8  1.3 
(R)-28
g
  NINDS  LCM  
4.5 [0.5] 
(3.7–5.5) 
 10  ND
h
  
27 [0.25] 
(26–28) 
 Ref  6.0   
(R)-65  UCB  H  ND
h
  >62  >62  >110  
 
    
(S)-65  UCB  H  ND
h
  >62  >62  >110  
 
    
(R,S)-65  UCB  H  ND
h
  >62  >62  >110  
 
   >1.8 
(R)-61  UCB  CH3  34  >67  >67  >120  
 
 >3.5  >1.8 
(R)-61  NINDS  CH3  
48 [0.25] 
(40–61) 
 ND
h
  ND
h
  
>30, <100 
[0.25] 
 
 
    
(S)-61  UCB  CH3  64  >70  120  63  
 
 1.0  0.5 
(R,S)-66  UCB  CH2CH3  73  120  71
i 
(19%)  ND
h
  
 
    
(R,S)-67  UCB  CH2CH2CH3  69  >130  >130  ND
h
  230 (C)     
  
 
6
3 
(R,S)-68  UCB  CH2CH=CH2  45  
130 
(MAD)
j
 
 75
i 
(12%)  ND
h
  
 
    
(R,S)-69  UCB  CH2C≡CH  46  
130 
(MAD)
j
 
 74
i 
(27%)  47  
 
 1.0   
phenytoin
k
      
9.5 [2.0] 
(8.1–10) 
     
66 [0.5] 
(53–72) 
 Ref     
phenobarbital
k
      
22 [1.0] 
(15–23) 
     
69 [0.5] 
(63–73) 
 Ref     
valproate
k
      
270 [0.25] 
(250–340) 
     
430 [0.25] 
(370–450) 
 Ref     
a 
The compounds were administered either intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to adult male 
albino CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 30 min after ip administration (UCB) or a 
dose-response curve was generated for all compounds that displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time 
of peak effect” (indicated in hours in the brackets) (NINDS ASP). Numbers in parentheses are 95% confidence intervals. 
b 
MES = maximal electroshock seizure 
test. 
c 
6 Hz test = psychomotor seizure model (44 mA, UCB; 32 mA, NINDS ASP). 
d
 Tox = neurological toxicity. TD50 value determined from the rotorod test. 
e
 
Dose in mg/kg is followed by whole animal pharmacological observation (Ref = reference, C = convulsions). 
f 
PI = protective index (TD50/ED50). 
g
 Choi, D. et al. 
J. Med. Chem. 1996, 39, 1907–1916. 
h 
ND = not determined. 
i
 Single dose experiments where the mg/kg used is followed by the percentage protected in 
parenthesis.
 j 
MAD = minimal active dose. 
k
 Porter, R.J. et al. Cleveland Clin. Q. 1984, 51, 293–305. 
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Table 6. Comparison of the pharmacological activities of C(3)-oxy N-benzylamide FAAs and their PAAD counterparts in 
mice (mg/kg) 
                           
      Mice (ip)
a
      Mice (ip)
a
 
R  
FAA 
Cpd No. 
 
FAA 
Test Site 
 
FAA 
MES,
b
 ED50 
 
FAA 
Tox,
c
 TD50 
 
PAAD 
Cpd No. 
 
PAAD 
Test Site 
 
PAAD 
MES,
b
 ED50 
 
PAAD 
Tox,
c
 TD50
 
H  (R)-217
d
  NINDS  
53 [2.0] 
(38–67) 
 >500 [2.0]  (R)-65  UCB  >62  >110 
H  (R,S)-217
d
  NINDS  >100, <300  <300  (R,S)-65  UCB  >62  >110 
CH3  (R)-28
d
  NINDS  
4.5 [0.5] 
(3.7–5.5) 
 
27 [0.25] 
(26–28) 
 (R)-61  NINDS  
48 [0.25] 
(40–61) 
 
>30, <100 
[0.25] 
CH3  (S)-28
d
  NINDS  >100, <300  > 300  (S)-61  UCB  64  63 
CH3  (R,S)-28
d
  NINDS  
8.3 [0.5] 
(7.9–9.8) 
 
43 [0.25] 
(38–47) 
 (R,S)-61
e
  NINDS  
84 [0.25] 
(65–97) 
 
290 [0.25] 
(240–320) 
CH2CH3  (R,S)-218
d
  NINDS  
17 [0.25] 
(15–19) 
 
78 [0.25] 
(64–90) 
 (R,S)-66  UCB  73  ND
g
 
CH2CH=CH2  (R,S)-219
d
  NINDS  >30, <100  >30, <100  (R,S)-68  UCB  45  ND
g
 
CH2C≡CH  (R,S)-220
f
  NINDS  
16 [0.25] 
(13–19) 
 
59 [0.25] 
(55–66) 
 (R,S)-69  UCB  46  47 
a 
The compounds were administered either intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to adult 
male albino CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 30 min after ip administration (UCB) 
or a dose-response curve was generated for all compounds that displayed sufficient activity and the dose-effect data for these compounds was obtained at 
the “time of peak effect” (indicated in hours in the brackets) (NINDS ASP). Numbers in parentheses are 95% confidence intervals. 
b 
MES = maximal 
electroshock seizure test. 
c 
Tox = neurological toxicity. TD50 value determined from the rotorod test. 
 d 
Choi, D. et al. J. Med. Chem. 1996, 39, 1907–1916. 
e
 
Béguin, C. et al. Bioorg. Med Chem. 2004, 12, 3079–3096. 
f
 Park, K. et al. J. Med. Chem. 2009, 52, 6897–6911. 
g
 ND = not determined. 
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2.3.1.2. C(3)-Amino PAADs 
Table 7 lists the neurological activities for C(3)-amino N-benzylamide PAADs (R,S)-
70, -72, and -73. In this series, we substituted the C(3)-amino with two methyl groups or 
embedded the C(3)-amino within a morpholino moiety. We proposed that the increased 
polarity and the possibility of C(3)-amino protonation could lead to an increase in PNS 
versus CNS biodistribution (Chapter 1, Figure 12). However, no significant neurological 
activity was observed in either the anticonvulsant models or the pain model, and toxicity was 
not evaluated due to the lack of activity. Comparison of the C(3)-amino PAADs with their 
corresponding FAAs (Table 8) showed that there is neither an advantage nor disadvantage 
of the C(3)-amino group on anticonvulsant activity. 
 
Table 7. Pharmacological activities of C(3)-amino N-benzylamide PAADs in mice 
(mg/kg) at UCB 
 
 
      Mice (ip)
a
 
Cmpd No.  R  
MES,
b
 
ED50 
 
6 Hz,
c
 
ED50 
 
Formalin, 
ED50 
 
Tox,
d
 
TD50
  
PI,
e
 
MES 
 
PI,
e 
Form 
(R)-28  LCM  3.3  10  15  19  5.8  1.3 
(R,S)-70  NH2  >68  ND
f
  ND
f
  ND
f
     
(R,S)-72  N(CH3)2  94  >110  83 (14%)
g
  ND
f
     
(R,S)-73  morpholino  89  >84  69  ND
f
     
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB. 
ED50 and TD50 values are in mg/kg and were determined 30 min after ip administration. 
b 
MES = maximal 
electroshock seizure test. 
c 
6 Hz test = psychomotor seizure model (44 mA). 
d 
Tox = neurological toxicity. TD50 
value determined from the rotorod test. 
e 
PI = protective index (TD50/ED50).
 f
 ND = not determined. 
g 
Single 
dose experiments where the mg/kg used is followed by the percentage protected in parenthesis.  
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Table 8. Comparison of the pharmacological activities of C(3)-amino N-benzylamide FAAs and their PAAD counterparts in 
mice (mg/kg) 
 
                     
      Mice (ip)
a
      Mice (ip)
a
 
R  
FAA 
Cpd No. 
 
FAA 
Test Site 
 
FAA 
MES,
b
 ED50 
 
FAA 
Tox,
c
 TD50 
 
PAAD 
Cpd No. 
 
PAAD 
Test Site 
 
PAAD 
MES,
b
 ED50 
 
PAAD 
Tox,
c
 TD50
 
NH2  (R,S)-221
d
  NINDS  >100  >100  (R,S)-70  UCB  >68  ND
e
 
N(CH3)2  (R,S)-222
d
  NINDS  >30, <100  >100, <300  (R,S)-72  UCB  94  ND
e
 
morpholino  (R,S)-223
d
  NINDS  >100, <300  300  (R,S)-73  UCB  89  ND
e
 
a 
The compounds were administered either intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to 
adult male albino CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 30 min after ip 
administration. 
b 
MES = maximal electroshock seizure test. 
c 
Tox = neurological toxicity. TD50 value determined from the rotorod test. 
d
 Choi, D. et al. 
unpublished results. 
e
 ND = not determined. 
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2.3.1.3. C(4)-Substituted PAADs 
Next, we examined the C(4)-substituted N-benzylamide PAADs (R)-74 and (R)-76 
(Table 9). PAADs containing an oxygen ((R)-74) or a sulfur ((R)-76) two atoms from the C(2) 
carbon were inactive in the MES test (ED50 (mg/kg): (R)-74, >160; (R)-76, 75). However, 
substitution of a carbon atom for the heteroatom that is two atoms removed from the C(2) 
carbon, giving (R)-96 and (R)-97, provided PAADs with considerable anticonvulsant activity 
(ED50 (mg/kg): (R)-96, 21; (R)-97, 23). The activities of (R)-96 and (R)-97 will be discussed 
in detail in Table 13 and are presented in Table 9 for comparative purposes. (R)-74 and (R)-
76 were also inactive in the 6 Hz and formalin tests (ED50 >60 mg/kg), therefore the 
inactivity did not justify toxicity studies. It is difficult to make generalizations based on the 
limited set of compounds but in conjunction with the data given in Table 5 and Table 7, we 
conclude that C(2)-acyclic PAADs containing a heteroatom two atoms removed from the 
C(2)-center did not show appreciable seizure protection, and provide a distinctive departure 
of the PAAD SAR from the corresponding FAAs. 
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Table 9. Pharmacological activities of C(4)-substituted N-benzylamide PAADs in mice 
(mg/kg) at UCB 
 
 
    Mice (ip)
a
 
Cmpd 
No. 
 R  
MES,
b
 
ED50 
 
6 Hz,
c
 
ED50 
 
Formalin, 
ED50 
 
Tox,
d
 
TD50
  
PI,
e
 
MES 
 
PI,
e 
Form 
(R)-28  LCM  3.3  10  15  19  5.8  1.3 
(R)-74  OH  >160  >120  >67  ND
g
     
(R)-76  SCH3  75  
130 
(MAD)
f
 
 >76  ND
g
     
(R)-96  CH3  21  
66 
(MAD)
f  35  57  2.8  1.6 
(R)-97  CH2CH3  23  93  >71  ND
g
     
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspice of UCB. ED50 
and TD50 values are in mg/kg and were determined 30 min after ip administration. 
b 
MES = maximal electroshock 
seizure test. 
c 
6 Hz test = psychomotor seizure model (44 mA). 
d 
Tox = neurological toxicity. TD50 value 
determined from the rotorod test. 
e 
PI = protective index (TD50/ED50). 
f 
MAD = minimal active dose. 
g
 ND = not 
determined. 
 
2.3.2. 6-Membered and 5-membered aromatic and heteroaromatic PAADs 
The neurological activities for C(2)-6-membered aromatic and heteroaromatic N-
benzylamide PAADs (R,S)-62 and (R,S)-77–88 in mice are listed in Table 10. Using (R,S)-
62 as a non-heteroatom-containing aromatic reference, we evaluated the effect of 
positioning either a 6-membered aromatic group [i.e., 2-, 3-, and 4-pyridyl ((R,S)-77–79), 2-
pyrazinyl ((R,S)-80), 4-fluorophenyl ((R,S)-86), 4-methylphenyl ((R,S)-87), 4-methoxyphenyl 
((R,S)-88)], or a benzoannulated 6-membered aromatic group [i.e., 1- and 2-naphthyl ((R,S)-
81 and -83), 1-isoquinolinyl ((R,S)-82), 2-quinolinyl ((R,S)-84), 2-quinoxalinyl ((R,S)-85)] at 
the C(2)-site on anticonvulsant activity and pain attenuation. The aromatic and 
heteroaromatic compounds showed a general lack of protection in the MES (>30 mg/kg) and 
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6 Hz (>30 mg/kg) tests in mice. Interestingly, we observed moderate activity in the formalin 
test for the 6-membered heteroaromatic PAADs (R,S)-77–79, -82, -84, and -85 (ED50 
(mg/kg): (R,S)-77, 33; (R,S)-78, 74; (R,S)-79, 67; (R,S)-82, 29; (R,S)-84, 54; (R,S)-85, 42) 
indicating that these compounds were more effective in the pain model compared with the 
seizure models. This finding differed from the PAADs containing a C(2)-acyclic moiety (i.e. -
CH2OR, -CH2NR, -CH2CH2R) where we consistently observed lower activity in the formalin 
test compared with the MES seizure model. There was lack of toxicity data gathered due to 
the inactivity in the MES and 6 Hz tests. In the pyridyl series, (R,S)-77 showed the greatest 
protection in the formalin test and protection was slightly improved upon benzoannulation 
(ED50 (mg/kg): (R,S)-77, 33; (R,S)-82, 29), while little or no protection was observed for the 
same compounds in the MES and 6 Hz tests (MES ED50 (mg/kg): (R,S)-77, 100 (MAD); 
(R,S)-82, >52); (6 Hz ED50 (mg/kg): (R,S)-77, >100; (R,S)-82, >93). The formalin activity of 
(R,S)-82 (ED50 = 29 mg/kg) is within 2-fold of the formalin activity of our benchmark (R)-28 
(ED50 = 15 mg/kg). Benzoannulation of (R,S)-80 to give (R,S)-85 also resulted in an 
increase in activity in the formalin test (ED50 (mg/kg): (R)-80, >160 mg/kg; (R)-85, 42 mg/kg). 
This result differed from patterns observed for the anticonvulsant activities of FAAs, where 
benzoannulation led to a sharp loss in seizure protection (see Table 12).54 Therefore, the 6-
membered heteroaromatic substituents and their benzoannulated analogs, where the 
heteroatom is one atom removed from the C(2)-center, represent the first examples of 
appreciable neuropathic pain protection in PAADs. Furthermore, these heteroaromatic 
PAADs ((R,S)-77, (R,S)-79, and (R,S)-85) are ~3-fold more selective for pain attenuating 
effects over anticonvulsant activity.  
We expanded the heteroaromatic PAADs to include C(2)-5-membered 
heteroaromatic N-benzylamide PAADs and select benzoannulated analogs (Table 11). We 
evaluated the effect of oxygen-containing (2-furanyl, (R,S)-89; 5-methyl-2-furanyl, (R,S)-90) 
and sulfur-containing (thiophen-2-yl, (R,S)-92; 2-thiazolyl, (R,S)-93) 5-membered 
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heteroaromatic PAADs and also tested the benzo-ring fused systems (2-benzofuranyl, 
(R,S)-91); benzo[b]thiophen-2-yl, (R,S)-94) on anticonvulsant and pain activity in mice. In 
contrast with the 6-membered heteroaromatic PAADs, the 5-membered heteroaromatic 
PAADs ((R,S)-89–(R,S)-94) displayed modest anticonvulsant activity (ED50 >67, <120 
mg/kg) in the MES test, but were insensitive in the 6 Hz test (ED50 >90 mg/kg). (R,S)-93 was 
the most active in this series (ED50 = 67 mg/kg) regarding the MES test, but (R,S)-93 is still 
~20-fold less active than our benchmark (R)-28 (ED50 = 3.3 mg/kg). (R,S)-89 displayed 
considerable activity in the formalin test (ED50 = 29 mg/kg) and is within 2-fold of the 
formalin activity of (R)-28 (ED50 = 15 mg/kg). Unlike the 6-membered heteroaromatic series, 
benzoannulation of both (R,S)-89 and (R,S)-92 to give (R,S)-91 and (R,S)-94, respectively, 
decreased pain attenuation ((ED50 (mg/kg): (R,S)-89, 29; (R,S)-91, 90 (31% reduction); 
(R,S)-92, 48; (R,S)-94, 66). Collectively, heteroaromatic systems containing a heteroatom 
one atom removed from the C(2) center in PAADs attenuate pain in the formalin test and are 
1.5 to 3-fold selective for neuropathic pain protection over anticonvulsant activity. 
Comparison of the MES activities of active heteroaromatic PAADs (R)-, (S)-, and 
(R,S)-62, (R,S)-77, (R,S)-80, (R,S)-83, and (R,S)-88–94 with their corresponding FAAs 
(Table 12) revealed a drop in activity up to 10-fold going from FAA to PAAD. Therefore, the 
C(2)-6-membered and 5-membered aromatic and heteroaromatic PAADs do not provide any 
significant advantage for the prevention of seizures. It would be informative to conduct a 
similar comparison of the formalin activity in PAADs and their corresponding FAAs but 
extensive formalin data is not available in the FAA series. 
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Table 10. Pharmacological activities of C(2)-6-membered aromatic and heteroaromatic N-benzylamide PAADs in mice 
(mg/kg) at UCB 
 
 
    Mice (ip)
a 
Cmpd No.  R  
MES,
b
 
ED50 
 
6 Hz,
c
 
ED50 
 
Formalin, 
ED50 
 
Tox,
d
 
TD50
  Comments
e
  
PI,
f
 
MES 
 PI,
f
 Form 
(R)-28  LCM  3.3  10  15  19  Ref  5.8  1.3 
(R,S)-62  
 
 >30  >43  24
g 
(37%)  51  
77 (C),  
140 (MT)
  >1.7  >1.2 
(R,S)-77  
 
 
100 
(MAD)
h
 
 >100  33  
180 
(MTD)
i
 
      
(R,S)-78  
 
 
120 
(MAD)
h
 
 >210  74  ND
j
       
(R,S)-79  
 
 
210 
(MAD)
h
 
 >120  67  ND
j
       
(R,S)-80  
 
 85  
28 
(MAD)
h
 
 >160  >160    >1.9  >1.0 
(R,S)-81  
 
 >69  >59  >33  ND
j
  105 (C, MT)     
(R,S)-82  
 
 >52  >93  29  ND
j
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(R,S)-83  
 
 45  >110  
<110 
(inactive) 
110
g 
(100%) 
 
110 
(MTD)
i
 
 
59 (T, W) 
110 (C, M) 
 <2.4   
(R,S)-84  
 
 >41  >130  54  ND
j
  130 (W, C)     
(R,S)-85  
 
 >120  >120  42  ND
j
       
(R,S)-86  
 
 >83  >83  26 (MAD)
h
  ND
j
  83 (C)     
(R,S)-87  
 
 
140 
(MAD)
h
 
 >140  
<25 
(inactive) 
 ND
j
  81 (C)    
 
(R,S)-88  
 
 
150 
(MAD)
h
 
 >86  
<27 
(inactive) 
86
g
 (48%) 
 ND
j
  270 (C, MT)    
 
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspice of UCB. ED50 and TD50 values are in mg/kg and were 
determined 30 min after ip administration. 
b 
MES = maximal electroshock seizure test. 
c 
6 Hz test = psychomotor seizure model (44 mA). 
d 
Tox = neurological 
toxicity. TD50 value determined from the rotorod test. 
e
 Dose in mg/kg is followed by whole animal pharmacological observation (Ref = reference, T =
 
tremors, C 
= convulsions, MT = mortality, W = writhing). 
f 
PI = protective index (TD50/ED50). 
g 
Single dose experiments where the mg/kg used is followed by the percentage 
protected in parenthesis.
 h 
MAD = minimal active dose. 
i
 MTD = maximal tolerated dose. 
j
 ND = not determined. 
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Table 11. Pharmacological activities of C(2)-5-membered heteroaromatic N-benzylamide PAADs in mice (mg/kg) at UCB 
 
 
    Mice (ip)
a 
Cmpd No.  R  
MES,
b
 
ED50 
 
6 Hz,
c
 
ED50 
 
Formalin, 
ED50 
 
Tox,
d
 
TD50
  Comments
e
  
PI,
f
 
MES 
 PI,
f
 Form 
(R)-28  LCM  3.3  10  15  19  Ref  5.8  1.3 
(R,S)-89  
 
 85  >150  29  >150  
 
 >1.8  >5.1 
(R,S)-90  
 
 
100 (MAD)
g 
140
h
 (100%) 
 >140  >78  ND
i
  100 (IG, T)     
(R,S)-91  
 
 90  >120  90
h 
(31%)  ND
i
  90 (T)     
(R,S)-92  
 
 68 (MAD)
g
  >91  48  
51 
(MTD)
j
 
 160 (C)  <0.8  <1.1 
(R,S)-93  
 
 67  >140  45  
140 
(MTD)
j
 
   <2.1  <3.1 
(R,S)-94  
 
 120  >170  66  ND
i
       
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB. ED50 and TD50 values are in mg/kg and were 
determined 30 min after ip administration. 
b 
MES = maximal electroshock seizure test. 
c 
6 Hz test = psychomotor seizure model (44 mA). 
d 
Tox = 
neurological toxicity. TD50 value determined from the rotorod test. 
e
 Dose in mg/kg is followed by whole animal pharmacological observation (Ref = 
reference, T =
 
tremors, C = convulsions, IG = impaired gait). 
f 
PI = protective index (TD50/ED50). 
g 
MAD = minimal active dose. 
h
 Single dose experiments 
where the mg/kg used is followed by the percentage protected in parenthesis. 
i
 ND = not determined. 
j 
MTD = maximal tolerated dose. 
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Table 12. Comparison of the pharmacological activities of C(2)-6-membered and 5-membered aromatic and 
heteroaromatic FAAs and their PAAD counterparts in mice (mg/kg) 
 
                   
      Mice (ip)
a
      Mice (ip)
a
 
R  
FAA 
Cpd No. 
 
FAA 
Test Site 
 
FAA 
MES,
b
 ED50 
 
FAA 
Tox,
c
 TD50 
 
PAAD 
Cpd No. 
 
PAAD 
Test Site 
 
PAAD 
MES,
b
 ED50 
 
PAAD 
Tox,
c
 TD50
 
 
 (R)-224
d
  Lilly  
26 [0.5] 
(21–32) 
 >80  (R)-62  UCB  43 (MAD)
e
  ND
f
 
 
 (S)-224
d
  Lilly  >300  >100, <300  (S)-62  UCB  ND
f
  140 (MTD)
g
 
 
 (R,S)-224
d
  Lilly  
32 [0.5] 
(28–40) 
 >40  (R,S)-62  UCB  >30  51 
 
 (R,S)-225
h
  NINDS  
11 [0.5] 
(9–12) 
 >25, <100  (R,S)-77
i
  UCB  100 (MAD)
e
  180 (MTD)
g
 
 
 (R,S)-226
h
  NINDS  
15 [0.5] 
(13–17) 
 
58 [0.5] 
(46–73) 
 (R,S)-80
i
  UCB  85  >160
 
 
 (R,S)-227
j
  NINDS  >300  >300  (R,S)-83
i
  UCB  45  110 (MTD)
g
 
 
 (R,S)-228
j
  NINDS  >300  ND  (R,S)-88
i
  UCB  150 (MAD)
e
  ND
f
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 (R,S)-34
j
  NINDS  
10 [0.5] 
(9–12) 
 ~ 40 [0.5]  (R,S)-89
k
  UCB  85  >150 
 
 (R,S)-229
j
  NINDS  
19 [0.5] 
(16–24) 
 75 [0.5]  (R,S)-90
k
  UCB  100 (MAD)
e
  ND
f
 
 
 (R,S)-230
j
  NINDS  >100, <300  >100, <300  (R,S)-91
k
  UCB  90  ND
f
 
 
 (R,S)-231
l
  NINDS  
45 [0.5] 
(39–51) 
 >30, <100  (R,S)-92
k
  UCB  68 (MAD)
e
  51 (MTD)
g
 
 
 (R,S)-232
h
  NINDS  
12 [0.5] 
(10–15) 
 
69 [0.5] 
(62–79) 
 (R,S)-93
k
  UCB  67  140 (MTD)
g
 
 
 (R,S)-233
j
  NINDS  >100, <300  >100, <300  (R,S)-94
k
  UCB  120  ND
f
 
a 
The compounds were administered either intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to 
adult male albino CF-1 mice under the auspices of the NINDS ASP or Lilly Research Laboratories. ED50 and TD50 values are in mg/kg and were 
determined 30 min after ip administration (UCB) or a dose-response curve was generated for all compounds that displayed sufficient activity and the 
dose-effect data for these compounds was obtained at the “time of peak effect” (indicated in hours in the brackets) (NINDS ASP and Lilly Research 
Laboratories). Numbers in parentheses are 95% confidence intervals. 
b 
MES = maximal electroshock seizure test. 
c 
Tox = neurological toxicity. TD50 
value determined from the rotorod test (UCB and NINDS) or the horizontal screen test (Lilly Research Laboratories). 
d
 Kohn, H. et al. Brain Res. 1988, 
457, 371–375. 
e
 MAD = minimal active dose. 
f
 ND = not determined. 
g
 MTD = maximal tolerated dose. 
h
 Bardel, P. et al. J. Med. Chem. 1994, 37, 4567–
4571. 
i
 Baruah, P. et al. unpublished results. 
j
 Kohn, H. et al. J. Med. Chem. 1990, 33, 919–926. 
k
 Dinsmore, J. et al. unpublished results. 
l
 Kohn, H. et 
al. J. Med. Chem. 1993, 36, 3350–3360. 
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2.3.3. C(2)-Hydrocarbon PAADs 
Table 13 lists the neurological activities in mice for C(2)-hydrocarbon N-benzylamide 
PAADs (R)-, (S)-, and (R,S)-60, (R)-95, (R)-, (S)-, and (R,S)-96, (R)-97, (R)- and (S)-98, (R)- 
and (S)-99, (R,S)-100, (R)-101, and (R)-102. Initially, we synthesized (R)-96 to serve as the 
hydrocarbon counterpart to (R)-61 (Table 5) and (R)-97 to serve as the hydrocarbon 
counterpart for (R)-74 and (R)-76 (Table 9). To our surprise, both hydrocarbon references 
((R)-96 and (R)-97) resulted in an increase in MES activity. However, the increase in MES 
activity was correlated with an increase in neurotoxicity. C(3)-Substitution of oxygen ((R)-61) 
with a methylene group ((R)-96) increased the anticonvulsant activity 1.6-fold (ED50 (mg/kg): 
(R)-61, 34; (R)-96, 21). C(4)-Substitution of oxygen ((R)-74) and sulfur ((R)-76) with a 
methylene group ((R)-97) increased the anticonvulsant activity 3–7-fold (ED50 (mg/kg): (R)-
74, >160; (R)-76, 75 mg/kg; (R)-97, 23). (R)-96 and (R)-97 also displayed significant activity 
in the formalin test (ED50 (mg/kg): (R)-96, 35; (R)-97, 20). The considerable anticonvulsant 
activity and pain attenuation of the propyl and n-butyl PAADs prompted the pharmacological 
evaluation of the corresponding C(2)-methyl, -ethyl, -isopropyl, -tert-butyl, -2-methylpropyl, -
cyclohexyl, and -benzyl PAADs. For PAADs 60 and 96, we determined the anticonvulsant 
activity and NP protection for the (R)-, (S)-, and (R,S)-stereoisomers, and for 98 and 99, the 
individual (R)- and (S)-enantiomers. During the C(2)-hydrocarbon investigation, we 
transitioned from pharmacological evaluation at UCB Pharma to pharmacological evaluation 
at the NINDS ASP. Several C(2)-hydrocarbons were evaluated at both facilities and the 
testing site is indicated in column two of Table 13. All of the PAADs evaluated at both UCB 
Pharma and the NINDS ASP are later presented in Table 18. 
The C(2)-hydrocarbon PAADs displayed significant anticonvulsant activity in the 
MES test, and to a lesser degree in the 6 Hz test. MES activity slightly decreased as the 
length of the alkyl chain increased (ED50 (mg/kg): ethyl ((R)-95, 16) > propyl ((R)-96, 21) > n-
butyl ((R)-97, 23)) but the MES activity slightly improved with an increase in branching (ED50 
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(mg/kg): ethyl ((R)-95, 16) < isopropyl ((R)-98, 15) < tert-butyl ((R)-99, 13)). However, the 
anticonvulsant activity of (R,S)-100 (ED50 = 46 mg/kg (100% reduction)) was lower than its 
unbranched constitutional isomer (R)-97 (ED50 = 23 mg/kg). Substitution of the terminal 
methyl group of (R)-95 (ED50 = 16 mg/kg) with a phenyl group ((R)-102, ED50 = 40 mg/kg) 
resulted in a 2.5-fold decrease in MES activity. The same trends were observed for 
anticonvulsant activity in the 6 Hz test, although 3–5-fold less sensitive. (R)-95, (R)-96, and 
(R)-98 displayed excellent activity in the formalin test (ED50 (mg/kg): (R)-95, 22; (R)-96, 35; 
(R)-98, 20) and approached the formalin activity of (R)-28 (ED50 = 15 mg/kg). We did not 
observe a correlation of C(2)-alkyl length and activity regarding formalin activity, as seen in 
the MES test. There was an initial 3-fold increase in activity from methyl to ethyl (ED50 
(mg/kg): (R)-60, 69; (R)-95, 22) but then a steady decrease in activity was observed as the 
C(2)-alkyl length increased (ED50 (mg/kg): ethyl ((R)-95, 22) > propyl ((R)-96, 35) > n-butyl 
((R)-97, >71). We observed an increase in activity in the formalin test upon branching. A 
three carbon C(2)-substituent displayed greater activity when in the isopropyl configuration 
((R)-98, ED50 = 20 mg/kg) compared with the n-propyl configuration ((R)-96, ED50 = 35 
mg/kg). Similarly, a four carbon C(2)-substituent displayed greater activity when in the tert-
butyl configuration ((R)-99, ED50 >22 mg/kg) compared with the n-butyl configuration ((R)-
97, ED50 >71 mg/kg). All C(2)-hydrocarbon PAADs that were tested as individual 
enantiomers (60, 96, 98, and 99) revealed a 2–20-fold preference for anticonvulsant activity 
in the (R)-isomer. The isopropyl group at the C(2)-carbon displayed the largest (R)- versus 
(S)- selectivity (ED50 (mg/kg): (R)-98, 15; (S)-98, >300), but the stereoselectivity was 
diminished to 3-fold using the tert-butyl group (ED50 (mg/kg): (R)-99, 14; (S)-99, 42). The 
stereoselectivity of (R)-98 resembles that of (R)-28, where (R)-28 is ~22-fold more potent 
than its (S)-stereoisomer. The large variation in (R)- versus (S)-selectivity in activity for the 
C(2)-hydrocarbon series was unexpected. In the FAAs, the eudismic ratio182 (the ratio of the 
affinity between the more tightly bound isomer [eutomer] and the less tightly bound isomer 
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[distomer]) ranged between 10–22. We are uncertain why this ratio varied within the PAAD 
series, but suspect that multiple factors (e.g., site selectivity, metabolism, transport, efflux) 
affected the observed anticonvulsant activities for the individual stereoisomers. The 
protective indices in the MES test in mice (PI: TD50/ED50) of (R)-98 (PI = 4.7) and (R)-99 (PI 
= 4.7) are similar to (R)-28 (5.8–6.0).  
In summary, considering the MES activity, formalin activity, and protective indices in 
mice, (R)-98 and (R)-99 both approached the therapeutic potential of (R)-28, the FDA-
approved FAA and benchmark for this study. The anticonvulsant activity of (R)-98 was 
slightly improved in rats upon oral administration (ED50 = 11 mg/kg) and with no apparent 
behavioral toxicity (TD50 >500 mg/kg) (Table 14).  
Comparison of the MES activities of PAADs (R)-, (S)-, and (R,S)-60, (R)-, and (R,S)-
95, (R,S)-96, (R)-98, and (R)-99 with their corresponding FAAs (R)-234, (R)-235, (R)-236, 
(R)-237, and (R)-238, respectively, in mice (ip) (Table 15) revealed similar activities of linear 
alkyl chains (i.e., (R,S)-96, ED50 = 39 mg/kg versus (R,S)-236, ED50 = 38 mg/kg) but there 
was a significant increase in PAAD activity of branched alkyl chains (i.e., (R)-98, 15 mg/kg 
versus (R)-237, ED50 >100, <300 mg/kg; (R)-99, 14 mg/kg versus (R)-238, ED50 >300 
mg/kg). FAAs (R)-237 and (R)-238 were inactive (ED50 (mg/kg): (R)-237, >100, <300; (R)-
238, >300) but the corresponding PAADs (R)-98 and (R)-99 displayed excellent activity 
(ED50 (mg/kg): (R)-98, 15; (R)-99, 14). Table 16 compared the MES activities of PAADs 
(R,S)-60, (R,S)-96, (R)-98, and (R)-99 with their corresponding FAAs (R)-234, (R)-236, (R)-
237, and (R)-238, respectively, in rats (po). It is difficult to make generalizations based on 
the limited PAAD rat data, but PAADs (R)-60 and (R)-98 displayed an increase in 
anticonvulsant activity compared with their FAA counterparts (ED50 (mg/kg): (R)-60, 14; (R)-
234, 48; (R)-98, 11; (R)-237, >30). Unlike the increase in PAAD toxicity observed in mice, 
(R)-60 and (R)-98 did not display any behavioral toxicity in rats (TD50 >500 mg/kg).  
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The data from Tables 13–16 suggest that a C(2)-heteroatom one atom removed from 
the C(2) center is not necessary for PAAD anticonvulsant activity or NP protection, and that 
the activities of C(2)-hydrocarbon PAADs reside predominantly in the (R)-stereoisomer, but 
the effect of stereochemistry on activity was less pronounced than reported for FAAs except 
for (R)-98. Furthermore, the dramatic improvement in MES seizure protection for PAADs 
(R)-98 and (R)-99 compared with their FAA counterparts suggests that C(2)-hydrocarbon 
PAADs may function, in part, by different pharmacological pathways than other PAADs and 
the FAA class. If this is the case, the basic structural premise of the PAAD backbone (59) 
may be invalid. In Chapter 3, we test these assumptions. PAADs (R)-98 and (R)-99 from the 
C(2)-hydrocarbon series emerged as leading compounds. These PAADs surpassed the 
MES activity of the traditional antiepileptic phenobarbital (22 mg/kg) and are approaching 
the activity of the antiepileptic phenytoin (9.5 mg/kg). Therefore, we chose (R)-98 and (R)-99 
for SAR optimization (Chapter 3). 
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Table 13. Pharmacological activities of C(2)-hydrocarbon N-benzylamide PAADs in mice (mg/kg) at UCB and the NINDS 
ASP 
 
 
      Mice (ip)
a 
Cmpd No.  
Test 
Site 
 R  MES,
b
 ED50  
6 Hz,
c
 
ED50 
 
Formalin, 
ED50 
 Tox,
d
 TD50
 
 
Com-
ments
e
 
 
PI,
f
 
MES 
 
PI,
f
 
Form 
(R)-28  UCB  LCM  3.3  10  15  19  Ref  5.8  1.3 
(R)-28
g
  NINDS  LCM  
4.5 [0.5] 
(3.7–5.5) 
 10  ND
h
  
27 [0.25] 
(26–28) 
 
Ref  6.0   
(R)-60
i
  NINDS  CH3  >10, <30  ND
h
  69  >100, <300  
  
    
(S)-60
i
  NINDS  CH3  >300  ND
h
  ND
h
  >300 
  
    
(R,S)-60
i
  NINDS  CH3  >100, <300  ND
h
  ND
h
  >300 
  
    
(R)-95  UCB  CH2CH3  16  
62 
(MAD)
j  22  ND
h
 
  
    
(R)-95  NINDS  CH2CH3  
18 [0.25] 
(10–25) 
 ND
h
  ND
h
  
80 [0.25] 
(65–95) 
   4.4   
(R)-96  UCB  (CH2)2CH3  21  
66 
(MAD)
j
 
 35  57  66 (LR)  2.8  1.6 
(S)-96  UCB  (CH2)2CH3  >37  >210  100  ND
h
 
  
    
(R,S)-96  UCB  (CH2)2CH3  39  
120 
(MAD)
j
 
 68
k
 (17%)  ND
h
 
 
68 (T), 
160 (IG, 
LR, C) 
    
(R)-97  UCB  (CH2)3CH3  23  93  >71  ND
h
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(R)-98  UCB  CH(CH3)2  16 (MAD)
j 
 74  20  47 
  
   2.4 
(R)-98  NINDS  CH(CH3)2  
15 [0.25] 
(13–18) 
 
<100 
[0.25–
1.0] 
 ND
h
  
70 [0.25] 
(63–80) 
  
 4.7   
(S)-98  NINDS  CH(CH3)2  >300 [0.5]  ND
h
  ND
h
  >300 [0.5] 
  
    
(R)-99  UCB  C(CH3)3  13  >71  >22  ND
h
  70 (C)     
(R)-99  NINDS  C(CH3)3  
14 [0.25] 
(11–17) 
 ND
h
  ND
h
  
66 [0.25] 
(58–73) 
   4.7   
(S)-99  NINDS  C(CH3)3  
42 [0.25] 
(37–46) 
 ND
h
  ND
h
  
100 [0.25] 
(100–110) 
      
(R,S)-100  UCB  CH(CH3)CH2CH3  
46 (MAD)
j 
46
k
 (100%) 
 >120  >22  ND
h
  
70 
(C,T,IG) 
    
(R)-101  UCB  C6H11  28  
140 
(MAD)
j
 
 
25 
(inactive) 
79
k
 (95%) 
 ND
h
  
140 
(C, MT) 
    
(R)-102  UCB  CH2C6H5  40  
81 
(MAD)
j
 
 >37  ND
h
  120 (C)     
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to adult male albino 
CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 30 min after ip administration (UCB) or a dose-
response curve was generated for all compounds that displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of 
peak effect” (indicated in hours in the brackets) (NINDS ASP). Numbers in parentheses are 95% confidence intervals. 
b 
MES = maximal electroshock seizure 
test. 
c 
6 Hz test = psychomotor seizure model (44 mA, UCB; 32 mA, NINDS ASP). 
d 
Tox = neurological toxicity. TD50 value determined from the rotorod test. 
e 
Dose in mg/kg is followed by whole animal pharmacological observation (Ref = reference, LR = loss of righting reflex, T =
 
tremors, C = convulsions, IG = 
impaired gait, MT = mortality). 
f 
PI = protective index (TD50/ED50).
 g
 Choi, D. et al. J. Med. Chem. 1996, 39, 1907–1916. 
h
 ND = not determined. 
i
 Bégiun, C. et 
al. Bioorg. Med. Chem. 2004, 12, 3079–3096. 
j
 MAD = minimal active dose. 
k 
Single dose experiments where the mg/kg used is followed by the percentage 
protected in parenthesis.
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Table 14. Pharmacological activities of C(2)-hydrocarbon N-benzylamide PAADs in 
rats (mg/kg) at the NINDS ASP 
 
    Rat (po)
a
 
Cmpd No.  R  MES,
b
 ED50  Tox,
c
 TD50  PI
d
 
(R)-28
f
  LCM  
3.9 [0.5] 
(2.6–6.2) 
 >500 [0.5]  >130 
(R)-60
g
  CH3  
19 [2.0] 
(13–25) 
 >30  >1.5 
(S)-60
g
  CH3  >80  >80   
(R,S)-60
g
  CH3  
14 [1.0] 
(7–22) 
 >500  >36 
(R)-98  CH(CH3)2  
11 [0.25] 
(9.1–13) 
 >500  >45 
(S)-99  C(CH3)3  
>30 
[0.25–4.0] 
 
>30 
[0.25–4.0] 
  
phenytoin    
30 [4.0] 
(22–39) 
 >3000  >100 
phenobarbital    
9.1 [5.0] 
(7.6–12) 
 
61 [0.5] 
(44–96) 
 6.7 
valproate    
490 [0.5] 
(350–730) 
 
280 [0.5] 
(190–350) 
 0.6 
a 
The compounds were administered orally to adult male albino Sprague Dawley rats. ED50 and 
TD50 values are in mg/kg. A dose-response curve was generated for all compounds that 
displayed sufficient activity and the dose-effect data for these compounds was obtained at the 
“time of peak effect” (indicated in hours in the brackets). Numbers in parentheses are 95% 
confidence intervals. 
b 
MES = maximal electroshock seizure test. 
c
 Tox = behavioral toxicity. 
d
 
PI = protective index (TD50/ED50). 
f
 Choi, D. et al. J. Med. Chem. 1996, 39, 1907–1916. 
g
 
Béguin, C. et al. Bioorg. Med. Chem. 2004, 12, 3079–3096. 
h
 Porter, R.J. et al. Cleveland Clin. 
Q. 1984, 51, 293–305. 
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Table 15. Comparison of the pharmacological activities of C(2)-hydrocarbon FAAs and their PAAD counterparts in mice 
(mg/kg) 
                        
      Mice (ip)
a
      Mice (ip)
a
 
R  
FAA 
Cpd No. 
 
FAA 
Test Site 
 
FAA 
MES,
b
 ED50 
 
FAA 
Tox,
c
 TD50 
 
PAAD 
Cpd No. 
 
PAAD 
Test Site 
 
PAAD 
MES,
b
 ED50 
 
PAAD 
Tox,
c
 TD50
 
CH3  (R)-234
d
  NINDS  
55 [0.5] 
(50–60) 
 
210 [0.5] 
(150–260) 
 (R)-60
e
  NINDS  >10, <30  >100, <300 
CH3  (S)-234
d
  NINDS  
550 [0.5] 
(460–740) 
 
840 [0.5] 
(690–950) 
 (S)-60
e
  NINDS  >300  >300 
CH3  (R,S)-234
d
  NINDS  
76 [0.5] 
(67–89) 
 
450 [0.5] 
(420–500) 
 (R,S)-60
e
  NINDS  >100, <300  >300 
CH2CH3  (R)-235  ND
f
  ND
f
  ND
f
  (R)-95  NINDS  
18 [0.25] 
(10–25) 
 
80 [0.25] 
(65–95) 
CH2CH3  (R,S)-235
g
  NINDS  >100, <300  >300  (R,S)-95  ND
f
  ND
f
  ND
f
 
CH2CH2CH3  (R,S)-236
h
  NINDS  
38 [0.25] 
(35–45) 
 
160 [0.25] 
(150–170) 
 (R,S)-96  UCB  39  ND
f
 
CH(CH3)2  (R)-237
i
  NINDS  >100, <300  >300  (R)-98  NINDS  
15 [0.25] 
(13–18) 
 
70 [0.25] 
(63–80) 
C(CH3)3  (R)-238
i
  NINDS  >300  >300  (R)-99  NINDS  
14 [0.25] 
(11–17) 
 
66 [0.25] 
(58–73) 
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to adult male 
albino CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 30 min after ip administration (UCB) or 
a dose-response curve was generated for all compounds that displayed sufficient activity and the dose-effect data for these compounds was obtained at 
the “time of peak effect” (indicated in hours in the brackets) (NINDS ASP). Numbers in parentheses are 95% confidence interva ls. 
b 
MES = maximal 
electroshock seizure test. 
c 
Tox = neurological toxicity. TD50 value determined from the rotorod test. 
d
 Kohn, H. et al. Brain Res. 1988, 457, 371–375. 
e
 
Béguin, C. et al. Bioorg. Med Chem. 2004, 12, 3079–3096. 
f
 ND = not determined. 
g
 Shen, M. et al. J. Med. Chem. 2002, 45, 2811–2823. 
h
 LeTiran, A. et 
al. J. Med. Chem. 2002, 45, 4762–4773. 
i
 Salomé, E. et al. J. Med. Chem. 2010, 53, 1288–1305.  
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Table 16. Comparison of the pharmacological activities of C(2)-hydrocarbon FAAs and their PAAD counterparts in rats 
(mg/kg) 
                             
      Rat (po)
a
      Rat (po)
a
 
R  
FAA 
Cpd No. 
 
FAA 
Test Site 
 
FAA 
MES,
b
 ED50 
 
FAA 
Tox,
c
 TD50 
 
PAAD 
Cpd No. 
 
PAAD 
Test Site 
 
PAAD 
MES,
b
 ED50 
 
PAAD 
Tox,
c
 TD50
 
CH3  (R,S)-234
d
  NINDS  
48 [1.0] 
(32–72) 
 >1000  (R,S)-60
e
  NINDS  
14 [1.0] 
(7–22) 
 >500 
CH2CH2CH3  (R,S)-236
e
  NINDS  ~30  >30  (R,S)-96  UCB  ND
f
  ND
f
 
CH(CH3)2  (R)-237  NINDS  
>30 
[0.25–4.0] 
 
>30 
[0.25–4.0] 
 (R)-98  NINDS  
11 [0.25] 
(9.1–13) 
 >500 
C(CH3)3  (R)-238  NINDS  
>30 
[0.25–4.0] 
 
>30 
[0.25–4.0] 
 (R)-99  NINDS  ND
f
  ND
f
 
a 
The compounds were administered orally to adult male albino Sprague Dawley rats. ED50 and TD50 values are in mg/kg. A dose-response curve was 
generated for all compounds that displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak effect” 
(indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b 
MES = maximal electroshock seizure test. 
c 
Tox = 
behavioral toxicity. 
d
 Béguin, C. et al. Bioorg. Med Chem. 2004, 12, 3079–3096. 
e
 LeTiran, A. et al. J. Med. Chem. 2002, 45, 4762–4773. 
f
 ND = not 
determined. 
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2.3.4. C(2) Stereochemistry and pharmacological activity 
PAADs evaluated as individual stereoisomers from Tables 5, 12, and 13 are 
presented in Table 17 to assess the importance of PAAD stereochemistry on neurological 
activity in mice. A global assessment revealed that MES activity resided predominantly in 
the (R)-isomer. The general insensitivity of PAADs to the 6 Hz test prevents the 
determination of stereochemical preference in this model. Similarly, although there are 
several examples of C(2)-hydrocarbon PAADs that displayed significant activity in the 
formalin test, a lack of data from the corresponding (S)-isomers prevents any generalized 
conclusions of (R) versus (S) selectivity. Not surprisingly, the PAADs that were active in the 
MES test showed higher neurological toxicity associated with the (R)-configuration 
compared with the (S)-configuration. Collectively, PAADs follow the FAA anticonvulsant 
activity trend with respect to stereochemistry in the MES test. However, the degree of 
separation between (R) versus (S) specificity is typically 3–4-fold in PAADs compared with 
the 10–20-fold difference in the FAAs. 
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Table 17. Pharmacological activities of C(2)-N-benzylamide PAAD chiral sets in mice (mg/kg) at UCB and the NINDS ASP 
 
      Mice (ip)
a 
Cmpd 
No. 
 
Test 
Site 
 R  MES
b
, ED50  6 Hz,
c
 ED50  
Formalin, 
ED50 
 Tox
d
, TD50
 
 Comments
e
  
PI
f
, 
MES 
 
PI
f
, 
Form 
(R)-28  UCB  LCM  3.3  10  15  19  Ref  5.8  1.3 
(R)-28
g
  NINDS  LCM  
4.5 [0.5] 
(3.7–5.5) 
 10  ND
h
  
27 [0.25] 
(26-28) 
 Ref  6.0   
(S)-28
g
  NINDS  LCM  >100, <300  ND
h
  ND
h
  >300  Ref     
(R)-65  UCB  CH2OH  ND
h
  >62  >62  >110       
(S)-65  UCB  CH2OH  ND
h
  >62  >62  >110       
(R,S)-65  UCB  CH2OH  ND
h
  >62  >62  >110       
(R)-61  UCB  CH2OCH3  34  >67  >67  >120    >3.5   
(R)-61  NINDS  CH2OCH3  
48 [0.25] 
(40–61) 
 ND
h
  ND
h
  
>30, <100 
[0.25] 
      
(R)-61
i
  NINDS  CH2OCH3  >30, <100  ND
h
  ND
h
  >100, <300       
(S)-61  UCB  CH2OCH3  64  >70  120  63    1.0  0.5 
(R)-60
j
  NINDS  CH3  >10, <30  ND
h
  ND
h
  >100, <300       
(S)-60
j
  NINDS  CH3  >300  ND
h
  ND
h
  >300       
(R,S)-60
j
  NINDS  CH3  >100, <300  ND
h
  ND
h
  >300       
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(R)-96  UCB  CH2CH2CH3  21  66 (MAD)
k 
 35  57  66 (LR)  2.8  1.6 
(S)-96  UCB  CH2CH2CH3  >37  >210  100  ND
h
       
(R,S)-96  UCB  CH2CH2CH3  39  120 (MAD)
k
  68
l 
(17%)  ND
h
  
68 (T), 160 
(IG, LR, C)
     
(R)-98  UCB  CH(CH3)2  
16 (MAD)
k
 
16
l
 (100%) 
 74  20  47  320 (S, H)  2.9  2.4 
(R)-98  NINDS  CH(CH3)2  
15 [0.25] 
(13–18) 
 
<100 
[0.25–1.0] 
 ND
h
  
70 [0.25] 
(63–80) 
   4.7   
(S)-98  NINDS  CH(CH3)2  >300 [0.5]  ND
h
  ND
h
  >300 [0.5]       
(R)-99  UCB  C(CH3)3  13  >71  >22  ND
h
  70 (C)     
(R)-99  NINDS  C(CH3)3  
14 [0.25] 
(11–17) 
 ND
h
  ND
h
  
66 [0.25] 
(58–73) 
   4.7   
(S)-99  NINDS  C(CH3)3  
42 [0.25] 
(37–46) 
 ND
h
  ND
h
  
100 [0.25] 
(100–110) 
     
 
(R)-62  UCB  C6H5  43 (MAD)
k
  >24  24
l 
(61%)  ND
h
  77 (MT)    
 
(S)-62  UCB  C6H5  ND
h
  >77  110  140 (MTD)
m 
 >140 (C)     
(R,S)-62  UCB  C6H5  >30  >43  24
l 
(37%)  51  
77 (C), 
140 (MT)
     
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to adult male albino 
CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 30 min after ip administration (UCB) or a dose-
response curve was generated for all compounds that displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of 
peak effect” (indicated in hours in the brackets) (NINDS ASP). Numbers in parentheses are 95% confidence intervals. 
b
 MES = maximal electroshock seizure 
test. 
c 
6 Hz test = psychomotor seizure model (44 mA, UCB; 32 mA, NINDS ASP). 
d 
Tox = neurological toxicity. TD50 value determined from the rotorod test. 
e
 
Dose in mg/kg is followed by whole animal pharmacological observation (Ref = reference, LR = loss of righting reflex, T =
 
tremors, C = convulsions, S = 
sedation, H = hypothermia, MT = mortality). 
f 
PI = protective index (TD50/ED50). 
g 
Choi, D. et al. J. Med. Chem. 1996, 39, 1907–1916. 
h 
ND = not determined. 
i
 
Andurkar, S.V. et al. Tetrahedron: Asymmetry 1998, 9, 3841–3854. 
j
 Béguin, C. et al. Bioorg. Med. Chem. 2004, 12, 3079–3096. 
k
 MAD = minimal active dose. 
l 
Single dose experiments where the mg/kg used is followed by the percentage protected in parenthesis. 
m
 MTD = maximal tolerated dose. 
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2.3.5. Comparison of the data acquired at UCB and the NINDS ASP 
The expiration of contractual obligations with UCB Pharma did not coincide with the 
conclusion of this project and we shifted the pharmacological evaluation of PAADs from 
UCB Pharma to the NINDS ASP. However, to allow our comparison of the data from 
different testing facilities, we determined the pharmacological activities of several active 
PAADs at both sites. Accordingly, (R)-61, (R)-95, (R)-98, and (R)-99 were evaluated at UCB 
Pharma and the NINDS ASP (Table 18). We chose (R)-61 due its direct connection to (R)-
28, and (R)-95, (R)-98, and (R)-99 because they displayed the highest activities in the MES 
test. Table 18 shows that the MES activities obtained from UCB Pharma and the NINDS 
ASP were in excellent agreement. However, there is a variance on the neurological toxicities 
reported, leading to different protective indices (PI). The PI values obtained from the NINDS 
ASP are consistently higher than those reported from UCB Pharma but differ by less than a 
factor of two. Overall, the data from UCB Pharma, and the NINDS ASP are consistent and 
comparisons between the two testing facilities are made in confidence. We build upon this 
table in Chapter 3 to include optimized PAADs. 
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Table 18. Comparison of the pharmacological activities of PAADs evaluated in mice (mg/kg) at UCB and the NINDS-ASP 
 
    UCB
a 
 NINDS-ASPb
 
Cmpd No.  R  MES,
c
 ED50  Tox,
d
 TD50
 
 PI
e 
 MES,
c
 ED50  Tox,
d
 TD50  PI
e 
(R)-28  LCM  3.3  19  5.8  
4.5 [0.5] 
(3.7–5.5) 
 
27 [0.25] 
(26–28) 
 6.0 
(R)-61  CH2OCH3  34  >117  >3.4  
48 [0.25] 
(40–61) 
 
>30, <100 
[0.25] 
  
(R)-95  CH2CH3  16  46  2.9  
18 [0.25] 
(10–25) 
 
80 [0.25] 
(65–95) 
 4.4 
(R)-98  CH(CH3)2  16 (MAD)
f 
 47  2.9  
15 [0.25] 
(13–18) 
 
70 [0.25] 
(63–80) 
 4.8 
(R)-99  C(CH3)3  13  ND
g
    
14 [0.25] 
(11–17) 
 
66 [0.25] 
(58–73) 
 4.7 
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB. ED50 and TD50 
values are in mg/kg and were determined 30 min after ip administration. 
b
 The compounds were administered 
intraperitoneally to adult male albino CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in 
mg/kg. A dose-response curve was generated for all compounds that displayed sufficient activity and the dose-effect data 
for these compounds was obtained at the “time of peak effect” (indicated in hours in the brackets). Numbers in 
parentheses are 95% confidence intervals. 
c
 MES = maximal electroshock seizure test. 
d
 Tox = neurological toxicity. TD50 
value determined from the rotorod test. 
e
 PI = protective index (TD50/ED50). 
f
 MAD = minimal active dose. 
g
 ND = not 
determined. 
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3. Conclusions 
We have developed the PAAD SAR from the pharmacological evaluation of more 
than 50 compounds in whole animal models of epilepsy and NP. We examined select 
substituents at the C(2) carbon (CH2OR, CH2N(R)R‟, CH2CH2XR, 6-membered aromatic and 
heteroaromatic, 5-membered heteroaromatic, and hydrocarbon) that tested the requirement 
for a heteroatom one atom removed from the C(2) center, the need for heteroatom 
substitution, and the stereochemical preference at the C(2) position. The SAR suggested 
that PAAD activity, unlike FAAs, does not improve with the inclusion of a substituted 
heteroatom one atom removed from the C(2) center. Although the PAADs that displayed the 
highest anticonvulsant activity in the MES test are 4–10-fold less active than (R)-28, four 
hydrocarbon PAADs (ED50 (mg/kg): (R)-95, 16; (R)-96, 21; (R)-98, 15; and (R)-99, 13) 
surpassed the MES activity observed for the traditional antiepileptic agent phenobarbital 
(ED50 = 22 mg/kg), and the majority of PAADs tested surpassed the MES activity observed 
for the traditional antiepileptic agent valproate (270 mg/kg).  
The original testing paradigm at UCB Pharma consisted of only the 6 Hz assay for 
anticonvulsant activity, but the MES test was included to serve as a complementary 
approach because each assay has shown different sensitivities to distinct classes of 
antiepileptic agents. A prime example is the efficacy of levetiracetam in the 6 Hz test but not 
in the MES test.178 Conversely, traditional antiepileptic agents are active in the MES test but 
are largely inactive in the 6 Hz test.183 The inclusion of the MES test proved beneficial in 
determining the anticonvulsant activity of PAADs since many were insensitive to the 6 Hz 
test.  
The finding that the C(2)-hydrocarbon PAADs (R)-98 (ED50 = 15 mg/kg) and (R)-99 
(ED50 = 14 mg/kg) exhibited superb protection in the MES test in mice was surprising. Their 
corresponding FAAs were inactive in the MES test (ED50 (mg/kg): (R)-98, >100, <300; (R)-
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99, >300). These findings raised the intriguing thought that these PAADs may function by 
different pathways from FAAs, and perhaps other PAADs. (R)-95, (R)-96, (R)-98, and (R)-99 
also displayed significant activity in the formalin test (ED50 <35 mg/kg), and were only 1.3–
2.3-fold less active than (R)-28 in this test. Evaluation of the individual stereoisomers of 
PAADs 61, 62, 96, 98, and 99 demonstrated that the (R)-stereoisomer exhibited greater 
anticonvulsant activity and pain attenuation than the (S)-isomer for these compounds. 
Nonetheless, we observed a general decrease in (R)- versus (S)- stereospecificity in the 
PAADs (3–4-fold) compared with the FAAs (10–20-fold), except for (R)-98, where the 
eudismic ratio was greater than 20. The modest (R)- versus (S)- difference in activities for 
the PAADs raises the possibility that factors (e.g. metabolism, transport, efflux) other than 
interaction with the site of function(s) may be responsible for this difference. The potency of 
small branched hydrocarbon PAADs (R)-98 and (R)-99 in both the MES and formalin tests, 
and the importance of the lacosamide PAAD (R)-61 to both the PAAD and FAA projects, 
prompted their selection as candidates for optimization studies. We will explore structural 
modifications of the N-terminal amine and N’-benzylamide moiety to determine their effects 
on anticonvulsant activity and pain attenuation. 
In addition to the C(2)-hydrocarbon PAADs that displayed significant activity in the 
formalin test (ED50 (mg/kg): (R)-95, 22; (R)-96, 35; (R)-98, 20; (R)-99, 22), several C(2)-6-
membered and 5-membered heteroaromatic PAADs also displayed significant activity in the 
same animal model (ED50 (mg/kg): (R,S)-77, 33; (R,S)-82, 29; (R,S)-85, 42, (R,S)-89, 29). 
PAADs (R,S)-77, (R,S)-82, and (R,S)-89 were only 2-fold less active than (R)-28 in the 
formalin test (ED50 = 15 mg/kg). However, it was unexpected that these PAADs were 1.5–3-
fold selective for pain attenuation over anticonvulsant activity (MES ED50 (mg/kg), formalin 
ED50 (mg/kg): (R,S)-77, 100 (MAD), 33; (R,S)-82, >52, 29; (R,S)-85, >120, 42; (R,S)-89, 85, 
29). The C(2)-6-membered and 5-membered heteroaromatic PAADs do not provide any 
significant advantage for the prevention of seizures compared with FAAs (~10-fold drop in 
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activity going from FAA to PAAD) but optimized C(2)-6-membered and 5-membered 
heteroaromatic PAADs could possess therapeutic value as pain modulating agents. 
Unfortunately, we cannot determine if this pattern is unique to PAADs due to the lack of 
formalin data in the FAA series. 
Comparison of the PAAD pharmacological data with their corresponding FAAs 
uncovered complicated SAR trends. First, it was clear that the inclusion of a heteroatom one 
atom removed from the C(2)-center in PAADs did not afford the same seizure protection as 
their FAA equivalent. On the contrary, C(2)-hydrocarbon PAADs displayed the greatest 
anticonvulsant activity in the PAAD series. However, there was a similar trend between the 
MES activities of C(3)-alkoxy PAADs and C(3)-alkoxy FAAs, but the activity was decreased 
~10-fold in magnitude and there was a sharp drop in C(2) (R)-stereospecificity for seizure 
protection. Therefore, C(3)-alkoxy PAADs could be interacting with the same receptor 
binding sites as C(3)-alkoxy FAAs, but with either a lower affinity or the relative brain 
concentration of the PAADs may be lower than that for FAAs at a given dose. We were 
unable to correlate the activities of C(3)-amino PAADs and C(3)-amino FAAs due to the 
limited data set. It is unclear whether C(2)-6-membered and 5-membered heteroaromatic 
PAADs are functioning in a similar manner to their FAA counterparts. The C(2)-
heteroaromatic PAAD series is 5–10-fold less sensitive in the MES test compared with FAAs 
(similar to that seen for C(3)-alkoxy PAADs), but ambiguous data points (minimal active 
dose) prevents reliable comparison with the FAAs. Moreover, when comparing the C(2)-
heteroaromatic PAADs and FAAs, we observed that benzoannulation in the former series 
resulted in anticonvulsant activities that either remained the same or improved, while in the 
latter set of compounds benzoannulation led to a precipitous drop in anticonvulsant activity. 
Therefore, while these PAADs may function at many of the same receptor sites used by 
FAAs, we cannot exclude the possibility of interaction with other receptor sites that affect NP 
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and possibly seizures. Lastly, the unexpected excellent activity for C(2)-hydrocarbon PAADs 
suggests binding interactions could be occurring at receptors not involved with FAA function.   
  
4. Experimental 
4.1. General methods 
Melting points were determined in open capillary tubes using a Thomas-Hoover 
melting point apparatus and are uncorrected. Infrared spectra (IR) were recorded on an ATI 
Mattson Genesis FT-IR spectrometer. Absorption values are expressed in wavenumbers 
(cm-1). Optical rotations were obtained on a Jasco P-1030 polarimeter at the sodium D line 
(589 nm) using a 1 dm path length cell. NMR spectra were recorded at 300 or 400 MHz (1H) 
and 75 or 100 MHz (13C) using tetramethylsilane (TMS) as an internal standard. Chemical 
shifts (δ) are reported in parts per million (ppm) from TMS. Low-resolution mass spectra 
(LRMS) were recorded with a BioToF-II-Bruker Daltonics spectrometer by Drs. M. Crowe 
and S. Habibi at the University of North Carolina Department of Chemistry. The high-
resolution mass spectra (HRMS) were recorded on a Bruker Apex-Q 12 Telsa FTICR 
spectrometer by Drs. M. Crowe and S. Habibi. Microanalyses were performed by Atlantic 
Microlab, Inc. (Norcross, GA). Reactions were monitored by analytical thin-layer 
chromatography (TLC) plates (Aldrich, catalog no. Z12272-6, or Dynamic Adsorbents Inc., 
catalog no. 84111) and analyzed with 254 nm light. The reaction mixtures were purified by 
medium pressure liquid chromatography (MPLC, CombiFlash Rf) with self-packed columns 
(silica gel from Dynamic Adsorbents Inc., catalog no. 02826-25) or by flash column 
chromatography using silica gel (Dynamic Adsorbents Inc., catalog no. 02826-25). All 
chemicals and solvents were reagent grade and used directly from commercial sources 
without further purification. THF was distilled from blue sodium benzophenone ketyl. Yields 
reported are for purified products and were not optimized. All compounds were checked by 
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TLC, 1H and 13C NMR, MS, and elemental analyses. The analytical results are within 0.40% 
of the theoretical value. The TLC, NMR, and analytical data confirmed the purity of the 
products was ≥95%. 
 
General Procedure for the Preparation of N-Benzyloxycarbonyl Amino Acids and N-
Benzyloxycarbonyl Amino Methyl Esters (Method A). NaHCO3 (2.5–3.3 equiv) was 
added to an aqueous solution of amino acid (0.4–0.5 M) and the solution was cooled to 0 ºC 
in an ice bath under an inert atmosphere (Ar or N2) before benzylchloroformate (1.1–1.5 
equiv) was added dropwise. The reaction proceeded for 45 min at 0 ºC and then allowed to 
warm to room temperature (24 h). Amino acid derivatives: The aqueous layer was washed 
with EtOAc (3x), acidified to pH ~1 with aqueous concentrated HCl, and extracted with 
EtOAc (3x). The second set of organic layers were combined, dried (MgSO4), and 
concentrated in vacuo. The crude product was used for the next step without further 
purification or purified by recrystallization from hot EtOAc/hexanes. Amino methyl ester 
derivatives: The aqueous layer was extracted with CH2Cl2 (3x), dried (Na2SO4), 
concentrated in vacuo, and purified by column chromatography (SiO2).  
 
General Procedure for the Preparation of N-Benzylamide Amino Acid Derivatives 
Using the Mixed Anhydride Coupling (MAC) Method (Method B). An anhydrous THF 
solution of carboxylic acid (0.5–2.0 M) was cooled to -78 ºC in a dry ice/acetone bath under 
an inert atmosphere (Ar or N2), and 4-methylmorpholine (NMM) (1.3–1.5 equiv) was added. 
After the mixture was stirred (2–10 min), isobutyl chloroformate (IBCF) (1.1–1.5 equiv) was 
added leading to the precipitation of a white solid. The reaction was allowed to proceed for 
an additional 15–25 min, and then benzylamine (1.05–1.36 equiv) was added at -78 ºC. The 
reaction mixture was allowed to stir at room temperature (1.5 h), and then the insoluble salts 
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were filtered. The organic layer was concentrated in vacuo, and the product was purified by 
column chromatography (SiO2).  
 
General Procedure for the Conversion of Cbz-Protected PAADs to PAADs Using Pd-
Catalyzed Hydrogenation (Method C). A MeOH solution of Cbz-protected PAAD (0.05–0.1 
M) was hydrogenated (1 atm) in the presence of 10% Pd-C at room temperature (3 h–7 d). 
The mixture was filtered through a bed of Celite®, the filtrate was evaporated in vacuo, and 
the product was purified by column chromatography (SiO2).  
 
General Procedure for the Preparation of Alkoxy-Substituted Cbz-PAADs Using Silver 
(I) Oxide-Mediated Alkylation (Method D). To a CH3CN solution of Cbz-protected PAAD 
(0.01–0.1 M) were successively added Ag2O (5 equiv) and the alkyl iodide (10 equiv) at 
room temperature. The reaction mixture was stirred (room temperature-50 ºC, 5–7 d) and 
then the insoluble salts were filtered and the filtrate evaporated in vacuo. The product was 
purified by column chromatography (SiO2) followed by recrystallization. 
 
General Procedure for PAAD Preparation Using TFA Deprotection (Method E). TFA (15 
equiv) was added to an anhydrous CH2Cl2 solution of the N-t-butoxycarbonyl N‟-
benzylamide (0.3 M) at room temperature. The solution was stirred (1 h) and then the 
solvent was evaporated in vacuo. The crude product was diluted with CH2Cl2 and extracted 
with aqueous 1 M HCl (3x). The combined aqueous layers were washed with CH2Cl2 (2x), 
basified (pH 10–12) with aqueous 4 M NaOH, and extracted with CH2Cl2 (3x). The combined 
organic layers were washed with brine (2x), dried (Na2SO4), evaporated in vacuo, and 
purified by column chromatography (SiO2). 
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General Procedure for the Preparation of N-(Benzyloxycarbonyl)-3-N-Aminopropanoic 
Methyl Ester Derivatives Using the Michael Addition of Amines to Dehydroalanine 
Derivatives (Method F). An anhydrous CH2Cl2 solution of serine methyl ester (0.2 M) was 
cooled to 0 ºC under an inert atmosphere (Ar or N2), and triethylamine (Et3N) (1.2 equiv) 
was added. After the mixture was stirred (10 min), methanesulfonyl chloride (MsCl) (1.2 
equiv) was added. The reaction was allowed to proceed for an additional 1 h, and then Et3N 
(1.2 equiv) was added at 0 ºC. The reaction was allowed to stir at room temperature (3 h), 
and then the solvent was evaporated in vacuo to give the crude Cbz-dehydroalanine-methyl 
ester. An anhydrous primary, secondary, or tertiary amine solution in THF (5–20 equiv) and 
MeOH (1:1) was added directly to the crude material and stirred overnight. The organic layer 
was concentrated in vacuo to give the crude product, which was diluted with CH2Cl2, 
successively washed with saturated aqueous Na2CO3 (3x) and brine (2x), dried (Na2SO4), 
concentrated in vacuo, and purified by column chromatography (SiO2). 
 
General Procedure for the Preparation of N-Benzylamide Amino Acid Derivatives 
Using the LiOH Hydrolysis/DMTMM Amide Coupling Method (Method G). Methyl ester 
(0.1 M) was dissolved in THF and H2O (1:2) and LiOH (1 equiv) was added. The reaction 
was stirred at room temperature (1.5 h) and then benzylamine hydrochloride (1.2 equiv) and 
DMTMM (1.2 equiv) were added and the solution stirred overnight (18 h). The organic layer 
was evaporated in vacuo, and CH2Cl2 was added to the remaining aqueous layer. The 
binary mixture was basified (pH 9–10) with aqueous 1 M NaOH, the organic layer was 
separated, and the aqueous layer was extracted with CH2Cl2 (3x). The organic layers were 
combined, washed with brine (3x), dried (Na2SO4), and purified by column chromatography. 
 
4.2. Synthesis 
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(R)-N-(Benzyloxycarbonyl)-2-amino-3-hydroxypropionic Acid ((R)-104).162 Utilizing 
Method A and using D-serine (5.00 g, 47.6 mmol), NaHCO3 (10.0 g, 118.9 mmol), H2O (100 
mL) and benzyl chloroformate (10.0 mL, 71.4 mmol) gave the crude product after workup 
that was further purified by recrystallization from hot EtOAc/hexanes to give the desired 
product (7.38 g, 65%) as a white solid: mp 115–116 °C (lit.162 mp 117–119 ºC); [α]25D –5.12° 
(c 6.0, acetic acid) (lit.184 (S): [α]12D +5.8º (c 6, acetic acid)); Rf = 0.43 (1:3 MeOH/CHCl3); 
1H 
NMR (300 MHz, DMSO-d6) δ 3.67 (d, J = 4.2 Hz, CH2OH), 4.03–4.09 (m, CH), 4.83–4.96 (br 
s, NH), 5.04 (s, CH2Ph), 7.32–7.38 (m, PhH); 
13C NMR (75 MHz, DMSO-d6) δ 56.7 (CH), 
61.4 (CH2OH), 65.5 (CH2Ph), 127.7, 127.8, 128.4, 137.0 (C6H5), 156.1 (OC(O)NH), 172.2 
(C(O)OH). 
 
 
(S)-N-(Benzyloxycarbonyl)-2-amino-3-hydroxypropionic Acid ((S)-104).184 The previous 
procedure was repeated using L-serine (5.00 g, 47.6 mmol), NaHCO3 (10.0 g, 118.9 mmol), 
H2O (100 mL), and benzyl chloroformate (10.0 mL, 71.4 mmol) to give the desired product 
(7.94 g, 70%) as a white solid: mp 116–117 °C (lit.184 mp 117–119 ºC); [α]25D +5.51° (c 6.0, 
acetic acid) (lit.184 [α]12D +5.8º (c 6, acetic acid)); Rf = 0.41 (1:3 MeOH/CHCl3); 
1H NMR (300 
MHz, DMSO-d6) δ 3.66 (d, J = 4.5 Hz, CH2OH), 4.02–4.09 (m, CH), 4.83–4.94 (br s, NH), 
5.04 (s, CH2Ph), 7.29–7.38 (m, PhH); 
13C NMR (75 MHz, DMSO-d6) δ 56.6 (CH), 61.3 
(CH2OH), 65.4 (CH2Ph), 127.7, 127.8, 128.3, 137.0 (C6H5), 156.0 (OC(O)NH), 172.1 
(C(O)OH). 
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(R,S)-N-(Benzyloxycarbonyl)-2-amino-3-hydroxypropionic Acid ((R,S)-104).185 The 
previous procedure was repeated using DL-serine (20.00 g, 0.19 mol), NaHCO3 (40.00 g, 
0.48 mol), H2O (400 mL), and benzyl chloroformate (40.0 mL, 0.29 mol) to give the desired 
product (38.04 g, 84%) as a white solid: mp 124–125 °C (lit.185 mp 120–122 ºC); Rf = 0.39 
(1:3 MeOH/CHCl3); 
1H NMR (300 MHz, DMSO-d6) δ 3.66 (d, J = 4.8 Hz, CH2OH), 4.03–4.09 
(m, CH), 4.72–4.97 (br s, NH), 5.04 (s, CH2Ph), 7.28–7.40 (m, PhH); 
13C NMR (75 MHz, 
DMSO-d6) δ 56.6 (CH), 61.3 (CH2OH), 65.4 (CH2Ph), 127.7, 127.8, 128.3, 137.0 (C6H5), 
156.0 (OC(O)NH), 172.1 (C(O)OH). 
 
 
(R)-N-Benzyl 2-N-(Benzyloxycarbonyl)amino-3-hydroxypropionamide ((R)-105).89 
Utilizing Method B, (R)-N-(benzyloxycarbonyl)-2-amino-3-hydroxypropionic acid (5.00 g, 
20.9 mmol), NMM (2.98 mL, 27.2 mmol), IBCF (2.98 mL, 23.0 mmol), and benzylamine 
(2.40 mL, 21.9 mmol) gave the crude product that was purified by flash column 
chromatography (SiO2; 1:20 MeOH/CHCl3) to give the desired product (5.16 g, 75%) as a 
white solid: mp 146–147 °C (lit.89 mp 147–149 ºC); [α]25D +5.1° (c 2.1, MeOH) (lit.
89 [α]23D 
+4.6° (c 2.0, MeOH); Rf = 0.44 (5% MeOH/CHCl3); 
1H NMR (300 MHz, DMSO-d6) δ 3.50–
3.67 (m, CH2OH), 4.06–4.13 (m, CH), 4.30 (d, J = 6.3 Hz, NHCH2), 4.90 (t, J = 5.7 Hz, OH), 
5.04 (s, CH2OC(O)), 7.20–7.38 (m, PhH and OC(O)NH), 8.42 (t, J = 6.0 Hz, C(O)NH); 
13C 
NMR (75 MHz, DMSO-d6) δ 42.0 (CH2NH), 57.4 (CH), 61.8 (CH2OH), 65.5 (OCH2Ph), 
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126.6, 127.0, 127.7, 127.8, 128.2, 128.3, 137.0, 139.3 (2 C6H5), 155.9 (C(O)O), 170.2 
(C(O)NH). 
 
 
(S)-N-Benzyl 2-N-(Benzyloxycarbonyl)amino-3-hydroxypropionamide ((S)-105).98 The 
previous procedure was repeated using (S)-N-(benzyloxycarbonyl)-2-amino-3-
hydroxypropionic acid (5.00 g, 20.9 mmol), NMM (2.98 mL, 27.2 mmol), IBCF (2.98 mL, 23.0 
mmol), and benzylamine (2.40 mL, 21.9 mmol) to give the desired product (4.84 g, 71%) as 
a white solid: mp 148–149 °C (lit.98 mp 148–149.5 ºC); [α]25D –5.8° (c 2.1, MeOH) (lit.
98 [α]23D 
–5.4° (c 1.04, MeOH)); Rf = 0.45 (1:20 MeOH/CHCl3); 
1H NMR (300 MHz, DMSO-d6) δ 
3.54–3.68 (m, CH2OH), 4.06–4.13 (m, CH), 4.30 (d, J = 6.0 Hz, NHCH2), 4.90 (t, J = 5.4 Hz, 
OH), 5.04 (s, CH2OC(O)), 7.20–7.38 (m, PhH and OC(O)NH), 8.42 (t, J = 6.3 Hz, C(O)NH); 
13C NMR (75 MHz, DMSO-d6) δ 42.0 (CH2NH), 57.3 (CH), 61.8 (CH2OH), 65.5 (OCH2Ph), 
126.6, 127.0, 127.7, 127.8, 128.2, 128.3, 137.0, 139.3 (2 C6H5), 155.9 (C(O)O), 170.1 
(C(O)NH).  
 
 
(R,S)-N-Benzyl 2-N-(Benzyloxycarbonyl)amino-3-hydroxypropionamide ((R,S)-105).186 
The previous procedure was repeated using (R,S)-N-(benzyloxycarbonyl)-2-amino-3-
hydroxypropionic acid (10.00 g, 41.8 mmol), NMM (5.97 mL, 54.4 mmol), IBCF (5.96 mL, 
46.0 mmol), and benzylamine (4.79 mL, 43.9 mmol) to give the desired product (12.25 g, 
89%) as a white solid: mp 140–141 °C (lit.186 mp 142 ºC); Rf = 0.33 (1:20 MeOH/CHCl3); 
1H 
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NMR (300 MHz, DMSO-d6) δ 3.54–3.67 (m, CH2OH), 4.06–4.13 (m, CH), 4.30 (d, J = 6.0 
Hz, NHCH2), 4.90 (t, J = 5.7 Hz, OH), 5.02 (s, CH2OC(O)), 7.20–7.38 (m, PhH and 
OC(O)NH), 8.42 (t, J = 6.0 Hz, C(O)NH); 13C NMR (75 MHz, DMSO-d6) δ 42.0 (CH2NH), 
57.3 (CH), 61.8 (CH2OH), 65.5 (OCH2Ph), 126.6, 127.0, 127.7, 128.2, 128.3, 137.0, 139.3 (2 
C6H5), 155.9 (C(O)O), 170.1 (C(O)NH), one aromatic peak was not detected and is believed 
to overlap with nearby signals. 
 
 
(R)-N-Benzyl 2-Amino-3-hydroxypropionamide ((R)-65). Utilizing Method C and using 
(R)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-hydroxypropionamide (1.82 g, 5.53 mmol), 
10% Pd-C (180 mg), and MeOH (200 mL) (8 h) gave the crude product that was purified by 
medium pressure liquid chromatography to give the desired product (0.56 g, 53%) as a 
white solid: mp 95–96 °C; [α]25D –0.48° (c 1.5, MeOH); 
1H NMR (300 MHz, DMSO-d6) δ 1.84 
(br s, NH2), 3.25 (dd, J = 4.8, 4.8 Hz, CH), 3.42–3.56 (m, CH2OH), 4.29 (d, J = 6.0 Hz, 
CH2NH), 4.72–4.86 (br s, OH), 7.20–7.33 (m, PhH), 8.35 (t, J = 6.0 Hz, NH); 
13C NMR (75 
MHz, DMSO-d6) δ 41.8 (NHCH2), 57.0 (CH), 64.4 (CH2OH), 126.6, 127.1, 128.2, 139.6 
(C6H5), 173.4 (C(O)NH); HRMS (ESI) 217.0953 [M + Na
+] (calcd for C10H14N2O2Na
+ 
217.0953); Anal. Calcd for C10H14N2O2: C, 61.84; H, 7.27; N, 14.42. Found C, 61.94; H, 
7.27; N, 14.31. 
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(S)-N-Benzyl 2-Amino-3-hydroxypropionamide ((S)-65). The previous procedure was 
repeated using (S)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-hydroxypropionamide (1.46 g, 
4.44 mmol), 10% Pd-C (140 mg), and MeOH (200 mL) (8 h) to give the desired product 
(0.54 g, 63%) as a white solid: mp 91–92 °C; [α]25D +4.88° (c 1.5, MeOH); 
1H NMR (300 
MHz, DMSO-d6) δ 3.27 (dd, J = 5.1, 5.1 Hz, CH), 3.42–3.57 (m, CH2OH), 4.30 (d, J = 6.2 
Hz, CH2NH), 7.19–7.34 (m, PhH), 8.37 (t, J = 6.2 Hz, NH); 
13C NMR (75 MHz, DMSO-d6) δ 
41.8 (NHCH2), 57.0 (CH), 64.3 (CH2OH), 126.6, 127.1, 128.2, 139.6 (C6H5), 173.2 
(C(O)NH); HRMS (ESI) 217.0953 [M + Na+] (calcd for C10H14N2O2Na
+ 217.0953); Anal. 
Calcd for C10H14N2O2: C, 61.84; H, 7.27; N, 14.42. Found C, 61.91; H, 7.31; N, 14.21. 
 
 
(R,S)-N-Benzyl 2-Amino-3-hydroxypropionamide ((R,S)-65). The previous procedure was 
repeated using (R,S)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-hydroxypropionamide (1.33 
g, 4.07 mmol), 10% Pd-C (130 mg), and MeOH (200 mL) (8 h) to give the desired product 
(0.52 g, 66%) as a white solid: mp 90–91 °C; 1H NMR (300 MHz, DMSO-d6) δ 2.14 (br s, 
NH2), 3.27 (dd, J = 4.5, 4.8 Hz, CH), 3.42–3.57 (m, CH2OH), 4.30 (d, J = 6.5 Hz, CH2NH), 
4.62–4.88 (br s, OH), 7.19–7.34 (m, PhH), 8.37 (t, J = 6.5 Hz, NH); 13C NMR (75 MHz, 
DMSO-d6) δ 41.8 (NHCH2), 57.0 (CH), 64.2 (CH2OH), 126.6, 127.1, 128.2, 139.5 (C6H5), 
173.2 (C(O)NH); HRMS (ESI) 217.0953 [M + Na+] (calcd for C10H14N2O2Na
+ 217.0953); 
Anal. Calcd for C10H14N2O2: C, 61.84; H, 7.27; N, 14.42. Found C, 61.69; H, 7.33; N, 14.41. 
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(R)-N-Benzyl 2-N-(Benzylcarboxycarbonyl)amino-3-methoxypropionamide ((R)-109).89 
Utilizing Method D and using (R)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-
hydroxypropionamide (4.00 g, 12.2 mmol), Ag2O (14.12 g, 60.9 mmol), MeI (7.59 mL, 121.9 
mmol), and CH3CN (400 mL) at room temperature (5 d) gave the crude product that was 
purified by flash column chromatography (SiO2, 1:10 MeOH/CH2Cl2) followed by 
recrystallization from hot EtOAc to give the desired product (2.86 g, 69%) as a white 
crystalline solid: mp 129–130 ºC (lit.89 mp 128–130 ºC); [α]25D +2.8° (c 1.0, MeOH) (lit.
89 
[α]23D +2.8° (c 1.1, MeOH)); Rf = 0.39 (1:1 EtOAc/hexanes); 
1H NMR (300 MHz, DMSO-d6) δ 
3.25 (s, OCH3), 3.46–3.55 (m, CH2OCH3), 4.24–4.30 (m, CH, NHCH2Ph), 5.04 (s, OCH2Ph), 
7.22–7.38 (m, 2 PhH), 7.47 (d, J = 8.1 Hz, NHC(O)O), 8.53 (t, J = 5.7 Hz, NHC(O)); 13C 
NMR (75 MHz, DMSO-d6) δ 41.7 (NHCH2), 54.3 (CH), 57.7 (OCH3), 65.1 (OCH2Ph), 71.6 
(CH2OCH3), 126.3, 126.6, 127.3, 127.4, 127.8, 127.9, 136.6, 138.8 (2 C6H5), 155.6 (OC(O)), 
169.3 (C(O)NH). 
 
 
(S)-N-Benzyl 2-N-(Benzylcarboxycarbonyl)amino-3-methoxypropionamide ((S)-109).98 
The previous procedure was repeated using (S)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-
hydroxypropionamide (4.00 g, 12.2 mmol), Ag2O (14.12 g, 60.9 mmol), MeI (7.59 mL, 121.9 
mmol), and CH3CN (400 mL) to give the desired product (3.13 g, 75%) as a white crystalline 
solid: mp 131–132 ºC (lit.98 mp 130–132 ºC); [α]25D –2.9° (c 1.1, MeOH) (lit.
98 [α]24D –3.3° (c 
1.1, MeOH)); Rf = 0.36 (1:1 EtOAc/hexanes); 
1H NMR (300 MHz, DMSO-d6) δ 3.25 (s, 
OCH3), 3.47–3.57 (m, CH2OCH3), 4.25–4.30 (m, CH, NHCH2Ph), 5.04 (s, OCH2Ph), 7.20–
7.37 (m, 2 PhH), 7.48 (d, J = 8.1 Hz, NHC(O)O), 8.53 (t, J = 5.4 Hz, NHC(O)); 13C NMR (75 
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MHz, DMSO-d6) δ 41.7 (NHCH2), 54.3 (CH), 57.8 (OCH3), 65.1 (OCH2Ph), 71.6 (CH2OCH3), 
126.3, 126.6, 127.3, 127.4, 127.8, 127.9, 136.6, 138.9 (2 C6H5), 155.6 (OC(O)), 169.3 
(C(O)NH). 
 
 
(R,S)-N-Benzyl 2-N-(Benzylcarboxycarbonyl)amino-3-methoxypropionamide ((R,S)-
109). The previous procedure was repeated using (R,S)-N-benzyl 2-N-
(benzyloxycarbonyl)amino-3-hydroxypropionamide (4.00 g, 12.2 mmol), Ag2O (14.12 g, 60.9 
mmol), MeI (7.59 mL, 121.9 mmol), and CH3CN (400 mL) to give the desired product (2.53 
g, 61%) as a white crystalline solid: mp 126–127 ºC; Rf = 0.39 (1:1 EtOAc/hexanes); IR 
(nujol mull) 3220, 2910, 1692, 1639, 1542, 1459, 1376, 1310, 1265, 1125, 1051, 967, 752, 
698 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 3.25 (s, OCH3), 3.50–3.52 (m, CH2OCH3), 4.22–
4.34 (m, CH, NHCH2Ph), 5.04 (s, OCH2Ph), 7.23–7.36 (m, 2 PhH), 7.48 (d, J = 8.1 Hz, 
NHC(O)O), 8.53 (t, J = 5.4 Hz, NHC(O)); 13C NMR (75 MHz, DMSO-d6) δ 41.7 (NHCH2), 
54.3 (CH), 57.7 (OCH3), 65.1 (OCH2Ph), 71.6 (CH2OCH3), 126.3, 126.6, 127.3, 127.4, 
127.8, 127.9, 136.7, 138.9 (2 C6H5), 155.6 (OC(O)), 169.3 (C(O)NH). 
 
 
(R)-N-Benzyl 2-Amino-3-methoxypropionamide ((R)-61).89 Utilizing Method C and using 
(R)-N-benzyl 2-N-(benzylcarboxycarbonyl)amino-3-methoxypropionamide (2.00 g, 5.85 
mmol), 10% Pd-C (0.2 g), and MeOH (100 mL) (5 h) gave the crude product that was 
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purified by flash column chromatography (SiO2; 1:10 MeOH/CHCl3). The resulting oil was 
dissolved in CH2Cl2 (20 mL) and was extracted with aqueous 0.1 N HCl (3 x 20 mL). The 
aqueous layers were combined and washed with CH2Cl2 (2 x 60 mL). The aqueous layer 
was basified to pH 10–12 with aqueous 0.1 N NaOH, and then extracted with CH2Cl2 (3 x 
100 mL). The CH2Cl2 layers were combined, dried (MgSO4), and concentrated in vacuo to 
give the desired product (0.89 g, 73%) as a waxy solid: mp 39–40 °C; [α]25D –1.5° (c 1.6, 
MeOH) (lit.89 [α]23D –2.0° (c 1.5, MeOH)); Rf = 0.26 (1:20 MeOH/CHCl3); IR (nujol mull) 3366, 
3302, 3140, 2904 (br), 1955, 1886, 1815, 1667, 1457, 1373, 1152, 966, 726 cm-1; 1H NMR 
(300 MHz, DMSO-d6) δ 1.82 (s, NH2), 3.25 (s, OCH3), 3.35–3.44 (m, CHCH2), 4.23–4.36 (m, 
CH2Ph), 7.20–7.34 (m, PhH), 8.36–8.44 (br t, NH); 
13C NMR (75 MHz, DMSO-d6) δ 41.5 
(CH2PH), 54.3 (CH), 57.8 (CH3), 74.8 (CHCH2), 126.3, 126.7, 127.8, 139.1 (C6H5), 172.6 
(C(O)); Anal. Calcd for C11H16N2O2·0.18H2O: C, 62.49; H, 7.80; N, 13.25. Found C, 62.13; H, 
7.82; N, 13.10. 
 
 
(S)-N-Benzyl 2-Amino-3-methoxypropionamide ((S)-61).98 The previous procedure was 
repeated using (S)-N-benzyl 2-N-(benzylcarboxycarbonyl)amino-3-methoxypropionamide 
(2.00 g, 5.85 mmol), 10% Pd-C (0.2 g), and MeOH (100 mL) to give the desired product 
(1.12 g, 92%) as a waxy solid: mp 39–40 °C; [α]25D +1.7° (c 1.5, MeOH) (lit.
98 [α]23D +1.8° (c 
0.8, MeOH)); Rf = 0.39 (1:20 MeOH/CHCl3);  IR (nujol mull) 3474, 3365, 3125 (br), 1949, 
1885, 1817, 1662, 1520, 1457, 1369, 1240, 1189, 1106, 970, 727 cm-1; 1H NMR (300 MHz, 
DMSO-d6) δ 1.84 (s, NH2), 3.25 (s, OCH3), 3.35–3.44 (m, CHCH2), 4.23–4.36 (m, CH2Ph), 
7.20–7.34 (m, PhH), 8.36–8.45 (br t, NH); 13C NMR (75 MHz, DMSO-d6) δ 41.5 (CH2PH), 
54.3 (CH), 57.8 (CH3), 74.8 (CHCH2), 126.3, 126.7, 127.8, 139.1 (C6H5), 172.6 (C(O)); Anal. 
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Calcd for C11H16N2O2·0.15H2O: C, 62.56; H, 7.79; N, 13.28. Found C, 62.25; H, 7.91; N, 
13.16. 
 
 
(R,S)-N-Benzyl 2-Amino-3-methoxypropionamide ((R,S)-61). The previous procedure 
was repeated using (R,S)-N-benzyl 2-N-(benzylcarboxycarbonyl)amino-3-
methoxypropionamide (2.00 g, 5.85 mmol), 10% Pd-C (0.2 g), and MeOH (100 mL) to give 
the desired product (0.42 g, 32%) as a pale yellow oil: Rf = 0.37 (1:20 MeOH/CHCl3); IR 
(neat) 3227, 3177, 3063, 2900 (br), 1959, 1884, 1814, 1540, 1456, 1361, 1253, 1187, 1110, 
927, 739, 701 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 1.82 (br s, NH2), 3.25 (s, OCH3), 3.37–
3.44 (m, CHCH2), 4.23–4.36 (m, CH2Ph), 7.19–7.34 (m, PhH), 8.36–8.44 (br t, NH);
 13C 
NMR (75 MHz, DMSO-d6) δ 41.5 (CH2PH), 54.3 (CH), 57.8 (CH3), 74.8 (CHCH2), 126.3, 
126.7, 127.8, 139.1 (C6H5), 172.6 (C(O)); Anal. Calcd for C11H16N2O2: C, 63.44; H, 7.74; N, 
13.45. Found C, 63.18; H, 7.66; N, 13.41. 
 
 
(R,S)-N-Benzyl 2-N-(Benzylcarboxycarbonyl)amino-3-ethoxypropionamide ((R,S)-110). 
Utilizing Method D and using (R,S)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-
hydroxypropionamide (1.88 g, 5.73 mmol), Ag2O (6.64 g, 8.59 mmol), EtI (6.94 mL, 85.9 
mmol), and CH3CN (400 mL) (40–50 °C, 7 d) gave the crude product that was further 
purified by flash column chromatography (SiO2, 1:10 MeOH/CH2Cl2) followed by 
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recrystallization from hot toluene to give the desired product (1.04 g, 51%) as a white 
crystalline solid: mp 100–101 ºC; Rf = 0.48 (1:1 EtOAc/hexanes); IR (nujol mull) 3297, 2941 
(br), 2729, 2680, 1688, 1645, 1538, 1457, 1374, 1242, 727 cm-1; 1H NMR (300 MHz, DMSO-
d6) δ 1.08 (t, J = 6.9 Hz, CH3), 3.44 (q, J = 6.9 Hz, OCH2CH3), 3.50–3.60 (m, CHCH2), 4.22–
4.37 (m, CH, CH2Ph), 5.04 (s, OCH2Ph), 7.22–7.46 (m, 2 PhH), 8.53 (t, J = 5.7 Hz,  
NHC(O)); 13C NMR (75 MHz, DMSO-d6) δ 14.6 (OCH2CH3), 41.6 (NHCH2), 54.5 (CH), 65.1 
(OCH2CH3 or OCH2Ph), 65.3 (OCH2Ph or OCH2CH3), 70.0 (CH2OCH2CH3), 126.3, 126.6, 
127.3, 127.4, 127.8, 127.9, 136.6, 138.9 (2 C6H5), 155.5 (C(O)O), 169.4 (C(O)NH); HRMS 
(ESI) 357.1814 [M + H+] (calcd for C20H24N2O4H
+ 357.1814); Anal. Calcd for C20H24N2O4; C, 
67.40; H, 6.79; N, 7.86. Found C, 67.12; H, 6.67; N, 7.89. 
 
 
(R,S)-N-Benzyl 2-Amino-3-ethoxypropionamide ((R,S)-67). Utilizing Method C and (R,S)-
N-benzyl 2-N-(benzylcarboxycarbonyl)amino-3-ethoxypropionamide (1.00 g, 2.81 mmol), 
10% Pd-C (0.1 g), and MeOH (30 mL) (18 h) gave the crude product that was purified by 
flash column chromatography (SiO2; 1:10 MeOH/CH2Cl2). The resulting oil was dissolved in 
CH2Cl2 (10 mL) and was extracted with aqueous 0.1 N HCl (3 x 10 mL). The aqueous layers 
were combined and washed with CH2Cl2 (2 x 30 mL). The aqueous layer was basified to pH 
10–12 with aqueous 0.1 N NaOH, and then extracted with CH2Cl2 (3 x 60 mL). The CH2Cl2 
layers were combined, dried (MgSO4), and concentrated in vacuo to give the desired 
product (0.42 g, 68%) as a pale yellow oil: Rf = 0.33 (1:1 EtOAc/hexanes); IR (neat) 3319, 
3177, 3062, 2865, 1957, 1883, 1812, 1662, 1535, 1455, 1361, 1254, 1107, 1022, 870, 738 
cm-1; 1H NMR (300 MHz, DMSO-d6) δ 1.10 (t, J = 7.2 Hz, CH3), 1.82 (s, NH2), 3.29–3.49 (m, 
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CHCH2OCH2CH3), 4.22–4.37 (m, CH2Ph), 7.20–7.33 (m, PhH), 8.36–8.45 (br t, NHC(O)); 
13C NMR (75 MHz, DMSO-d6) δ 14.7 (OCH2CH3), 41.5 (NHCH2), 54.5 (CH), 65.3 
(OCH2CH3), 72.7 (CH2OCH2CH3), 126.3, 126.7, 127.8, 139.2 (C6H5), 172.8 (C(O)NH); 
HRMS (ESI) 223.1450 [M + H+] (calcd for C12H18N2O2H
+ 223.1447); Anal. Calcd for 
C12H18N2O2·0.06CH2Cl2; C, 63.63; H, 8.02; N, 12.30. Found C, 63.67; H, 8.21; N, 12.32. 
 
 
(R,S)-N-Benzyl 2-N-(Benzylcarboxycarbonyl)amino-3-propoxypropionamide ((R,S)-
111). Utilizing Method D and using  (R,S)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-
hydroxypropionamide (3.29 g, 10.0 mmol), Ag2O (11.59 g, 50.1 mmol), propyl iodide (14.7 
mL, 150.4 mmol), and CH3CN (100 mL) (40–50 °C, 7 d) gave the crude product that was 
further purified by flash column chromatography (SiO2, 1:10 MeOH/CH2Cl2) followed by 
recrystallization from hot EtOAc/hexanes gave the desired product (1.71 g, 46%) as a pale 
orange crystalline solid: mp 101–102 ºC; Rf 0.58 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3279, 
2927 (br), 2728, 1682, 1644, 1544, 1459, 1377, 1237, 696 cm-1; 1H NMR (300 MHz, DMSO-
d6) δ 0.83 (t, J = 6.9 Hz, CH3), 1.42–1.53 (m, CH2CH3), 3.33 (1/2 ABq, J = 6.0 Hz, 
OCHH‟CH2CH3), 3.35 (1/2 ABq, J = 6.0 Hz, OCHH’CH2CH3), 3.50–3.60 (m, CHCH2), 4.23–
4.36 (m, CH, CH2Ph), 5.01 (1/2 ABq, J = 12.6 Hz, OCHH‟Ph), 5.07 (1/2 ABq, J = 12.6 Hz, 
OCHH‟Ph), 7.23–7.37 (m, 2 C6H5), 7.43 (d, J = 8.1 Hz, NHC(O)), 8.52 (t, J = 6.3 Hz, 
NHCH2Ph); 
13C NMR (75 MHz, DMSO-d6) δ 10.0 (CH3), 21.9 (CH2CH3), 41.7 (NHCH2Ph), 
54.5 (CH), 65.1 (OCH2Ph), 69.8 (CH2OCH2 or CH2OCH2CH2), 71.5 (CH2OCH2 or 
CH2OCH2CH2), 126.3, 126.6, 127.3, 127.4, 127.8, 127.9, 136.6, 138.9 (2 C6H5), 155.6 
(C(O)O), 169.4 (C(O)NH); HRMS (ESI) 393.1790 [M + Na+] (calcd for C21H26N2O4Na
+ 
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393.1790); Anal. Calcd for C21H26N2O4; C, 68.09; H, 7.07; N, 7.56. Found C, 68.20; H, 7.19; 
N, 7.64. 
 
 
(R,S)-N-Benzyl 2-Amino-3-propoxypropionamide ((R,S)-68). Utilizing Method C and 
(R,S)-N-benzyl 2-N-(benzylcarboxycarbonyl)amino-3-propoxypropionamide (1.42 g, 3.85 
mmol), 10% Pd-C (0.15 g), and MeOH (50 mL) (6 h) gave the crude product that was 
purified by flash column chromatography (SiO2; 1:100 MeOH/CH2Cl2). The resulting oil was 
dissolved in CH2Cl2 (10 mL) and extracted with aqueous 0.1 N HCl (3 x 10 mL). The 
aqueous layers were combined and washed with CH2Cl2 (2 x 30 mL). The aqueous layer 
was basified to pH 10–12 with aqueous 0.1 N NaOH, and then extracted with CH2Cl2 (3 x 60 
mL). The second set of CH2Cl2 layers were combined, dried (NaSO4), and concentrated in 
vacuo to give the desired product (0.66 g, 72%) as a pale orange oil: Rf 0.52 (1:100 
MeOH/CH2Cl2); IR (neat) 3338, 3123, 2935, 2868, 1661, 1528, 1457, 1362, 1256, 1108, 699 
cm-1; 1H NMR (300 MHz, DMSO-d6) δ 0.85 (t, J = 7.8 Hz, CH3), 1.44–1.56 (m, CH2CH3), 
1.82 (br s, NH2), 3.31–3.46 (m, CHCH2OCH2CH2), 4.23–4.37 (m, CH2Ph), 7.19–7.32 (m, 
C6H5), 8.36–8.45 (br t, NHC(O)); 
13C NMR (75 MHz, DMSO-d6) δ 10.1 (CH3), 22.0 (CH2CH3), 
41.5 (NHCH2), 54.4 (CH), 71.6 (CH2OCH2 or CH2OCH2CH2), 72.8 (CH2OCH2 or 
CH2OCH2CH2), 126.2, 126.6, 127.7, 139.2 (C6H5), 172.7 (C(O)NH); Anal. Calcd for 
C13H20N2O2; C, 66.07; H, 8.53; N, 11.85. Found C, 65.80; H, 8.29; N, 11.58. 
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Diethoxytriphenylphosphorane (377).100 Triphenylphosphine (75.00 g, 0.29 mol) was 
dissolved in anhydrous CH2Cl2 (600 mL) and cooled to -78 ºC. While stirring, Br2 (14.7 mL, 
0.29 mol) was added all at once with a syringe and the reaction was stirred at -78 ºC (30 
min). NaOEt in denatured EtOH (21% w/w, 213 mL 0.57 mol) was added dropwise over 4 h. 
The reaction was stirred at -78 ºC (2 h), and allowed to warm to room temperature (12 h). 
The supernatant was decanted and filtered over a Celite® bed. The remaining suspension 
was centrifuged at 4500 rpm for 15 min. The supernatant layers obtained from both fractions 
were combined and evaporated at 30 ºC. Hexanes (500 mL) were added to the oily residue 
and the mixture was shaken for 5 min. The triphenylphosphine oxide (TPPO) was filtered, 
and the solvent removed in vacuo. Additional hexanes (500 mL) were added to the solid and 
the flask was let stand on ice for 30 min. Additional TPPO was filtered and the solvent 
evaporated to yield DTPP as a white to pale yellow solid (36.40 g, 36% yield, 85% pure by 
wt): 1H NMR (300 MHz, CDCl3) δ 0.75 (t, J = 9.0 Hz, P(OCH2CH3)2), 2.48–2.58 (m, 
P(OCH2CH3)2), 7.37–7.54 (m, 9 ArH), 8.04–8.12 (m, 6 ArH); 
13C NMR (75 MHz, CDCl3) δ 
16.4 (d, J = 5.3 Hz, P(OCH2CH3)2), 57.6 (d, J = 7.5 Hz, P(OCH2CH3)2), 127.7, 129.4, 132.8 
(15 ArC), 139.2 (d, J = 173.3 Hz, 3 ArC). The DTPP obtained under these conditions was 
~85% pure by weight and was contaminated with TPPO (1H NMR analysis). 
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(R,S)-N-Benzyl 1-Aziridine-2-carboxamide ((R,S)-116).187  Utilizing Method C and using 
(R,S)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-hydroxypropionamide (4.27 g, 13.01 
mmol), 10% Pd-C (0.45 g), and MeOH (200 mL) (3 h) gave crude (R,S)-N-benzyl 2-amino-3-
hydroxypropionamide that was then directly dissolved in CH3CN (130 mL). DTPP (8.39 g, 
14.31 mmol, 60% w/w) was added and the reaction was stirred overnight (24 h), filtered, and 
the filtrate evaporated in vacuo. The crude product was purified by flash column 
chromatography (SiO2; 1:100 MeOH/CH2Cl2) to give the desired product (0.92 g, 40%) as an 
orange oil: 1H NMR (300 MHz, DMSO-d6) δ 1.03–1.11 (NHCH), 1.47–1.90 (m, NHCH2CH), 
2.36–2.40 (br t, NHCHC(O)), 4.22–4.35 (m, NHCH2), 7.23–7.36 (m, C6H5), 8.89–8.90 (br t, 
NHCH2); 
13C NMR (75 MHz, DMSO-d6) δ 29.0 (NHCH2), 30.3 NHCH), 42.2 (NHCH2Ph), 
126.6, 127.0, 128.0, 139.9 (C6H5), 170.4 (C(O)). 
 
 
(R,S)-Methyl 3-Hydroxy-2-(N-tritylamino)propionate ((R,S)-129).127 To a solution of DL-
serine methyl ester hydrochloride (20.00 g, 0.13 mol) and Et3N (35.82 mL, 0.26 mol) in 
CH2Cl2 (80 mL) at 0 ºC, was added in one portion a solution of TrCl (36.53 g, 0.13 mol) in 
CH2Cl2 (80 mL). The mixture was allowed to stir at 0 ºC (18 h) under N2 and then 
successively washed with aqueous 10% citric acid (120 mL) and saturated aqueous brine 
(120 mL). The organic layer was dried (Na2SO4) and evaporated in vacuo to give the crude 
product (44.58 g, 96%) as a pale yellow crystalline solid. The product was used in the next 
step without further purification: Rf 0.72 (1:10 EtOAc/hexanes); 
1H NMR (300 MHz, CDCl3) δ 
2.38–2.54 (br s, 1 H), 2.89–3.02 (br s, 1 H), 3.26 (s, OCH3), 3.50–3.59 (m, CH, CHH‟OH), 
3.69–3.73 (m, CHH’OH), 7.15–7.29 (m, 9 PhH), 7.44–7.50 (6 PhH); 13C NMR (75 MHz, 
 111 
 
CDCl3) δ 52.1 (OCH3), 58.0 (CH), 65.1 (CH2OH), 126.8, 128.1, 128.9, 145.8 (3 C6H5), 174.1 
(C(O)). 
 
 
(R,S)-Methyl N-Tritylaziridine-2-carboxylate ((R,S)-130).125 Crude (R,S)-methyl 3-
hydroxy-2-(N-tritylamino)propionate (44.00 g, 0.12 mol) was dissolved in CH2Cl2 (250 mL) 
and cooled to 0 ºC under N2. Methanesulfonyl chloride (10.37 mL, 0.13 mol) was added to 
the cooled solution, followed by the dropwise addition of Et3N (25.47 mL, 0.18 mol). The 
resulting solution was allowed to stir at 0 ºC (30 min) and then successively washed with 
aqueous 10% citric acid (250 mL) and saturated aqueous brine (250 mL), dried (Na2SO4), 
and evaporated in vacuo to give the crude mesylate. The crude mesylate was dissolved in 
DME (250 mL) and Et3N (33.97 mL, 0.24 mol) was added. The mixture was stirred at 80 ºC 
(72 h) and then concentrated to dryness in vacuo. The crude product was dissolved in 
EtOAc (250 mL), successively washed with aqueous 10% citric acid (250 mL) and saturated 
aqueous brine (250 mL), dried (Na2SO4), evaporated in vacuo, and purified by 
recrystallization from hot EtOH to give the desired product (26.43 g, 63%) as an off white 
solid: mp 131–132 ºC (lit.125 mp 133 ºC); Rf 0.16 (1:10 EtOAc/hexanes); IR (nujol mull) 2927, 
2859, 1719, 1596, 1454, 1375, 1291, 1216, 1077, 1027, 923, 869, 754, 707, 637 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 1.41 (dd, J = 1.6, 6.2 Hz, NCHH‟CH), 1.89 (dd, J = 2.7, 6.2 Hz, 
CHH‟CHN), 2.26 (dd, J = 1.6, 2.7 Hz, NCHH’CH), 3.75 (s, OCH3), 7.18–7.30 (9 PhH), 7.48–
7.52 (6 PhH); 13C NMR (75 MHz, CDCl3) δ 28.8 (NCH2CH), 31.9 (CH2CHN), 52.3 (OCH3), 
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74.6 (NCPh3), 127.1, 127.9, 129.5, 143.8 (3 C6H5), 172.1 (C(O)); HRMS (ESI) 344.1663 [M 
+ H+] (calcd for C23H21NO2H
+ 344.1651). 
 
 
(R,S)-Methyl N-(t-Butoxycarbonyl)aziridine-2-carboxylate ((R,S)-131).132 (R,S)-Methyl N-
(trityl)aziridine-2-carboxylate (16.48 g, 48.02 mmol) was dissolved in CH2Cl2 (240 mL) and 
MeOH (1.53 mL, 48.02 mmol) was added and the solution was cooled to 0 ºC in an ice bath 
under N2 before TFA (7.13 mL, 96.05 mmol) was added dropwise. Et3N (33.47 mL, 0.24 
mol) was added dropwise at 0 ºC and the reaction stirred at 0 ºC (10 min) before Boc2O 
(11.53 g, 52.83 mmol) in CH2Cl2 (60 mL) was added dropwise. The reaction was allowed to 
warm to room temperature (18 h) and then successively washed with aqueous 10% citric 
acid (3 x 300 mL), H2O (3 x 300 mL), and saturated aqueous brine (2 x 300 mL), dried 
(Na2SO4), evaporated in vacuo, and purified by flash column chromatography (SiO2; 1:100–
1:10 MeOH/CH2Cl2) to give the desired product (6.79 g, 70%) as a pale yellow oil and as a 
1:1 mixture of isomers A and B: Rf 0.47 (1:10 EtOAc/hexanes); IR (neat) 3483, 3427, 2980, 
1737, 1630, 1449, 1378, 1328, 1156, 1029, 965, 853, 801, 751, 686, 597, 530 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 1.45, 1.46 (2 s, (C(CH3)3), 2.52–2.58 (m, NHCH2CH), 3.03–3.06 (m, 
NHCH2CH), 3.78, 3.79 (2 s, OCH3); 
13C NMR (75 MHz, CDCl3) δ 27.6 (C(CH3)3), 31.0 
(NCH2CH), 34.6 (CH2CHN), 52.3 (OCH3), 81.9 (C(CH3)3), 159.3 (NC(O)O), 168.6 
(C(O)OCH3); HRMS (ESI) 224.0909 [M + Na
+] (calcd for C9H15NO4Na
+ 224.0899). 
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(R,S)-Methyl 2-N’-(t-Butoxycarbonyl)amino-3-allyloxypropionate ((R,S)-132). (R,S)-
Methyl N-(t-butoxycarbonyl)aziridine-2-carboxylate (6.22 g, 30.93 mmol) was dissolved in 
anhydrous CH2Cl2 (30 mL) and cooled to 0 ºC in an ice bath. Then, allyl alcohol (6.31 mL, 
92.79 mmol) followed by BF3•Et2O (3.82 mL, 30.93 mmol) were successively added. The 
reaction was continued at 0 ºC (45 min) and then saturated aqueous NaHCO3 (30 mL) was 
added and stirred (30 min). The organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 30 mL). Both sets of organic layers were combined, dried 
(Na2SO4), evaporated in vacuo, and purified by flash column chromatography (SiO2; 1:10–
1:1 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired product (1.52 g, 
19%) as a pale yellow oil: Rf 0.55 (1:10 EtOAc/hexanes); IR (neat) 3379, 3301, 2930, 1716, 
1507, 1453, 1362, 1167, 929, 866, 781, 658 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.46 (s, 
C(CH3)3), 3.65 (dd, J = 3.6, 9.2 Hz, CHH‟OCH2), 3.76 (s, OCH3), 3.85 (dd, J = 3.2, 9.2 Hz, 
CHH’OCH2), 3.93–4.03 (m, CH2OCH2), 4.42–4.44 (m, CH), 5.17–5.27 (m, OCH2CHCH2), 
5.42 (d, J = 9.2 Hz, NH), 5.79–5.95 (m, OCH2CHCH2); 
13C NMR (100 MHz, CDCl3) δ 28.4 
(C(CH3)3), 52.5 (OCH3), 54.1 (CH), 70.0 (CH2OCH2), 72.3 (CH2OCH2), 80.0 (C(CH3)3), 117.4 
(OCH2CHCH2), 134.2 (OCH2CHCH2), 155.6 (C(O)N), 171.3 (C(O)OCH3). 
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(R,S)-Methyl 2-N’-(t-Butoxycarbonyl)amino-3-allyloxypropionic Acid ((R,S)-134). (R,S)-
Methyl 2-N’-(t-butoxycarbonyl)amino-3-allyloxypropionate (1.13 g, 4.36 mmol) was dissolved 
in anhydrous THF (44 mL) and a solution of LiOH (0.6 M, 7.27 mL, 4.36 mmol) was added at 
room temperature (18 h) and then the solvent was evaporated in vacuo. The crude product 
was diluted with H2O (25 mL), acidified to pH 3 with aqueous 1 M KHSO4, and extracted with 
EtOAc (6 x 25 mL). The combined organic layers were dried (Na2SO4) and evaporated in 
vacuo to give the crude product (1.07 g, 99%) as a pale yellow oil. The product was used for 
the next step without further purification: Rf 0.44 (1:20 MeOH/CH2Cl2);
 1H NMR (400 MHz, 
CD3OD) δ 1.45 (s, C(CH3)3), 3.68 (dd, J = 3.4, 9.8 Hz, CHH‟OCH2), 3.79 (dd, J = 5.0, 9.8 Hz, 
CHH’OCH2), 3.95–4.04 (m, CH2OCH2), 4.30 (t, J = 4.0 Hz, CH), 5.14–5.30 (m, 
OCH2CHCH2), 5.83–5.93 (m, OCH2CHCH2); 
13C NMR (100 MHz, CD3OD) δ 27.3 (C(CH3)3), 
53.8 (CH), 69.4 (CH2OCH2), 71.7 (CH2OCH2), 79.3 (C(CH3)3), 116.0 (OCH2CHCH2), 134.3 
(OCH2CHCH2), 156.4 (C(O)N), 172.4 (C(O)OH). 
 
 
(R,S)-N-Benzyl 2-N’-(t-Butoxycarbonyl)amino-3-allyloxypropionamide ((R,S)-136). 
Employing Method B and using (R,S)-methyl 2-N’-(t-butoxycarbonyl)amino-3-
allyloxypropionic acid (1.05 g, 4.28 mmol), NMM (0.62 mL, 5.57 mmol), IBCF (0.61 mL, 4.71 
mmol), and benzylamine (0.49 mL, 4.50 mmol) gave the crude product that was purified by 
flash column chromatography (SiO2; 10–50% EtOAc/hexanes followed by 10% 
MeOH/CH2Cl2) to give the desired product (1.25 g, 87%) as a pale yellow solid: Rf 0.19 
(10% EtOAc/hexanes); mp 70–71 C; IR (neat) 3305, 3037, 2968, 1707, 1532, 1365, 1250, 
1167, 1041, 948, 869, 744, 700 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.41 (s, C(CH3)3), 3.56 
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(dd, J = 6.4, 9.4 Hz, CHH‟OCH2), 3.87 (dd, J = 4.0, 9.4 Hz, CHH’OCH2), 3.95–4.04 (m, 
CH2OCH2), 4.26–4.34 (m, CH), 4.47 (d, J = 5.6 Hz, NHCH2Ph), 5.15–5.25 (m, 
OCH2CHCH2), 5.37–5.52 (br d, C(O)NH), 5.78–5.88 (m, OCH2CHCH2), 6.81–6.87 (br t, 
NHCH2Ph), 7.23–7.33 (C6H5); 
13C NMR (100 MHz, CDCl3) δ 28.4 (C(CH3)3), 43.6 
(NHCH2Ph), 54.3 (CH), 69.9 (CH2OCH2), 72.4 (CH2OCH2), 80.4 (C(CH3)3), 117.7 
(OCH2CHCH2), 127.5, 127.6, 128.8 (3 ArC), 134.1 (OCH2CHCH2), 138.1 (1 ArC), 155.6 
(OC(O)N), 171.3 (CC(O)N). 
 
 
(R,S)-N-Benzyl 2-Amino-3-allyloxypropionamide ((R,S)-68). Utilizing Method E and using 
(R,S)-N-benzyl 2-N’-(t-butoxycarbonyl)amino-3-allyloxypropionamide (1.17 g, 3.50 mmol), 
TFA (3.90 mL, 52.52 mol), and CH2Cl2 (12 mL) gave the crude product after workup that 
was further purified by flash column chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to 
give the desired product (285 mg, 35%) as a pale yellow oil: Rf 0.44 (1:20 MeOH/CH2Cl2); IR 
(neat) 3446, 3299, 2920, 2863, 1658, 1530, 1454, 1355, 1256, 1090, 1001, 930, 737, 700 
cm-1; 1H NMR (400 MHz, CDCl3) δ 1.61–1.73 (br s, NH2), 3.62 (t, J = 5.6 Hz, CH), 3.66–3.74 
(m, CH2OCH2), 4.00 (app. t, J = 1.2 Hz, CH2OCHH‟), 4.02 (app. t, J = 1.6 Hz, CH2OCHH’), 
4.41–4.51 (m, NHCH2Ph), 5.17–5.29 (m, OCH2CHCH2), 5.84–5.93 (m, OCH2CHCH2), 7.24–
7.35 (C6H5), 7.73–7.81 (br t, NHCH2Ph); 
13C NMR (100 MHz, CDCl3) δ 43.3 (NHCH2Ph), 
55.2 (CH), 72.3 (CH2OCH2), 72.4 (CH2OCH2), 117.5 (OCH2CHCH2), 127.5, 127.8, 128.8 (3 
ArC), 134.5 (OCH2CHCH2), 138.6 (1 ArC), 172.8 (C(O)N); HRMS (ESI) 235.1452 [M + H
+] 
(calcd for C13H18N2O2H
+ 235.1447); Anal. Calcd for C13H18N2O2•0.20H2O: C, 65.61; H, 7.80; 
N, 11.77. Found: C, 65.21; H, 7.92; N, 11.60. 
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(R,S)-Methyl 2-N-(t-Butoxycarbonyl)amino-3-(prop-2-ynyloxy)propionate ((R,S)-133). 
(R,S)-Methyl N-(t-butoxycarbonyl)aziridine-2-carboxylate (6.85 g, 34.06 mmol) was 
dissolved in anhydrous CH2Cl2 (48 mL) and cooled to 0 ºC in an ice bath. Then, propargyl 
alcohol (6.03 mL, 102.18 mmol) followed by BF3•Et2O (4.20 mL, 34.06 mmol) were 
successively added. The reaction was continued at 0 ºC (15 min) and then saturated 
aqueous NaHCO3 (48 mL) was added and stirred (30 min). The organic layer was separated 
and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). Both sets of organic layers 
were combined, dried (Na2SO4), evaporated in vacuo, and purified by flash column 
chromatography (SiO2; 1% MeOH/CH2Cl2) to give the desired product (1.06 g, 12%) as a 
pale yellow oil: Rf 0.35 (1:10 EtOAc/hexanes); IR (neat) 3396, 3265, 2976, 2880, 2118, 
1713, 1507, 1451, 1358, 1213, 1169, 1108, 1065, 925, 869, 778, 663 cm-1; 1H NMR (400 
MHz, CDCl3) δ 1.45 (s, C(CH3)3), 2.45 (t, J = 2.4 Hz, CH2CCH), 3.77 (dd, J = 3.6, 9.2 Hz, 
CHH‟OCH2), 3.78 (s, OCH3), 3.96 (dd, J = 2.8, 9.2 Hz, CHH’OCH2), 4.15 (d, J = 2.4 Hz, 
CH2OCH2), 4.43–4.44 (m, CH), 5.38 (d, J = 8.4 Hz, NH); 
13C NMR (100 MHz, CDCl3) δ 28.5 
(C(CH3)3), 52.7 (OCH3), 54.0 (CH), 58.7 (CH2CCH), 69.9 (CH2OCH2), 75.2 (CH2CCH), 79.0 
(CH2CCH), 80.2 (C(CH3)3), 155.6 (C(O)N), 171.1 (C(O)OCH3); HRMS (ESI) 280.1167 [M + 
Na+] (calcd for C12H19NO5Na
+ 280.1161). 
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(R,S)-2-N-(t-Butoxycarbonyl)amino-3-(prop-2-ynyloxy)propionic Acid ((R,S)-135). 
(R,S)-Methyl 2-N-(t-butoxycarbonyl)amino-3-(prop-2-ynyloxy)propionate (959 mg, 37.30 
mmol) was dissolved in anhydrous THF (37 mL) and a solution of LiOH (0.6 M, 6.22 mL, 
37.30 mmol) was added at room temperature (18 h) and then the solvent was evaporated in 
vacuo. The crude product was diluted with H2O (25 mL), acidified to pH 3 with aqueous 1 M 
KHSO4, and extracted with EtOAc (6 x 25 mL), dried (Na2SO4), and evaporated in vacuo to 
give the crude product (916 mg, 99%) as a pale yellow, waxy solid. The product was used 
for the next step without further purification: Rf 0.46 (1:20 MeOH/CH2Cl2);
 1H NMR (300 
MHz, CD3OD) δ 1.45 (s, C(CH3)3), 2.87 (t, J = 2.3 Hz, CH2CCH), 3.76 (dd, J = 3.9, 9.6 Hz, 
CHH‟OCH2), 3.89 (dd, J = 4.6, 9.6 Hz, CHH’OCH2), 4.17 (d, J = 2.3 Hz, CH2OCH2), 4.32 (t, 
J = 4.2 Hz, CH); 13C NMR (75 MHz, CD3OD) δ 28.8 (C(CH3)3), 55.2 (CH), 59.3 (CH2CCH), 
70.6 (CH2OCH2), 76.4 (CH2CCH), 80.2 (CH2CCH), 80.9 (C(CH3)3), 158.1 (C(O)N), 173.7 
(C(O)OCH3). 
 
 
(R,S)-N-Benzyl 2-N’-(t-Butoxycarbonyl)amino-3-(prop-2-ynyloxy)propionamide ((R,S)-
137). Employing Method B and using (R,S)-methyl 2-N-(t-butoxycarbonyl)amino-3-(prop-2-
ynyloxy)propionic acid (894 mg, 3.68 mmol), NMM (0.53 mL, 4.78 mmol), IBCF (0.52 mL, 
4.05 mmol), and benzylamine (0.42 mL, 3.86 mmol) gave the crude product that was 
purified by flash column chromatography (SiO2; 10–50% EtOAc/hexanes) to give the desired 
product (1.10 g, 90%) as a pale yellow solid: mp 100–101 ºC; Rf 0.77 (1:1 EtOAc/hexanes);  
IR (nujol mull) 3332, 3263, 2878, 2114, 1710, 1660, 1539, 1457, 1369, 1300, 1249, 1166, 
1092, 1020, 943, 871, 663 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.43 (s, C(CH3)3), 2.45 (t, J = 
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2.4 Hz, CH2CCH), 3.70 (dd, J = 6.2, 9.2 Hz, CHH‟OCH2), 3.97 (dd, J = 3.8, 9.2 Hz, 
CHH’OCH2), 4.11–4.23 (m, CH2OCH2), 4.25–4.39 (m, CH), 4.49 (d, J = 5.2 Hz, NHCH2Ph), 
5.31–5.42 (br d, C(O)NH), 6.66–6.72 (br t, NHCH2Ph), 7.25–7.34 (m, C6H5); 
13C NMR (100 
MHz, CDCl3) δ 28.5 (C(CH3)3), 43.7 (NHCH2Ph), 54.3 (CH), 58.8 (CH2CCH), 69.7 
(CH2OCH2), 75.4 (CH2CCH), 79.1 (CH2CCH), 80.6 (C(CH3)3), 127.7, 127.8, 128.9, 138.1 
(C6H5), 155.2 (OC(O)N), 170.2 (CC(O)N); HRMS (ESI) 355.1645 [M + Na
+] (calcd for 
C18H24N2O4Na
+ 355.1634); Anal. Calcd for C18H24N2O4: C, 65.04; H, 7.28; N, 8.43. Found: C, 
65.26; H, 7.44; N, 8.42. 
 
 
(R,S)-N-Benzyl 2-Amino-3-(prop-2-ynyloxy)propionamide ((R,S)-69). Utilizing Method E 
and using (R,S)-N-benzyl 2-N’-(t-butoxycarbonyl)amino-3-(prop-2-ynyloxy)propionamide 
(973 mg, 2.93 mmol), TFA (3.26 mL, 43.94 mol), and CH2Cl2 (10 mL) gave the crude 
product after workup that was further purified by flash column chromatography (SiO2; 1:100–
1:10 MeOH/CH2Cl2) to give the desired product (512 mg, 75%) as a pale yellow oil: Rf 0.29 
(1:100 MeOH/CH2Cl2); IR (neat) 3344, 3295, 3142, 3066, 2909, 2114, 1659, 1527, 1454, 
1357, 1258, 1095, 1023, 916, 737, 697 cm-1; 1H NMR (100 MHz, CDCl3) δ 1.64–1.72 (br s, 
NH2), 2.45 (t, J = 2.4 Hz, CH2CCH), 3.62 (dd, J = 4.0, 6.2 Hz, CH), 3.76 (dd, J = 6.2, 9.2 Hz, 
CHH‟OCH2), 3.84 (dd, J = 4.0, 9.2 Hz, CHH’OCH2), 4.13–4.24 (m, CH2OCH2), 4.41–4.51 (m, 
NHCH2Ph), 7.24–7.35 (m, C6H5), 7.73–7.81 (br t, NHCH2Ph);
 13C NMR (400 MHz, CDCl3) δ 
43.4 (NHCH2Ph), 55.1 (CH), 58.7 (CH2CCH), 72.3 (CH2OCH2), 75.1 (CH2CCH), 79.4 
(CH2CCH), 127.6, 127.8, 128.8, 138.5 (C6H5), 172.5 (CC(O)N); HRMS (ESI) 233.1294 [M + 
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H+] (calcd for C13H16N2O2H
+ 233.1290); Anal. Calcd for C13H16N2O2•0.09CH2Cl2: C, 65.59; H, 
6.80; N, 11.69. Found: C, 65.54; H, 6.97; N, 11.68. 
 
Synthesis of hydantoin derivatives 
A suspension of (R,S)-N-benzyl-2-N-(benzyloxycarbonyl)amino-3-
hydroxypropionamide (2.25 g, 6.86 mmol) in anhydrous CH2Cl2 (70 mL) was cooled to 0 ºC 
and triethylamine (2.1 mL, 15.09 mmol) and methanesulfonyl chloride (0.9 mL, 11.66 mmol) 
were successively added. After 1 h at 0 ºC, DBU (2.1 mL, 13.71 mmol) was added and the 
reaction was maintained at 0 ºC for 30 min before warming to room temperature (4 h). Then, 
DBU (2.1 mL, 13.71 mmol) was added and the reaction continued overnight. The reaction 
was diluted with Et2O (30 mL), and successively washed with aqueous 10% citric acid (3 x 
100 mL), saturated aqueous NaHCO3 (3 x 100 mL), and saturated aqueous brine (2 x 100 
mL), dried (Na2SO4), concentrated in vacuo, and further purified by flash column 
chromatography (SiO2; 1:10–1:0 EtOAc/hexanes) to give benzyl alcohol (0.27 g, 37%) as a 
pale yellow oil, 3-benzyl-5-(benzyloxy)-5-methylimidazolidine-2,4-dione (0.06 g, 3%) as a 
pale yellow solid, 3-benzyl-5-methyleneimidazolidine-2,4-dione (0.37 g, 27%) as a colorless 
oil, and compound C (0.31 g, 11%) as a white solid.  
Benzyl alcohol (143): Rf 0.38 (1:5 EtOAc/hexanes); 
1H NMR (300 MHz, CDCl3) δ 
2.42 (s, OH), 4.60 (s, CH2Ph), 7.22–7.36 (m, C6H5); 
13C NMR (CDCl3) δ 65.3 (CH2Ph), 
127.1, 127.7, 128.7, 141.0 (C6H5). 
 
 
3-Benzyl-5-(benzyloxy)-5-methylimidazolidine-2,4-dione was further purified by 
recrystallization from EtOAc (144): mp 130–131 ºC; Rf 0.34 (1:5 EtOAc/hexanes); 
1H 
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NMR (300 MHz, CDCl3) δ 1.64 (s, CH3), 4.18 (d, J = 10.5 Hz, NCHH‟Ph), 4.37 (d, J = 10.5 
Hz, NCHH’Ph), 4.66 (1/2 ABq, J = 14.6 Hz, OCHH‟Ph), 4.72 (1/2 ABq, J = 14.6 Hz, 
OCHH’Ph), 5.92 (s, NH), 7.22–7.43 (m, 2 C6H5); 
13C NMR (75 MHz, CDCl3) δ 23.7 (CH3), 
42.5 (NCH2Ph), 66.4 (OCH2Ph), 87.0 (CCH3), 128.1, 128.2, 128.3, 128.6, 128.7, 129.0, 
136.0, 136.7 (2 C6H5), 155.5 (NC(O)N), 171.9 (CC(O)N); HRMS (ESI) 333.1216 [M + Na
+] 
(calcd for C18H18N2O3Na
+ 333.1215); Anal. Calcd for C18H18N2O3; C, 69.66; H, 5.85; N, 9.03. 
Found C, 69.93; H, 5.67; N, 9.04.  
 
 
Crystallographic data collection and processing parameters for 3-benzyl-5-
(benzyloxy)-5-methylimidazolidine-2,4-dione (Table 19).  
 
Table 19. Crystal data and structure refinement for 3-benzyl-5-(benzyloxy)-5-
methylimidazolidine-2,4-dione 
Empirical formula  C18H18N2O3 
Formula weight  310.34 
Temperature  296(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 18.6606(15) Å 
 
b = 8.1395(7) Å 
 
c = 11.1590(10) Å 
 
α= 90°. 
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β= 106.943(5)°. 
 
γ = 90°. 
Volume 1621.3(2) Å
3
 
Z 4 
Density (calculated) 1.271 Mg/m
3
 
Absorption coefficient 0.712 mm
-1
 
F(000) 656 
Crystal size 0.30 x 0.25 x 0.25 mm
3
 
Theta range for data collection 2.48 to 66.58°. 
Index ranges -22<=h<=21, -9<=k<=9, -11<=l<=13 
Reflections collected 16778 
Independent reflections 2811 [R(int) = 0.0393] 
Completeness to theta = 66.58° 98.1%  
Absorption correction Numerical 
Max. and min. transmission 0.8420 and 0.8147 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 2811 / 0 / 210 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0389, wR2 = 0.1014 
R indices (all data) R1 = 0.0473, wR2 = 0.1061 
Extinction coefficient 0.0040(5) 
Largest diff. peak and hole 0.224 and -0.264 e.Å
-3
 
 
 
 
3-Benzyl-5-methyleneimidazolidine-2,4-dione149 (145): Rf 0.61 (1:1 
EtOAc/Hexanes); 1H NMR (300 MHz, CDCl3) δ 4.72 (s, NCH2Ph), 4.92 (d, J = 2.0 Hz, 
CCHH‟), 5.44 (d, J = 2.0 Hz, CCHH’), 7.21–7.41 (m, C6H5), 8.28–8.36 (br s, NH). 
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Compound C was further purified by recrystallization from hot EtOAc (146): mp 
228–229 ºC; 1H NMR (300 MHz, DMSO-d6) δ 1.56 (CH3), 4.55 (s, NCH2Ph), 4.62 (m, 
NCH2Ph), 5.62 (s, CH), 7.22–7.37 (m, 2 C6H5), 8.56 (s, NH), 10.28 (s, NH); 
13C NMR (75 
MHz, DMSO-d6) δ 23.7 (CH3), 41.0 (NCH2Ph), 41.1 (NCH2Ph), 59.8 (CCH3), 108.4 (CH), 
126.8, 127.0, 127.1, 127.2, 128.2, 128.6, 135.9, 136.0 (2 C6H5), 153.9 (CH3CC(O)N), 154.8 
(CHCNC(O)N), 162.7 (CHCC(O)N), 173.9 (CH3CC(O)N); HRMS (ESI) 405.1566 [M + H
+] 
(calcd for C22H20N4O4H
+ 405.1556); Anal. Calcd for C22H20N4O4; C, 65.34; H, 4.98; N, 13.85. 
Found C, 65.39; H, 4.83; N, 13.50. HSQC (Figure 13) and HMBC (Figure 14) experiments 
were performed to corroborate the assigned structure.  
 
 
 
Figure 13. Bond correlations obtained from HSQC experiment 
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Figure 14. Two and three bond correlations obtained from HMBC experiment 
 
 
(R,S)-N-(Benzyloxycarbonyl)-serine Methyl Ester ((R,S)-138).188 Utilizing Method A and 
using DL-serine methyl ester hydrochloride (10.0 g, 64.3 mmol), NaHCO3 (17.8 g, 212.1 
mmol), and H2O (130 mL) gave the crude product after workup that was further purified by 
flash column chromatography (SiO2; 1:100 MeOH/CH2Cl2) to give the desired product (12.17 
g, 75%) as a pale yellow oil: Rf 0.29 (1:100 MeOH/CH2Cl2); IR (neat) 3413, 3362, 3033, 
2954, 2893, 1708, 1522, 1219, 1065, 912, 746, 700 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 
3.59–3.69 (m, CH2OH, CH3), 4.14–4.20 (m, CH), 4.98 (t, J = 6.0 Hz, OH), 5.05 (s, OCH2Ph), 
7.29–7.38 (m, C6H5), 7.55 (d, J = 7.8 Hz, NH); 
13C NMR (75 MHz, DMSO-d6) δ 51.5 (CH3), 
56.3 (CH), 60.9 (CH2OH), 65.3 (OCH2Ph), 127.4, 127.5, 128.0, 136.6 (C6H5), 155.7 
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(NC(O)O), 170.9 (CHC(O)); HRMS (ESI) 276.0844 [M + Na+] (calcd for C12H15NO5Na
+ 
276.0848). 
 
 
(R,S)-N-(Benzyloxycarbonyl)amino-dehydroalanine Methyl Ester ((R,S)-140). (R,S)-N-
(Benzyloxycarbonyl)-serine methyl ester (1.00 g, 3.95 mmol) was dissolved in anhydrous 
THF (20 mL) and cooled to 0 ºC before the dropwise addition of Et3N (0.66 mL, 4.74 mmol). 
After 10 min, MsCl (0.37 mL, 4.74 mmol) was added dropwise at 0 ºC, which led to the 
formation of a precipitate. After 1 h at 0 ºC, Et3N (0.66 mL, 4.74 mmol) was added and the 
reaction was warmed to room temperature (3 h). The precipitate was filtered, washed with 
anhydrous THF, and the filtrate was evaporated in vacuo to give a crude oil (0.58 g, 62%) 
that was used without further purification: Rf 0.54 (1:10 EtOAc/hexanes); 
1H NMR (300 MHz, 
CDCl3) δ 3.30–3.75 (br s, NH), 3.83 (s, OCH3), 5.16 (s, OCH2Ph), 5.79 (s, CHH‟), 6.25 (s, 
CHH’), 7.26–7.39 (m, C6H5). 
 
 
(R,S)-2-N-(Benzyloxycarbonyl)amino-3-(N’,N’-dimethyl)aminopropionic Methyl Ester 
((R,S)-156). Utilizing Method F and using (R,S)-N-(benzyloxycarbonyl)-serine methyl ester 
(6.11 g, 24.14 mmol), Et3N (4.0 mL, 28.97 mmol), MsCl (2.2 mL, 28.97 mmol), 
dimethylamine (in 2 M THF, 100 mL, 193.1 mmol), and MeOH (100 mL) gave the crude 
product after workup that was further purified by flash column chromatography (SiO2, 1:100–
1:10 MeOH/CH2Cl2) to give the desired product (4.51 g, 67%) as an orange oil: Rf 0.47 (1:20 
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MeOH/CH2Cl2); IR (neat) 3494, 3248, 3145, 1718, 1524, 1458, 1213, 1056, 908, 850, 745, 
700 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.21 (s, N(CH3)2), 2.57–2.69 (m, CH2N(CH3)2), 3.73 
(s, OCH3), 4.30–4.36 (m, CH), 5.10 (s, OCH2Ph), 5.89 (d, J = 6.3 Hz, NH), 7.27–7.36 (m, 
C6H5); 
13C NMR (75 MHz, CDCl3) δ 45.6 (N(CH3)2), 52.4 (CH3 or CH), 52.8 (CH3 or CH), 59.9 
(CH2N(CH3)2), 67.0 (OCH2Ph), 128.2, 128.5, 136.4 (C6H5), 156.2 (NC(O)O), 172.4 
(CHC(O)), one aromatic peak was not detected and is believed to overlap with nearby 
signals; HRMS (ESI) 303.1322 [M + Na+] (calcd for C14H20N2O4Na
+ 303.1321); Anal. Calcd 
for C14H20N2O2; C, 59.99; H, 7.19; N, 9.99. Found C, 60.17; H, 7.29; N, 9.85. 
 
 
(R,S)-N-Benzyl 2-N’-(Benzyloxycarbonyl)amino-3-(N’’,N’’-dimethyl)aminopropionamide 
((R,S)-158). Utilizing Method G and using (R,S)-N-(benzyloxycarbonyl)amino-3-(N’,N’-
dimethyl)aminopropionic methyl ester (3.88 g, 13.85 mmol), LiOH (0.33 g, 13.85 mmol), 
benzylamine hydrochloride (2.39 g, 16.62 mmol), DMTMM (4.60 g, 16.62 mmol), and 
THF/H2O (140 mL/70 mL) gave the crude product after workup that was further purified by 
flash column chromatography (SiO2, 1:3 CH2Cl2/EtOAc followed by 1:10 MeOH/CH2Cl2) to 
give the desired product (1.67 g, 34%) as an orange solid: mp 82-83 ºC; Rf 0.44 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 3403, 3149, 2856 (br), 1706, 1655, 1550, 1457, 1375, 1255, 
1058, 904, 850, 732, 694 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.26 (s, N(CH3)2), 2.43 (dd, J = 
8.7, 12.4 Hz, CHH‟N(CH3)2), 2.60 (dd, J = 6.2, 12.4 Hz, CHH‟N(CH3)2), 4.09–4.19 (m, CH), 
4.38 (dd, J = 5.3, 14.9 Hz, NHCHH‟Ph), 4.53 (dd, J = 6.2, 14.9 Hz, NHCHH’Ph), 5.08 (1/2 
ABq, J = 12.2 Hz, OCHH‟Ph), 5.13 (1/2 ABq, J = 12.2 Hz, OCHH’Ph), 5.86–6.01 (br d, 
NHC(O)), 7.23–7.36 (m, 2 C6H5), 8.36–8.55 (br t, NHCH2Ph); 
13C NMR (75 MHz, CDCl3) δ 
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43.5 (NHCH2Ph), 45.2 (N(CH3)2), 51.2 (CH), 61.2 (CH2N(CH3)2), 67.1 (OCH2Ph), 127.5, 
127.6, 128.2, 128.3, 128.7, 128.8, 136.4, 138.5 (C6H5), 156.4 (NC(O)O), 171.1 (CHC(O)); 
HRMS (ESI) 378.1798 [M + Na+] (calcd for C20H25N3O3Na
+ 378.1794); Anal. Calcd for 
C20H25N3O3; C, 67.58; H, 7.09; N, 11.82. Found C, 67.58; H, 7.15; N, 12.02. 
 
 
(R,S)-N-Benzyl 2-Amino-3-(N’,N’-dimethyl)aminopropionamide ((R,S)-72). Utilizing 
Method C and using (R,S)-N-benzyl 2-N’-(benzyloxycarbonyl)amino-3-(N’’,N’’-
dimethyl)aminopropionamide (1.08 g, 3.03 mmol), 10% Pd-C (0.1 g), and MeOH (30 mL) 
gave a crude oil that was purified by flash column chromatography (SiO2; 1:100–1:5% 
MeOH/CH2Cl2) to give the desired product (0.40 g, 60%) as a pale orange oil: Rf 0.26 (1:10 
MeOH/CH2Cl2); IR (neat) 3447, 3116, 3006, 2848, 2731, 1661, 1526, 1458, 1362, 1259, 
1113, 1037, 935, 870, 739, 701, 602 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.86 (s, NH2), 2.26 
(s, N(CH3)2), 2.42 (dd, J = 8.8, 12.3 Hz, CHH‟N(CH3)2), 2.60 (dd, J = 6.0, 12.3 Hz, 
CHH’N(CH3)2), 3.50 (dd, J = 6.0, 8.8 Hz, CH), 4.38–4.52 (m, NHCH2Ph), 7.24–7.36 (m, 
C6H5), 8.20–8.34 (br t, NHCH2Ph); 
13C NMR (75 MHz, CDCl3) δ 43.2 (NHCH2Ph), 45.4 
(N(CH3)2), 52.5 (CH), 63.0 (CH2N(CH3)2), 127.5, 127.8, 128.8, 138.8 (C6H5), 174.4 
(CHC(O)); HRMS (ESI) 244.1434 [M + Na+] (calcd for C12H19N3ONa
+ 244.1426); Anal. Calcd 
for C12H19N3O2•0.33H2O; C, 63.41; H, 8.72; N, 18.49. Found C, 63.38; H, 8.52; N, 18.21. 
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 (R,S)-2-N-(Benzyloxycarbonyl)amino-3-morpholinopropionic Methyl Ester ((R,S)-157). 
Utilizing Method F and using (R,S)-N-(benzyloxycarbonyl)-serine methyl ester (7.00 g, 27.66 
mmol), Et3N (4.6 mL, 33.19 mmol), MsCl (2.6 mL, 33.19 mmol), and morpholine (24.2 mL, 
276.6 mmol) gave the crude product after workup that was further purified by flash column 
chromatography (SiO2, 1:100–1:5% MeOH/CH2Cl2) to give the desired product (6.58 g, 
74%) as a white solid: mp 69–70 ºC; Rf 0.53 (1:10 MeOH/CH2Cl2); IR (nujol mull) 3284, 
2904 (br), 1749, 1679, 1528, 1457, 1373, 1302, 1269, 1207, 1159, 1109, 1054, 1007, 904, 
862, 737 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.37–2.50 (m, N(CH2CH2)2O), 2.65–2.76 (m, 
CH2N(CH2CH2)2O), 3.64 (t, J = 4.5 Hz, N(CH2CH2)2O), 3.75 (s, OCH3), 4.35–4.41 (m, CH), 
5.09 (1/2 ABq, J = 12.2 Hz, OCHH‟Ph), 5.14 (1/2 ABq, J = 12.2 Hz, OCHH’Ph), 5.67–5.69 
(d, J = 6.6 Hz, NH), 7.31–7.40 (m, C6H5); 
13C NMR (75 MHz, CDCl3) δ 52.2 (OCH3), 52.5 
(CH), 53.8 (N(CH2CH2)O), 59.2 (CH2N(CH2CH2)O), 67.0 (N(CH2CH2)O), 67.2 (OCH2Ph), 
128.4, 128.7, 136.4 (C6H5), 156.1 (NC(O)O), 172.4 (CHC(O)), one aromatic peak was not 
detected and is believed to overlap with nearby signals; HRMS (ESI) 345.1431 [M + Na+] 
(calcd for C16H22N2O5Na
+ 345.1427); Anal. Calcd for C16H22N2O5; C, 59.61; H, 6.88; N, 8.69. 
Found C, 59.53; H, 6.79; N, 8.59. 
 
 
(R,S)-N-Benzyl 2-N’-(Benzyloxycarbonyl)amino-3-morpholinopropionamide ((R,S)-
159). Utilizing Method G and using (R,S)-2-N-(benzyloxycarbonyl)amino-3-
morpholinopropionic methyl ester (5.00 g, 15.52 mmol), LiOH (0.37 g, 15.52 mmol), 
benzylamine hydrochloride (2.67 g, 18.62 mmol), DMTMM (5.15 g, 18.62 mmol), and 
THF/H2O (150 mL/75 mL) gave the crude product after workup that was further purified by 
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column chromatography (SiO2, 1:100–1:10 MeOH/CH2Cl2) followed by recrystallization from 
hot EtOAc/hexanes to give the desired product (3.49 g, 57%) as a white solid: mp 103–104 
ºC; Rf 0.50 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3418, 3290, 3140, 2912 (br), 1658, 1554, 
1457, 1376, 1260, 1113, 1037, 869, 732, 697 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.26–2.82 
(m, CH2N(CH2CH2)2O), 3.41–3.56 (m, N(CH2CH2)2O), 4.10–4.21 (m, CH), 4.33 (dd, J = 4.8, 
14.6 Hz, NCHH‟Ph), 4.54 (dd, J = 6.3, 14.6 Hz, NCHH’Ph), 5.08 (1/2 ABq, J = 12.3 Hz, 
OCHH‟Ph), 5.13 (1/2 ABq, J = 12.3 Hz, OCHH’Ph), 5.87–5.94 (br d, NHC(O)), 7.25–7.39 
(m, C6H5) 8.10–8.23 (m, NHCH2Ph); 
13C NMR (75 MHz, CDCl3) δ 43.9 (NHCH2Ph), 50.6 
(CH), 53.5 (N(CH2CH2)O), 60.3 (CH2N(CH2CH2)O), 67.0 (N(CH2CH2)O), 67.2 (OCH2Ph), 
127.9, 128.0, 128.3, 128.4, 128.7, 129.0, 136.4, 138.2 (2 C6H5), 156.3 (NC(O)O), 170.7 
(CHC(O)); HRMS (ESI) 420.1884 [M + Na+] (calcd for C22H27N3O4Na
+ 420.1899); Anal. 
Calcd for C22H27N3O4; C, 66.48; H, 6.85; N, 10.57. Found C, 66.52; H, 6.82; N, 10.64. 
 
 
(R,S)-N-Benzyl 2-Amino-3-morpholinopropionamide ((R,S)-73). Utilizing Method C and 
using (R,S)-N-benzyl 2-N‟-(benzyloxycarbonyl)amino-3-morpholinopropionamide (2.50 g, 
6.29 mmol), 10% Pd-C (0.25 g), and MeOH (60 mL) gave the crude product that was further 
purified by flash column chromatography (SiO2; 1:100 MeOH/CH2Cl2) to give the desired 
compound (0.94 g, 57%) as a white solid: mp 84–85 ºC; Rf 0.24 (5% MeOH/CH2Cl2); IR 
(nujol mull) 3401, 3237, 3168, 3096, 2920 (br), 1650, 1598, 1458, 1375, 1115, 946, 876, 
720 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.83 (s, NH2), 2.37–2.55 (m, CHH‟N(CH2CH2)2O), 
2.67 (dd, J = 5.7, 12.3 Hz, CHH’N(CH2CH2)2O), 3.53–3.69 (m, CH, N(CH2CH2)2O), 4.43 (d, J 
= 5.7 Hz, NHCH2Ph), 7.24–7.36 (m, C6H5), 8.06–8.18 (br t, NHCH2Ph); 
13C NMR (75 MHz, 
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CDCl3) δ 43.2 (NHCH2Ph), 51.6 (CH), 53.5 (N(CH2CH2)O), 61.9 (CH2N(CH2CH2)O), 67.0 
(N(CH2CH2)O), 127.5, 127.8, 128.8, 138.5 (C6H5), 174.1 (CHC(O)); HRMS (ESI) 286.1533 
[M + Na+] (calcd for C14H21N3O2Na
+ 286.1532); Anal. Calcd for C14H21N3O2; C, 63.85; H, 
8.04; N, 15.96. Found C, 63.71; H, 7.99; N, 15.77. 
 
 
(R,S)-N,N’-2,3-Bis(t-butoxycarbonyl)aminopropionic Acid ((R,S)-161).150,152 2,3-
Diaminopropionic acid hydrochloride (5.00 g, 35.57 mmol) and NaHCO3 (29.88 g, 0.36 mol) 
were dissolved in H2O (150 mL) and dioxane (150 mL). Di-tert-butyl-dicarbonate (31.05 g, 
142.3 mmol) was added and the reaction was stirred at room temperature (18 h). The 
mixture was diluted with H2O (100 mL), washed with CH2Cl2 (2 x 150 mL), acidified to pH 2 
with aqueous concentrated HCl, and extracted with CH2Cl2 (3 x 200 mL). The organic layers 
were combined, washed with H2O (3 x 200 mL), dried (Na2SO4), and evaporated in vacuo. 
The residue was recrystallized from hot toluene to give the desired product (6.72 g, 62%) as 
a white solid: mp 126–127 ºC (lit.152 mp 118–124 ºC); IR (nujol mull) 3311, 2920 (br), 1741, 
1689, 1530, 1469, 1372, 1284, 1161, 1107, 1044, 868, 773, 719, 671 cm-1; 1H NMR (300 
MHz, DMSO-d6) δ 1.41 (s, C(CH3)3), 1.42 (s, (C(CH3)3)’), 3.24 (t, J = 5.9 Hz, CH2NH), 3.96–
4.03 (m, CH), 6.80 (t, J = 5.9 Hz, (CH3)3COC(O)NH), 6.88–6.91 (d, J = 8.1 Hz, 
(CH3)3COC(O)NH’); 
13C NMR (75 MHz, DMSO-d6) δ 27.8 (2 C(CH3)3), 40.8 (CH2NH), 53.4 
(CH), 77.6, 77.8 (2 C(CH3)3), 155.0, 155.3 (2 C(O)OC(CH3)3), 171.9 (C(O)OH). 
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(R,S)-N-Benzyl N’,N’’-2,3-Bis(t-butoxycarbonyl)aminopropionamide ((R,S)-162). 
Utilizing Method B and using (R,S)-N,N‟-2,3-bis(t-butoxycarbonyl)amino-2,3-propionic acid 
(1.77 g, 5.82 mmol), NMM (0.83 mL, 7.57 mmol), IBCF (0.75 mL, 6.40 mmol), and 
benzylamine (0.64 mL, 6.11 mmol) gave the crude product that was recrystallized twice from 
hot EtOAc to give the desired product (1.54 g, 67%) as a white solid: mp 141–142 ºC; Rf 
0.52 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3319, 2919, 2860, 1687, 1531, 1456, 1371, 1304, 
1247, 1169, 1044, 952, 873, 746, 698, 639 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.42 (s, 
C(CH3)3), 1.43 (s, C(CH3)3’), 3.45–3.60 (m, CH2NH), 4.18–4.29 (m, CH), 4.39 (dd, J = 5.0, 
15.4 Hz, NHCHH‟Ph), 4.51 (dd, J = 5.6, 15.4 Hz, NHCHH’Ph), 5.11–5.24 (br t, 
(CH3)3COC(O)NH), 5.89 (d, J = 6.0 Hz, (CH3)3COC(O)NH’), 6.96–7.05 (br t, NHCH2Ph), 
7.24–7.35 (C6H5); 
13C NMR (75 MHz, CDCl3) δ 28.3, 28.4 (2 C(CH3)3), 42.5 (NHCH2Ph), 
43.5 (CH2NH), 56.0 (CH), 80.0, 80.4 (2 C(CH3)3), 127.5, 127.6, 128.8, 138.1 (C6H5), 156.4, 
157.3 (2 C(O)OC(CH3)3), 170.8 (C(O)NHCH2Ph); HRMS (ESI) 416.2151 [M + Na
+] (calcd for 
C20H31N3O5Na
+ 416.2162); Anal. Calcd for C20H31N3O5: C, 61.05; H, 7.94; N, 10.68. Found: 
C, 61.16; H, 7.98; N, 10.49. 
 
 
(R,S)-N-Benzyl 2,3-Diaminopropionamide ((R,S)-70). Utilizing Method E and using (R,S)-
N-benzyl-N’,N’‟-2,3-bis(t-butoxycarbonyl)aminopropionamide (1.71 g, 4.35 mmol), TFA (4.86 
mL, 65.23 mmol), and CH2Cl2 (15 mL) gave the crude product after workup that was further 
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purified by recrystallization from hot EtOAc/hexanes to give the desired product (427 mg, 
51%) as a white solid: mp 119–120 ºC; Rf 0.17 (1–10 MeOH/CH2Cl2); IR (nujol mull) 3316, 
2924, 2858, 1645, 1523, 1459, 1376, 731 cm-1; 1H NMR (300 MHz, CD3OD) δ 2.70–2.95 (m, 
CH2NH2), 3.35–3.42 (m, CH), 4.40 (s, NHCH2Ph), 7.21–7.35 (m, C6H5); 
13C NMR (75 MHz, 
CD3OD) δ 44.2 (NHCH2Ph), 46.7 (CH2NH2), 57.5 (CH), 128.5, 128.8, 129.8, 140.0 (C6H5), 
175.9 (C(O)NH); HRMS (ESI) 216.1107 [M + Na+] (calcd for C10H15N3ONa
+ 216.1113); Anal. 
Calcd for C10H15N3O•H2O: C, 61.91; H, 7.84; N, 21.66. Found: C, 61.54; H, 7.90; N, 21.38. 
 
 
(R,S)-2-N-(Benzyloxycarbonyl)amino-3-(N’-methylamino)propionic Methyl Ester ((R,S)-
155).189,153 Utilizing Method F and using (R,S)-N-(benzyloxycarbonyl)-serine methyl ester 
(4.67 g, 18.45 mmol), Et3N (3.1 mL, 22.14 mmol), MsCl (1.7 mL, 22.14 mmol), methylamine 
(in 2 M THF, 92.3 mL, 184.51 mmol), and MeOH (92.3 mL) gave the crude product after 
workup that was further purified by flash column chromatography (SiO2, 1–20% 
MeOH/CH2Cl2) to give the desired product (1.38 g, 28%) as an orange oil and (R,S)-N-
methyl-2-N‟-(benzyloxycarbonyl)amino-3-(N’’-methylamino)propionamide (2.06 g, 42%) as 
an orange solid.  
 
 
(R,S)-2-N-(Benzyloxycarbonyl)amino-3-(N’-methylamino)propionic Methyl Ester 
((R,S)-155): Rf 0.26 (1:20 MeOH/CH2Cl2); IR (neat) 3326, 3032, 2952, 2853, 2800, 2360, 
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1960, 1716, 1530, 1451, 1218, 1054, 912, 746, 700 cm-1; 1H NMR (300 MHz, CDCl3) δ 
1.16–1.26 (br s, NHCH3), 2.40 (s, NHCH3), 2.89–3.02 (m, CH2NHCH3), 3.75 (s, OCH3), 
4.42–4.48 (m, CH), 5.12 (s, OCH2Ph), 5.81 (d, J = 7.5 Hz, NHC(O)O), 7.27–7.37 (m, C6H5); 
13C NMR (75 MHz, CDCl3) δ 36.4 (NHCH3), 52.7 (OCH3 or CH2NHCH3), 52.8 (OCH3 or 
CH2NHCH3), 53.9 (CH), 67.2 (OCH2Ph), 128.2, 128.3, 128.7, 136.4 (C6H5), 156.3 (NC(O)O), 
172.3 (CHC(O)); HRMS (ESI) 267.1352 [M + H+] (calcd for C13H18N2O4H
+ 267.1345); Anal. 
Calcd for C13H18N2O4; C, 58.63; H, 6.81; N, 10.52. Found C, 58.36; H, 6.82; N, 10.67.  
 
 
(R,S)-N-Methyl 2-N’-(Benzyloxycarbonyl)amino-3-(N’’-
methylamino)propionamide ((R,S)-163): mp 122–123 ºC; Rf 0.32 (1:10 MeOH/CH2Cl2); IR 
(nujol mull) 3319, 3217, 3170, 3041 (br), 1719, 1660, 1593, 1547, 1457, 1377, 1250, 1153, 
1052, 850, 735 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.72 (s, NHCH3), 2.42 (s, NHCH3), 2.64 
(dd, J = 8.0, 11.7 Hz, CHH‟NHCH3), 2.80 (d, J = 4.8 Hz, C(O)NHCH3), 3.11 (dd, J = 3.6, 
11.7 Hz, CHH’NHCH3), 4.08–4.14 (m, CH), 5.11 (s, OCH2Ph), 6.11 (d, J = 5.7 Hz, NHC(O)), 
7.28–7.36 (m, C6H5) 7.49–7.60 (br s, OC(O)NHCH3); 
13C NMR (75 MHz, CDCl3) δ 26.3 
(C(O)NHCH3), 36.3 (NHCH3), 53.2 (CH, CHCH2), 67.2 (OCH2Ph), 128.2, 128.4, 128.7, 
136.4 (C6H5), 156.6 (NC(O)O), 171.8 (CHC(O)); HRMS (ESI) 288.1327 [M + Na
+] (calcd for 
C13H19N3O3Na
+ 288.1324); Anal. Calcd for C13H19N3O3; C, 58.85; H, 7.22; N, 15.84. Found 
C, 58.82; H, 7.22; N, 15.66. 
 
 133 
 
 
(R,S)-N-Methyl 2-Amino-3-(N’-methylamino)propionamide Maleate Salt ((R,S)-165). 
Utilizing Method C and using (R,S)-N-methyl 2-N‟-(benzyloxycarbonyl)amino-3-(N’’-
methylamino)propionamide (4.00 g, 15.09 mmol), 10% Pd-C (0.40 g), and MeOH (150 mL) 
gave a crude oil that was then dissolved in THF (13.7 mL). A THF solution (13.7 mL) of 
maleic acid (6.36 g, 54.89 mmol) was added dropwise to the crude product and allowed to 
stand at room temperature (18 h) before the precipitate was collected as a yellow crystalline 
solid. The precipitate was purified by recrystallization from MeOH/Et2O (2x) to give the 
desired product (2.53 g, 67%) as a white solid and as a 1:2 ratio of PAAD:maleic acid: mp 
95–96 ºC; Rf 0.17 (1:4 MeOH/CH2Cl2); IR (nujol mull) 3156, 2906 (br), 1694, 1574, 1458, 
1373, 1208, 866, 721, 650, 574 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 2.64 (s, CH2NHCH3), 
2.69 (d, J = 4.7 Hz, C(O)NCH3), 3.20 (dd, J = 6.5, 13.7 Hz, CHH‟NHCH3), 3.30 (dd, J = 5.3, 
13.7 Hz, CHH’NHCH3), 3.96–4.02 (br t, CH), 6.11 (s, HCO2CHCHCO2H), 8.43–8.48 (m, 
NH); 13C NMR (75 MHz, DMSO-d6) δ 26.0  (CH2NHCH3), 33.5 (C(O)NHCH3), 49.0, 49.8 
(CH2NH, CH), 135.4 (HCO2CHCHCO2H), 166.9 (C(O)NHCH3), 167.5 (HCO2CHCHCO2H); 
LRMS (ESI) 132.10 [M + H+] (calcd for C5H13N3OH
+ 132.10); Anal. Calcd for 
C13H21N3O9•0.47CH3OH: C, 42.36; H, 6.20; N, 10.92. Found: C, 42.76; H, 6.09; N, 11.10. 
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(R,S)-Methyl 2-N-(Benzyloxycarbonyl)amino-3-(N’-benzyloxycarbonyl-N’-
methyl)aminopropionate ((R,S)-166). Benzyl chloroformate (0.65 mL, 4.64 mmol) was 
added dropwise to a solution of (R,S)-methyl 2-N-(benzyloxycarbonylamino)-3-(N’-
methylamino)propanoate. (1.18 g, 4.42 mmol) and DIEA (0.81 mL, 4.64 mmol) in dioxane 
(23 mL) at room temperature while stirring under N2. The reaction was maintained at room 
temperature (18 h) before the solvent was evaporated in vacuo. The resulting crude oil was 
dissolved in EtOAc (25 mL) and was successively washed with aqueous 10% citric acid (3 x 
25 mL), saturated aqueous NaHCO3 (3 x 25 mL), and saturated aqueous brine (2 x 25 mL), 
dried (Na2SO4), evaporated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 1:100–1:5 MeOH/CH2Cl2) followed by a second flash column (SiO2, 
1:10–1:1% EtOAc/hexanes) to give the desired compound (0.33 g, 18%) as a pale yellow 
oil: IR (neat) 3343, 3033, 2953, 1712, 1518, 1454, 1403, 1341, 1218, 1059, 746, 700, 605 
cm-1; 1H NMR (300 MHz, CDCl3) δ 2.95 (s, NCH3), 3.57–3.79 (m, CH2NCH3, OCH3), 4.48–
4.55 (m, CH), 5.10 (s, 2 OCH2Ph), 5.90 (d, J = 7.2 Hz, NHC(O)O), 7.26–7.38 (m, 2 C6H5); 
13C NMR (75 MHz, CDCl3) δ 35.8 (NCH3), 50.8 (OCH3 or CH2NCH3), 51.2 (OCH3 or 
CH2NCH3), 54.0 (CH), 67.6, 68.1 (2 OCH2Ph), 128.4, 128.5, 128.6, 128.7, 129.1, 136.9, 
137.1 (2 C6H5), 156.6, 157.9 (2 NC(O)O), 171.6 (CHC(O)), one aromatic peak was not 
detected and is believed to overlap with nearby signals; HRMS (ESI) 423.1539 [M + Na+] 
(calcd for C21H24N2O6Na 423.1532); Anal. Calcd for C21H24N2O6: C, 62.99; H, 6.04; N, 7.00. 
Found: C, 62.71; H, 6.11; N, 6.98. 
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4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium Chloride (378).5 2-Chloro-
4,6-dimethoxy-1,3,5-triazine (5.00 g, 28.5 mmol) was dissolved in reagent grade THF (570 
mL) and NMM (3.44 mL, 31.4 mmol) was added at room temperature. After 1 h, the white 
precipitate was filtered, washed with THF, and dried in vacuo to give the desired product 
(5.32 g, 68%) as a white powder: mp 126–127 ºC (lit.5 mp 120–122 ºC); 1H NMR (300 MHz, 
CD3OD) δ 3.55 (s, NCH3), 3.80–3.96 (m, 2 CH2), 4.04–4.11 (m, CH2), 4.18 (s, 2 OCH3), 
4.52–4.57 (m, CH2); 
13C NMR (75 MHz, CD3OD) δ 56.6 (NCH3), 57.7 (2 NCH2C), 61.5 (2 
OCH3), 63.3 (2 OCH2C), 171.9 (NCN), 175.5 (2 NCO). 
 
 
(R,S)-N-Benzyl 2-N’-(Benzyloxycarbonyl)amino-3-(N’’-benzyloxycarbonyl-N’’-
methyl)aminopropionamide ((R,S)-167). Utilizing Method G and using (R,S)-methyl 2-N-
(benzyloxycarbonyl)amino-3-(N‟-benzyloxycarbonyl-N‟-methyl)aminopropionate (259 mg, 
0.65 mmol), LiOH (15 mg, 0.65 mmol), benzylamine hydrochloride (110 mg, 0.78 mmol), 
DMTMM (215 mg, 0.78 mmol), and THF/H2O (6 mL/3 mL) gave the crude product after 
workup that was further purified by recrystallization from hot EtOAc/hexanes to give the 
desired product (205 mg, 69%) as a white solid: mp 119–120 ºC; Rf 0.44 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 3298, 2932 (br), 1699, 1645, 1547, 1458, 1375, 1235, 1137, 
1065, 728 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.93 (s, NCH3), 3.57–3.81 (m, CH2NCH3), 
4.28–4.50 (m, CH, NHCH2Ph), 5.09 (s, 2 OCH2Ph), 6.32–6.44 (br d, NHC(O)O), 6.81–6.89 
(br t, NHCH2Ph), 7.16–7.35 (m, 3 C6H5); 
13C NMR (75 MHz, CDCl3) δ 36.4 (NCH3), 44.1 
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(NHCH2Ph), 52.2 (CH2NCH3), 56.6 (CH), 67.8, 68.3 (2 OCH2Ph), 128.1, 128.2, 128.4, 128.7, 
128.9, 129.2, 129.3, 136.7, 136.8, 138.3 (3 C6H5), 156.6, 157.9 (2 NC(O)O), 171.6 
(CHC(O)), two aromatic peaks were not detected and are believed to overlap with nearby 
signals; HRMS (ESI) 476.2184 [M + H+] (calcd for C27H29N3O5H
+ 476.2185); Anal. Calcd for 
C27H29N3O5: C, 68.19; H, 6.15; N, 8.84. Found: C, 68.22; H, 6.10; N, 8.85. 
 
 
 (R,S)-3-N-(Benzylcarboxycarbonyl)amino β-Propiolactone ((R,S)-171).158 PPh3 (5.49 g, 
20.91 mmol) was dissolved in anhydrous THF (140 mL) and cooled to -78 ºC. DEAD (40 wt. 
in toluene, 9.52 mL, 20.91 mL) was added dropwise, followed by the dropwise addition of an 
anhydrous THF solution (30 mL) of (R,S)-2-N-(benzyloxycarbonyl)amino-3-
hydroxypropanoic acid (5.00 g, 90.91 mmol). The solution stirred at -78 ºC (30 min) and then 
warmed to room temperature (3 h). The solvent was evaporated in vacuo to give the crude 
product that was further purified by recrystallization from hot CHCl3/hexanes to give the 
desired product (1.00 g, 22%) as a white solid: mp 107-109 ºC (lit.158 mp 114-116 ºC); Rf 
0.84 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2981 (br), 1839, 1685, 1532, 1459, 1376, 1270, 
1105, 1019, 885, 752 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.42–4.44 (br d, OCH2), 5.07–5.17 
(m, CH, OCH2Ph), 5.67 (d, J = 6.9 Hz, NH), 7.32–7.36 (m, C6H5).
 13C NMR (100 MHz, 
CDCl3) δ 59.6 (NHCH), 66.3 (OCH2Ph), 67.8 (OCH2CH), 128.3, 125.5, 128.6, 135.5 (C6H5), 
155.2 (NC(O)), 168.8 (CC(O)); HRMS (ESI) 353.9730 [M + Cs+] (calcd for C11H11NO4Cs
+ 
353.9742). 
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(R)-2-N-(t-Butoxycarbonyl)amino-4-(methylthio)butanoic Acid ((R)-175).166 D-Methionine 
(5.00 g, 33.55 mmol) was dissolved in dioxane (20 mL) and aqueous 1.25 M NaOH (25 mL) 
and then cooled to 0 ºC in an ice bath under N2. Boc2O (7.69 g, 35.22 mmol) in dioxane (5 
mL) was added dropwise and the reaction was allowed to warm to room temperature (18 h) 
before the organic layer was evaporated in vacuo. The remaining aqueous layer was diluted 
with aqueous 1 M KHSO4 (50 mL) and extracted with EtOAc (3 x 75 mL). The organic layers 
were combined and washed with brine (2 x 200 mL), dried (Na2SO4), and evaporated in 
vacuo to give the crude product (8.19 g, 98%) as a pale yellow oil. The product was used for 
the next step without further purification: 1H NMR (300 MHz, CDCl3) δ 1.46 (s, C(CH3)3), 
1.95–2.06 (m, CHH‟CH2SCH3), 2.11 (s, SCH3), 2.12–2.26 (m, CHH’CH2SCH3), 2.58 (t, J = 
8.0 Hz, CH2SCH3), 4.18–4.64 (m, CH), 5.24–5.27 (d, J = 8.0 Hz, NHC(O)).  
 
 
(R)-N-Benzyl 2-N’-(t-Butoxycarbonyl)amino-4-(methylthio)butanamide ((R)-176). 
Utilizing Method B and using (R)-2-N-(t-butoxycarbonyl)amino-4-(methylthio)butanoic acid 
(7.10 g, 28.50 mmol), NMM (4.07 mL, 37.05 mmol), IBCF (4.04 mL, 31.35 mmol), and 
benzylamine (3.27 mL, 29.92 mmol) gave the crude product that was purified by 
recrystallization (2x) from hot EtOAc/hexanes to give the desired compound (4.21 g, 44%) 
as a white solid: mp 104–105 ºC; Rf 0.59 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3369, 3305, 
2924, 1655, 1527, 1456, 13.73, 1328, 1293, 1247, 1170, 1055, 856, 739, 692 cm-1; 1H NMR 
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(300 MHz, CDCl3) δ 1.40 (s, C(CH3)3), 1.87–1.99 (m, CHH‟CH2SCH3), 2.06 (s, SCH3), 2.07–
2.16 (m, CHH’CH2SCH3), 2.50–2.60 (m, CH2SCH3), 4.29–4.48 (m, CH, NHCH2Ph), 5.40–
5.42 (d, J = 7.5 Hz, NHC(O)), 6.88–6.96 (br t, NHCH2Ph), 7.23–7.34 (C6H5); 
13C NMR (75 
MHz, CDCl3) δ 15.0 (SCH3), 28.0 (C(CH3)3), 30.0 (CH2SCH3), 31.4 (CH2CH2SCH3), 43.1 
(NHCH2Ph), 53.2 (CH), 79.8 (C(CH3)3), 127.1, 127.3, 128.4, 137.7 (m, C6H5), 155.4 
(NC(O)O), 171.3 (NC(O)C); HRMS (ESI) 339.1751 [M + H+] (calcd for C17H26N2O3SH
+ 
339.1742); Anal. Calcd for C17H26N2O3S: C, 60.33; H, 7.74; N, 8.28; S, 9.47. Found: C, 
60.18; H, 7.80; N, 8.25; S, 9.18. 
 
 
(R)-N-Benzyl 2-Amino-4-(methylthio)butanamide ((R)-76). Utilizing Method E and using 
(R)-N-benzyl 2-N‟-(t-Butoxycarbonyl)amino-4-(methylthio)butanamide (1.64 g, 4.85 mmol), 
TFA (5.40 mL, 72.74 mol), and CH2Cl2 (15 mL) gave the crude product that was further 
purified by flash column chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to give the 
desired product (0.87 g, 76%) as a pale yellow oil: Rf 0.58 (1:20 MeOH/CH2Cl2); IR (neat) 
3315, 3032, 2918, 1655, 1524, 1441, 1356, 1249, 1082, 1027, 956, 737, 700 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 1.48 (s, NH2), 1.73–1.87 (m, CHH‟CH2SCH3), 2.10 (s, SCH3), 2.16–2.27 
(m, CHH’CH2SCH3), 2.62 (t, J = 7.4 Hz, CH2SCH3), 3.55 (dd, J = 4.4, 8.3 Hz, CH), 4.45 (d, J 
= 6.0 Hz, NHCH2Ph), 7.25–7.36 (m, C6H5), 7.57–7.64 (br t, NHCH2Ph); 
13C NMR (75 MHz, 
CDCl3) δ 15.5 (SCH3), 30.9 (CH2SCH3), 34.3 (CH2CH2SCH3), 43.4 (NHCH2Ph), 54.5 (CH), 
127.6, 127.9, 128.9, 138.6 (C6H5), 174.6 (NC(O)); HRMS (ESI) 239.1224 [M + H
+] (calcd for 
C12H18N2OSH
+ 239.1218); Anal. Calcd for C12H18N2OS: C, 60.47; H, 7.61; N, 11.75; S, 
13.45. Found: C, 60.17; H, 7.62; N, 11.52; S, 13.69. 
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(R)-2-(Benzyloxycarbonyl)amino-γ-lactone ((R)-179).169 D-Homoserine (5.00 g, 42.00 
mmol) was dissolved in aqueous 1 M Na2CO3 (50 mL) and cooled to 0 ºC in an ice bath 
under N2. Benzyl chloroformate (6.48 mL, 46.20 mmol) was added dropwise and the 
reaction was maintained at 0 ºC (30 min) before warming to room temperature (18 h). The 
solution was acidified to pH 2 with aqueous concentrated HCl and extracted with EtOAc (3 x 
75 mL). The combined organic layers were dried (Na2SO4), evaporated in vacuo, and 
purified by recrystallization from hot EtOAc/hexanes to give the desired product (7.32 g, 
74%) as a white solid: mp 130–131 ºC (lit.169 mp 118–120 ºC); Rf 0.67 (1:20 MeOH/CH2Cl2); 
IR (nujol mull) 3428, 3062, 2856, 1777, 1694, 1550, 1458, 1380, 1295, 1176, 1076, 1011, 
946, 844, 739, 694, 629 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.14–2.29 (m, CHCHH‟), 2.74–
2.82 (m, CHCHH’), 4.21–4.29 (m, CH), 4.34–4.48 (m, CHCH2CH2O), 5.13 (s, OCH2Ph), 
5.34–5.42 (br d, NH), 7.32–7.38 (m, C6H5); 
13C NMR (75 MHz, CDCl3) δ 30.2 
(CHCH2CH2O), 50.6 (CHCH2CH2O), 65.9 (CHCH2CH2O), 67.4 (OCH2Ph), 128.3, 128.5, 
128.7, 136.0 (C6H5), 156.3 (NC(O)O), 175.3 (C(O)O); HRMS (ESI) 258.0753 [M + Na
+] 
(calcd for C12H13NO4Na
+ 258.0742); Anal. Calcd for C12H13NO4: C, 61.27; H, 5.57; N, 5.59. 
Found: C, 61.26; H, 5.65; N, 6.00. 
 
 
(R)-N-Benzyl 2-N’-(Benzyloxycarbonyl)amino-4-hydroxybutanamide ((R)-180). A 
mixture of (R)-2-(benzyloxycarbonyl)amino-γ-lactone (4.20 mg, 17.87 mmol) and 
benzylamine (3.90 mL, 35.73 mmol) was stirred in anhydrous pyridine (70 mL) at 80 ºC (18 
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h). The mixture was allowed to cool to room temperature and was diluted with CH2Cl2 (50 
mL). The organic layer was successively washed with aqueous 1 M HCl (3 x 50 mL), H2O (3 
x 50 mL), and brine (2 x 50 mL), dried (Na2SO4), and evaporated in vacuo. The crude 
product was purified by recrystallization from hot EtOAc to give the desired product (3.57 g, 
58%) as a white solid: mp 126–127 ºC; Rf 0.56 (1:20 MeOH/CH2Cl2);  IR (nujol mull) 3087, 
2916 (br), 1694, 1656, 1552, 1457, 1343, 1255, 1159, 1085, 1019, 727 cm-1; 1H NMR (300 
MHz, DMSO-d6) δ 1.65–1.89 (m, CHCH2), 3.40-3.46 (m, CH2OH), 4.10-4.17 (m, CH), 4.21-
4.35 (m, NHCH2), 4.59 (t, OH), 5.03 (s, OCH2Ph), 7.23–7.37 (m, 2 C6H5), 7.46 (d, J = 8.1 
Hz, OC(O)NH), 8.46 (t, J = 6.0 Hz NHCH2Ph); 
13C NMR (75 MHz, DMSO-d6) δ 34.9 
(CHCH2), 42.0 (NHCH2), 52.3 (CH2OH), 57.5 (CH), 65.4 (OCH2Ph), 126.6, 127.0, 127.7, 
127.7, 128.2, 128.3, 137.0, 139.5 (2 C6H5), 155.9 (OC(O)), 172.1 (CC(O)); HRMS (ESI) 
365.1462 [M + Na+] (calcd for C19H22N2O4Na
+ 365.1477). 
 
 
(R)-N-Benzyl 2-Amino-4-hydroxybutanamide ((R)-74). Utilizing Method C and using (R)-
N-benzyl 2-N‟-(benzyloxycarbonyl)amino-4-hydroxybutanamide (1.50 g, 4.38 mmol), 10% 
Pd-C (0.15 g), and MeOH (45 mL)  gave the crude product that was further purified by flash 
column chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to give the desired product (0.53 
g, 57%) as a white solid: mp 88–89 ºC; Rf 0.40 (1:10 MeOH/CH2Cl2);  [α]
25
D + 4.8° (c 1.1, 
CH2Cl2); IR (nujol mull) 3265, 2965 (br), 1649, 1540, 1457, 1365, 1251, 1142, 1080, 1024, 
952, 801, 724, 602, 549 cm-1;  1H NMR (300 MHz, CDCl3) δ 1.79–1.90 (m, CHH‟CH2OH), 
1.93–2.19 (m, CHH’CH2OH, NH2), 3.61 (t, J = 6.6 Hz, CH), 3.76–3.88 (CH2CH2OH), 4.46 (d, 
J = 6.3 Hz, NHCH2Ph), 7.25–7.38 (m, C6H5), 7.56–7.64 (br t, NHCH2Ph); 
13C NMR (75 MHz, 
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CDCl3) δ 37.6 (CH2CH2OH), 43.0 (NHCH2Ph), 54.1 (CH), 60.6 (CH2CH2OH), 127.3, 127.5, 
128.5, 137.9 (C6H5), 175.0 (C(O)N); HRMS (ESI) 209.1288 [M + H
+] (calcd for C11H16N2O2H
+ 
209.1290); Anal. Calcd for C11H16N2O2: C, 63.44; H, 7.74; N, 13.45. Found: C, 63.31; H, 
7.86; N, 13.31. 
 
 
(R)-2-Amino-γ-lactone and (R)-Methyl 4-Hydroxy-2-aminobutanoate ((R)-182).171,172 An 
anhydrous MeOH solution (35 mL) was cooled to 0 ºC in an ice bath under N2 and SOCl2 
(2.44 mL, 33.60 mmol) was added dropwise. After 30 min at 0 ºC, D-homoserine (4.00 g, 
33.60 mmol) was added and the reaction warmed to room temperature (18 h). The solvent 
was evaporated in vacuo and the crude product was triturated with Et2O (3 x 50 mL) to give 
a 5:1 mixture of lactone:ester. The crude product was used for the next step without further 
purification: Rf 0.00 (1:20 MeOH/CH2Cl2);
 1H NMR (400 MHz, D2O) Lactone: δ 2.45–2.56 (m, 
H2), 2.83–2.90 (m, H3), 4.47–4.56 (m, H1, H5), 4.67 (t, J = 9.2 Hz, H4); Ester: δ 2.17–2.40 (m, 
CH2CH2OH), 3.84 (t, J = 5.6 Hz, CH2OH), 3.90 (s, OCH3), 4.33–4.39 (m, CH). 
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(R)-2-N-(Trityl)amino-γ-lactone and (R)-Methyl 4-Hydroxy-2-(N-trityl)aminobutanoate 
((R)-183).171,172 A mixture of (R)-2-amino-γ-lactone and (R)-methyl 4-hydroxy-2-
aminobutanoate (4.47 g, 33.60 mmol) was dissolved in CH2Cl2 (25 mL) and Et3N (9.37 mL, 
67.20 mmol) was added at room temperature. The mixture was cooled to 0 ºC in an ice bath 
and TrtCl (9.37 g, 33.60 mmol) in CH2Cl2 (25 mL) was added in one portion. The mixture 
was stirred overnight (18 h) at 0 ºC and then the solvent was evaporated in vacuo. The 
crude product was diluted with CH2Cl2 (50 mL) and washed with aqueous 10% citric acid (3 
x 50 mL). The aqueous layers were combined and washed with CH2Cl2 (2 x 50 mL). Both 
sets of organic layers were combined, washed with brine (2 x 200 mL), dried (Na2SO4), and 
evaporated in vacuo to give the crude product (11.83 g, 94%) as a pale orange solid and as 
a 5:1 mixture of modified lactone:ester. The product was used for the next step without 
further purification: Rf 0.38, 0.63 (1:10 EtOAc/hexanes);
 1H NMR (400 MHz, CDCl3) Lactone: 
δ 1.15–1.21 (m, H3), 1.53–1.64 (m, H2), 3.38–3.43 (m, H1), 3.74–3.80 (m, H5), 4.09 (t, J = 8.8 
Hz, H4), 7.15–7.31 (m, 9 PhH), 7.39–7.55 (m, 6 PhH); Ester: δ 1.83–2.07 (m, CH2CH2OH), 
3.20 (s, OCH3), 3.56 (t, J = 6.4 Hz, CH2OH), 7.15–7.31 (m, 9 PhH), 7.39–7.55 (m, 6 PhH). 
 
 
(R)-N-Benzyl 2-N’-(Trityl)amino-4-hydroxybutanamide ((R)-184). Benzylamine (8.96 mL, 
82.04 mmol) was added to a suspension of (R)-2-N-(trityl)amino-γ-lactone and (R)-methyl 4-
hydroxy-2-(N-trityl)aminobutanoate (10.26 g, 27.35 mmol) in anhydrous MeOH (35 mL). The 
mixture was heated to 50 ºC (48 h) and cooled to room temperature before evaporating the 
solvent in vacuo. The crude product was purified by flash column chromatography (SiO2; 5–
50% EtOAc/hexanes followed by 10% MeOH/CH2Cl2) to give the desired product (5.03 g, 
 143 
 
41%) as a white solid: mp 64–65 ºC; Rf 0.65 (1:1 EtOAc/hexanes); [α]
28
D + 59.8° (c 1.0, 
CHCl3); IR (nujol mull) 3319, 3062, 2931 (br), 2863, 1958, 1890, 1815, 1651, 1456, 1377, 
1240, 1122, 1071, 906, 704 cm-1; 1H NMR (400 MHz, CDCl3): δ 1.44–1.52 (m, 
CHH‟CH2OH), 1.63–1.71 (m, CHH’CH2OH), 2.88–3.02 (br s, OH), 3.45 (dd, J = 4.2, 7.8 Hz, 
CH), 3.54–3.64 (m, CH2OH), 4.05 (dd, J = 6.0, 14.8 Hz, NHCHH‟), 4.20 (dd, J = 6.0 Hz, 14.8 
Hz, NHCHH’), 7.18–7.38 (m, 4 C6H5, NH); 
13C NMR (100 MHz, CDCl3) δ 37.0 (CH2CH2OH), 
43.4 (NHCH2), 56.9 (CH), 60.2 (CH2OH), 71.9 (C(C6H5)3), 126.9, 127.5, 127.7, 128.0, 128.7, 
128.8, 138.1, 145.5 (4 (C6H5)), 175.3 (C(O)); HRMS (ESI) 583.1352 [M + Cs
+] (calcd for 
C30H30N2O2Cs
+ 583.1362); Anal. Calcd for C30H30N2O2•0.18EtOAc: C, 79.12; H, 6.79; N, 
6.01. Found: C, 78.74; H, 6.76; N, 6.08. 
 
 
(R)-N-Benzyl 2-N’-(Trityl)amino-4-methoxybutanamide ((R)-185). Utilizing Method D and 
using (R)-N-benzyl 2-N’-(trityl)amino-4-hydroxybutanamide (90 mg, 0.20 mmol), Ag2O (232 
mg, 1.01 mmol), CH3I (0.13 mL, 2.02 mmol), and CH3CN (3 d) gave the crude product that 
was purified by flash column chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to give the 
desired product (64 mg, 68%) as a white solid: mp 120–121 ºC; Rf 0.29 (1:5 
EtOAc/hexanes); [α]28D + 40.5° (c 1.0, CHCl3); IR (nujol mull) 2962, 2866, 1635, 1558, 1456, 
1377, 1306, 1206, 1117, 1031, 899, 744, 704 cm-1; 1H NMR (400 MHz, CDCl3): δ 1.41–1.49 
(m, CHH‟CH2OCH3), 1.89–1.96 (m, CHH’CH2OCH3), 3.18 (s, OCH3), 3.27–3.32 (m, CH), 
3.38–3.43 (m, CH2OCH3), 4.04 (dd, J = 5.6, 14.8 Hz, NHCHH‟), 4.17 (dd, J = 6.2, 14.8 Hz, 
NHCHH’), 7.07 (t, J = 5.6 Hz, NHCH2), 7.18–7.40 (m, 4 C6H5, NHCH); 
13C NMR (100 MHz, 
CDCl3) δ 33.4 (CH2CH2OCH3), 43.3 (NHCH2), 57.1 (CH), 58.7 (OCH3), 70.2 (CH2OCH3), 
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71.7 (C(C6H5)3), 126.7, 127.3, 127.8, 127.9, 128.6, 128.9, 138.5, 145.9 (4 (C6H5)), 174.5 
(C(O)); HRMS (ESI) 597.1518 [M + Cs+] (calcd for C31H32N2O2Cs
+ 597.1552); Anal. Calcd 
for C31H32N2O2•0.04H2O: C, 80.01; H, 6.95; N, 6.02. Found: C, 79.64; H, 6.94; N, 6.02. 
 
 
(R)-N-Benzyl N-Methyl 2-N’-(Trityl)amino-4-methoxybutanamide ((R)-186). The previous 
procedure was repeated using (R)-N-benzyl 2-N’-(trityl)amino-4-hydroxybutanamide (3.00 g, 
6.66 mmol), Ag2O (7.71 g, 33.31 mmol), CH3I (4.14 mL, 66.63 mmol), and CH3CN (66 mL) 
(3 d) to isolate three fractions: (1) (R)-N-benzyl 2-N’-(trityl)amino-4-methoxybutanamide 
(~300 mg) as a pale yellow solid; (2) a 2:1 mixture of (R)-N-benzyl 2-N’-(trityl)amino-4-
methoxybutanamide and (R)-N-benzyl N-methyl 2-N’-(trityl)amino-4-methoxybutanamide 
(2.70 g, 85%) as a pale yellow solid; (3) (R)-N-benzyl N-methyl 2-N’-(trityl)amino-4-
methoxybutanamide (~200 mg) as a pale yellow solid. 
(R)-N-Benzyl N-methyl 2-N’-(trityl)amino-4-methoxybutanamide ((R)-186): mp 
126–127 ºC; Rf 0.75 (1:1 EtOAc/hexanes); IR (nujol mull) 2858 (br), 1634, 1557, 1458, 
1376, 1300, 1206, 1118, 1029, 897, 704 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.91–1.99 
(CHCH2), 2.39 (s, NCH3), 3.16 (d, J = 14.8 Hz, N(CH3)CHH‟), 3.23 (s, OCH3), 3.28–3.30 (m, 
CH), 3.65–3.73 (m, CH2OCH3), 4.75 (d, J = 14.8 Hz, N(CH3)CHH’), 7.04–7.52 (m, 4 C6H5, 
NH), a COSY spectrum supported the proton-proton connectivity pattern; 13C NMR (100 
MHz, CDCl3) δ 33.7 (CHCH2), 36.0 (NCH3), 50.0, 50.9 (CH, NHCH2), 58.4 (OCH3), 68.9 
(CH2OCH3), 71.1 (C(C6H5)3), 126.3. 127.1, 127.5, 128.2, 128.4, 129.0, 137.4, 146.4 (4 
C6H5), 174.3 (C(O)); HRMS (ESI) 611.1644 [M + Cs
+] (calcd for C32H34N2O2Cs
+ 611.1675). 
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(R)-N-Benzyl 2-Amino-4-methoxybutanamide ((R)-75). (R)-N-Benzyl 2-N’-(trityl)amino-4-
methoxybutanamide (30 mg, 0.07 mmol) was dissolved in 1% TFA/CH2Cl2 solution (0.5 mL). 
The reaction was stirred at room temperature (5 h) before the solvent was evaporated in 
vacuo to give the crude product (12 mg, 83%) as a pale yellow solid: Rf 0.33 (1:20 
MeOH/CH2Cl2); 
1H NMR (400 MHz, CDCl3): δ 1.76 (s, NH2), 1.77–1.88 (m, CHH‟CH2OCH3), 
2.09–2.17 (m, CHH’CH2OCH3), 3.30 (s, OCH3), 3.50–3.59 (m, CH, CH2OCH3), 4.40–4.50 
(m, NHCH2), 7.24–7.35 (m, C6H5), 7.68–7.74 (br t, NH). 
 
 
(R)-N-Benzyl N-Methyl 2-N’-Amino-4-methoxybutanamide. ((R)-187) The previous 
procedure was repeated using a 2:1 mixture of (R)-N-benzyl 2-N’-(trityl)amino-4-
methoxybutanamide and (R)-N-benzyl N-methyl 2-N’-(trityl)amino-4-methoxybutanamide 
(2.45 g, 5.12 mmol) and 1% TFA/CH2Cl2 solution (35 mL) (5 h) to isolate three fractions: (1) 
(R)-N-benzyl 2-amino-4-methoxybutanamide (~100 mg) as a pale yellow solid; (2) a 2:1 
mixture of (R)-N-benzyl 2-amino-4-methoxybutanamide and (R)-N-benzyl N-methyl 2-N’-
amino-4-methoxybutanamide (0.97 g, 80%) as a pale yellow solid; (3) (R)-N-benzyl N-methyl 
2-N’-amino-4-methoxybutanamide (~50 mg) as a pale yellow solid and as a 2:1 mixture of 
conformers A (major) and B (minor). 
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(R)-N-Benzyl N-Methyl 2-N’-Amino-4-methoxybutanamide ((R)-187): 1H NMR 
(400 MHz, CDCl3) δ 1.60–1.74 (m, NH2, CHCHH‟), 1.86–1.96 (m, CHCHH’), 2.96 (s, NCH3), 
3.30 (s, (OCH3)B), 3.32 (s, (OCH3)A), 3.34–3.48 (m, CHH‟OCH3), 3.53–3.65 (m, CHH’OCH3), 
3.88 (dd, J = 4.2, 8.8 Hz, (CH)B), 3.92 (dd, J = 4.2, 8.8 Hz, (CH)A), 4.40 (d, J = 16.8 Hz, 
(N(CH3)CHH‟)B), 4.46 (d, J = 14.7 Hz, (N(CH3)CHH‟)A), 4.76 (d, J = 14.7 Hz, (N(CH-
3)CHH’)A), 4.80 (d, J = 16.8 Hz, (N(CH3)CHH’)B), 7.17–7.39 (m, C6H5). 
 
 
(R)-N-Benzyl 2-N’-(t-Butoxycarbonyl)amino-4-methoxybutanamide ((R)-188). A 2:1 
mixture of (R)-N-benzyl 2-N’-amino-4-methoxybutanamide and (R)-N-benzyl N-methyl 2-N’-
amino-4-methoxybutanamide (0.91 g, 3.85 mmol) and Na2CO3 (1.02 g, 9.63 mmol) was 
dissolved in a mixture of H2O/acetone (10 mL/10 mL). Boc2O (0.93 g, 4.24 mmol) was 
added in one portion at room temperature and the mixture stirred overnight (18 h). The 
reaction was partially evaporated in vacuo and the remaining aqueous layer was washed 
with Et2O (3 x 20 mL). The organic layers were combined, dried (Na2SO4), evaporated in 
vacuo, and purified by flash column chromatography (SiO2; 1:100 MeOH/CH2Cl2). Three 
fractions were isolated: (1) (R)-N-benzyl N-methyl 2-N’-(t-butoxycarbonyl)amino-4-
methoxybutanamide (0.19 g, 15%) as a colorless oil; (2) a 2:1 mixture of (R)-N-benzyl 2-N’-
(t-butoxycarbonyl)amino-4-methoxybutanamide and (R)-N-benzyl N-methyl 2-N’-(t-
butoxycarbonyl)amino-4-methoxybutanamide (1.06, 81%) as a colorless oil; (3) (R)-N-benzyl 
2-N’-(t-butoxycarbonyl)amino-4-methoxybutanamide (0.03 g, 2%) as a colorless oil.  
 
 147 
 
 
(R)-N-Benzyl 2-N’-(t-Butoxycarbonyl)amino-4-methoxybutanamide ((R)-188): Rf 
0.25 (1:20 MeOH/CH2Cl2); 
 1H NMR (400 MHz, CDCl3) δ 1.43 (s, C(CH3)3), 2.03–2.07 (m, 
CHCH2), 3.27 (s, OCH3), 3.41–3.54 (m, CH2OCH3), 4.24–4.32 (m, CH), 4.41–4.51 (m, 
NHCH2), 5.62 (d, J = 7.2 Hz, OC(O)NH), 6.76–6.82 (br t, NHCH2), 7.20–7.34 (m, C6H5); 
13C 
NMR (100 MHz, CDCl3) δ 28.3 (C(CH3)3), 32.1 (CHCH2), 43.4 (NHCH2), 53.3 (CH), 58.8 
(OCH3), 70.0 (CH2OCH3), 80.1 (C(CH3)3), 127.4, 127.6, 128.6, 138.1 (C6H5), 155.7 (OC(O)), 
171.6 (CC(O)). 
 
 
(R)-N-Benzyl N-Methyl 2-N’-(t-Butoxycarbonyl)amino-4-methoxybutanamide 
((R)-189). Rf 0.29 (1:20 MeOH/CH2Cl2); IR (neat) 3067 (br), 1669, 1533, 1453, 1365, 1254, 
1169, 1116, 910, 862, 739, 701 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.44 (s, C(CH3)3), 1.77–
1.99 (m, CHCH2), 3.01 (s, NCH3), 3.31 (s, OCH3), 3.38–3.49 (CH, CH2OCH3), 4.48 (d, J = 
14.4 Hz, NHCHH‟), 4.72 (d, J = 14.4 Hz, NHCHH’), 5.45 (d, J = 8.0 Hz, NH), 7.21–7.37 (m, 
C6H5); HRMS (ESI) 469.1102 [M + Cs
+] (calcd for C18H28N2O4Cs
+ 469.1103). 
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(R)-2-N-(Benzyloxycarbonyl)amino-2-phenylacetic Acid ((R)-191).173 NaOH (1.32 g, 33.1 
mmol) was added to a suspension of D-phenylglycine (5.00 g, 33.1 mmol) in THF/H2O 
(100:100 mL) at 0 ºC. After the suspension dissolved, benzylchloroformate (4.64 mL, 33.1 
mmol) in THF (15 mL) was added drop wise. The reaction was maintained at 0 ºC (3 h), and 
then a second equivalent of NaOH (1.32 g, 33.1 mmol) followed by benzylchloroformate 
(4.64 mL, 33.1 mmol) in THF (15 mL) were added and then the reaction was allowed to 
warm to room temperature (48 h). The mixture was filtered and the filtrate was concentrated 
to half of its volume in vacuo and the remaining aqueous layer was basified to pH ~12 with 
aqueous 10 M NaOH, and then extracted with CH2Cl2 (3 x 100 mL). The aqueous layer was 
acidified (pH 1) with aqueous concentrated HCl and extracted with EtOAc (3 x 100 mL). The 
EtOAc layers were combined, dried (MgSO4), and concentrated in vacuo. The crude product 
was recrystallized from hot EtOAc/hexanes to give the desired product (7.53 g, 80%) as a 
light yellow solid: mp 123–124 °C (lit.173 mp 125–128 ºC); [α]25D –108.5° (c 1.3, MeOH) (lit.
173 
[α]D –108.5º (c 1.0, MeOH)); Rf = 0.29 (1:10 MeOH/CHCl3); 
1H NMR (300 MHz, DMSO-d6) δ 
5.04 (s, CH2Ph), 5.13 (d, J = 8.1 Hz, CH), 7.26–7.42 (m, 2 PhH), 8.02 (d, J = 8.1 Hz, NH); 
13C NMR (75 MHz, DMSO-d6) δ 58.2 (CH), 65.5 (OCH2Ph), 127.6, 127.7, 127.8, 128.3, 
136.9, 137.6 (2 C6H5), 155.8 (NC(O)O), 172.0 (CHC(O)), two aromatic peaks were not 
detected and are believed to overlap with nearby signals. 
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(S)-2-N-(Benzyloxycarbonyl)amino-2-phenylacetic Acid ((S)-191). The previous 
procedure was repeated using L-phenylglycine (5.00 g, 33.1 mmol) in THF/H2O (100:100 
mL), NaOH (1.32 g, 33.1 mmol), benzylchloroformate (4.64 mL, 33.1 mmol) in THF (15 mL), 
followed by a second equivalent of NaOH (1.32 g, 33.1 mmol) and benzylchloroformate 
(4.64 mL, 33.1 mmol) in THF (15 mL) to give the desired product (8.06 g, 85%) as a light 
yellow solid: mp 125–126 °C (lit.173 mp 125–128 ºC); [α]25D +108.8° (c 1.1, MeOH) (lit.
173 (R): 
[α]D –108.5º (c 1.0, MeOH)); Rf = 0.26 (1:10 MeOH/CHCl3); IR (nujol mull) 3441, 3363, 2935 
(br), 1737, 1666, 1458, 1375, 1303, 1245, 1160, 1051, 724 cm-1; 1H NMR (300 MHz, DMSO-
d6) δ 5.05 (s, CH2Ph), 5.18 (d, J = 8.1 Hz, CH), 7.29–7.43 (m, 2 PhH), 8.14 (d, J = 8.1 Hz, 
NH); 13C NMR (75 MHz, DMSO-d6) δ 58.0 (CH), 65.6 (OCH2Ph), 127.7, 127.8, 127.9, 128.3, 
128.4, 136.9, 137.1 (2 C6H5), 155.8 (NC(O)O), 172.0 (CHC(O)), one aromatic peak was not 
detected and is believed to overlap with nearby signals. 
 
 
(R,S)-2-N-(Benzyloxycarbonyl)amino-2-phenylacetic Acid ((R,S)-191).175 The previous 
procedure was repeated using DL-phenylglycine (5.00 g, 33.1 mmol) in THF/H2O (100:100 
mL), NaOH (1.32 g, 33.1 mmol), benzylchloroformate (4.64 mL, 33.1 mmol) in THF (15 mL), 
followed by a second equivalent of NaOH (1.32 g, 33.1 mmol) and benzylchloroformate 
(2.32 mL, 16.6 mmol) in THF (15 mL) to give the desired product (5.73 g, 61%) as a light 
yellow solid: mp 130–131 °C (lit.175 mp 128–130 ºC); Rf = 0.31 (1:10 MeOH/CHCl3); 
1H NMR 
(300 MHz, DMSO-d6) δ 5.06 (s, CH2Ph), 5.18 (d, J = 8.1 Hz, CH), 7.30–7.43 (m, 2 PhH), 
8.14 (d, J = 8.1 Hz, NH); 13C NMR (75 MHz, DMSO-d6) δ 58.0 (CH), 65.6 (OCH2Ph), 127.7, 
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127.8, 127.9, 128.3, 128.4, 136.9, 137.1 (2 C6H5), 155.8 (NC(O)O), 172.0 (CHC(O)), one 
aromatic peak was not detected and is believed to overlap with nearby signals. 
 
 
(R)-N-Benzyl 2-N-(Benzylcarboxycarbonyl)amino-2-phenylacetamide ((R)-192).190 
Utilizing Method B and using (R)-2-N-(benzyloxycarbonyl)amino-2-phenylacetic acid (3.50 g, 
12.3 mmol), NMM (1.75 mL, 16.0 mmol), IBCF (1.58 mL, 13.5 mmol), and benzylamine 
(1.41 mL, 12.9 mmol) gave the crude product that was recrystallized from hot 
EtOAc/hexanes to give the desired compound (3.51 g, 77%) as a white solid: mp 186–187 
°C (lit.190 mp 186–190 °C); [α]25D –105.5° (c 0.6, CH2Cl2) (lit.
190 [α]23D –105° (c 0.5, CH2Cl2)); 
Rf = 0.67 (1:1 EtOAc/hexanes);  
1H NMR (300 MHz, DMSO-d6) δ 4.27 (d, J = 5.7 Hz, 
CH2Ph), 5.05 (s, CH2OC(O)), 5.29 (d, J = 8.3 Hz, CH), 7.13–7.47 (m, 3 C6H5), 7.97 (d, J = 
8.3 Hz, NHC(O)O), 8.72 (t, J = 5.7 Hz, NHC(O)); 13C NMR (75 MHz, DMSO-d6) δ 41.7 
(NHCH2), 58.0 (CH), 65.2 (OCH2Ph), 126.4, 126.7, 126.9, 127.3, 127.4, 127.8, 127.9, 128.0, 
136.6, 138.2, 138.7 (3 C6H5), 155.3 (OC(O)), 169.6 (C(O)NH), one aromatic peak was not 
detected and is believed to overlap with nearby signals; HRMS (ESI) 397.1522 [M + Na+] 
(calcd for C23H22N2O3Na
+ 397.1528); Anal. Calcd for C23H22N2O3; C, 73.78; H, 5.92; N, 7.48. 
Found C, 73.90; H, 5.91; N, 7.47.  
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(S)-N-Benzyl 2-N-(Benzylcarboxycarbonyl)aminophenylacetamide ((S)-192). The 
previous procedure was repeated using (S)-2-N-(benzyloxycarbonyl)amino-2-phenylacetic 
acid (5.00 g, 17.5 mmol), NMM (2.51 mL, 22.8 mmol), IBCF (2.49 mL, 19.3 mmol), and 
benzylamine (2.01 mL, 18.4 mmol) to give the crude product that was recrystallized from hot 
EtOAc/hexanes to give the desired compound (4.56 g, 70%) as a white solid: mp 186–187 
°C (lit.9 mp 186–190 °C); [α]25D +107.5° (c 0.6, CH2Cl2) (lit.
9 (R): [α]23D –105° (c 0.5, CH2Cl2)); 
Rf = 0.74 (1:1 EtOAc/hexanes); IR (nujol mull) 3416, 3165, 2865 (br), 1645, 1527, 1458, 
1373, 1248, 1156, 1065, 707 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 4.27 (d, J = 5.7 Hz, 
CH2Ph), 5.05 (s, CH2OC(O)), 5.30 (d, J = 8.6 Hz, CH), 7.13–7.47 (m, 3 C6H5), 7.98 (d, J = 
8.6 Hz, NHC(O)O), 8.72 (t, J = 5.7 Hz, NHC(O)); 13C NMR (75 MHz, DMSO-d6) δ 41.8 
(NHCH2), 58.0 (CH), 65.2 (OCH2Ph), 126.4, 126.7, 127.0, 127.3, 127.4, 127.8, 127.9, 128.0, 
136.6, 138.2, 138.7 (3 C6H5), 155.3 (OC(O)), 169.6 (C(O)NH), one aromatic peak was not 
detected and is believed to overlap with nearby signals; HRMS (ESI) 397.1522 [M + Na+] 
(calcd for C23H22N2O3Na
+ 397.1528); Anal. Calcd for C23H22N2O3; C, 73.78; H, 5.92; N, 7.48. 
Found C, 73.74; H, 5.94; N, 7.54.   
 
 
(R,S)-N-Benzyl 2-N-(Benzylcarboxycarbonyl)aminophenylacetamide ((R,S)-192). The 
previous procedure was repeated using (R,S)-2-N-(benzyloxycarbonyl)amino-2-phenylacetic 
acid (5.00 g, 17.5 mmol), NMM (2.51 mL, 22.8 mmol), IBCF (2.49 mL, 19.3 mmol), and 
benzylamine (2.01 mL, 18.4 mmol) to give the crude product that was recrystallized from hot 
EtOAc/hexanes to give the desired compound (2.84 g, 44%) as a white solid: mp 178–179 
°C (lit.9 mp 186–190 °C); Rf = 0.70 (1:1 EtOAc/hexanes); IR (nujol mull) 3423, 2889 (br), 
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2358, 1649, 1457, 1374, 724 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 4.27 (d, J = 5.9 Hz, 
CH2Ph), 5.05 (s, CH2OC(O)), 5.30 (d, J = 8.4 Hz, CH), 7.13–7.47 (m, 3 C6H5), 7.97 (d, J = 
8.4 Hz, NHC(O)O), 8.72 (t, J = 5.9 Hz, NHC(O)); 13C NMR (75 MHz, DMSO-d6) δ 41.7 
(NHCH2), 58.0 (CH), 65.2 (OCH2Ph), 126.4, 126.7, 127.0, 127.3, 127.4, 127.8, 127.9, 128.0, 
136.6, 138.1, 138.7 (3 C6H5), 155.4 (OC(O)), 169.6 (C(O)NH), one aromatic peak was not 
detected and is believed to overlap with nearby signals; HRMS (ESI) 397.1522 [M + Na+] 
(calcd for C23H22N2O3Na
+ 397.1528); Anal. Calcd for C23H22N2O3; C, 73.78; H, 5.92; N, 7.48. 
Found C, 73.50; H, 5.94; N, 7.53.   
 
 
(R)-N-Benzyl 2-Amino-2-phenylacetamide ((R)-62). Utilizing Method C and using (R)-N-
benzyl 2-N-(benzyloxycarbonyl)amino-2-phenylacetamide (2.50 g, 6.68 mmol), 10% Pd-C 
(250 mg), and MeOH (100 mL) (18 h) gave the crude product that was purified by flash 
column chromatography (SiO2; 1:10 MeOH/CHCl3). The oil was dissolved in CH2Cl2 (20 mL) 
and was extracted with aqueous 0.1 N HCl (3 x 20 mL). The aqueous layers were combined 
and extracted with CH2Cl2 (2 x 60 mL). The aqueous layer was basified to pH 10–12 with 
aqueous 0.1 N NaOH, and then extracted with CH2Cl2 (3 x 100 mL). The CH2Cl2 layers were 
combined, dried (MgSO4), and concentrated in vacuo to give the desired product (1.31 g, 
82%) as a waxy solid: mp 87–88 °C; [α]25D –75.1° (c 0.7, CH2Cl2); Rf = 0.39 (1:20 
MeOH/CHCl3); IR (nujol mull) 3374, 2873 (br), 1647, 1458, 700 cm
-1; 1H NMR (300 MHz, 
DMSO-d6) δ 2.26 (s, NH2), 4.27 (d, J = 6.0 Hz, CH2), 4.40 (s, CH), 7.17–7.42 (m, 2 PhH), 
8.57 (t, J = 6.0 Hz, NH); 13C NMR (75 MHz, DMSO-d6) δ 41.6 (CH2PH), 58.7 (CH), 126.3, 
126.5, 126.7, 127.6, 127.8, 139.1, 142.5 (2 C6H5), 172.9 (C(O)), one aromatic peak was not 
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detected and is believed to overlap with nearby signals; HRMS (ESI) 241.1342 [M + H+] 
(calcd for C15H16N2OH
+ 241.1341); Anal. Calcd for C15H16N2O; C, 74.97; H, 6.71; N, 11.66. 
Found C, 74.72; H, 6.72; N, 11.57. 
 
 
(S)-N-Benzyl 2-Amino-2-phenylacetamide ((S)-62). The previous procedure was repeated 
using (S)-N-benzyl 2-N-(benzyloxycarbonyl)amino-2-phenylacetamide (3.00 g, 8.02 mmol), 
10% Pd-C (300 mg), and MeOH (100 mL) to give the desired product (1.60 g, 83%) as a 
waxy solid: mp 85–86 °C; [α]25D +74.1° (c 0.7, CH2Cl2); Rf = 0.43 (1:20 MeOH/CHCl3); IR 
(nujol mull) 3152, 2957 (br), 1647, 1458, 700 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 2.25 (s, 
NH2), 4.27 (d, J = 6.2 Hz, CH2), 4.40 (s, CH), 7.17–7.43 (m, 2 PhH), 8.57 (t, J = 6.2 Hz, NH); 
13C NMR (75 MHz, DMSO-d6) δ 41.6 (CH2PH), 58.7 (CH), 126.3, 126.5, 126.7, 127.6, 127.8, 
139.1, 142.5 (2 C6H5), 172.9 (C(O)), one aromatic peak was not detected and is believed to 
overlap with nearby signals; HRMS (ESI) 241.1342 [M + H+] (calcd for C15H16N2OH
+ 
241.1341); Anal. Calcd for C15H16N2O; C, 74.97; H, 6.71; N, 11.66. Found C, 74.69; H, 6.73; 
N, 11.53. 
 
 
(R,S)-N-Benzyl 2-Amino-2-phenylacetamide ((R,S)-62).52 The previous procedure was 
repeated using (R,S)-N-benzyl 2-N-(benzyloxycarbonyl)amino-2-phenylacetamide (2.00 g, 
5.35 mmol), 10% Pd-C (250 mg), and MeOH (100 mL) to give the desired product (1.07 g, 
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83%) as a waxy solid: mp 67–68 °C; Rf = 0.52 (1:20 MeOH/CHCl3); IR (nujol mull) 3361, 
2856 (br), 1646, 1459, 699 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 2.25 (s, NH2), 4.27 (d, J = 
5.9 Hz, CH2), 4.40 (s, CH), 7.17–7.43 (m, PhH), 8.57 (t, J = 5.9 Hz, NH); 
13C NMR (75 MHz, 
DMSO-d6) δ 41.6 (CH2PH), 58.7 (CH), 126.3, 126.5, 126.7, 127.6, 127.8, 139.1, 142.5 (2 
C6H5), 172.9 (C(O)), one aromatic peak was not detected and is believed to overlap with 
nearby signals; HRMS (ESI) 241.1342 [M + H+] (calcd for C15H16N2OH
+ 241.1341); Anal. 
Calcd for C15H16N2O; C, 74.97; H, 6.71; N, 11.66. Found C, 74.74; H, 6.76; N, 11.61. 
 
 
(R)-2-N-(t-Butoxycarbonyl)aminobutanoic Acid ((R)-200).191 D-2-Aminobutanoic acid 
(3.50 g, 33.94 mmol) and Na2CO3 (8.99 g, 84.85 mmol) was dissolved in a mixture of 
H2O/acetone (70 mL/70 mL). Boc2O (8.15 g, 37.34 mmol) was added in one portion at room 
temperature and the mixture stirred overnight (18 h). The organic layer was evaporated in 
vacuo and the remaining aqueous layer was washed with Et2O (50 mL), acidified to pH ~2 
with aqueous 1 M KHSO4, and extracted with EtOAc (3 x 50 mL). The second set of organic 
layers was combined, dried (Na2SO4), and evaporated in vacuo to give the crude product 
(6.83 g, 99%) as a colorless oil and as a 2:1 mixture of conformers A (major) and B (minor). 
The product was used for the next step without further purification: Rf 0.55 (1:20 
MeOH/CH2Cl2);
 1H NMR (400 MHz, CDCl3) δ 0.98 (t, J = 7.6 Hz, CH2CH3), 1.45 (s, C(CH3)3), 
1.68–1.79 (m, CHH‟CH3), 1.86–1.95 (m, CHH’CH3), 4.04–4.13 (m, CHB), 4.24–4.35 (m, 
CHA), 5.11 (d, J = 7.6 Hz, NHA), 6.41 (d, J = 7.6 Hz, NHB), 9.20–9.65 (br s, OH); 
13C NMR 
(400 MHz, CDCl3) δ 9.8 ((CH2CH3)A), 9.9 ((CH2CH3)B), 25.8 (CH2CH3), 28.5 (C(CH3)3), 54.6 
((CH)A), 56.0 ((CH)B), 80.3 ((C(CH3)3)A), 81.8 ((C(CH3)3)B), 155.8 ((OC(O)N)A), 157.1 
((OC(O)N)A), 177.2 ((C(O)OH)A), 177.5 ((C(O)OH)B).  
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(R)-N-Benzyl 2-N’-(t-Butoxycarbonyl)aminobutanamide ((R)-207). Utilizing Method B and 
using (R)-2-N-(t-butoxycarbonyl)aminobutanoic acid (6.16 g, 30.33 mmol), NMM (4.33 mL, 
39.43 mmol), IBCF (4.30 mL, 33.36 mmol), and benzylamine (3.48 mL, 31.84 mmol) gave 
the crude product that was recrystallized from hot EtOAc/hexanes to give the desired 
product (5.94 g, 67%) as a white solid: mp 70–71 ºC; Rf 0.33 (1:10 EtOAc/hexanes); [α]
25
D + 
18.6° (c 1.0, CH2Cl2); IR (nujol mull) 3317, 2869 (br), 1688, 1648, 1525, 1457, 1376, 1245, 
1166, 1058, 1012, 908, 865, 757, 656 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.93 (t, J = 7.6 Hz, 
CH2CH3), 1.39 (s, C(CH3)3), 1.58–1.69 (m, CHH‟CH3), 1.80–1.91 (m, CHH’CH3), 4.04–4.16 
(m, CH), 4.36 (dd, J = 6.0, 14.8 Hz, NHCHH‟Ph), 4.45 (dd, J = 6.0, 14.8 Hz, NHCHH’Ph), 
5.26 (d, J = 8.4 Hz, NH), 6.82–6.89 (br t, NHCH2Ph), 7.22–7.31 (m, 2 C6H5);
 13C NMR (400 
MHz, CDCl3) δ 10.2 (CH2CH3), 26.0 (CH2CH3), 28.4 (C(CH3)3), 43.5 (NHCH2Ph), 56.0 (CH), 
80.0 (C(CH3)3), 127.5, 127.7, 128.8, 138.3 (C6H5), 156.0 (OC(O)N), 172.3 (C(O)NH); HRMS 
(ESI) 315.1694 [M + Na+] (calcd for C16H24N2O3Na
+ 315.1685); Anal. Calcd for C16H24N2O3: 
C, 65.73; H, 8.27; N, 9.58. Found: C, 66.00; H, 8.33; N, 9.56. 
 
 
(R)-N-Benzyl 2-Aminobutanamide ((R)-95). Utilizing Method E and using (R)-N-benzyl 2-
N’-(t-butoxycarbonyl)aminobutanamide (4.87 g, 16.67 mmol), TFA (18.57 mL, 0.25 mol), and 
CH2Cl2 (55 mL) gave the crude product after workup that was further purified by flash 
column chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to give the desired compound 
(1.86 g, 58%) as a pale yellow oil: Rf 0.53 (1:20 MeOH/CH2Cl2); IR 2966, 1659, 1529, 1456, 
1357, 1292, 1082, 1025, 928, 736, 700 cm-1; 1H NMR (300 MHz, CDCl3) δ 0.97 (t, J = 7.2 
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Hz, CH2CH3), 1.38–1.46 (br s, NH2), 1.51–1.66 (m, CHH‟CH3), 1.83–1.97 (m, CHH’CH3), 
3.35 (dd, J = 4.5, 7.8 Hz, CH), 4.44 (d, J = 5.7 Hz, NHCH2Ph), 7.26–7.35 (m, C6H5), 7.61–
7.73 (br t, NHCH2Ph); 
13C NMR (75 MHz, CDCl3) δ 10.2 (CH2CH3), 28.2 (CH2CH3), 43.2 
(NHCH2Ph), 56.5 (CH), 127.5, 127.8, 128.8, 138.7 (C6H5), 175.0 (C(O)N); HRMS (ESI) 
193.1348 [M + H+] (calcd for C11H16N2OH
+ 193.1341); Anal. Calcd for 
C11H16N2O•0.06CH2Cl2: C, 67.22; H, 8.22; N, 14.17. Found: C, 67.23; H, 8.31; N, 14.36. 
 
 
(R)-2-N-(Benzyloxycarbonyl)aminopentanoic Acid ((R)-379).192 Utilizing Method A and 
using D-norvaline (5.00 g, 42.7 mmol), NaHCO3 (8.97 g, 106.8 mmol), benzyl chloroformate 
(9.00 mL, 64.1 mmol) and H2O (100 mL) gave the desired product (9.15 g, 85%) as a white 
solid after workup and the compound was used for the next step without further purification: 
mp 88–89 °C (lit.192 mp 84–85 ºC); [α]25D + 4.2° (c 2.0, acetone) (lit.
193 (S): [α]12D –4.2º (c 2, 
acetone)); Rf 0.61 (1:1 EtOAc/hexanes); 
1H NMR (300 MHz, DMSO-d6) δ 0.86 (t, J = 7.8 Hz, 
CH2CH3), 1.24–1.41 (m, CH2CH3), 1.51–1.67 (m, CHCH2), 3.91–3.99 (m, CH), 5.03 (s, 
OCH2Ph), 7.27–7.41 (m, C6H5), 7.58 (d, J = 8.1 Hz, NH); 
13C NMR (75 MHz, DMSO-d6) δ 
13.1 (CH3), 18.4 (CH2CH3), 32.5 (CHCH2), 53.2 (CH), 65.0 (OCH2Ph), 127.4, 127.5, 128.0, 
136.7 (C6H5), 155.9 (NC(O)O), 173.7 (CHC(O)). 
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(S)-2-N-(Benzyloxycarbonyl)aminopentanoic Acid ((S)-379).193 The previous procedure 
was repeated using L-norvaline (5.00 g, 42.7 mmol), NaHCO3 (8.97 g, 106.8 mmol), and 
benzyl chloroformate (9.00 mL, 64.1 mmol), and H2O (100 mL) to give the desired product 
(7.78 g, 73%) as a white solid: mp 85–86 °C (lit.193 mp 86 ºC); [α]25D – 4.3° (c 2.1, acetone) 
(lit.193 [α]12D –4.2º (c 2, acetone)); Rf = 0.43 (1:10 MeOH/CHCl3); 
1H NMR (300 MHz, DMSO-
d6) δ 0.86 (t, J = 7.5 Hz, CH2CH3), 1.25–1.41 (m, CH2CH3), 1.50–1.71 (m, CHCH2), 3.90–
3.98 (m, CH), 5.03 (s, OCH2Ph), 7.29–7.37 (m, PhH), 7.58 (d, J = 8.1 Hz, NH); 
13C NMR (75 
MHz, DMSO-d6) δ 13.4 (CH3), 18.7 (CH2CH3), 32.8 (CHCH2), 53.5 (CH), 65.3 (OCH2Ph), 
127.7, 127.8, 128.3, 137.0 (C6H5), 156.2 (NC(O)O), 174.0 (CHC(O)). 
 
 
(R,S)-2-N-(Benzyloxycarbonyl)aminopentanoic Acid ((R,S)-379).194 The previous 
procedure was repeated using DL-norvaline (5.00 g, 42.7 mmol), NaHCO3 (8.97 g, 106.8 
mmol), benzyl chloroformate (9.00 mL, 64.1 mmol), and H2O (100 mL) to give the desired 
product (8.55 g, 80%) as a white solid: mp 90–91 °C (lit.193 mp 86 ºC); Rf 0.57 (1:1 
EtOAc/hexanes);  1H NMR (300 MHz, DMSO-d6) δ 0.86 (t, J = 7.2 Hz, CH2CH3), 1.26–1.42 
(m, CH2CH3), 1.51–1.69 (m, CHCH2), 3.91–3.99 (m, CH), 5.04 (s, OCH2Ph), 7.27–7.39 (m, 
C6H5), 7.58 (d, J = 8.1 Hz, NH); 
13C NMR (75 MHz, DMSO-d6) δ 13.1 (CH3), 18.4 (CH2CH3), 
32.5 (CHCH2), 53.2 (CH), 65.0 (OCH2Ph), 127.4, 127.5, 128.0, 136.7 (C6H5), 155.8 
(NC(O)O), 173.7 (CHC(O)). 
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(R)-N-Benzyl 2-N-(Benzyloxycarbonyl)aminopentanamide ((R)-380). Utilizing Method B 
and using (R)-2-N-(benzyloxycarbonyl)aminopentanoic acid (5.00 g, 19.9 mmol), NMM (2.85 
mL, 25.9 mmol), IBCF (2.82 mL, 21.9 mmol), and benzylamine (2.28 mL, 20.9 mmol) gave 
the crude product that was purified by flash column chromatography (SiO2; 10% 
MeOH/CH2Cl2) followed by recrystallization from hot toluene to give the desired compound 
(3.49 g, 52%) as a white solid: mp 139–141 °C; [α]25D + 11.5° (c 1.1, MeOH); Rf 0.27 (1:100 
MeOH/CH2Cl2); IR (nujol mull) 3290, 2934 (br), 2358, 1692, 1643, 1540, 1458, 1375, 1258, 
1058, 737, 694 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 0.85 (t, J = 7.5 Hz, CH2CH3), 1.20–
1.37 (m, CH2CH3), 1.46–1.67 (m, CH2CH2CH3), 3.98–4.06 (m, CH), 4.28 (d, J = 5.9 Hz, 
CH2Ph), 5.03 (s, OCH2Ph), 7.23–7.37 (m, 2 C6H5), 7.43 (d, J = 8.1 Hz, NHC(O)), 8.43 (t, J = 
5.9 Hz, NHCH2Ph); 
13C NMR (75 MHz, DMSO-d6) δ 13.2 (CH3), 18.3 (CH2CH3), 33.6 
(CHCH2), 41.6 (CH2Ph), 54.1 (CH), 65.0 (OCH2Ph), 126.3, 126.7, 127.3, 127.4, 127.8, 
127.9, 136.7, 139.0 (2 C6H5), 155.6 (NC(O)O), 171.7 (CHC(O)); HRMS (ESI) 363.1686 [M + 
Na+] (calcd for C20H24N2O3Na
+ 363.1685); Anal. Calcd for C20H24N2O3·0.12H2O; C, 70.11; H, 
7.13; N, 8.18. Found C, 69.75; H, 7.20; N, 8.35. 
 
 
(S)-N-Benzyl 2-N-(Benzyloxycarbonyl)aminopentanamide ((S)-380). The previous 
procedure was repeated using (S)-2-N-(benzyloxycarbonyl)aminopentanoic acid (5.00 g, 
19.9 mmol), NMM (2.85 mL, 25.9 mmol), IBCF (2.82 mL, 21.9 mmol), and benzylamine 
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(2.28 mL, 20.9 mmol) to give the crude product that was further purified by flash column 
chromatography (SiO2; 1:10 MeOH/CHCl3) to give the desired compound (4.02 g, 60%) as a 
white solid: mp 134–135 °C; [α]25D – 13.2° (c 1.1, MeOH); Rf 0.28 (1:100 MeOH/CH2Cl2); IR 
(nujol mull) 3285, 2938 (br), 1693, 1644, 1542, 1458, 1377, 1260, 1112, 1059, 739, 695 cm-
1; 1H NMR (300 MHz, DMSO-d6) δ 0.85 (t, J = 7.5 Hz, CH2CH3), 1.20–1.38 (m, CH2CH3), 
1.46–1.65 (m, CH2CH2CH3), 3.98–4.06 (m, CH), 4.28 (d, J = 6.0 Hz, CH2Ph), 5.03 (s, 
OCH2Ph), 7.20–7.44 (m, 2 PhH, NHC(O)), 8.42 (t, J = 6.0 Hz, NHCH2Ph); 
13C NMR (75 
MHz, DMSO-d6) δ 13.2 (CH3), 18.3 (CH2CH3), 33.6 (CHCH2), 41.6 (CH2Ph), 54.1 (CH), 65.0 
(OCH2Ph), 126.7, 126.9, 127.3, 127.4, 127.8, 127.9, 136.7, 139.0 (2 C6H5), 155.6 (NC(O)O), 
171.7 (CHC(O)); HRMS (ESI) 363.1687 [M + Na+] (calcd for C20H24N2O3Na
+ 363.1685); 
Anal. Calcd for C20H24N2O3; C, 70.56; H, 7.11; N, 8.23. Found C, 70.28; H, 7.19; N, 8.31. 
 
 
(R,S)-N-Benzyl 2-N-(Benzyloxycarbonyl)aminopentanamide ((R,S)-380).105 The previous 
procedure was repeated using (R,S)-2-N-(benzyloxycarbonyl)aminopentanoic acid (5.00 g, 
19.9 mmol), NMM (2.85 mL, 25.9 mmol), IBCF (2.82 mL, 21.9 mmol), and benzylamine 
(2.28 mL, 20.9 mmol) to give the crude product that was further purified by flash column 
chromatography (SiO2; 1:10 MeOH/CH2Cl2) followed by recrystallization from hot toluene to 
give the desired compound (4.72 g, 70%) as a white solid: mp 136–137 °C (lit.105 mp 138–
139 ºC); Rf 0.27 (1:100 MeOH/CH2Cl2); IR (nujol mull) 3290, 2930 (br), 1689, 1641, 1538, 
1459, 1375, 1257, 1057, 753, 702 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 0.85 (t, J = 6.9 Hz, 
CH2CH3), 1.17–1.40 (m, CH2CH3), 1.47–1.68 (m, CH2CH2CH3), 3.99–4.06 (m, CH), 4.28 (d, 
J = 5.9 Hz, CH2Ph), 5.03 (s, OCH2Ph), 7.23–7.37 (m, 2 C6H5), 7.43 (d, J = 8.4 Hz, NHC(O)), 
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8.43 (t, J = 5.9 Hz, NHCH2Ph); 
13C NMR (75 MHz, DMSO-d6) δ 13.2 (CH3), 18.3 (CH2CH3), 
33.6 (CHCH2), 41.6 (CH2Ph), 54.1 (CH), 65.0 (OCH2Ph), 126.3, 126.7, 127.3, 127.4, 127.8, 
127.9, 136.7, 139.1 (2 C6H5), 155.6 (NC(O)O), 171.7 (CHC(O)); HRMS (ESI) 363.1685 [M + 
Na+] (calcd for C20H24N2O3Na
+ 363.1685); Anal. Calcd for C20H24N2O3; C, 70.56; H, 7.11; N, 
8.23. Found C, 70.36; H, 7.17; N, 8.19. 
 
 
(R)-N-Benzyl 2-Aminopentanamide ((R)-96). Utilizing Method C and using (R)-N-benzyl 2-
N-(benzyloxycarbonyl)aminopentanamide (2.00 g, 5.88 mmol), 10% Pd-C (0.2 g), and 
MeOH (60 mL) gave the crude product further purified by flash column chromatography 
(SiO2; 1:100 MeOH/CH2Cl2). The resulting oil was dissolved in CH2Cl2 (10 mL) and was 
extracted with aqueous 1 M HCl (3 x 10 mL). The aqueous layers were combined and 
extracted with CH2Cl2 (2 x 30 mL). The aqueous layer was basified to pH 10–12 with 
aqueous 1 M NaOH, and then extracted with CH2Cl2 (3 x 60 mL). The CH2Cl2 layers were 
combined, dried (NaSO4), and concentrated in vacuo to give the desired product (0.95 g, 
79%) as a pale yellow oil: [α]25D –9.4° (c 1.0, MeOH); Rf 0.64 (1:10 MeOH/CH2Cl2); IR (neat) 
3307, 3033, 2956, 2870, 1658, 1525, 1456, 1358, 1250, 700 cm-1; 1H NMR (300 MHz, 
DMSO-d6) δ 0.86 (t, J = 7.4 Hz, CH2CH3), 1.19–1.42 (m, CH2CH3, CHH‟CH2CH3), 1.47–1.61 
(m, CHH‟CH2CH3), 1.78 (br s, NH2), 3.15–3.20 (app. t, CH), 4.28 (d, J = 5.7 Hz, CH2Ph), 
7.20–7.34 (m, C6H5), 8.34 (t, J = 5.7 Hz, NHCH2Ph);
 1H NMR (300 MHz, CDCl3) δ 0.95 (t, J 
= 7.2 Hz, CH2CH3), 1.32–1.58 (m, CH2CH3, CHH‟CH2CH3, NH2), 1.81–1.93 (m, 
CHH’CH2CH3), 3.41 (dd, J = 4.1, 8.0 Hz, CH), 4.45 (d, J = 6.0 Hz, CH2Ph), 7.24–7.37 (m, 
C6H5), 7.60–7.72 (br s, NHCH2Ph); 
1H NMR (300 MHz, CD3OD) δ 0.92 (t, J = 7.2 Hz, 
CH2CH3), 1.28–1.42 (m, CH2CH3), 1.44–1.56 (m, CHH‟CH2CH3), 1.58–1.71 (m, 
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CHH‟CH2CH3), 3.28–3.33 (m, CH), 4.35 (1/2 ABq, J = 15.0 Hz, CHH‟Ph), 4.41 (1/2 ABq, J = 
15.0 Hz, CHH‟Ph), 4.86 (s, NH2), 7.20–7.34 (m, C6H5); 
13C NMR (75 MHz, DMSO-d6) δ 13.5 
(CH3), 18.2 (CH2CH3), 37.1 (CHCH2), 41.5 (CH2Ph), 54.2 (CH), 126.3, 126.8, 127.8, 139.3 
(C6H5), 175.0 (CHC(O)); HRMS (ESI) 229.1317 [M + Na
+] (calcd for C12H18N2ONa
+ 
229.1317); Anal. Calcd for C12H18N2O; C, 69.87; H, 8.80; N, 13.58. Found C, 69.98; H, 8.73; 
N, 13.37. 
 
 
(S)-N-Benzyl 2-Aminopentanamide ((S)-96).  The previous procedure was repeated using 
(R)-N-benzyl 2-N-(benzyloxycarbonyl)aminopentanamide (3.00 g, 8.82 mmol), 10% Pd-C 
(0.3 g), and MeOH (100 mL) to give the desired product (1.76 g, 97%) as a pale yellow oil: 
[α]25D +9.4° (c 1.5, MeOH); Rf 0.65 (1:10 MeOH/CH2Cl2); IR (neat) 3351, 3265, 3032, 2928, 
2873, 1655, 1534, 1456, 1358, 1250, 701 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 0.86 (t, J = 
6.6 Hz, CH2CH3), 1.22–1.42 (m, CH2CH3, CHH‟CH2CH3), 1.48–1.61 (m, CHH‟CH2CH3), 1.78 
(br s, NH2), 3.17 (t, J = 6.9 Hz, CH), 4.28 (d, J = 6.0 Hz, CH2Ph), 7.20–7.34 (m, PhH), 8.34 
(t, J = 4.8 Hz, NHCH2Ph); 
13C NMR (75 MHz, DMSO-d6) δ 13.5 (CH3), 18.2 (CH2CH3), 37.1 
(CHCH2), 41.5 (CH2Ph), 54.2 (CH), 126.3, 126.8, 127.8, 139.3 (C6H5), 175.0 (CHC(O)); 
LRMS (ESI) 207.12 [M + H+] (calcd for C12H18N2OH
+ 207.12); Anal. Calcd for 
C12H18N2O•0.32H2O; C, 67.99; H, 8.86; N, 13.22. Found C, 67.93; H, 8.76; N, 13.21. 
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(R,S)-N-Benzyl 2-Aminopentanamide ((R,S)-96). The previous procedure was repeated 
using (R,S)-N-benzyl 2-N-(benzyloxycarbonyl)aminopentanamide (2.00 g, 11.76 mmol), 
10% Pd-C (0.2 g), and MeOH (60 mL) to give the desired product (0.88 g, 72%) as a pale 
yellow oil: Rf 0.65 (1:10 MeOH/CH2Cl2); IR (neat) 3292, 3064, 2957, 1655, 1528, 1457, 
1358, 1250, 700 cm-1; 
1H NMR (300 MHz, DMSO-d6) δ 0.86 (t, J = 6.6 Hz, CH2CH3), 1.24–
1.42 (m, CH2CH3, CHH‟CH2CH3), 1.48–1.61 (m, CHH‟CH2CH3), 1.74 (br s, NH2), 3.15-3.18 
(app. t, CH), 4.28 (d, J = 5.9 Hz, CH2Ph), 7.20–7.34 (m, C6H5), 8.36 (t, J = 5.9 Hz, 
NHCH2Ph); 
1H NMR (300 MHz, CDCl3) δ 0.95 (t, J = 7.2 Hz, CH2CH3), 1.32–1.58 (m, 
CH2CH3, CHH‟CH2CH3, NH2), 1.81–1.93 (m, CHH’CH2CH3), 3.41 (dd, J = 4.2, 8.1 Hz, CH), 
4.45 (d, J = 6.0 Hz, CH2Ph), 7.24–7.37 (m, C6H5), 7.58–7.70 (br s, NHCH2Ph); 
1H NMR (300 
MHz, CD3OD) δ 0.92 (t, J = 7.2 Hz, CH2CH3), 1.28–1.43 (m, CH2CH3), 1.44–1.56 (m, 
CHH‟CH2CH3), 1.58–1.71 (m, CHH‟CH2CH3), 3.28–3.32 (m, CH), 4.35 (1/2 ABq, J = 14.9 Hz, 
CHH‟Ph), 4.41 (1/2 ABq, J = 14.9 Hz, CHH‟Ph), 4.88 (s, NH2), 7.21–7.34 (m, C6H5); 
13C NMR 
(75 MHz, DMSO-d6) δ 13.5 (CH3), 18.2 (CH2CH3), 37.1 (CHCH2), 41.5 (CH2Ph), 54.2 (CH), 
126.3, 126.8, 127.9, 139.3 (C6H5), 175.1 (CHC(O)); HRMS (ESI) 229.1320 [M + Na
+] (calcd 
for C12H18N2ONa
+ 229.1317); Anal. Calcd for C12H18N2O·0.18H2O; C, 68.81; H, 8.83; N, 
13.37. Found C, 68.48; H, 8.81; N, 13.27. 
 
 
(R)-2-N-(t-Butoxycarbonyl)amino-3-methylbutanoic Acid ((R)-202).195 D-Valine (5.00 g, 
42.71 mmol) was dissolved in aqueous 2 M NaOH (43 mL) and cooled to 0 ºC in an ice 
water bath. Boc2O (11.18 g, 51.25 mmol) was slowly added and the reaction was allowed to 
warm to room temperature (18 h). The mixture was acidified to pH 2 using aqueous 
concentrated HCl and then extracted with EtOAc (3 x 50 mL). The combined organic layers 
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were dried (Na2SO4) and evaporated in vacuo to give the crude product as a pale yellow oil 
(8.50 g, 92%). The product was used for the next step without further purification: 1H NMR 
(300 MHz, CDCl3) δ 0.83–1.02 (m, CH(CH3)2), 1.45 (s, C(CH3)3), 2.15–2.28 (m, CH(CH3)2), 
4.27 (dd, J = 4.7, 9.1 Hz, CHCH(CH3)2), 5.06 (d, J = 9.1 Hz, NH). 
 
 
(R)-N-Benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-209).196,197 
Utilizing Method B and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (8.50 
g, 39.14 mmol), NMM (5.60 mL, 50.89 mmol), IBCF (5.55 mL, 43.06 mmol), and 
benzylamine (4.50 mL, 41.10 mmol) gave the crude product that was recrystallized from hot 
EtOAc to give the desired compound (6.64 g, 55%) as a white solid: mp 122–123 ºC (lit.197 
mp 112–115 ºC); Rf 0.67 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3297, 2900 (br), 1690, 1645, 
1530, 1458, 1378, 1299, 1247, 1166, 1020, 930, 875, 744, 693, 585, 508 cm-1; 1H NMR (300 
MHz, CDCl3) δ 0.92 (d, J = 6.9 Hz, CH(CH3)CH3), 0.95 (d, J = 6.6 CH(CH3)CH3), 1.40 (s, 
C(CH3)3), 2.18–2.26 (m, CH(CH3)2), 3.94–4.00 (br t, CHCH(CH3)2), 4.36 (dd, J = 6.0, 14.7 
Hz, NHCHH‟Ph), 4.46 (dd, J = 6.0, 14.7 Hz, NHCHH’Ph), 5.25 (d, J = 9.3 Hz, NHC(O)), 
6.71–6.79 (br t, NHCH2Ph), 7.21–7.33 (C6H5); 
13C NMR (75 MHz, CDCl3) δ 18.5 
(CH(CH3)(CH3)‟), 19.9 (CH(CH3)(CH3)‟), 28.9 (C(CH3)3), 31.4 (CH(CH3)(CH3)‟), 43.9 
(NHCH2Ph), 60.7 (CH), 80.4 (C(CH3)3), 128.0, 128.2, 129.2, 138.7 (C6H5), 156.6 (NC(O)O), 
172.3 (CC(O)N). 
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(S)-N-Benzyl 2-N’-(tert-Butoxycarbonyl)amino-3-methylbutanamide ((S)-209).198,199 The 
previous procedure was repeated using commercially available (S)-2-N-(t-
butoxycarbonyl)amino-3-methylbutanoic acid (4.00 g, 18.42 mmol), NMM (2.63 mL, 23.95 
mmol), IBCF (2.61 mL, 20.26 mmol), and benzylamine (2.11 mL, 19.34 mmol) to give the 
crude product that was recrystallized from hot EtOAc to give the desired compound (2.89 g, 
51%) as a white solid: mp 122–123 ºC (lit.199 mp 123–124 ºC); Rf 0.24 (1:10 
EtOAc/hexanes); IR (nujol mull) 3116, 2910 (br), 1689, 1646, 1527, 1458, 1375, 1301, 1249, 
1163, 1018, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.92 (d, J = 7.2 Hz, CH(CH3)CH3), 0.97 
(d, J = 7.2 Hz, CH(CH3)CH3), 1.42 (s, (CH3)3), 2.12–2.23 (m, CH(CH3)2), 3.92 (dd, J = 6.2, 
8.6 Hz, CH), 4.39–4.50 (m, NHCH2), 5.06–5.14 (br d, C(O)NH), 6.36–6.44 (br t, NHCH2Ph), 
7.25–7.34 (C6H5); 
13C NMR (100 MHz, CDCl3) δ 17.9 (CH(CH3)(CH3)‟), 19.4 
(CH(CH3)(CH3)‟), 28.3 ((CH3)3), 30.7 (CH(CH3)2), 43.5 (NHCH2), 60.2 (CH), 80.0 (C(CH3)3), 
127.5, 127.7, 128.7, 138.0 (C6H5), 156.0 (OC(O)), 171.6 (CC(O)). 
 
 
(R)-N-Benzyl 2-Amino-3-methylbutanamide ((R)-98).196 Utilizing Method E and using (R)-
N-benzyl 2-N-(t-butoxycarbonyl)amino-3-methylbutanamide (4.00 g, 13.06 mmol), TFA 
(14.56 mL, 0.20 mol), and CH2Cl2 (45 mL) gave the crude product after workup that was 
further purified by flash column chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to give 
the desired compound (2.25 g, 83%) as a pale yellow oil: Rf 0.70 (5% MeOH/CH2Cl2); IR 
(neat) 3316, 3064, 2961, 1952, 1881, 1812, 1655, 1525, 1459, 1364, 1240, 1081, 1028, 
882, 700, 608, 488 cm-1; 1H NMR (300 MHz, CDCl3) δ 0.82 (d, J = 6.8 Hz, CH(CH3)CH3), 
0.97 (d, J = 6.8 Hz, CH(CH3)CH3), 1.31 (s, NH2), 2.24–2.35 (m, CH(CH3)2), 3.23 (d, J = 3.9 
Hz, CHCH(CH3)2), 4.35–4.49 (m, NHCH2Ph), 7.21–7.33 (m, C6H5), 7.72–7.81 (br t, 
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NHCH2Ph); 
13C NMR (75 MHz, CDCl3) δ 16.1 (CH(CH3)CH3), 19.7 (CH(CH3)CH3), 30.1 
(CH(CH3)2), 43.0 (NHCH2Ph), 60.2 (CH), 127.2, 127.7, 128.6, 138.7 (C6H5), 174.4 (NC(O)); 
HRMS (ESI) 207.1501 [M + H+] (calcd for C12H18N2OH
+ 207.1497); Anal. Calcd for 
C12H18N2O•0.04CH2Cl2: C, 68.93; H, 8.69; N, 13.35. Found: C, 68.97; H, 8.82; N, 13.37. 
 
 
(S)-N-Benzyl 2-Amino-3-methylbutanamide ((S)-98).198 The previous procedure was 
repeated using (S)-N-benzyl 2-N-(t-butoxycarbonyl)amino-3-methylbutanamide (2.57 g, 8.39 
mmol), TFA (9.35 mL, 0.13 mol), and CH2Cl2 (28 mL) to give the crude product after workup 
that was further purified by flash column chromatography (SiO2; 1:20 EtOAc/hexanes 
followed by 10% MeOH/CH2Cl2) to give the desired compound (1.65 g, 96%) as a white 
solid: mp 52–53 ºC (lit.198 mp 53–54 ºC); [α]28.5D – 27.1° (c 0.6, CH2Cl2) (lit.
196 [α]20D – 27.2° 
(c 0.5, CH2Cl2)); Rf 0.47 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3012, 2904 (br), 1645, 1550, 
1458, 1375, 1165, 1078, 1028, 965, 727 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.84 (d, J = 6.8 
Hz, CH(CH3)CH3), 0.99 (d, J = 6.8 Hz, CH(CH3)CH3), 1.43 (s, NH2), 2.28–2.40 (m, 
CH(CH3)2), 3.27 (d, J = 4.0 Hz, CH), 4.42 (dd, J = 6.2, 14.8 Hz, NHCHH‟), 4.48 (dd, J = 6.0, 
14.8 Hz, NHCHH’), 7.24–7.34 (C6H5), 7.62–7.70 (br t, NHCH2); 
13C NMR (100 MHz, CDCl3) 
δ 16.1 (CH(CH3)CH3), 19.8 (CH(CH3)CH3), 30.9 (CH(CH3)2), 43.1 (NHCH2), 60.2 (CH), 
127.3, 127.7, 128.6, 138.6 (m, C6H5), 174.3 (C(O)); HRMS (ESI) 207.1502 [M + H
+] (calcd 
for C12H18N2OH
+ 207.1497); Anal. Calcd for C12H18N2O•0.30H2O: C, 68.09; H, 8.86; N, 
13.23. Found: C, 67.71; H, 8.89; N, 13.19. 
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(R)-2-N-(t-Butoxycarbonyl)amino-3,3-dimethylbutanoic Acid ((R)-203).200 Boc2O (9.16 g, 
41.96 mmol) was added to an acetone/H2O (75/75 mL) solution of D-tert-leucine (5.00 g, 
38.14 mmol) and Na2CO3 (10.11 g, 95.35 mmol). The reaction was stirred at room 
temperature (18 h) and then Et2O was added. The layers were separated and the aqueous 
layer was acidified with an aqueous 1 M solution of KHSO4 to pH 1–2. The acid aqueous 
layer was extracted with EtOAc (3 x 100 mL) and then the EtOAc layers were combined, 
dried (Na2SO4), and evaporated in vacuo to give the crude product (8.12 g, 92%) as a pale 
yellow solid and as a 2:1 mixture of conformers A (major) and B (minor). The product was 
used for the next step without further purification: 1H NMR (400 MHz, CDCl3) δ 1.02 (s, 
CC(CH3)3), 1.45 (s, OC(CH3)3), 3.85–3.92 (br d, CHB), 4.13 (d, J = 8.0 Hz, CHA), 5.12 (d, J = 
8.0 Hz, NHA), 6.16–6.22 (br d, NHB), 10.02–10.45 (br s, OH). 
13C NMR (100 MHz, CDCl3) δ 
26.5 (CHC(CH3)3), 28.3 (OC(CH3)3), 34.0 (CHCB(CH3)3), 34.5 (CHCA(CH3)3), 61.6 (CHA), 
63.6 (CHB), 80.0 (OCA(CH3)3), 81.6 (OCB(CH3)3), 155.6 (OCA(O)), 156.6 (OCB(O)), 176.8 
(CC(O)). 
 
 
(S)-2-N-(t-Butoxycarbonyl)amino-3,3-dimethylbutanoic Acid ((S)-204).194,198,201 Boc2O 
(8.24 g, 37.76 mmol) was added to a t-butyl alcohol/H2O (45 mL/45 mL) solution of L-tert-
leucine (4.50 g, 34.33 mmol) and NaOH (1.51 g, 37.76 mmol). The reaction was stirred at 
room temperature (18 h) and then the organic layer was evaporated in vacuo. The aqueous 
layer was acidified with an aqueous 1 M KHSO4 to pH 2–3. The aqueous layer was 
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extracted with EtOAc (3 x 50 mL) and the organic layers were combined, dried (Na2SO4), 
and evaporated in vacuo to give the crude product (7.55 g, 95%) as a white solid and as a 
2:1 mixture of conformers A (major) and B (minor): mp 105–106 ºC (lit.201 mp 122 ºC); [α]25D 
– 2.8° (c 1.1, CH2Cl2); Rf 0.77 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2910 (br), 1660, 1531, 
1458, 1373, 1223, 1161, 1061, 1011, 900, 850, 724 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.02 
(s, CC(CH3)3), 1.45 (s, OC(CH3)3), 3.88 (d, J = 7.4 Hz, CHB), 4.14 (d, J = 9.5 Hz, CHA), 5.16 
(d, J = 9.5 Hz, NHA), 6.38 (d, J = 7.4 Hz, NHB), 10.91–11.16 (br s, CO2H). 
13C NMR (75 
MHz, CDCl3) δ 26.7 (CHC(CH3)3), 28.5 (OC(CH3)3), 34.7 (CHC(CH3)3), 61.8 (CAHC(CH3)3), 
63.8 (CBHC(CH3)3), 80.2 (OCA(CH3)3), 81.8 (OCB(CH3)3), 155.9 (OCA(O)NH), 157.7 
(OCB(O)NH), 176.9 (C(O)OH). 
 
 
(R)-N-Benzyl 2-N’-(t-Butoxycarbonyl)amino-3,3-dimethylbutanamide ((R)-210). Utilizing 
Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3,3-dimethylbutanoic acid (3.50 g, 
15.14 mmol), 4-methylmorpholine (2.16 mL, 19.68 mmol), isobutyl chloroformate (2.15 mL, 
16.66 mmol), and benzylamine (1.74 mL, 15.90 mmol) in anhydrous THF (150 mL) gave the 
crude product (3.97 g, 82%) as a pale solid. The product was used immediately for the next 
step without further purification. 
 
 
(S)-N-Benzyl 2-N’-(tert-Butoxycarbonyl)amino-3,3-dimethylbutanamide ((S)-210).198,196 
The previous procedure was repeated using (S)-2-N-(t-butoxycarbonyl)amino-3,3-
 168 
 
dimethylbutanoic acid (4.53 g, 19.60 mmol), NMM (2.80 mL, 25.48 mmol), IBCF (2.78 mL, 
21.56 mmol), and benzylamine (2.25 mL, 20.57 mmol) in anhydrous THF (200 mL) to give 
the crude product that was purified by flash column chromatography (SiO2; 1:10–1:1 
EtOAc/hexanes) to give the desired product (4.58 g, 73%) as a white solid: mp 150–151 ºC; 
[α]25D + 3.1° (c 1.0, CH2Cl2); Rf 0.36 (1:10 EtOAc/hexanes); IR (nujol mull) 2911 (br), 1714, 
1644, 1543, 1459, 1374, 1228, 1170, 1066, 732 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.00  (s, 
CHC(CH3)3), 1.39 (s, OC(CH3)3), 3.91 (d, J = 9.5 Hz, CH), 4.35 (dd, J = 5.4, 15.0 Hz, 
NHCHH‟Ph), 4.48 (dd, J = 5.9, 15.0 Hz, NHCHH’Ph), 5.35 (d, J = 9.5 Hz, OC(O)NH), 6.44–
6.51 (br m, CC(O)NH), 7.20–7.33 (m, C6H5); 
13C NMR (75 MHz, CDCl3) δ 26.6 (CC(CH3)3), 
28.3 (OC(CH3)3), 34.5 (CC(CH3)3), 43.4 (NHCH2Ph), 62.3 (CH), 79.6 (OC(CH3)3), 127.3, 
127.7, 128.6, 138.1 (C6H5), 156.0 (OC(O)N), 171.1 (C(O)N). 
 
 
(R)-N-Benzyl 2-N’-Amino-3,3-dimethylbutanamide ((R)-99).202 Utilizing Method E and 
using (R)-N-benzyl 2-N’-(tert-butoxycarbonyl)amino-3,3-dimethylbutanamide (3.80 g, 11.87 
mmol), TFA (13.22 mL, 0.18 mol), and CH2Cl2 (40 mL) to give the crude product after 
workup that was further purified by flash column chromatography (SiO2; 1:20 
EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired compound (2.17 g, 
83%) as a pale yellow solid: mp 65–66 ºC (lit.202 mp 53–54 ºC); [α]28.5D + 21.8° (c 0.5, 
CH2Cl2); Rf 0.48 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3291, 2957, 1643, 1555, 1452, 1361, 
1259, 1188, 1018, 831 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.00 (s, (CH3)3), 1.45 (s, NH2), 
3.12 (s, CH), 4.42 (dd, J = 4.0, 12.8 Hz, NHCHH‟), 4.46 (dd, J = 4.0, 12.8 Hz, NHCHH’), 
7.05–7.13 (br m, NH), 7.24–7.34 (m, C6H5); 
13C NMR (100 MHz, CDCl3) δ 26.8 ((CH3)3), 
34.2 (C(CH3)3), 43.1 (NCH2), 64.4 (CH), 127.4, 127.9, 128.6, 138.6 (C6H5), 173.5 (C(O)); 
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HRMS (+ESI) 221.1654 [M+H]+ (calcd. for C13H20N2OH
+ 221.1653). Anal. Calcd for 
C13H20N2O: C, 70.87; H, 9.25; N, 12.72. Found: C, 70.83; H, 9.20; N, 12.75. 
 
 
(S)-N-Benzyl 2-Amino-3,3-dimethylbutanamide ((S)-99).198,196 The previous procedure 
was repeated using (S)-N-benzyl 2-N’-(tert-butoxycarbonyl)amino-3,3-dimethylbutanamide 
(2.50 g, 7.81 mmol), TFA (8.70 mL, 0.12 mol), and CH2Cl2 (26 mL) to give the crude product 
after workup that was further purified by flash column chromatography (SiO2; 1:100–1:10 
MeOH/CH2Cl2) to give the desired compound (1.58 g, 92%) as a white solid: mp 65–66 ºC 
(lit.1 mp 53–54 ºC); [α]25D – 15.2° (c 0.51, CH2Cl2) (lit.
3 [α]20D – 17.5° (c 0.56, CH2Cl2); Rf 0.19 
(100% EtOAc); IR (nujol mull) 2912 (br), 1649, 1555, 1459, 1372, 1260, 1192, 1023, 941, 
839, 707 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.00  (s, C(CH3)3), 1.47 (s, NH2), 3.14 (s, CH), 
4.44 (d, J = 5.7 Hz, NHCH2Ph), 7.04–7.12 (br t, C(O)NH), 7.24–7.36 (m, C6H5); 
13C NMR (75 
MHz, CDCl3) δ 27.0 (C(CH3)3), 34.4 (C(CH3)3), 43.4 (NHCH2Ph), 64.7 (CH), 127.6, 128.1, 
128.9, 138.8 (C6H5), 173.6 (C(O)N); HRMS (ESI) 221.1652 [M + H
+] (calcd for C13H20N2OH
+ 
221.1654); Anal. Calcd for C13H20N2O: C, 70.87; H, 9.15; N, 12.72. Found: C, 70.90; H, 9.10; 
N, 12.54. 
 
 
(R,S)-2-N-(t-Butoxycarbonyl)amino-3-methylpentanoic Acid ((R,S)-204).203 A solution of 
DL-isoleucine (5.00 g, 38.14 mmol) in a mixture of dioxane (75 mL) and aqueous 1 M NaOH 
(37.5 mL) was cooled to 0 ºC in an ice water bath. Boc2O (9.16 g, 41.97 mmol) was added 
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slowly and the reaction was allowed to warm to room temperature (18 h), and then the 
solvent was evaporated in vacuo. The resulting crude oil was dissolved in EtOAc (50 mL), 
the aqueous layer was acidified to pH 2 with aqueous 1 M KHSO4 and extracted with EtOAc 
(3 x 50 mL). The combined organic layers were dried (Na2SO4) and evaporated in vacuo to 
give the crude product with minor impurities (9.10 g) as a pale yellow oil and as a 1:1 
mixture of conformers A and B. The product was used for the next step without further 
purification: 1H NMR (300 MHz, CDCl3) δ 0.82–0.98 (m, 2 CH3), 1.18–1.32 (m, CH2), 1.45 (s, 
C(CH3)3), 1.82–2.03 (m, CH), 4.33 (dd, J = 4.4, 8.7 Hz, NHCHA), 4.43 (dd, J = 3.5, 9.5 Hz, 
NHCHB), 5.02 (d, J = 9.5 Hz, NHB), 5.08 (d, J = 8.7 Hz, NHA), 10.52–11.35 (br s, OH). 
 
 
(R,S)-N-Benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylpentanamide ((R,S)-211). 
Utilizing Method B and using (R,S)-2-N-(t-butoxycarbonyl)amino-3-methylpentanoic acid 
(9.10 g, 39.37 mmol), NMM (5.63 mL, 51.18 mmol), IBCF (5.59 mL, 43.31 mmol), and 
benzylamine (4.52 mL, 41.34 mmol) gave the crude product that was purified by 
recrystallization from hot EtOAc/hexanes to give the desired compound (7.16 g, 57%) as a 
white solid and as a 1:1 mixture of conformers A and B: mp 104–105 ºC; Rf 0.59 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 3393, 3282, 2912, 1658, 1554, 1458, 1375, 1308, 1253, 
1168, 1041, 723 cm-1; 1H NMR (300 MHz, CDCl3) δ 0.84–0.96 (m, 2 CH3), 1.01–1.26 (m, 
CH2), 1.40, 1.41 (2 s, OC(CH3)3), 1.74–2.04 (m, CHCH), 3.98 (dd, J = 6.7, 8.7 Hz, NHCHA or 
NHCHB), 4.15 (dd, J = 3.5, 9.5 Hz, NHCHB or NHCHA), 4.36–4.51 (m, NHCH2Ph), 4.96–5.18 
(m, (CH3)3COC(O)NH), 6.54–6.62 (br t, NHCH2Ph), 7.17–7.35 (m, C6H5); 
13C NMR (75 MHz, 
CDCl3) δ 11.8, 12.1 (CH2CH3), 14.9, 16.1 (CHCH3), 19.6, 22.3 (CH2CH3), 26.8, 28.8 
(C(CH3)3), 37.9, 38.0 (CHCH), 43.8, 43.9 (NHCH2Ph), 58.9, 59.8 (CH), 80.2, 80.3 (C(CH3)3), 
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127.9, 128.2, 129.0, 129.1, 138.7, 138.8 ((C6H5)A, (C6H5)B), 156.3, 156.6 (NC(O)O), 172.4, 
172.6 (CC(O)N), two aromatic peaks were not detected and are believed to overlap with 
nearby signals; HRMS (ESI) 321.2187 [M + H+] (calcd for C18H28N2O3H
+ 321.2178); Anal. 
Calcd for C18H28N2O3: C, 67.47; H, 8.81; N, 8.74. Found C, 67.22; H, 9.00; N, 8.65. 
 
 
(R,S)-N-Benzyl 2-Amino-3-methylpentanamide ((R,S)-100). Utilizing Method E and using 
(R,S)-N-benzyl-2-N‟-(t-butoxycarbonyl)amino-3-methylpentanamide (4.00 g, 12.49 mmol), 
TFA (13.92 mL, 0.19 mol), and CH2Cl2 (40 mL) gave the crude product after workup that 
was further purified by flash column chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to 
give the desired compound (2.24 g, 81%) as a pale yellow oil and as a 1:1 mixture of 
diastereomers: Rf 0.73 (1:20 MeOH/CH2Cl2); IR (neat) 3308, 3068, 2962, 2926, 2876, 1656, 
1521, 1457, 1365, 1247, 1081, 1026, 934, 852, 737, 700 cm-1; 1H NMR (300 MHz, CDCl3) δ 
0.77–0.96 (m, 2 CH3), 1.00–1.46 (m, (CH2CH3), NH2), 1.92–2.17 (m, CHCH), 3.26 (d, J = 3.6 
Hz, (CH)A or (CH)B), 3.36 (d, J = 3.6 Hz, (CH)A or (CH)B), 4.36–4.49 (m, NHCH2Ph), 7.21–
7.33 (m, C6H5), 7.74–7.82, 7.83–7.91 (2 br t, NHCH2Ph); 
13C NMR (75 MHz, CDCl3) δ 11.9 
(CH2CH3), 13.1, 16.2 (CHCH3), 23.7, 26.7 (CH2CH3), 37.1, 38.0 (CHCH), 42.9, 43.0 
(NHCH2Ph),  57.9, 59.9 (CH), 127.2, 127.6, 127.7, 128.5, 138.7, 138.7 ((C6H5)A, (C6H5)B), 
174.4, 174.7 (CC(O)N), two aromatic peaks were not detected and are believed to overlap 
with nearby signals; HRMS (ESI) 221.1663 [M + H+] (calcd for C13H20N2OH
+ 221.1654); 
Anal. Calcd for C13H20N2O•0.03CH2Cl2: C, 70.20; H, 9.07; N, 12.57. Found: C, 70.19; H, 
9.21; N, 12.54. 
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(R)-2-N-(Benzyloxycarbonyl)amino-3-phenylpropionic Acid ((R)-206).204,205 Benzyl 
chloroformate (5.09 mL, 36.35 mmol) and aqueous 4 M NaOH (12 mL) were added 
simultaneously over a 30 min period to a vigorously stirred solution of D-phenylalanine (5.00 
g, 30.29 mmol) dissolved in aqueous 4 M NaOH (10 mL)/aqueous 1 M NaHCO3 (30 mL) at 0 
ºC. The mixture was then warmed to room temperature and stirred overnight (18 h). The 
reaction was washed with Et2O (2 x 100 mL) and then the aqueous mixture was added to a 
stirred mixture of aqueous 4 M HCl (66 mL) and EtOAc (100 mL). The aqueous layer was 
separated and then extracted with EtOAc (3 x 100 mL). All of the organic layers were 
combined, successively washed with H2O (3 x 100 mL) and brine (2 x 100 mL), dried 
(Na2SO4), and then evaporated in vacuo to give the desired product (6.74 g, 74%) as an off-
white solid and as a 2:1 mixture of conformers A (major) and B (minor): mp 88–89 ºC (lit.204 
mp 85–88 ºC); [α]25D + 4.3° (c 1.0, MeOH) (lit.
204 [α]25D +4.1º (c 1.0, MeOH)); Rf 0.52 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 3461, 3319, 2919, 1695, 1531, 1457, 1260, 1053, 904, 735 
cm-1; 1H NMR (300 MHz, CDCl3) δ 2.87–2.95 (m, (CHCH2Ph)B), 3.07 (dd, J = 6.6, 14.1 Hz, 
(CHCHH‟Ph)A), 3.19 (dd, J = 5.6, 14.1 Hz, (CHCHH’Ph)A), 4.60–4.53 (m, CHB), 4.65–4.72 
(m, CHA), 5.03 (d, J = 4.5 Hz, (OCH2Ph)B), 5.07 (d, J = 3.3 Hz, (OCH2Ph)A), 5.36 (d, J = 8.1 
Hz, NHA), 6.45 (d, J = 8.1 Hz, NHB), 7.12–7.32 (m, 2 C6H5), 10.32–10.58 (br s, OH);
 13C 
NMR (75 MHz, CDCl3) δ 37.8 (CHCH2Ph), 54.8 (CH), 67.3 (OCH2Ph), 127.3, 128.2, 128.4, 
128.7, 128.7, 129.5, 135.7, 136.2 (2 C6H5), 156.1 (OC(O)N), 176.2 (C(O)OH). 
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(R)-N-Benzyl 2-N’-(Benzyloxycarbonyl)amino-3-phenylpropionamide ((R)-213). Utilizing 
Method B and using (R)-2-N-(benzyloxycarbonyl)amino-3-phenylpropionic acid (5.00 g, 
16.71 mmol), NMM (2.39 mL, 21.73 mmol), IBCF (2.37 mL, 18.38 mmol), and benzylamine 
(1.92 mL, 17.55 mmol) gave the crude product that was recrystallized from hot EtOAc to 
give the desired compound (4.67 g, 72%) as an off-white solid: mp 154–155 ºC; [α]25D + 5.1° 
(c 1.1, CH2Cl2); Rf 0.85 (1:100 MeOH/CH2Cl2); IR (nujol mull) 3412, 3292, 2923, 2860, 1688, 
1645, 1537, 1457, 1380, 1288, 1239, 1045, 743, 696 cm-1; 1H NMR (300 MHz, CDCl3) δ 
2.99–3.15 (m, CHCH2Ph), 4.24–4.44 (m, CH, NHCH2Ph), 5.46 (d, J = 7.2 Hz, NH), 6.10–
6.19 (br t, NHCH2Ph), 7.03–7.36 (m, 3 C6H5); 
13C NMR (75 MHz, CDCl3) δ 39.0 (CHCH2Ph), 
43.7 (NHCH2Ph), 56.7 (CH), 67.3 (OCH2Ph), 127.2, 127.7, 127.9, 128.2, 128.4, 128.7, 
128.8, 128.9, 129.5, 136.2, 136.6, 137.7 (3 C6H5), 156.2 (OC(O)N), 170.9 (CC(O)N); HRMS 
(ESI) 411.1697 [M + Na+] (calcd for C24H24N2O3Na
+ 411.1685); Anal. Calcd for C24H24N2O3: 
C, 74.21; H, 6.23; N, 7.21. Found: C, 74.18; H, 6.28; N, 7.28. 
 
 
(R)-N-Benzyl 2-Amino-3-phenylpropionamide ((R)-102). Utilizing Method C and using 
(R)-N-benzyl 2-N’-(benzyloxycarbonyl)amino-3-phenylpropionamide (3.50 g, 9.02 mmol), 
10% Pd-C (0.35 g), and MeOH (90 mL) gave the crude product that was purified by flash 
column chromatography (SiO2; 1:10 MeOH/CH2Cl2) to give the desired compound (2.22 g, 
97%) as a pale yellow solid: mp 66–67 ºC; [α]25D + 63.3° (c 1.4, CH2Cl2); Rf 0.43 (1:20 
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MeOH/CH2Cl2); IR (nujol mull) 3293, 2924, 2859, 1641, 1539, 1457, 1373, 1261, 1105, 
1031, 950, 845, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 0.98–1.62 (br s, NH2), 2.75 (dd, J = 
9.0, 13.7 Hz, CHCHH‟Ph), 3.29 (dd, J = 4.2, 13.7 Hz, CHCHH’Ph), 3.65 (dd, J = 4.2, 9.0 Hz, 
CH), 4.37–4.50 (m, NHCH2Ph), 7.20–7.35 (m, 2 C6H5), 7.56–7.64 (br t, NHCH2Ph); 
13C NMR 
(75 MHz, CDCl3) δ 41.2 (CHCH2Ph), 43.3 (NHCH2Ph), 56.6 (CH), 127.0, 127.5, 127.9, 
128.8, 128.9, 129.5, 138.0, 138.5 (2 C6H5), 171.3 (CC(O)N); HRMS (ESI) 277.1321 [M + 
Na+] (calcd for C16H18N2ONa
+ 277.1317); Anal. Calcd for C16H18N2O: C, 75.56; H, 7.13; N, 
11.01. Found: C, 75.53; H, 7.16; N, 10.85. 
 
  
 (R)-N-Benzyl 2-N-((R)-2-Phenylpropionyl)amino-3-methoxypropionamide ((R,R)-215). 
Utilizing Method B and using (R)-2-phenylpropionic acid (41 mg, 0.27 mmol), NMM (39 μL, 
0.36 mmol), IBCF (34 μL, 0.26 mmol), and (R)-N-benzyl 2-amino-3-methoxypropionamide 
(60 mg, 0.29 mmol) gave the crude product that was purified by flash column 
chromatography (SiO2; 1:100 MeOH/CH2Cl2). The major fraction gave the following 
spectrum: 1H NMR (300 MHz, DMSO-d6) δ 1.32 (d, J = 7.2 Hz, CH3), 3.26 (s, OCH3),  3.50 
(d, J = 6.3 Hz, CH2OCH3), 3.81 (q, J = 7.2 Hz, CHCH3), 4.23 (d, J = 6.3 Hz, CH2Ph), 4.50–
4.56 (m, CHCH2), 7.14–7.34 (m, 2 C6H5), 8.23 (d, J = 7.8 Hz, NHC(O)), 8.37 (t, J = 6.3 Hz, 
NHCH2Ph), minor signals attributed to impurities were detected. The major fraction was 
recrystallized from hot EtOAc to give the desired product (52 mg, 53%) as a white solid: mp 
146–147 °C; Rf  0.63 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3287, 2859 (br), 1633, 1544, 
1458, 1374, 1227, 1099, 906, 704 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 1.32 (d, J = 7.4 Hz, 
CH3), 3.26 (s, OCH3),  3.50 (d, J = 6.3 Hz, CH2OCH3), 3.79 (q, J = 7.4 Hz, CHCH3), 4.23 (d, 
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J = 6.0 Hz, CH2Ph), 4.49–4.52 (m, CHCH2), 7.14–7.34 (m, 2 C6H5), 8.23 (d, J = 8.1 Hz, 
NHC(O)), 8.37 (t, J = 6.0 Hz, NHCH2Ph);  
13C NMR (75 MHz, DMSO–d6) δ 18.3 (CHCH3), 
41.6 (CH2Ph), 44.0 (CHCH3), 52.0 (CHCH2), 57.9 (OCH3), 71.7 (CH2OCH3), 126.0, 126.3, 
126.5, 127.0, 127.7, 127.8, 138.6, 141.7 (2 C6H5), 169.1 (CHNHC(O)), 173.0 (CH2NHC(O)); 
HRMS (ESI) 363.1686 [M + Na+] (calcd for C20H24N2O3Na
+ 363.1685); Anal. Calcd for 
C20H24N2O3·0.05CH2Cl2; C, 69.83; H, 7.04; N, 8.14. Found C, 69.87; H, 6.83; N, 8.01. 
 
 
(R)-N-Benzyl 2-N-((R)-2-Phenylpropionyl)amino-2-phenylacetamide ((R,R)-216). 
Utilizing Method B and using (R)-2-phenylpropionic acid (60 mg, 0.40 mmol), NMM (57 μL, 
0.52 mmol), IBCF (49 μL, 0.38 mmol), and (R)-N-benzyl 2-amino-2-phenylacetamide (100 
mg, 0.42 mmol) gave the crude product that was purified by flash column chromatography 
(SiO2; 1:100 MeOH/CH2Cl2). The major fraction gave the following spectra: 
1H NMR (300 
MHz, DMSO-d6) δ 1.29 (d, J = 7.1 Hz, CH3), 3.95 (q, J = 7.1 Hz, CHCH3), 4.22 (d, J = 5.7 
Hz, CH2Ph), 5.53 (d, J = 7.8 Hz, CHPh), 7.06–7.46 (m, 3 C6H5), 8.70–8.78 (m, NHC(O), 
NHCH2Ph), minor signals attributed to impurities were detected; 
13C NMR (75 MHz, DMSO-
d6) δ 18.3 (CH3), 41.6 (CH2Ph), 43.7 (CHCH3), 55.8 (CHPh), 126.1, 126.4, 126.5, 126.6, 
127.0, 127.1, 127.8, 127.9, 138.5, 138.8, 141.8 (3 C6H5), 169.4 (CHNHC(O)), 172.6 
(CH2NHC(O)), one aromatic peak was not detected and is believed to overlap with nearby 
signals. The major fraction was recrystallized from hot CHCl3 to give the desired product (83 
mg, 54%) as a white solid: mp 213-214 °C; [α]25D –48.8° (c 0.9, DMSO); Rf 0.48 (1:100 
MeOH/CH2Cl2); IR (nujol mull) 3313, 2934 (br), 1634, 1531, 1458, 1375, 1216, 724 cm
-1; 1H 
NMR (300 MHz, DMSO-d6) δ 1.28 (d, J = 6.9 Hz, CH3), 3.94 (q, J = 6.9 Hz, CHCH3), 4.22 (d, 
 176 
 
J = 6.0 Hz, CH2Ph), 5.52 (d, J = 8.4 Hz, CHPh), 7.05-7.46 (m, 3 C6H5), 8.70-8.77 (m, 
NHC(O), NHCH2Ph); 
13C NMR (75 MHz, DMSO-d6) δ 18.3 (CH3), 41.6 (CH2Ph), 43.7 
(CHCH3), 55.8 (CHPh), 126.1, 126.4, 126.6, 127.0, 127.1, 127.7, 127.8, 127.9, 138.5, 138.8, 
141.8 (3 C6H5), 169.4 (CHNHC(O)), 172.6 (CH2NHC(O)), one aromatic peak was not 
detected and is believed to overlap with nearby signals; HRMS (ESI) 395.1735 [M + Na+] 
(calcd for C24H24N2O2Na
+ 395.1736). 
 
 
(S)-N-Benzyl 2-N-((R)-2-Phenylpropionyl)amino-2-phenylacetamide ((R,S)-216). The 
previous procedure was repeated using (R)-2-phenylpropionic acid (60 mg, 0.40 mmol), 
NMM (57 μL, 0.52 mmol), IBCF (56 μL, 0.44 mmol), and (S)-N-benzyl 2-amino-2-
phenylacetamide (100 mg, 0.42 mmol) to give the crude product that was purified by flash 
column chromatography (SiO2; 1:100 MeOH/CH2Cl2). The major fraction gave the following 
spectra: 1H NMR (300 MHz, DMSO-d6) δ 1.34 (d, J = 6.5 Hz, CH3), 3.94 (q, J = 6.5 Hz, 
CHCH3), 4.29 (d, J = 5.9 Hz, CH2Ph), 5.47 (d, J = 8.1 Hz, CHPh), 7.14–7.33 (m, 3 C6H5), 
8.63 (d, J = 7.8 Hz, NHC(O)), 8.82 (t, J = 5.9 Hz, NHCH2Ph), minor signals attributed to 
impurities were detected; 13C NMR (75 MHz, DMSO-d6) δ 17.9 (CH3), 41.7 (CH2Ph), 43.8 
(CHCH3), 56.0 (CHPh), 126.1, 126.4, 126.6, 126.7, 127.0, 127.1, 127.7, 127.8, 127.9, 138.3, 
138.7, 141.7 (3 C6H5), 169.5 (CHNHC(O)), 172.7 (CH2NHC(O)); The major fraction was 
recrystallized from hot CHCl3 to give the desired product (82 mg, 53%) as a white solid: mp 
224–225 °C; [α]25D +47.3° (c 1.0, DMSO); Rf 0.57 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3297, 
2924 (br), 1636, 1537, 1457, 1375, 1218, 702 cm-1;  1H NMR (300 MHz, DMSO-d6) δ 1.34 
(d, J = 7.4 Hz, CH3), 3.91 (q, J = 7.4 Hz, CHCH3), 4.28 (d, J = 5.3 Hz, CH2Ph), 5.46 (d, J = 
 177 
 
7.4 Hz, CHPh), 7.14–7.33 (m, 3 C6H5), 8.63 (d, J = 7.4 Hz, NHC(O)), 8.82 (t, J = 5.3 Hz, 
NHCH2Ph); 
13C NMR (75 MHz, DMSO-d6) δ 18.0 (CH3), 41.7 (CH2Ph), 43.8 (CHCH3), 55.9 
(CHPh), 126.1, 126.4, 126.5, 126.7, 127.0, 127.1, 127.7, 127.8, 127.9, 138.3, 138.7, 141.7 
(3 C6H5), 169.5 (CHNHC(O)), 172.7 (CH2NHC(O)); HRMS (ESI) 395.1734 [M + Na
+] (calcd 
for C24H24N2O2Na
+ 395.1736); Anal. Calcd for C24H24N2O2·0.64H2O; C, 75.07; H, 6.64; N, 
7.30. Found C, 74.69; H, 6.24; N, 7.17. 
 
4.3. Pharmacology 
Compounds were screened under the auspices of UCB Pharma (Braine L‟Alleud, 
Belgium) and the NINDS ASP (Rockville, MD). Pharmacological evaluation by UCB Pharma 
consisted of four mice assays: the 6 Hz test and the MES test to assess anticonvulsant 
activity, the formalin test to assess NP protection, and the rotorod test to assess 
neurological toxicity. After the expiration of contractual obligations with UCB Pharma, 
compounds were screened under the auspices of the NINDS ASP. Initial pharmacological 
evaluation by the NINDS ASP consisted of the MES test (mice and rats) and the 
subcutaneous pentylenetetrazol (Metrazol®) (scMET) (mice) seizure threshold test to assess 
anticonvulsant activity, the rotorod test to assess neurological toxicity (mice), and the 
positional sense test or gait and stance test to assess behavioral toxicity (rats). The effective 
dose (50%) (ED50) values were obtained in quantitative screenings for compounds that 
showed significant activity. Also provided were the median doses for neurological 
impairment (50%) (TD50) in mice using the rotorod test, and the behavioral toxicity effects 
observed in rats. TD50 values were determined for those compounds that demonstrated 
significant activity in the MES test.  
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4.3.1. Pharmacological evaluation conducted at UCB Pharma 
All experiments were performed with the use of male NMRI mice (Charles River, 
France) weighing 25–30 g. All mice were kept on a 12/12 h light/dark cycle with lights on at 
6 am and were housed at a temperature maintained at 20–24 ºC and at a humidity of 40–
70%. The mice were kept in groups of 10 in Makrolon cages (Type III, 425 x 266 x 155 mm) 
containing a bedding layer of sawdust. The mice were allowed ad libitum access to standard 
dry pellet food and tap water before random assignment to experimental groups. Each 
experiment consisted of several groups of 10 mice, one group receiving the vehicle control 
and the other groups receiving different doses of compounds. All compounds were 
dissolved in 0.5% methylcellulose and injected ip (10 mL/kg volume) 30 min before testing. 
An effective dose protecting 50% of the mice (ED50) against the convulsive endpoint and its 
associated 95% confidence interval, and a toxic dose impairing the rotorod performance of 
50% of the mice (TD50), were calculated using a non-linear fitting of the dose-response 
curve with GraphPad Prism 4 (GraphPad Software, San Diego, CA). In cases where the 
dose-response could not be established, the minimal active dose (MAD) or maximal 
tolerated dose (MTD) was determined after statistical comparison (Fisher‟s exact test). This 
occurred when no further increase in protection was observed at a higher dose (plateau 
effect), a higher dose could not be tested because of CNS side effects, or there was loss of 
activity at higher doses.   
In the 6 Hz test, partial-onset seizures were induced by a stimulator (ECT Unit 
57800, Ugo Basile, Comerio, Italy) using a current intensity of 44 mA, delivered with 0.2 
msec monopolar pulses at 6 Hz, for a duration of 3 sec through corneal electrodes as 
described by Kaminski and coworkers.179 A drop of saline/Unicain 0.1% was placed on the 
eyes to ensure good conductivity and mild local anesthesia before electrical stimulation. 
After stimulation, each mouse was observed for 30 sec and the duration of immobility 
(stunned posture) was noted. Untreated mice reliably respond with seizures. After 
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compound treatment, the mice were considered as protected against seizures if the duration 
of immobility was shorter than 7 sec. 
The maximal electroshock seizures (MES) test identified compounds that prevent 
seizure spread and was induced by a stimulator (WITT Industrie Elektronik, Berlin, 
Germany) using a current of 50 mA, delivered with a pulse frequency of 50 Hz for 0.2 sec, 
through corneal electrodes as described by Klitgaard and coworkers.178 Stimulation with this 
current caused tonic hindlimb extension in 100% of the vehicle-treated mice. The mice were 
considered as protected by the compound if they did not exhibit the tonic hindlimb extension 
following stimulation. 
In the formalin test, mice were pretreated ip with compound or vehicle 30 min before 
intrapaw injection of formalin and then returned to their cage. Twenty min after pretreatment 
(10 min before the injection of formalin), the mice were individually placed in 6 mm thick 
Plexiglas cages (26 cm x 17 cm x 28 cm) and observed for drug induced side effects over a 
10 min period. Then, 25 µL of 1.5% formalin (1.5% aqueous solution of formaldehyde) was 
injected into the midplantar aspect of the right hindpaw (subplantar injection) and the mice 
were returned to the observation cage. The nociceptive response was defined as the 
duration of licking directed at the right hindpaw and was measured to the nearest sec for 
each consecutive 5 min time bin for 30 min after the injection of formalin. A typical triphasic 
pattern of nociceptive response occurs.180 An immediate (0–5 min) bout of intense flinching, 
licking, or biting behavior is followed by nociceptive silence (5–10 min), followed by a 
gradual increase in nociceptive licking that peaks at 15–20 min. The nociceptive response 
gradually decays to zero by 25–30 min after injection.181 The bin 0–5 min after formalin 
injection constituted the early phase, where pain is due to direct excessive stimulation of 
primary afferent neurons. The sum of the remain four time bins (10–15 min, 15–20 min, 20–
25 min, and 25–30 min) constituted the late phase, where pain is due to peripheral and 
central sensitization. The compound‟s efficacy in the late phase is viewed as predictive of 
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efficacy in animal models of NP. Therefore, the compound‟s primary outcome measure is 
the late-phase value at which 50% of mice display a paw lick duration ≤72 sec (ED50), which 
corresponds to a 50% reduction of the nociceptive response relative to the mean of vehicle-
treated mice. ED50 values, with 95% confidence limits where applicable, were calculated 
using JMP Version 5 for Windows (SAS Institute Inc.).  
The adverse effects on motor coordination were assessed in a rotorod test (Treadmill 
for Mice, Ugo Basile, Italy) as described by Klitgaard and coworkers.178 The device 
consisted of a rod with a diameter of 3 cm rotating at a constant speed of 6 rpm. Mice were 
pretrained and only mice that were able to remain on the rotorod for at least 60 sec in three 
consecutive trials were retained for testing. Within 24 h, the compound was administered 
and the number of mice unable to remain on the rod for at least 60 sec was recorded.  
 
4.3.2. Pharmacological evaluation conducted at the NINDS ASP 
Experiments were performed with the use of male albino Carworth Farms No. 1 mice 
(18–25 g) or male albino Sprague-Dawley rats (100-150 g). Housing, handling, and feeding 
were all in accordance with the recommendations in the “Guide for the Care and Use of 
Laboratory Animals”.206 All compounds were dissolved in 0.5% methylcellulose and 
administered ip (10 mL/kg volume) in mice and po (20 mL/kg) in rats. An effective dose 
protecting 50% of the mice and rats (ED50) against the convulsive endpoint and its 
associated 95% confidence interval, as well as the toxic dose impairing the rotorod 
performance of 50% of the mice, or the positional sense/gait and stance performance of 
50% of the rats (TD50), were calculated by a computer program based on the methods 
described by Finney.207 
The MES test was induced by a stimulator using a current of 50 mA in mice, or 150 
mA in rats, and delivered with a pulse frequency of 60 Hz for 0.2 sec through corneal 
electrodes.42 A drop of 0.5% butacaine hemisulfate in 0.9% sodium chloride was placed on 
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the eyes to ensure good conductivity and mild local anesthesia before electrical stimulation. 
Qualitative assessment of activity in mice was determined at 30 min and 4 h following doses 
of 30, 100, and 300 mg/kg of compound. Rats were tested at 0.25–4 h in 30 min intervals at 
a dose of 30 mg/kg. The mice or rats were considered as protected by the compound if they 
did not exhibit the tonic hindlimb extension following stimulation. 
The scMET model primarily identifies compounds that raise the seizure threshold 
and was induced by subcutaneous injection of 0.5% solution of pentylenetetrazol in the 
posterior midline (85 mg/kg) in mice. This produces clonic seizures that last at least 5 sec in 
97% (CD97) of animals tested.
42 Mice were tested at 30 min and 4 h following doses of 30, 
100, and 300 mg/kg of compound. The animals were considered protected when the 
compound abolished the effect of pentylenetetrazol on seizure threshold.    
The adverse effects on motor coordination in mice were assessed in a rotorod test, 
similar to that conducted at UCB Pharma. Mice were positioned on a rod with a diameter of 
1 in rotating at a constant speed of 6 rpm, and the ability of the mice to remain on the rod for 
at least 60 sec was recorded. Mice were tested at 30 min and 4 h following doses of 30, 
100, and 300 mg/kg of compound. The adverse effects on motor coordination in rats were 
assessed in a positional sense test or gait and stance test. In the positional sense test, one 
hind leg was lowered over the edge of the table and the ability to transition back to a stable 
stance was recorded. In the gait and stance test, neurotoxicity was indicated by circular or 
zig-zag gait, ataxia, abnormal stance or posture, tremor, somnolence, stupor, or catalepsy.42 
Rats were tested at 0.25–4 h in 30 min intervals at a dose of 30 mg/kg. 
 
 CHAPTER 3. PAAD Optimization
 
1. Introduction 
In this study, we discovered a series of C(3)-O-methoxy and C(2)-hydrocarbon 
PAADs that possessed significant anticonvulsant activity and notable NP protection. To 
optimize the neurological activities of PAADs, we demonstrate that anticonvulsant activity 
can be improved upon substitution at the 4‟-N-benzyl position in C(3)-O-methoxy, C(2)-
isopropyl, and C(2)-tert-butyl PAADs. The 4‟-substituents included simple electron-donating 
or electron-withdrawing groups, as well as more complex substituents using a rationally 
designed multiple ligand (DML) approach.208  
DMLs challenge the current “one-target, one-disease” paradigm and are developed 
to modulate multiple targets simultaneously with the goal of enhancing efficacy or improving 
safety. DMLs are compounds that contain multiple ligands that are responsible for the 
compound‟s pharmacological activity, and the single formulation is thought to provide a 
different risk-benefit profile compared to drug cocktails (two or more active ingredients in 
separate formulations) or multicomponent drugs (two or more active ingredients in one 
formulation). The risk involved with the increased complexity and optimization of DMLs is 
concentrated toward the earlier (and less expensive) stages of the drug discovery process. 
Also, DMLs possibly lower the risk of drug-drug interactions compared with cocktails or 
multicomponent drugs.208 
 Multiple ligand-containing compounds are rationally designed by connecting the 
ligands via a linker (conjugated DMLs), directly attaching the ligands (fused DMLs), or 
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overlapping common functional groups within the ligands (merged DMLs).208 We took the 
latter approach and overlapped commonalities of PAADs (59) and α-aminoamides (AAAs, 
239), a class of amino acid-based anticonvulsants that display exhibit excellent activities in 
various animal seizure models,209,210 to create 4‟-chimeric PAADs. The archetypal AAA, 
safinamide (30), was initially discovered due to its anticonvulsant activity and has recently 
moved into phase III clinical trials for the treatment of Parkinson‟s disease.209,211-213  
 
.  
 
 
2. Results and discussion 
2.1. Choice of compounds: 4’-N-Benzyl substituted PAADs 
We systematically modified the 4‟-N-benzyl position according to three categories: 
(1) 4‟-N-benzyl substituted C(3)-O-methoxy PAADs (240–242); (2) 4‟-N-benzyl substituted 
C(2)-hydrocarbon PAADs (243–253); and (3) 4‟-chimeric C(3)-O-methoxy PAADs and 4‟-
chimeric C(2)-hydrocarbon PAADs (254–262). The stereochemical preference determined 
from Chapter 2 prompted the synthesis of all 4‟-N-benzyl substituted PAADs in the (R)-
configuration, and select compounds were synthesized in the (S)-configuration to confirm 
that the stereochemical preference applied to optimized PAADs. Since most optimized 
PAADs were evaluated at the NINDS ASP rather than UCB, the majority of the whole animal 
pharmacological data was in seizure and neurotoxicity models rather than NP screens. 
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2.1.1. 4‟-N-Benzyl substituted C(3)-O-methoxy PAADs 
The 4‟-N-benzyl position of (R)-61 was systematically modified with a bromo, 
trifluoromethyl, trifluoromethoxy, and phenyl group ((R)-240, -241, -126, and -242, 
respectively) by Dr. Christophe Salomé and Elise Salomé-Grosjean. We wanted to 
determine the importance of size, electronics, and hydrophobic interactions of the 4‟-
substituents on anticonvulsant activity. Although several C(2)-hydrocarbon PAADs displayed 
higher anticonvulsant activity than (R)-61, the short series of optimized C(3)-O-methoxy 
PAADs provided a useful comparison for the C(2)-hydrocarbon optimizations, and also 
served as the PAAD counterpart to a recently published FAA SAR study of (R)-28 by the 
Kohn laboratory.102    
 
 
 
2.1.2. 4‟-N-Benzyl substituted C(2)-hydrocarbon PAADs 
The 4‟-N-benzyl position of (R)-98 was systematically modified with a fluoro, chloro, 
methyl, trifluoromethyl, methoxy, trifluoromethoxy, and phenyl group ((R)-243–249). 
Similarly, the 4‟-N-benzyl position of (R)-99 was modified with a chloro, trifluoromethyl, 
trifluoromethoxy, and phenyl group ((R)-250–253). Like the C(3)-O-methoxy derivatives, we 
wanted to determine the importance of size, electronics, and hydrophobic interactions of the 
4‟-substituents on anticonvulsant activity. Initially, we began with optimization of the C(2)-
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isopropyl PAAD ((R)-98) because of its significant MES activity (MAD: 16 mg/kg) and 
formalin activity (20 mg/kg). Then, we paralleled the 4‟-N-benzyl substitution of (R)-98 using 
C(2)-tert-butyl PAAD ((R)-99) after the results of (R)-99 showed a slight improvement in 
MES activity (13 mg/kg) compared with (R)-98 (MAD 16 mg/kg). We omitted further tert-
butyl derivatives due to the relatively high cost of D-tert-leucine.  
 
 
 
2.1.3. 4‟-Chimeric C(2)-hydrocarbon PAADs 
Over the last decade, AAAs have emerged as powerful neurological agents that 
possess significant anticonvulsant activity.211-213 Therefore, we overlaid the N-benzylamino 
unit in PAADs and AAAs (see structural unit in box in 59 and 30) to create a series of 
chimeric PAADs in an effort to improve anticonvulsant activity and neuropathic pain 
protection, and reduce neurological toxicity (254–258, 260, 261). Initial pharmacological 
data suggested that small substituents at the 4‟-N-benzyl position of C(3)-O-methoxy and 
C(2)-hydrocarbon PAADs improved anticonvulsant activity, and this chimeric series 
evaluated the effect of a substantially larger substituent on pharmacological activity. Each 
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chimeric PAAD was defined by the R1 and R2 regions, where R1 consists of the PAAD 
functionality and R2 consists of the AAA functionality. R1 is either CH2OCH3, CH3, CH(CH3)2, 
or C(CH3)3, and R2 either is a safinamide-like pharmacophore or a safinamide-like 
pharmacophore with a reversed ether linkage (-CH2O- as opposed to -OCH2-). All chimeric 
PAADs were synthesized in the (R)-configuration. The excellent activities of (R)-255 and 
(R)-258 prompted the synthesis of the (S)-stereoisomers to determine if the anticonvulsant 
activity of chimeric PAADs resided in the (R)-stereoisomer. An attempt was made to 
synthesize a chimeric agent with a sulfonamide linker (R)-262 (-NHSO2- as opposed to -
OCH2-). Sulfonamides possess diverse therapeutic application, including broad-spectrum 
anticonvulsant activity as exemplified by the anticonvulsant topiramate (18).214,215   However, 
purification issues were experienced late in the synthesis of (R)-262 and we were unable to 
complete the synthesis of the sulfonamide analog.  
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(R)-259 is an exception in the chimeric series, where R1 is CH(CH3)2 but R2 is a 5-
aryl-2-furfuramide. Interest in the 5-aryl-2-furfuramide substituent came after Abbott 
Laboratories reported the discovery and biological evaluation of a series of 5-aryl-2-
furfuramides.31,32 Within the series, A-803467 (48) was identified as a potent (IC50 = 8 nM) 
and selective peripheral sodium channel blocker (hNav1.8) in recombinant human cells 
(HEK-293).31 We wanted to capitalize on the reported neuropathic pain attenuation of A-
803467 (48) and proposed a 4‟-chimeric PAAD that overlaid the amide ring of A-803467 (48) 
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with the benzyl ring of (R)-98 (see structural unit in box in 48 and 98). We chose to overlap 
the amide ring, instead of the 5-aryl ring, due to the commercial availability of the reagents 
needed to complete the synthesis of (R)-259. 
 
 
 
2.2. Choice of compounds: N-Substituted 3-methylbutanamides 
Currently, our strategy has focused on primary amino acid derivatives (PAADs). We 
wanted to determine the effect of functionalization of the terminal amine on pharmacological 
activity. Literature support for this investigation was obtained from Paruszewski and 
coworkers, who demonstrated that N-methyl (secondary amino acid derivatives, SAADs) 
and N,N-dimethyl (tertiary amino acid derivatives, TAADs) N‟-benzyl propionamides were 
potent anticonvulsants (ED50 <100 mg/kg).
216-218 Correspondingly, the Kohn laboratory 
previously altered the N-terminus of C(2)-methyl, C(2)-phenyl, and C(3)-O-methoxy N‟-
benzylamides (PAADs) by incorporating acyclic, cyclic alkylamine, and alkoxyamino units, 
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and found inconsistent anticonvulsant activity trends as the terminal amine went from 
unsubstituted, to monomethyl-substituted, to dimethyl-substituted (Table 20).92  
 
 
Table 20. Pharmacological activities of primary (PAAD), secondary (SAAD), and 
tertiary (TAAD) amino acid analogs in mice (mg/kg) 
 
          Mice (ip)
a
 
Cmpd No.  Class  R1  R2  R3  
MES
b
, 
ED50 
 
Tox,
c
 
TD50
  
PI,
d
 
MES 
(R,S)-60
e
  PAAD  CH3  H  H  >100, <300  >300   
(R,S)-263
e,f
  SAAD  CH3  CH3  H  
31 
(21–41) 
 
99 
(75–121) 
 3.2 
(R,S)-264
e,f
  TAAD  CH3  CH3  CH3  
75 [0.25] 
(61–90) 
 
160 [0.25] 
(140–180) 
 2.1 
(R,S)-62
e
  PAAD  C6H5  H  H  >100, <300  >100, <300   
(R,S)-265
e
  SAAD  C6H5  CH3  H  
46 [0.25] 
(34–59) 
 
83 [0.25] 
(64–104) 
 1.8 
(R,S)-266
e
  TAAD  C6H5  CH3  CH3  
36 [0.25] 
(30–46) 
 
72 [0.25] 
(57–86) 
 2.0 
(R,S)-61
e
  PAAD  CH2OCH3  H  H  
84 [0.25] 
(65–97) 
 
290 [0.25] 
(240–320) 
 3.5 
(R,S)-267
e
  SAAD  CH2OCH3  CH3  H  
68 [0.25] 
(55–96) 
 
290 [0.25] 
(250–330) 
 4.3 
(R,S)-268
e
  TAAD  CH2OCH3  CH3  CH3  >300  ~300   
a 
The compounds were administered intraperitoneally to adult male albino CF-1 mice under the auspices of the 
NINDS ASP. ED50 and TD50 values are in mg/kg. A dose-response curve was generated for all compounds that 
displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak 
effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b 
MES = 
maximal electroshock seizure test. 
c
 Tox = neurological toxicity. TD50 values determined from the rotorod test. 
d
 
PI = protective index (TD50/ED50). 
e
 Bégiun, C. et al. Bioorg. Med. Chem. 2004, 12, 3079–3096. 
f
 Paruszewski, R. 
et al. Pharmazie, 1996, 51, 145–148. 
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Not knowing the effect of N-substitution on D-valine amino acid derivatives, we 
selected to synthesize the secondary amino acid derivative (SAAD) (R)-269 and the tertiary 
amino acid derivative (TAAD) (R)-270. We chose to examine the functionalization of (R)-98 
due to the combination of (1) the excellent activity in the MES and formalin tests; (2) the 
availability and inexpensive cost of the D-amino acid starting material; and (3) the reported 
synthesis of the intermediate N,N-dimethyl-D-valine.219,220  
 
 
 
2.3. Choice of compounds: C(2)-isopropyl PAAD analogs  
Several C(2)-hydrocarbon PAADs possess significant anticonvulsant activity and 
activity was improved upon functionalization of the 4‟-N-benzyl position. Our studies 
indicated that many of the FAA hallmarks do not apply to PAADs. Therefore, it was 
necessary to interrogate the original proposed structural framework of PAADs. We 
investigated the importance of six properties that were common between the PAADs and 
the FAAs (271–284): (1) the carbonyl unit (Site A); (2) the amide bond (Site B); (3) the 
amide methylene linker length (Site C); (4) the N-benzylamide regiosubstitution (Site D); (5) 
the need for an arylamide (Site E); and (6) the C(2)-amino functionality (Site F). All C(2)-
isopropyl PAAD analogs were synthesized in the (R)-configuration, except 283, which was 
synthesized in the (S)- and (R,S)-configurations, and 284 was synthesized in the (R)-
configuration. 
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2.3.1. C(2)-Isopropyl PAAD analogs (Sites A–C) 
The importance of the carbonyl unit to FAAs has been demonstrated by an 
isoelectronic substitution of the amide carbonyl with a thiocarbonyl group,56 and we 
conducted a similar investigation using (R)-271. We further examined the value of the 
carbonyl unit by substitution with a methylene group ((R)-272). The Kohn laboratory has 
previously reported that functionalized amido ketones (FAK) exhibited significant 
anticonvulsant activities that were comparable to FAAs however, an increase in neurological 
toxicity was also observed.91 In a similar manner, we replaced of the nitrogen of the amide 
bond of (R)-98 with a methylene group ((R)-273) or oxygen ((R)-274) to create either a 
primary amino ketone (PAK) or primary amino ester (PAE), respectively. Several 
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perturbations are analogous to the work completed in the FAA series, but the distance 
between the amide bond and the aromatic ring has not been extensively investigated. 
Therefore, we examined the anticonvulsant activities of PAADs containing 0–4 methylene 
units between the amide bond and the aromatic ring ((R)-275–(R)-278).   
 
2.3.2. N-Benzyl substituted regioisomeric PAADs (Site D) 
Recently, Salomé and coworkers systematically evaluated both a fluoro and 
trifluoromethoxy group at the 2‟-, 3‟-, and 4‟-postions of the N-benzyl moiety of FAAs and 
determined that the 4‟-modified derivatives displayed the highest degree of anticonvulsant 
activity,102 which is in agreement with previous studies conducted by the Kohn 
laboratory.60,98 Accordingly, we evaluated the anticonvulsant activities at the 2‟-, 3‟- and 4‟-
positions of (R)-98 using a trifluoromethoxy group ((R)-279, (R)-280, and (R)-248).    
 
2.3.3. N-Substituted C(2)-isopropyl PAADs (Site E) 
The benzylamide unit is vital for the excellent anticonvulsant activity of FAAs. The 
Kohn laboratory evaluated several N-substituted FAAs, including N-methylamide, N-
benzhydrylamide, and two derivatives where an electron-donating (methoxy) or electron-
withdrawing (fluoro) group was placed at the meta position of the aromatic ring.52 We altered 
our approach compared with previous studies and examined the importance of aromaticity 
for pharmacological activity. Accordingly, we substituted the aromatic ring in (R)-98 for a 
cyclohexyl ring ((R)-281) to examine the influence of the planar ring system on 
anticonvulsant activity  
 
2.3.4. α-Substituted N-benzylbutanamides (Site F) 
The final analysis examined the choice of the amino group. The limited availability of 
2-substituted 3-methylbutanoic acid reagents prompted the investigation of N-
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benzylbutanamide derivatives instead of N-benzyl 3-methylbutanamide derivatives. 
Previously, the 2-acetamido of (R,S)-N-benzyl 2-acetamido-2-phenylacetamide ((R,S)-224, 
ED50 = 20 mg/kg) was systematically replaced by a hydrogen, methyl, hydroxy, or halogen 
group, and the hydroxy and methoxy groups provided moderate MES activities (>30, <100 
mg/kg).93 In a similar study, the 2-acetamido group of (R,S)-N-benzyl 2-acetamido-3-
methoxypropionamide ((R,S)-28, ED50 = 8.3 mg/kg) was replaced with a methyl, hydroxy, 
and amino group and the methyl and amino groups also resulted in moderate MES activities 
(>30, <100 mg/kg).90 Both studies concluded that the 2-acetamido group resulted in superior 
anticonvulsant activity. We conducted a similar study that systematically replaced the amino 
group with a hydrogen (282), methyl ((R,S)-283), or hydroxy group ((R)-284). The moderate 
activity of (R,S)-283 prompted our efforts to prepare (R)-283 and (S)-283 to determine if 
anticonvulsant activity resided in the (R)-stereoisomer. We successfully synthesized (S)-283 
but were unable to complete the synthesis of (R)-283. 
 
2.4. Synthesis 
2.4.1. 4‟-N-Benzyl substituted C(2)-hydrocarbon PAADs 
4‟-N-Benzyl substituted C(2)-hydrocarbon PAADs (R)-243–253 were synthesized 
from either (R)-202 or (R)-203 following standard MAC procedures and using commercially 
available 4‟-modified benzylamines (285–291) (Scheme 21). 
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Scheme 21. Synthesis of 4'-N-benzyl substituted hydrocarbon PAADs (R)-243–253 
 
 
2.4.2. 4‟-Chimeric C(2)-hydrocarbon PAADs 
PAADs (R)-256, (R)-257, (R)-258, (S)-258, (R)-260, and (R)-261 were synthesized 
as described in Scheme 22 from either (R)-304, (R)-202, (S)-202, or (R)-203 following 
standard MAC procedures and using 4‟-modified benzylamines 305 or 306 (Scheme 23). 
PAADs (R)-254, (R)-255, and (S)-255 were synthesized in the same manner beginning with 
(R)- and (S)-303, except alkylation of (R)-307, (R)-308, and (S)-308 using methyl iodide 
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(106) and Ag2O gave (R)-314, (R)-315, and (S)-315, respectively, before acidic deprotection 
to the corresponding PAADs. 
 
Scheme 22. Synthesis of 4’-chimeric PAADs 254–258, 260, and 261 
 
 
 
Amines 305 and 306 were prepared by the Williamson reaction of phenols 316 and 
320 with organohalides 317 and 319, respectively, followed by LiAlH4 reduction of the nitriles 
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318 and 321 to their corresponding amines, which were immediately converted to the 
hydrochlorides using HCl in Et2O (Scheme 23).
105  
 
Scheme 23. Synthesis of 4’-modified benzylamines 305 and 306 
 
 
 
We attempted to synthesize sulfonamide (R)-262 (Scheme 24). 4-Aminobenzylamine 
(322) was N-protected with Boc2O to give 323, then converted to the sulfonamide 325, and 
deprotected in acidic media to obtain the corresponding amine 326.221 Amine 326 was 
coupled with (R)-203 following the standard MAC procedure to give sulfonamide (R)-327, 
which was then deprotected in acidic media to give the corresponding PAAD (R)-262. 
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Purification difficulties prompted the conversion to the oxalate salt (R)-328 but we were 
unable to obtain a sufficient amount that met the purity standards for biological testing.   
 
Scheme 24. Attempted synthesis of (R)-N-(4-((-3-
fluorophenyl)sulfonamido)phenyl)benzyl 2-amino-3,3-dimethylbutanamide ((R)-262) 
 
 
 
Chimeric (R)-259 was prepared by a convergent synthesis, requiring (R)-202 and 
amine 332 (Scheme 25). Amine 332 was prepared by reacting 323 with acyl chloride 330, 
prepared from commercially available carboxylic acid 329 and oxalyl chloride in DMF, to 
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give 331 that was then deprotected (TFA).32 MAC coupling of (R)-202 with 332 provided (R)-
333 that was deprotected (TFA) in the final step to give the PAAD (R)-259. 
 
Scheme 25. Synthesis of (R)-4-((5-(4-chloro)phenyl)furan-2-carboxamido)benzyl 2-
amino-3-methylbutanamide ((R)-259) 
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2.4.3. N-Benzyl N’,N’-dimethylamino-3-methylbutanamide 
Reductive condensation of (R)-195 with formaldehyde using 10% Pd-C in the 
presence of H2 gave (R)-334.
219,220,222 We attempted to couple (R)-334 with benzylamine 
using the MAC protocol but the limited solubility of (R)-334 in THF resulted in low yields 
(<5%) (Scheme 26). Accordingly, we used the condensing reagent DMTMM. Benzylamine 
was first added to a THF suspension of (R)-334 and the resulting ammonium carboxylate 
dissolved after several minutes. Then, the reaction solution was treated with DMTMM to give 
(R)-270 in 10% yield.  
 
Scheme 26. Synthesis of (R)-N-benzyl N,N-dimethylamino-3-methylbutanamide ((R)-
270) 
 
 
 
2.4.4. C(2)-Isopropyl PAAD analogs 
Thioamide (R)-355 was prepared directly from (R)-209 upon the treatment with 
excess Lawesson‟s reagent (2.2 equiv) at reflux,56 and then deprotected in acidic media to 
give PAAD (R)-271 (Scheme 27). We were mindful of the potential for thiation of the 
carbamate carbonyl but the 13C NMR spectrum contained a signal at ~155 ppm, the typical 
shift for carbamate carbon. If thiation of the carbamate carbonyl had occurred, we would 
have expected a significant downfield shift in the signal (~190 ppm).223 In agreement with 
 200 
 
the proposed structure of (R)-271, we observed the thioamide carbon signal in the 13C NMR 
at 205 ppm. 
 
Scheme 27. Synthesis of (R)-N-benzyl 2-amino-3-methylthiobutanamide ((R)-271) 
 
 
 Diamine (R)-272 was synthesized by the direct reduction of (R)-98 with borane in 
THF (Scheme 28).196 Previously, Ramalingam and coworkers purified (R)-272 by Kugelrohr 
distillation (145 ºC/0.06 mbar),196 but we used an acid/base extraction method followed by 
flash column chromatography. Using these conditions, we found that the purification of (R)-
272 was complicated by the ring opening of THF, to give trace amounts of 1,4-butanediol. 
Extraction of 2,3-butanediol from fermentation broths using an ethanol/phosphate system 
was reported by Jiang and coworkers224 and we optimized their extraction system to fit our 
needs. We successfully removed 1,4-butanediol by washing a dichloromethane solution of 
(R)-272 with a 1:1 mixture of EtOH/H2O.  
 
Scheme 28. Synthesis of (R)-1-N-benzylamino-2-amino-3-methylbutane ((R)-272) 
 
 
 We attempted to synthesize PAAD (R)-273 via the intermediate (R)-336 (Scheme 
29). Previously, the Kohn laboratory introduced a ketone unit starting from either a N-acetyl 
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or N-Cbz amino acid.91 Accordingly, we treated N-tBoc amino acid (R)-202 with n-butyl 
lithium, followed by phenethylmagnesium chloride, in an effort to obtain (R)-336. However, 
the 1H NMR spectrum for the crude reaction product showed a complex mixture. Therefore, 
we prepared Weinreb amide (R)-337 by coupling (R)-202 with N,O-dimethylhydroxylamine in 
the presence of CMDT and base.225 Weinreb amides (N-methoxy-N-methylamides) readily 
react with Grignard reagents and are widely known as useful precursors to ketones.225-227 
Next, (R)-337 was directly reacted with phenethylmagnesium bromide to give (R)-336. This 
method provided a relatively clean reaction mixture permitting isolation of (R)-336. 
Deprotection of this intermediate gave the corresponding PAAD (R)-273.  
 
Scheme 29. Synthesis of (R)-4-amino-2-methyl-6-phenyl-4-hexanone hydrochloride 
((R)-273) 
 
 
 
 We attempted to synthesize (R)-338 from (R)-202 and benzyl alcohol, following the 
standard MAC coupling procedure, in an effort to reach PAAD (R)-274 (Scheme 30). 
However, we recovered starting material from the MAC reaction. Next, we used the mild 
esterification method reported by Kim and coworkers.228 The desired ester (R)-338 was 
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achieved by the addition of benzylchloroformate in the presence of base and catalytic 
amounts of DMAP. Subsequent deprotection of (R)-338 in acidic media gave PAAD (R)-274. 
 
Scheme 30. Synthesis of (R)-O-benzyl 2-amino-3-methylbutanoate ((R)-274) 
 
 
PAADs (R)-275–278 were synthesized from (R)-202 following standard MAC 
procedures and using commercially available amines (339–342) (Scheme 31). 
 
Scheme 31. Synthesis of C(2)-isopropyl analog: the N-amide Site A ((R)-275–278) 
 
 
Similarly, we prepared PAADs (R)-279 and (R)-280 from (R)-202 and the 
commercially available amines 347 and 348 using the MAC procedure (Scheme 32). 
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Scheme 32. Synthesis of C(2)-isopropyl analogs: N-benzyl substituted regioisomers 
((R)-279 and (R)-280) 
 
 
We found that the MAC protocol worked well for cyclohexylmethylamine (351). Thus, 
treatment of (R)-202 with 351 yielded (R)-352. Removal of the tBoc protecting group in the 
final step gave (R)-281 (Scheme 33). 
 
Scheme 33. Synthesis of C(2)-isopropyl analogs: the N-amide Site B ((R)-281) 
 
 
PAADs 282, (S)-283, (R,S)-283, and (R)-284 were synthesized from commercially 
available carboxylic acids 353, (S)-354, (R,S)-354, and (R)-355, respectively (Scheme 34). 
An attempt was made to synthesize PAAD (R)-284 from commercially available (R)-355 
using the MAC coupling procedure but we obtained carbonate (R)-356 as the major product. 
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Scheme 34. Synthesis of C(2)-isopropyl analog: α-substituted N-benzylbutanamides 
(282, (S)-283, (R,S)-283, and (R)-284) 
 
 
Therefore, we modified a procedure reported by Ishihara and coworkers that utilized 
an arylboronic acid bearing electron-withdrawing groups as an efficient catalyst for the 
amidation of (R)-355.229 Accordingly, (R)-355 was treated in the presence of benzylamine 
and commercially available 3,5-bis(trifluoromethyl)benzeneboronic acid (357) to give PAAD 
(R)-284 (Scheme 34). 
 We wanted to prepare (R)-283 to compare its pharmacological activity with (S)-283 
and (R,S)-283, but the lack of commercially available (R)-354 required our use of a more 
extensive synthetic pathway (Scheme 35). Adapted from the synthesis of Santangelo and 
coworkers,230 we protected the hydroxyl group of commercially available (S)-3-hydroxy-2-
methylpropionate ((S)-358) using dihydropyran to give (S)-359, reduced the methylester to 
the corresponding alcohol ((R)-360) with LiAlH4 and then protected the alcohol ((R)-360) 
 205 
 
with tosyl chloride to give (S)-361. Next, we made several attempts to displace the tosylate 
group in (S)-361 with MeMgI and Li2CuCl4 to give (R)-362, where we varied reagent 
concentrations and reaction temperatures. Copper reagents are widely used in organic 
synthesis for the formation of carbon-carbon bonds and the development of higher order 
cuprates has allowed the coupling of alkyl halides and alkyl sulfonates with several types of 
organometallic reagents.231 We were mindful of possible by-products from competitive 
nucleophilic substitution and elimination reactions but recovered starting material after each 
attempt, with one exception. We isolated the iodo intermediate (R)-363 upon lowering the 
reaction temperature to 0 °C but were unable to duplicate this result.  
 
Scheme 35. Attempted synthesis of (R)-N-benzyl 2-methylbutanamide ((R)-283) 
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2.5. Pharmacological evaluation 
PAADs 240–284 were evaluated for anticonvulsant activity using the MES test at 
either UCB Pharma, following the procedures described by Klitgaard,178 or at the NINDS 
ASP, following the procedures described by Stables and Kupferberg,42 or both. 
Anticonvulsant activity using the 6 Hz test was performed either at UCB Pharma, following 
the procedures described by Kaminski and coworkers (44 mA),179 or at the NINDS ASP, 
following the procedures described by Stables and Kupferberg (32 mA),42 or both. PAADs 
evaluated at UCB Pharma were also tested for NP protection (formalin test).180 All 
compounds were administered intraperitoneally (ip) to mice at UCB Pharma or ip to mice 
and orally (po) to rats at the NINDS ASP. The pharmacological data from the MES, 6 Hz, 
and formalin tests are summarized in Tables 21, 23, 24, 26, 27, and 29–35. The MES 
activities of PAADs are compared with the MES activities of their corresponding FAAs in 
Tables 22 and 28. (R)-255 and (R)-258 were evaluated at UCB Pharma and the NINDS 
ASP and these compounds were added to the list of four compounds (Chapter 2) that 
compared the MES activities of PAADs at both testing facilities (Table 36). The tables list the 
results obtained from either qualitative (dose range) or quantitative (ED50) testing in mice (ip) 
and rats (po). We also included qualitative (dose range) or median neurological impairing 
dose (TD50) values in mice (ip) using the rotorod test in mice and the behavioral toxicity 
effects observed in rats (po). The protective indices (PI = TD50/ED50) were provided, when 
applicable. PAADs tested at the NINDS ASP were evaluated in the subcutaneous Metrazol® 
(scMET) seizure model but protection was not observed at the doses (30, 100, 300 mg/kg) 
and times (0.5 and 4 h) tested (data not shown), with three exceptions. (R)-248 displayed 
protection in the scMET seizure model for four out of eight mice treated with 62 mg/kg of 
compound and the remaining four mice displayed continuous seizure activity. Similarly, (R)-
251 protected one out of eight mice treated with 70 mg/kg and the remaining seven mice 
displayed continuous seizure activity, while two out of eight mice treated with 135 mg/kg of 
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(R)-251 were protected and the remaining six mice displayed continuous seizure activity. 
Lastly, (R,S)-283 was quantitatively determined to prevent seizures with an effective dose of 
140 mg/kg (0.25 h) (95% confidence interval: 120–160 mg/kg).  
 
2.5.1. 4‟-N-Benzyl substituted PAADs 
2.5.1.1. 4‟-N-Benzyl substituted C(3)-O-methoxy PAADs 
The neurological activities for 4‟-N-benzyl substituted C(3)-O-methoxy PAADs (R)-
126, -240–242 in mice are listed in Table 21. We systematically evaluated the effect of a 
bromo, trifluoromethyl, trifluoromethoxy, and phenyl group placed at the 4‟-N-benzyl position 
on anticonvulsant and pain activity. The MES activities of all 4‟-N-benzyl substituted C(3)-O-
methoxy PAADs increased compared to the unsubstituted PAAD (R)-61 (ED50 = 34 mg/kg). 
The 4‟-phenyl derivative (R)-242 (ED50 = 15 mg/kg) and the 4‟-trifluoromethyl derivative (R)-
241 (ED50 = 19 mg/kg) displayed the highest MES activities, a ~2-fold improvement from 
(R)-61. However, the 4‟-bromo derivative (R)-240 (ED50 = 31 mg/kg) showed only marginal 
improvement in anticonvulsant activity. While PAADs (R)-126, -240–242 displayed 
significant activity in the MES test, they are 2–6-fold less sensitive to the 6 Hz test. This 
result is not surprising because a similar decrease in sensitivity (~3-fold) was observed for 
(R)-28 (MES ED50 = 3.3 mg/kg, 6 Hz ED50 = 10 mg/kg) and a >2-fold decrease in sensitivity 
was observed for (R)-61 (MES ED50 = 34 mg/kg, 6 Hz ED50 >67 mg/kg). All 4‟-N-benzyl 
substituted C(3)-O-methoxy PAADs displayed a lack of activity in the formalin test at the 
tested doses. Comparison of the MES activities of (R)-126, -240–242 with their 
corresponding FAAs (Table 22) revealed a consistent drop in activity (2–10-fold) as we go 
from FAA to PAAD. This drop in activity is similar to the drop in activity observed for the 
unsubstituted C(3)-oxy PAADs (Table 6). Therefore, we conclude that substitution at the 4‟-
N-benzyl position of C(3)-O-methoxy PAADs moderately improves anticonvulsant activity in 
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the MES test, but the substitutions do not provide any advantage over the corresponding 
FAAs.  
  
 
2
0
9 
Table 21. Pharmacological activities of 4’-N-benzyl-substituted C(3)-O-methoxy PAADs in mice (mg/kg) at UCB 
 
    Mice (ip)
a 
Cmpd No.  R  
MES
b
, 
ED50 
 
6 Hz,
c
 
ED50 
 
Formalin, 
ED50 
 
Tox
d
, 
TD50
  Comments
e
  
PI
f
, 
MES 
 PI
f
, Form 
(R)-28  LCM  3.3  10  15  19  Ref  5.8  1.3 
(R)-61  
H 
 
 34  >67  >67  >120    >3.5   
(R)-240  Br  31  >180  70  115    3.7  1.6 
(R)-241  CF3  19  55  >31  48  75 (LR)  2.5   
(R)-126  OCF3  >10, <30  ND
g
  ND
g
  >30, <100       
(R)-242  C6H5  15  
59 
(MAD)
h
 
 >33  ND
g
  100 (C)     
phenytoin
i
    
9.5 [2.0] 
(8.1–10) 
     
66 [0.5] 
(53–72) 
 Ref     
phenobarbital
i
    
22 [1.0] 
(15–23) 
     
69 [0.5] 
(63–73) 
 Ref     
valproate
i
    
270 [0.25] 
(250–340) 
     
430 [0.25] 
(370–450) 
 Ref     
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB. ED50 and TD50 values are in mg/kg and were 
determined 30 min after ip administration.
 b
 MES = maximal electroshock seizure test. 
c 
6 Hz test = psychomotor seizure model (44 mA). 
d 
Tox = neurological 
toxicity. TD50 value determined from the rotorod test. 
e
 Dose in mg/kg is followed by whole animal pharmacological observation (Ref = reference, LR = loss of 
righting reflex, C = convulsions). 
f 
PI = protective index (TD50/ED50). 
g 
ND = not determined. 
h
 MAD = minimal active dose.  
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Table 22. Comparison of the pharmacological activities of 4’-N-benzyl-substituted C(3)-O-methoxy FAAs and their PAAD 
counterparts in mice (mg/kg) 
                            
      Mice (ip)
a
      Mice (ip)
a
 
R  
FAA 
Cpd No. 
 
FAA 
Test Site 
 
FAA 
MES,
b
 ED50 
 
FAA 
Tox,
c
 TD50 
 
PAAD 
Cpd No. 
 
PAAD 
Test Site 
 
PAAD 
MES,
b
 ED50 
 
PAAD 
Tox,
c
 TD50
 
H 
 
 (R)-28
d
  NINDS  
4.5 [0.5] 
(3.7–5.5) 
 
27 [0.25] 
(26–28) 
 (R)-61  UCB  34  >120 
Br  (R)-364
e
  NINDS  
8.7 [0.25] 
(7.2–10) 
 
30 [0.25] 
(24–36) 
 (R)-240  UCB  31  115 
CF3  (R)-365
e
  NINDS  
>10, <30 
[0.5] 
 
>100, <300 
[0.5] 
 (R)-241  UCB  19  48 
OCF3  (R)-123
e
  NINDS  
3.6 [0.25] 
(3.0–4.3) 
 
13 [0.25] 
(9.2–19) 
 (R)-126  UCB  >10, <30  >30, <100 
C6H5  (R)-366
e
  NINDS  
8.0 [0.5] 
(5.3–12) 
 11 [0.5]  (R)-242  UCB  15  ND
f
 
a 
The compounds were either administered intraperitoneally to adult male NMRI mice under the auspices of UCB or administered 
intraperitoneally to adult male albino CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 
30 min after ip administration (UCB) or a dose-response curve was generated for all compounds that displayed sufficient activity and the dose-
effect data for these compounds was obtained at the “time of peak effect” (indicated in hours in the brackets) (NINDS ASP). Numbers in 
parentheses are 95% confidence intervals. 
b 
MES = maximal electroshock seizure test. 
c 
Tox = neurological toxicity. TD50 value determined from 
the rotorod test. 
 d 
Choi, D. et al. J. Med. Chem. 1996, 39, 1907–1916. 
e
 Salomé, C. et al. J. Med. Chem. 2010, 53, 1288–1305. 
f
 ND = not 
determined. 
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2.5.1.2. 4‟-N-Benzyl substituted C(2)-hydrocarbon PAADs 
The data from Chapter 2 suggested that a C(2)-heteroatom one atom removed from 
the C(2) center is not necessary for optimal PAAD anticonvulsant activity or NP protection. 
Hydrocarbon PAADs (R)-98 and (R)-99 displayed excellent activity in both the MES and 
formalin tests, and their MES activity surpassed the MES activity of the traditional 
antiepileptic phenobarbital (22 mg/kg) and approached the MES activity of the antiepileptic 
phenytoin (9.5 mg/kg). Therefore, we chose to expand the SAR of (R)-98 and (R)-99 to 
include functionalization of both the N-benzylamide moiety and the N-terminal amine in an 
attempt to optimize anticonvulsant activity. Unfortunately, we were unable to evaluate the 
optimized PAADs for NP modulation due to the shift of testing location from UCB Pharma to 
the NINDS ASP.  
We gauged the importance of electronic effects, hydrophobic interactions, and size 
of the 4‟-substitution in C(2)-hydrocarbon PAADs (R)-243–253 on anticonvulsant activity in 
mice (Table 23). The MES activity for the 4‟-chloro-substituted C(2)-isopropyl ((R)-244) and 
C(2)-tert-butyl ((R)-250) PAADs were similar (ED50 (mg/kg): (R)-244, 22; (R)-250, 25) but 
were slightly lower than their respective parent compounds (R)-98 and (R)-99 (ED50 (mg/kg): 
(R)-98, 15; (R)-99, 14 mg/kg). The 4‟-flouro derivative (R)-243 was evaluated in the 
isopropyl series and displayed similar activity to the 4‟-chloro derivative (R)-244 (ED50 
(mg/kg): (R)-243, >10, <30; (R)-244, 22). Therefore, the electron-withdrawing effects of 
halogens (F and Cl) slightly decreased anticonvulsant activity compared with the 
unsubstituted parent compounds. A similar trend was observed in rats, where the 4‟-fluoro-
substituted isopropyl PAAD (R)-243 resulted in a 2-fold decrease in seizure protection from 
the parent PAAD (R)-98 (ED50 (mg/kg): (R)-98, 11; (R)-243, 21) (Table 24). Next, we 
compared the 4‟-methyl-substitued C(2)-isopropyl PAAD (R)-245 and the 4‟-trifluoromethyl 
analog (R)-246. The 4‟-methyl moiety resulted in the complete loss of anticonvulsant activity 
in the MES test (>300 mg/kg), while the 4‟-trifluoromethyl moiety displayed excellent activity 
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(ED50 = 14 mg/kg). These results were paralleled when we evaluated the 4‟-methoxy ((R)-
247) and 4‟-trifluoromethoxy ((R)-248) derivatives in the C(2)-isopropyl series (ED50 (mg/kg): 
(R)-247, >300; (R)-248, 16). The 4‟-trifluoromethyl ((R)-251) and 4‟-trifluoromethoxy ((R)-
252) compounds also displayed significant anticonvulsant activities in the C(2)-tert-butyl 
series (ED50 (mg/kg): (R)-251, 24; (R)-252, 28), although to a lesser degree than found in 
the isopropyl series, and were less active than the parent compound (R)-99 (ED50 = 14 
mg/kg). The 4‟-methyl and 4‟-methoxy analogs were not evaluated in the tert-butyl series 
due to the inactivity in the isopropyl series. (R)-246, -248, -251, and -252 also showed 
substantial MES activity in the rat (ED50 (mg/kg): (R)-246, 13; (R)-248, ~20; (R)-251, <30; 
and (R)-252, 23). Finally, the 4‟-substituted phenyl derivatives (R)-249 and (R)-253 
displayed only moderate activity (ED50 >30, <100 mg/kg).  
Several possible physiochemical properties may account for the observed 4‟-N-
benzyl SAR. Modification of the 4‟-site in the C(2)-hydrocarbon PAADs altered the electronic 
and hydrophobic properties at this site in the drug candidates. Our data indicates that the 
electronic properties of 4‟-N-benzyl substituents impacted pharmacological activity to a 
greater extent than the hydrophobic properties of 4‟-N-benzyl substituents. We found that 
electron-withdrawing 4‟-substituents (defined as a positive Hammett sigma value, Table 25) 
maintained or increased seizure protection while electron-donating groups (defined as a 
negative Hammett sigma value, Table 25) at this site dramatically decreased activity (Figure 
15). We are at a loss to explain the abrupt loss of activity as the sigma value approached 
zero. Many, but not all, of the electron-withdrawing moieties contained fluorine-substituents. 
The greatest activity was observed in C(2)-isopropyl PAADs containing a CF3 ((R)-246) or 
OCF3 ((R)-248) group at the 4‟-N-benzyl position. When the corresponding non-fluorinated 
moieties CH3 ((R)-245) and OCH3 ((R)-247) were incorporated at the 4‟-N-benzylamide site, 
the compounds were inactive suggesting that hydrophobic interactions (defined by their π-
value) may affect anticonvulsant activity (Table 25) (π: (R)-246, 0.88; and (R)-248, 1.04; (R)-
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245, 0.56; and (R)-247, -0.02).232,233 However, there is not a direct correlation between 
hydrophobicity and pharmacological activity (Figure 16). For example, the 4‟-OCH3 and 4‟-F 
have similar π-values (-0.02 and 0.14) but strikingly different ED50 values (ED50 (mg/kg): (R)-
243, >10, <30; (R)-247, >300). In addition, the 4‟-phenyl derivative was the most 
hydrophobic substituent incorporated at the 4‟-site, yet it exhibited only moderate 
anticonvulsant activity (ED50 >30, <100 mg/kg). 
Our finding that the pharmacological activities of C(2)-hydrocarbon PAADs was 
highly dependent upon the electronic properties of the 4‟-substitutent was unexpected. In a 
related study, Salomé and coworkers showed for 4‟-substituted derivatives of the FAA (R)-
28, anticonvulsant activity did not correlate with the electronic properties of the 4‟-group, and 
that both electron-donating and electron-withdrawing substituents displayed excellent 
protection in the MES seizure model.102 The sensitivity of the C(2)-hydrocarbon PAADs to 
the electronic properties of the 4‟-N-benzyl substituent provides another difference in the 
SAR of this series of compounds compared with the findings reported for FAAs. We 
appreciate that these PAADs and FAAs differ not only by the absence or presence of the N-
terminal acetyl group, but also in the nature of the C(2)-substituent (e.g., hydrocarbon, 
CH2OCH3).  
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Table 23. Pharmacological activities of 4’-N-benzyl-substituted C(2)-hydrocarbon 
PAADs in mice (mg/kg) at the NINDS ASP 
 
      Mice (ip)
a
  
Cmpd 
No. 
 R1  R2  
MES,
b
 
ED50 
 
6 Hz,
c
 
ED50 
 Tox,
d
 TD50
 
 
PI,
e
 
MES 
 
PI,
e
  
6 Hz 
(R)-28  LCM  H  
4.5 [0.5] 
(3.7–5.5) 
 10  
27 [0.25] 
(26–28) 
 6.0  2.7 
(R)-98  CH(CH3)2  H  
15 [0.25] 
(13–18) 
 ND
f
  
70 [0.25] 
(63–80) 
 
4.8   
(R)-243  CH(CH3)2  F  
>10, <30 
[0.5] 
 ND
f
  
>100, <300 
[0.5] 
 
   
(R)-244  CH(CH3)2  Cl  
22 [0.25] 
(20–25) 
 ~50  
74 [0.25] 
(72–78) 
 
3.4  ~1.5 
(R)-245  CH(CH3)2  CH3  >300 [0.5]  ND
f
  >300 [0.5] 
 
   
(R)-246  CH(CH3)2  CF3  
14 [0.5] 
(12–16) 
 >20, <60  
57 [0.25] 
(54–54) 
 
4.1   
(R)-247  CH(CH3)2  OCH3  >300 [0.5]  ND
f
  
>30, <100 
[0.5] 
 
   
(R)-248  CH(CH3)2  OCF3  
16 [0.25] 
(14–20) 
 ND
f
  
84 [0.25] 
(67–109) 
 
5.3   
(R)-249  CH(CH3)2  C6H5  
>30, <100 
[0.5] 
 ND
f
  >300 [0.5] 
 
   
(R)-99  C(CH3)3  H  
14 [0.25] 
(11–17) 
 ND
f
  
66 [0.25] 
(58–73) 
 4.7   
(R)-250  C(CH3)3  Cl  
25 [0.25] 
(21–29) 
 ND
f
  
84 [0.5] 
(75–100) 
 
3.4   
(R)-251  C(CH3)3  CF3  
24 [0.25] 
(21–28) 
 
<100 
[0.25-2.0] 
 
133 [0.25] 
(93–197) 
 
5.5   
(R)-252  C(CH3)3  OCF3  
28 [1.0] 
(22–34) 
 ND
f
  
73 [0.25] 
(60–86) 
 
2.6   
(R)-253  C(CH3)3  C6H5  
>30, <100 
[0.5] 
 ND
f
  
>30, <100 
[0.5] 
 
   
a 
The compounds were administered intraperitoneally to adult male albino CF-1 mice under the auspices of the 
NINDS ASP. ED50 and TD50 values are in mg/kg. A dose-response curve was generated for all compounds that 
displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak 
effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b 
MES = 
maximal electroshock seizure test. 
c 
6 Hz test = psychomotor seizure model (44 mA). 
d 
Tox = neurological 
toxicity. TD50 value determined from the rotorod test. 
e 
PI = protective index (TD50/ED50). 
f
 ND = not determined. 
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Table 24. Pharmacological activities of 4’-N-benzyl-substituted C(2)-hydrocarbon 
PAADs in rats (mg/kg) at the NINDS ASP 
 
      Rat (po)
a
 
Cmpd No.  R1  R2  MES,
b
 ED50  Tox,
c
 TD50  PI
d
 
(R)-28  LCM  H  
3.9 [2.0] 
(2.9–6.2) 
 >500  >120 
(R)-98  CH(CH3)2  H  
11 [0.25] 
(9.1–13) 
 >500  >45 
(R)-243  CH(CH3)2  F  
21 [0.5] 
(13–31) 
 >500  >24 
(R)-244  CH(CH3)2  Cl  ND
e
  ND
e
   
(R)-245  CH(CH3)2  CH3  ND
e
  ND
e
   
(R)-246  CH(CH3)2  CF3  
13 [1.0] 
(9–18) 
 >500  >38 
(R)-247  CH(CH3)2  OCH3  ND
e
  ND
e
   
(R)-248  CH(CH3)2  OCF3  
~20 
[0.25–2.0] 
 
>30 
[0.25–4.0] 
  
(R)-249  CH(CH3)2  C6H5  
~30 
[2.0] 
 
>30 
[0.25–4.0] 
  
(R)-99  C(CH3)3  H  ND
e
  ND
e
   
(R)-250  C(CH3)3  H  >30  >30   
(R)-251  C(CH3)3  Cl  
~30 
[0.25–0.5] 
 
>30 
[0.25–4.0] 
  
(R)-252  C(CH3)3  CF3  
<30 
[0.5–4.0] 
 
>30 
[0.25–4.0] 
  
(R)-253  C(CH3)3  OCF3  
23 [2.0] 
(17–33) 
 
>30 
[0.25–4.0] 
  
(R)-28  C(CH3)3  C6H5  ND
e
  ND
e
   
a 
The compounds were administered orally to adult male albino Sprague Dawley rats. ED50 and TD50 
values are in mg/kg. A dose-response curve was generated for all compounds that displayed sufficient 
activity and the dose-effect data for these compounds was obtained at the “time of peak effect” (indicated 
in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b 
MES = maximal 
electroshock seizure test. 
c
 Tox = behavioral toxicity. 
d 
PI = protective index (TD50/ED50). 
e
 ND = not 
determined. 
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Table 25. Physical properties of aromatic substituents 
R
 
 σp
a
  π
a
  
Pauling
b
 
electronegativity 
H  0.00  0.00  2.28 
Br  0.23  0.86  2.80 
Cl  0.23  0.71  3.03 
F  0.06  0.14  3.95 
CH3  -0.17  0.56  2.30 
CF3  0.54  0.88  3.35 
OCH3  -0.27  -0.02  NA
c
 
OCF3  0.35  1.04  NA
c
 
C6H5  -0.01  1.96  3.0 
a
 Hansch, C. Substituent constants for correlation analysis in chemistry 
and biology. Wiley: New York, 1979, pp. 49–51. 
b
 Carey, F. A. 
Advanced organic chemistry. Part A: Structure and mechanisms. 
Springer: New York, 2006, p. 17. 
c
 NA = not available.  
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Figure 15. Effect of σp on MES activity 
 
 
Figure 16. Effect of π on MES activity 
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2.5.1.3. 4‟-Chimeric C(2)-hydrocarbon PAADs 
Next, we evaluated the neurological activities of 4‟-N-benzyl-chimeric PAADs (R)-
254–261 in mice (Table 26) and rats (Table 27). Evaluation occurred during the transition 
from UCB Pharma to the NINDS ASP and (R)-255 and (R)-258 were tested at both facilities 
(location indicated in column two of Table 26). First, we approached the data analysis from 
the standpoint of R1, where R2 was kept the same and we looked at the effect of R1 on 
activity. Then, we examined the effect of R2 on activity, where we kept R1 the same and 
looked at the effect of R2 on activity. The first method examined which R1 unit was optimal 
for 4‟-chimeric PAADs, irrespective of the R2 unit, and the second method examined if there 
was a preference in the ether linkage orientation of R2 (-OCH2- versus –CH2O-), irrespective 
of the R1 unit. Finally, we evaluated the stereochemical preference for 4‟-N-benzyl-chimeric 
PAADs 255 and 258. 
Using this approach, we determined how introduction of either a (3-fluoro)benzyloxy 
or a (3-fluoro)phenyloxymethyl moiety at the 4‟-N-benzyl position (R2) in the C(2)-CH2OCH3, 
C(2)-methyl, C(2)-isopropyl, or C(2)-tert-butyl PAADs affected pharmacological activity. 
When R2 was (3-fluoro)benzyloxy, we did not observe any distinct trends in MES activity 
(mice) as we varied R1 from C(2)-CH2OCH3 ((R)-254, ED50 = 15 mg/kg)  to C(2)-methyl ((R)-
256, ED50 = 17 mg/kg) to C(2)-isopropyl ((R)-257, ED50 = 12 mg/kg) to C(2)-tert-butyl ((R)-
260, ED50 >30, <100 mg/kg). However, when R2 was (3-fluoro)phenyloxymethyl, we 
observed a decrease in MES activity (mice) as we varied R1 from C(2)-CH2OCH3 ((R)-255, 
ED50 = 8.9 mg/kg)  to C(2)-isopropyl ((R)-258, ED50 = 12 mg/kg) to C(2)-tert-butyl ((R)-261, 
ED50 >30, <100 mg/kg). In both cases, the C(2)-tert-butyl derivatives (R)-260 and (R)-261 
were considerably less active in the MES test than the corresponding C(2)-isopropyl 
derivatives (R)-257 and (R)-258. Correspondingly, a C(2)-tert-butyl group at R1 displayed 
only moderate MES activity in rats (ED50 (mg/kg): (R)-260, >30; (R)-261, ~30) while a C(2)-
CH2OCH3 group displayed excellent activity, irrespective of the ether orientation in the R2 
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unit (ED50 (mg/kg): (R)-254, <30; (R)-255, 12) (Table 27). The near equivalence in activity of 
the C(2)-CH2OCH3 and C(2)-isopropyl groups is unique to chimeric PAADs. In the 
unsubstituted PAADs (R)-61 and (R)-98, we observed that C(2)-isopropyl (R)-98 was 3.2-
fold more active than C(2)-CH2OCH3 (R)-61 (ED50 (mg/kg): (R)-8, 48; (R)-44, 15). Similarly, 
when the FAA counterpart of C(2)-CH2OCH3 PAAD ((R)-367), and C(2)-isopropyl ((R)-370) 
were compared, there is a remarkable difference in their anticonvulsant activities (ED50 
(mg/kg): (R)-367, 13; (R)-370, >300) (Table 28).  
 Next, we examined the C(2)-CH2OCH3, C(2)-isopropyl, and C(2)-tert-butyl PAADs 
containing either a (3-fluoro)benzyloxy or a (3-fluoro)phenyloxymethyl moiety (R2) to 
determine if there was a preferred ether linker orientation between the two aromatic rings. 
Each R1 set (C(2)-CH2OCH3, C(2)-isopropyl, C(2)-tert-butyl) displayed similar MES activities 
in mice for the two ether linkages (-OCH2- ED50 (mg/kg): (R)-254, 15; (R)-257, 12; (R)-260, 
>30, <100; and -CH2O- ED50 (mg/kg): (R)-255, 12; (R)-258, 12; and (R)-261, >30, <100). 
The only notable difference in regard to linker orientation was in the formalin test of the C(2)-
isopropyl PAADs (R)-257 (-OCH2-, ED50 = 110 mg/kg (80% reduction)) and (R)-258 (-CH2O-, 
ED50 = 30 mg/kg). The formalin activity was evaluated for the C(2)-isopropyl PAAD (R)-255 
(ED50 = 37 mg/kg (94% reduction)) but the lack of data for (R)-254, (R)-260, and (R)-261 
prevents any generalized statements. Therefore, using the available data, both (3-
fluoro)benzyloxy and (3-fluoro)phenyloxymethyl moieties at the 4‟-N-benzyl position of  C(2)-
CH2OCH3 ((R)-254 and (R)-255) and C(2)-isopropyl ((R)-257 and (R)-258) PAADs resulted 
in an increase in MES activity from the unsubstituted parent compounds ((R)-61 and (R)-98, 
respectively). Additionally, we observed no preference for the -CH2O- linker orientation when 
R1 was a C(2)-isopropyl group. Nonetheless, both 4‟-N-benzyl substitutions provided PAADs 
with excellent anticonvulsant activities. The activity of (R)-255 was noteworthy and is among 
the most active PAADs prepared. Using the conventional unit mg/kg, it was 2-fold less active 
than (R)-28, but it exhibited nearly the same PI value as (R)-28 (PI: (R)-255, 5.4; (R)-28, 
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5.8). When the ED50 values are converted to µmol/kg, the difference in activities between 
(R)-255 and (R)-28 reduces to 1.4-fold (~30% increase). 
 Comparison of the MES activities of (R)-255 with (S)-255, and (R)-258 with (S)-258, 
revealed that the higher activity was associated with the (R)-isomer (ED50 (mg/kg): (R)-255, 
8.9; (S)-255, >30, <100; (R)-258, 12; (S)-258, >30, <100). This was not unexpected, as 
similar trends were observed in the unsubstituted PAADs (ED50 (mg/kg): (R)-60, >10, <30; 
(S)-60, >300; (R)-61, 34; (S)-61, 64; (R)-96, 21; (S)-96, >37; (R)-98, 15; (S)-98, >300; (R)-
99, 14; (S)-99, 42) and in the FAA series (ED50 (mg/kg): (R)-367, 13; (S)-367, >300). 
 Lastly, we evaluated a 5-aryl-2-furfuramide at the 4‟-N-benzyl position of (R)-N-
benzyl 2-amino-3-methylbutanamide (a C(2)-isopropyl PAAD) ((R)-259) with the intention of 
observing pain attenuation. However, (R)-259 displayed no MES activity (ED50 >300 mg/kg) 
compared with its parent compound ((R)-98, ED50 = 15 mg/kg) and as a result, the formalin 
test was not run.  
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Table 26. Pharmacological activity of 4'-N-benzyl-chimeric PAADs in mice (mg/kg) at UCB and the NINDS ASP 
 
        Mice (ip)
a
 
Cmpd 
No. 
 
Test 
Site 
 R1  R2  MES,
b
 ED50  6 Hz,
c
 ED50  
Formalin, 
ED50 
 
Tox,
d 
TD50
  PI,
e
 
(R)-28  UCB  LCM  H  3.3  10  15  19  5.8 
(R)-28
f
  NINDS  LCM  H  
4.5 [0.5] 
(3.7–5.5) 
 10  ND
g
  
27 [0.25] 
(26–28) 
 6.0 
(R)-61  UCB  CH2OCH3  
 
H 
 34  >67  >67  >120  >3.5 
(R)-61  NINDS  CH2OCH3  H  
48 [0.25] 
(40–61) 
 ND
g
  ND
g
  
>30, <100 
[0.25] 
  
(S)-61  UCB  CH2OCH3  H  64  >70  120  63  1.0 
(R)-254  NINDS  CH2OCH3  
 
 
15 [0.5] 
(13–17) 
 
 ND
g
  ND
g
  
58 [0.25] 
(53–62) 
 3.9 
(R)-255  UCB  CH2OCH3  
 
 8.9  58  
12 (inactive) 
37
h
 (94%) 
 46  5.4 
(R)-255  NINDS  CH2OCH3  
 
 ~10 [0.5]  <30  ND
g
  
>30, <100 
[0.5] 
  
(S)-255  NINDS  CH2OCH3  
 
 >30, <100  ND
g
  ND
g
  
>100, 
<300 
  
  
 
2
2
2 
(R)-60  NINDS  CH3  H  >10, <30  ND
g
  69  
>100, 
<300 
  
(S)-60  NINDS  CH3  H  >300  ND
g
  ND
g
  >300   
(R)-256  UCB  CH3  
 
 17  >120  >37  ND
g
   
(R)-98  UCB  CH(CH3)2  H  16
i
 (MAD)  74  20  47  2.9 
(R)-98  NINDS  CH(CH3)2  H  
15 [0.25] 
(13–18) 
 ND
g
  ND
g
  
70 [0.25] 
(63–80) 
 4.7 
(S)-98  NINDS  CH(CH3)2  H  >300  ND
g
  ND
g
  >300   
(R)-257  UCB  CH(CH3)2  
 
 12  >110  
110
h 
(80%) 
 ND
g
   
(R)-258  UCB  CH(CH3)2  
 
 12  >110  30  ND
g
   
(R)-258  NINDS  CH(CH3)2  
 
 >10, <30 [0.5]  ND
g
  ND
g
  
>30, <100 
[0.5] 
  
(S)-258  NINDS  CH(CH3)2  
 
 >30, <100      
>100, 
<300 
  
(R)-259  NINDS  CH(CH3)2  
 
 
>300 
[0.5] 
 ND
g
  ND
g
  
>300 
[0.5] 
  
(R)-99  UCB  C(CH3)3  H  13  >71  >22  ND   
(R)-99  NINDS  C(CH3)3  H  
14 [0.25] 
(11–17) 
 ND
g
  ND
g
  
66 [0.25] 
(58–73) 
 4.7 
  
 
2
2
3 
(R)-260  NINDS  C(CH3)3  
 
 
>30, <100 
[0.5] 
 ND
g
  ND
g
  ~300 [0.5]   
(R)-261  NINDS  C(CH3)3  
 
 
>30, <100 
[0.5] 
 >75  ND
g
  
>100, 
<300 [0.5] 
  
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to adult male albino 
CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 30 min after ip administration (UCB) or a dose-
response curve was generated for all compounds that displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of 
peak effect” (indicated in hours in the brackets) (NINDS ASP). Numbers in parentheses are 95% confidence intervals. 
b 
MES = maximal electroshock seizure 
test. 
c 
6 Hz test = psychomotor seizure model (44 mA, UCB; 32 mA, NINDS ASP). 
d
 Tox = neurological toxicity. TD50 value determined from the rotorod test. 
e
 PI 
= protective index (TD50/ED50). 
f
 Choi, D. et al. J. Med. Chem. 1996, 39, 1907–1916. 
g 
ND = not determined. 
h
 Single dose experiments where the mg/kg used is 
followed by the percentage protected in parenthesis. 
i
 MAD = minimal active dose. 
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Table 27. Pharmacological activity of 4'-N-benzyl-chimeric PAADs in rats (mg/kg) at 
the NINDS ASP 
 
      Rat (po)
a
 
Cmpd 
No. 
 R1  R2  MES,
b
 ED50  Tox,
c
 TD50  PI
d
 
(R)-28  LCM  H  
3.9 [2.0] 
(2.9–6.2) 
 >500  >120 
(R)-61  CH2OCH3  H  18 [4.0]  >500 [4.0]  >28 
(R)-254  CH2OCH3  
 
 
<30 
[0.25–2.0] 
 
>30 
[0.25–4.0] 
  
(R)-255  CH2OCH3  
 
 
12 [0.5] 
(8.2–18) 
 >500  
 
>42 
(R)-98  CH(CH3)2  H  
11 [0.25] 
(9.1–13) 
 >500  >45 
(S)-258  CH(CH3)2  
 
 
>30 
[0.25–4.0] 
 
>30 
[0.25–4.0] 
  
(R)-260  C(CH3)3  
 
 
>30 
[0.25–4.0] 
 
>30 
[0.25–4.0] 
  
(R)-261  C(CH3)3  
 
 
~30  
[2.0–4.0] 
 
>30 
[0.25–4.0] 
  
a 
The compounds were administered orally to adult male albino Sprague Dawley rats. ED50 and TD50 values 
are in mg/kg. A dose-response curve was generated for all compounds that displayed sufficient activity and 
the dose-effect data for these compounds was obtained at the “time of peak effect” (indicated in hours in the 
brackets) (NINDS ASP). Numbers in parentheses are 95% confidence intervals. 
b 
MES = maximal 
electroshock seizure test. 
c 
Tox = behavioral toxicity. 
d 
PI = protective index (TD50/ED50). 
  
 
2
2
5 
Table 28. Comparison of the pharmacological activities of 4’-N-benzyl-chimeric FAAs and their PAAD counterparts in mice 
(mg/kg) 
                                                                
          Mice (ip)
a
      Mice (ip)
a
 
R  X  Y  
FAA 
Cpd No. 
 
FAA 
Test Site 
 
FAA 
MES,
b
 ED50 
 
FAA 
Tox,
c
 TD50 
 
PAAD 
Test Site 
 
PAAD 
Cpd No. 
 
PAAD 
MES,
b
 ED50 
 
PAAD 
Tox,
c
 TD50
 
CH2OCH3  O  CH2  (R)-367
d
  NINDS  
13 [0.25] 
(11–16) 
 
26 [0.5] 
(21–34) 
 (R)-254  NINDS  
>10, <30 
[0.5] 
 
>30, <100 
[0.5] 
CH2OCH3  O  CH2  (S)-367
d
  NINDS  >300  >300  (S)-254  NINDS  ND
e
  ND
e
 
CH2OCH3  CH2  O  (R)-368
d
  NINDS  
5.9 [0.25] 
(4.3–7.3) 
 
10 [0.25] 
(9.1–13) 
 (R)-255  UCB  8.9  46 
CH2OCH3  CH2  O  (S)-368
d
  NINDS  ND
e
  ND
e
  (S)-255  NINDS  >30, <100  
>100, 
<300 
CH3  O  CH2  (R)-369
d
  NINDS  >30, <100  >300  (R)-256  UCB  17  ND
e
 
CH(CH3)2  O  CH2  (R)-370
d
  NINDS  >300  >300  (R)-257  UCB  12  ND
e
 
C(CH3)3  O  CH2  (R)-371
d
  NINDS  >300  >300  (R)-260  NINDS  
>30, <100 
[0.5] 
 ~300 [0.5] 
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to adult male albino CF-1 
mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 30 min after ip administration (UCB) or a dose-response curve 
was generated for all compounds that displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak effect” (indicated in 
hours in the brackets) (NINDS ASP). Numbers in parentheses are 95% confidence intervals. 
b 
MES = maximal electroshock seizure test. 
c 
Tox = neurological toxicity. 
TD50 value determined from the rotorod test. 
d
 Salomé, C. et al. J. Med. Chem. 2010, 53, 3756–3771. 
e
 ND = not determined. 
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2.5.2. N-Substituted 3-methylbutanamides  
The activities of the primary (PAAD), secondary (SAAD), and tertiary (TAAD) amino 
acid analogs of (R)-N-benzyl 2-amino-3-methylbutanamide are summarized in Table 29. 
Comparison of the SAAD (R)-269 with the PAAD (R)-98 showed a decrease in activity in the 
MES test (ED50 (mg/kg): (R)-98, 15; (R)-269, 25), as well as in the 6 Hz test (ED50 (mg/kg): 
(R)-98, 74; (R)-269, 82 (MAD)). The decrease in activity in the formalin test is much more 
pronounced (ED50 (mg/kg): (R)-98, 20; (R)-269, 82 (42% reduction)). Furthermore, 
comparison of the TAAD (R)-270 with the SAAD (R)-269 showed a decrease in activity in 
the MES test (ED50 (mg/kg): (R)-269, 25; (R)-270, >30, <100).  Therefore, the MES data for 
PAAD (R)-98, SAAD (R)-269, and TAAD (R)-270 revealed a linear decrease in 
anticonvulsant activity as we successively N-methylated the C(2)-amine. This trend differed 
from the reported pattern for racemic C(2)-methyl, C(2)-phenyl, and C(2)-CH2OCH3 PAADs, 
where successive N-methylation led to non-linear trends in MES activity in C(2)-methyl and 
C(2)-CH2OCH3 series, and resulted in a linear increase in anticonvulsant activity in the C(2)-
phenyl series (Table 20).92  
  
 
2
2
7 
Table 29. Pharmacological activities of primary (PAAD), secondary (SAAD), and tertiary (TAAD) amino acid derivatives of 
(R)-N-benzyl 2-amino-3-methylbutanamide in mice (mg/kg) at UCB and the NINDS ASP 
 
 
        Mice (ip)
a
 
Cmpd 
No. 
 
Test 
Site 
 R1  R2  
MES
b
, 
ED50 
 
6 Hz,
c
 
ED50 
 
Formalin, 
ED50 
 
Tox,
d
 
TD50
  
PI,
e
 
MES 
(R)-98  UCB  H  H  
16 (MAD)
h 
16
i
 (100%) 
 74  20  47   
(R)-98  NINDS  H  H  
15 [0.25] 
(13–18) 
 ND
g
  ND
g
  
70 [0.25] 
(63–80) 
 4.7 
(R)-269  UCB  CH3  H  25  
82 
(MAD)
h
 
 82
i
 (42%)  ND
g
   
(R)-270  NINDS  CH3  CH3  
>30, <100 
[0.5] 
 ND
g
  ND
g
  
>100, <300 
[0.5] 
  
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB or administered intraperitoneally to 
adult male albino CF-1 mice under the auspices of the NINDS ASP. ED50 and TD50 values are in mg/kg and were determined 30 min after ip 
administration (UCB) or a dose-response curve was generated for all compounds that displayed sufficient activity and the dose-effect data for 
these compounds was obtained at the “time of peak effect” (indicated in hours in the brackets) (NINDS ASP). Numbers in parentheses are 95% 
confidence intervals. 
b 
MES = maximal electroshock seizure test. 
c 
6 Hz test = psychomotor seizure model (44 mA). 
d
 Tox = neurological toxicity. 
TD50 value determined from the rotorod test. 
e
 PI = protective index (TD50/ED50). 
f
 Choi, D. et al. J. Med. Chem. 1996, 39, 1907–1916. 
g 
ND = not 
determined. 
h
 MAD = minimal active dose.
 i
 Single dose experiments where the mg/kg used is followed by the percentage protected in 
parenthesis.  
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2.5.3. C(2)-Isopropyl PAAD analogs  
Compound (R)-98 emerged as a potent anticonvulsant that possessed pain 
attenuating properties from the SAR investigation at the C(2)-carbon, and we improved the 
anticonvulsant activity in mice upon functionalization at the 4‟-N-benzyl position ((R)-246, 
(R)-248, (R)-257, and (R)-258). The excellent activity of (R)-98 came as a surprise since it 
did not follow the trends observed in the FAA series. Therefore, we questioned several 
aspects of the original PAAD structural framework to determine if the basic tenets of the 
FAA blueprint applied to this C(2)-hydrocarbon PAAD. We investigated the importance of six 
properties (Sites A–F) that were common with the FAAs and report their anticonvulsant 
activity and neurological toxicity in Tables 30–35.  
First, we determined the effect of the carbonyl unit (Site A) on anticonvulsant activity 
(Table 30). Replacement of the carbonyl unit ((R)-98) with a thiocarbonyl unit ((R)-271) 
resulted in a decrease in MES activity in mice (ED50 (mg/kg): (R)-98, 15; (R)-271, >30, <100) 
but notable activity was observed in the rat (ED50 <30 mg/kg). Reduction of the carbonyl unit 
in (R)-98 to a methylene group ((R)-272) led to decreased activity in both the mice (ED50 
>30, <100 mg/kg) and rats (ED50 >30 mg/kg). Next, we determined the effect of the amide 
bond (Site B) on anticonvulsant activity (Table 31). Conversion of the amide (X = NH, (R)-
98) to a ketone (X = CH2, (R)-273) resulted in a decrease in MES activity (ED50 (mg/kg): (R)-
98, 15; (R)-273, >30, <100). Conversion of the amide (X = NH, (R)-98) to an ester (X = O, 
(R)-274) abolished anticonvulsant activity (ED50 >300 mg/kg). Then, Site C looked at the 
optimal methylene linker length between the amide bond and the aromatic ring (Table 32). 
Direct linkage of the aromatic ring to the amide bond (n = 0, (R)-275) resulted in a significant 
drop in activity from the parent compound (n = 1, (R)-98) (ED50 (mg/kg): (R)-98, 15; (R)-275, 
>30, <100). However, extending the linkage of the parent compound (n = 1, (R)-98) by one 
methylene unit (n = 2, (R)-276) resulted in a ~30% increase in anticonvulsant activity (ED50 
= 10 mg/kg). The increase in activity was also associated with an increase in toxicity 
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compared with the parent compound (TD50 (mg/kg): (R)-98, 70; (R)-276, 50), however, the 
protective indices of (R)-98 (4.8) and (R)-276 (5.0) are nearly equal. Extension of the linker 
by another carbon (n = 3, (R)-277) led to comparable activity with (R)-98 (ED50 (mg/kg): (R)-
98, 15; (R)-277, 16) but the increased toxicity for (R)-277 (TD50 = 43 mg/kg) reduced the 
protective index to 2.7. A final extension to n = 4 ((R)-278) resulted in comparable activity 
with (R)-98 and (R)-277 (ED50 (mg/kg): (R)-278, >10, <30; (R)-98, 15; (R)-277, 16). Site D 
compared the regiosubstitution on the N-benzylamide, where we systematically placed a 
trifluoromethoxy group at the 2‟-, 3‟-, and 4‟-positions on the N-benzylamide moiety (2‟: (R)-
279, 3‟: (R)-280, and 4‟: (R)-248) (Table 33). All regiosubstitutions displayed excellent MES 
activities (ED50 (mg/kg): (R)-279, 9.2; (R)-280, >3, <10; (R)-278, 16). The 2‟-substitution 
afforded the highest activity (ED50 = 9.2 mg/kg) and was 1.6-fold more active than the parent 
compound (R)-98 (ED50 = 15 mg/kg). There was also an increase in the neurotoxicity 
observed for (R)-279 compared with (R)-98 (ED50 (mg/kg): (R)-98, 70; (R)-279, 51) but 
comparison of the protective indices revealed that (R)-279 (PI = 5.5) may provide a slight 
advantage over (R)-98 (PI = 4.8). However, comparison of the MES activity in rats (Table 
33) showed ~3-fold drop in activity in the rat (ED50 (mg/kg): (R)-98, 11; (R)-279, 33). The 
MES activity of (R)-280 in the rat (ED50 = 10 mg/kg) was comparable with (R)-98 (ED50 = 11 
mg/kg) but there was a sharp increase in behavioral toxicity (TD50 (mg/kg): (R)-98, >500; 
(R)-280, 43). Next, we examined the need for a benzyl moiety (Site E) (Table 34). We 
replaced the aromatic ring ((R)-98) with a cyclohexyl ring ((R)-281) and observed a 
decrease in anticonvulsant activity (ED50 (mg/kg): (R)-98, 15; (R)-281, >30, <100). When 
(R)-281 was evaluated in the rat, we found this PAAD to have excellent activity (ED50 ~15 
mg/kg). While our data indicates that the N-benzyl substituent is preferred over the 
saturated N-cyclohexylmethyl unit, the anticonvulsant activity of (R)-281 was not anticipated. 
Finally, we investigated the importance of the C(2)-amino functionality (Site F) by comparing 
the unsubstituted (282, X = H), methyl-substituted ((S)-, and (R,S)-283, X = CH3), and 
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hydroxy-substituted ((R)-284, X = OH) N-benzyl butanamides with the parent PAAD (R)-95 
(X = NH2) (Table 35). Compounds 282 and (R)-284 gave similar results, where modest 
activity was observed in mice (ED50 >30, <100 mg/kg) and there was a lack of activity in rats 
(ED50 >30 mg/kg). (R,S)-283 also displayed modest protection in mice (ED50 = 56 mg/kg) 
with minimal neurotoxicity (TD50 = 165 mg/kg), and moderate activity was observed in the rat 
(ED50 = 51 mg/kg) without any detectable behavioral toxicity (TD50 >500 mg/kg). We were 
surprised by the activity of (R,S)-283 since the methyl group lacks the hydrogen bonding 
capabilities afforded by an amino or a hydroxyl group. Evaluation of (S)-283 resulted in a 
decrease in anticonvulsant activity (ED50 >100, <300 mg/kg), suggesting that activity 
predominantly resided in the (R)-isomer. Unfortunately, we were unable to complete the 
synthesis of (R)-283 to confirm this suggestion.  
Examination of Sites A–F of PAADs revealed that the amide bond (Sites A and B) 
were necessary for seizure protection. Alteration of this unit affects the hydrogen bonding 
properties of the compounds. Assessment of the methylene linker (Site C) showed that at 
least one carbon between the amide bond and the aromatic rings was necessary for 
anticonvulsant activity but incorporation of up to three additional methylene units still 
provided excellent activity. When considering activity, toxicity, and the protective index for 
these C(2)-isopropyl PAADs, the optimal linker length appeared to be when n = 2, instead of 
the n = 1 seen in FAAs. Similarly, we found that replacement of the benzylamide group by a 
cyclohexylmethylamide (Site E) led to lower anticonvulsant activity, but the drop was only 
modest. Thus, there seems to be structural latitude at Sites C and E, where modifications 
still retain excellent activities. Comparison of trifluoromethoxy regioisomers of (R)-N-benzyl 
2-amino-3-methylbutanamide (Site D) revealed that superb seizure protection was 
associated with all positions but the increase in activity was associated with an increase in 
neurotoxicity. Lastly, we evaluated our choice of the C(2)-amino group (Site F) since the 
SAR project was centered around primary amino acid derivatives. Of the other C(2)-groups 
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investigated, the amino group was most active but further analysis of the C(2)-methyl group 
((R)-isomer) and other analogs should be conducted to show that the C(2)-amino group is 
not mandatory for activity. Collectively, this data, along with the finding that activity for 
hydrocarbon PAADs does not improve with inclusion of a substituted heteroatom one atom 
removed from the C(2)-center, suggests that the C(2)-hydrocarbon PAADs have an unique 
SAR and possibly a pathway(s) of function that differ from FAA and other PAADs. 
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Table 30. Pharmacological activities of C(2)-isopropyl PAAD amide analogs (Site A) in 
mice (mg/kg) and rats (mg/kg) at the NINDS ASP 
 
 
    Mice (ip)
a
  Rat (po)
b
 
Cmpd 
No 
 X  MES,
c
 ED50  Tox,
d
 TD50
 
 PI
e
  MES,
c 
ED50  Tox,
f
 TD50  PI
e
 
(R)-98  C=O  
15 [0.25] 
(13–18) 
 
70 [0.25] 
(63–80) 
 4.8  
11 [0.25] 
(9.1–13) 
 >500  >45 
(R)-271  C=S  
>30, <100 
[0.5] 
 
>30, <100 
[0.5] 
   
<30 
[0.5–2.0] 
 
>30 
[0.25–4.0] 
  
(R)-272  CH2  
>30, <100 
[0.5] 
 
>100, <300 
[0.5] 
   
>30 
[0.25–4.0] 
 
>30 
[0.25–4.0] 
  
a 
The compounds were administered intraperitoneally to adult male albino CF-1 mice under the auspices of the 
NINDS ASP. ED50 and TD50 values are in mg/kg. A dose-response curve was generated for all compounds that 
displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak 
effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b
 The 
compounds were administered orally to adult male albino Sprague Dawley rats under the auspices of the NINDS 
ASP. ED50 and TD50 values are in mg/kg. 
c 
MES = maximal electroshock seizure test. 
d 
TD50 value determined 
from the rotorod test. 
e 
PI = protective index (TD50/ED50). 
f
 Tox = behavioral toxicity.
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Table 31. Pharmacological activities of C(2)-isopropyl PAAD amide analogs (Site B) in 
mice (mg/kg) and rats (mg/kg) at the NINDS ASP 
 
 
    Mice (ip)
a
  Rat (po)
b
 
Cmpd 
No 
 X  MES,
c
 ED50  Tox,
d
 TD50
 
 PI
e
  MES,
c
 ED50  Tox,
f
 TD50  PI
e
 
(R)-98  NH  
15 [0.25] 
(13–18) 
 
70 [0.25] 
(63–80) 
 4.8  
11 [0.25] 
(9.1–13) 
 >500  >45 
(R)-273  CH2  >30, <100  >100, <300    ND
g
  ND
g
   
(R)-274  O  
>300 
[0.5] 
 
>300 
[0.5] 
   >30 [0.25]  
>30 
[0.25–
4.0] 
  
a 
The compounds were administered intraperitoneally to adult male albino CF-1 mice under the auspices of the 
NINDS ASP. ED50 and TD50 values are in mg/kg. A dose-response curve was generated for all compounds that 
displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak 
effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b
 The 
compounds were administered orally to adult male albino Sprague Dawley rats under the auspices of the NINDS 
ASP. ED50 and TD50 values are in mg/kg. 
c 
MES = maximal electroshock seizure test. 
d 
TD50 value determined 
from the rotorod test. 
e 
PI = protective index (TD50/ED50). 
f
 Tox = behavioral toxicity. 
g
 ND = not determined.
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Table 32. Pharmacological activities of C(2)-isopropyl PAADs: N-Aryl and N-alkylaryl 
analogs (Site C) in mice (mg/kg) and rats (mg/kg) at the NINDS ASP 
 
 
    Mice (ip)
a
  Rat (po)
b
 
Cmpd 
No. 
 n  MES,
c
 ED50  Tox,
d
 TD50
 
 PI
e
  MES,
c
 ED50  Tox,
f
 TD50  PI
e
 
(R)-275  0  
>30, <100 
[0.5] 
 
>30, <100 
[0.5] 
   ND
g
  ND
g
   
(R)-98  1  
15 [0.25] 
(13–18) 
 
70 [0.25] 
(63–80) 
 4.8  
11 [0.25] 
(9.1–13) 
 >500  >45 
(R)-276  2  
10 [0.25] 
(8.3–14) 
 
50 [0.25] 
(42–80) 
 5.0  ND
g
  ND
g
   
(R)-277  3  
16 [0.25] 
13–17 
 
43 [0.25] 
(38–47) 
 2.7  
<30 
[0.25–0.5] 
 
>30 
[0.25–4.0] 
  
(R)-278  4  
>10, <30 
[0.5] 
 
>30, <100 
[0.5] 
   ND
g
  ND
g
   
a 
The compounds were administered intraperitoneally to adult male albino CF-1 mice under the auspices of the 
NINDS ASP. ED50 and TD50 values are in mg/kg. A dose-response curve was generated for all compounds that 
displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak 
effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b
 The 
compounds were administered orally to adult male albino Sprague Dawley rats under the auspices of the NINDS 
ASP. ED50 and TD50 values are in mg/kg. 
c 
MES = maximal electroshock seizure test. 
d 
TD50 value determined 
from the rotorod test. 
e 
PI = protective index (TD50/ED50). 
f
 Tox = behavioral toxicity.
 g
 ND = not determined. 
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Table 33. Pharmacological activities of trifluoromethoxy regioisomers (Site D) of (R)-
N-benzyl 2-amino-3-methylbutanamide in mice (mg/kg) and rats (mg/kg) at the NINDS 
ASP 
 
 
    Mice (ip)
a
  Rat (po)
b
 
Cmpd 
No. 
 R  
MES,
c
 
ED50 
 Tox,
d
 TD50
 
 PI
e
  
MES,
c
 
ED50 
 Tox,
f
 TD50  PI
e
 
(R)-98  H  
15 [0.25] 
(13–18) 
 
70 [0.25] 
(63–80) 
 4.8  
11 [0.25] 
(9.1–13) 
 >500  >45 
(R)-279  2‟-OCF3  
9.2 [0.25] 
(7.7–11) 
 
51 [0.25] 
(38–65) 
 5.5  
33 [0.5] 
(27–44) 
 >500  >15 
(R)-280  3‟-OCF3  
>3, <10 
[0.5] 
 
>30, <100 
[0.5] 
   
10 [1.0] 
(7.5–14) 
 
43 [1.0] 
(35–57) 
 4.3 
(R)-248  4‟-OCF3  
16 [0.25] 
(14–20) 
 
84 [0.25] 
(67–109) 
 5.3  
~20 
[0.25–4.0] 
 
>20 
[0.25–4.0] 
  
a 
The compounds were administered intraperitoneally to adult male albino CF-1 mice under the auspices of the 
NINDS ASP. ED50 and TD50 values are in mg/kg. A dose-response curve was generated for all compounds that 
displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak 
effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b
 The 
compounds were administered orally to adult male albino Sprague Dawley rats under the auspices of the NINDS 
ASP. ED50 and TD50 values are in mg/kg. 
c 
MES = maximal electroshock seizure test. 
d 
TD50 value determined 
from the rotorod test. 
e 
PI = protective index (TD50/ED50). 
f
 Tox = behavioral toxicity. 
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Table 34. Pharmacological activities of N-substituted C(2)-isopropyl PAADs (Site E) in 
mice (mg/kg) and rats (mg/kg) at the NINDS ASP 
 
 
    Mice (ip)
a
  Rat (po)
b
 
Cmpd 
No. 
 R  MES,
c
 ED50  Tox,
d
 TD50
 
 PI
e
  MES,
c
 ED50  Tox,
f
 TD50  PI
e
 
(R)-98  C6H5  
15 [0.25] 
(13–18) 
 
70 [0.25] 
(63–80) 
 4.8  
11 [0.25] 
(9.1–13) 
 >500  >45 
(R)-281  C6H11  
>30, <100 
[0.5] 
 
>100, <300 
[0.5] 
   
~15 
[0.25-1.0] 
 
>30 
[0.25-4.0] 
  
a 
The compounds were administered intraperitoneally to adult male albino CF-1 mice under the auspices of the 
NINDS ASP. ED50 and TD50 values are in mg/kg. A dose-response curve was generated for all compounds that 
displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak 
effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b
 The 
compounds were administered orally to adult male albino Sprague Dawley rats under the auspices of the NINDS 
ASP. ED50 and TD50 values are in mg/kg. 
c 
MES = maximal electroshock seizure test. 
d 
TD50 value determined 
from the rotorod test. 
e 
PI = protective index (TD50/ED50). 
f
 Tox = behavioral toxicity.
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Table 35. Pharmacological activities of C(2)-substituted N-benzyl butanamides (Site F) 
in mice (mg/kg) and rats (mg/kg) at the NINDS ASP 
 
 
    Mice (ip)
a
  Rat (po)
b
 
Cmpd No.  X  MES,
c
 ED50  Tox,
d 
TD50
 
 PI
e
  
MES,
c
 
ED50 
 Tox,
f
 TD50  PI
e
 
(R)-95  NH2  
18 [0.25] 
(10–25) 
 
80 [0.25] 
(65–95) 
 4.4  ND
g
  ND
g
   
282  H  
>30, <100 
[0.5] 
 
>100, <300 
[0.5] 
   
>30 
[0.25–4.0] 
 
>30 
[0.25-4.0] 
  
(S)-283  CH3  
>100, <300 
[0.5] 
 
~300 
[0.5] 
   
>30 
[0.25–4.0] 
 
>30 
[0.25-4.0] 
  
(R,S)-283  CH3  
56 [0.25] 
(45–69) 
 
165 [0.25] 
(148–180) 
 2.9  
51 [0.5] 
(35–71) 
 >500  <9.8 
(R)-284  OH  
>30, <100 
[0.5] 
 
>100, <300 
[0.5]
    
>30 
[0.25–4.0] 
 
>30 
[0.25-4.0] 
  
a 
The compounds were administered intraperitoneally to adult male albino CF-1 mice under the auspices of the 
NINDS ASP. ED50 and TD50 values are in mg/kg. A dose-response curve was generated for all compounds that 
displayed sufficient activity and the dose-effect data for these compounds was obtained at the “time of peak 
effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
b
 The 
compounds were administered orally to adult male albino Sprague Dawley rats under the auspices of the NINDS 
ASP. ED50 and TD50 values are in mg/kg. 
c 
MES = maximal electroshock seizure test. 
d 
TD50 value determined 
from the rotorod test. 
e 
PI = protective index (TD50/ED50). 
f
 Tox = behavioral toxicity. 
g
 ND = not determined. 
 
 
2.5.4. Comparison of data acquired at UCB and the NINDS ASP 
Lastly, we expanded the list of PAADs evaluated at UCB Pharma and the NINDS 
ASP (Table 18) to include the 4‟-N-benzyl-chimeric PAADs (R)-255 and (R)-258 (Table 36). 
In total, six PAADs that displayed excellent activity in the MES test ((R)-61, (R)-95, (R)-98, 
(R)-99, (R)-255, and (R)-258) were evaluated at both UCB Pharma and the NINDS ASP.  
The addition of (R)-255 and (R)-258 further supports the consistency of reported MES 
activities from the two testing facilities. 
  
2
3
8 
Table 36. Comparison of the pharmacological activities of PAADs evaluated in mice (mg/kg) at UCB and the NINDS ASP 
 
      UCB
a 
 NINDS-ASP
b 
Cmpd No.  R1  R2  MES,
c
 ED50  Tox,
d
 TD50
 
 PI
e 
 MES,
c
 ED50  Tox,
d
 TD50  PI
e 
(R)-28  LCM  H  3.3  19  5.8  
4.5 [0.5] 
(3.7–5.5) 
 
27 [0.25] 
(26–28) 
 6.0 
(R)-61  CH2OCH3  H  34  >117  >3.4  
48 [0.25] 
(40–61) 
 
>30, <100 
[0.25] 
  
(R)-255
f,g
  CH2OCH3  
 
 8.9  46  5.2  ~10 [0.5]  
>30, <100 
[0.5] 
  
(R)-95  CH2CH3  H  16  46  2.9  
18 [0.25] 
(10–25) 
 
80 [0.25] 
(65–95) 
 4.4 
(R)-98  CH(CH3)2  H  16 (MAD)
h 
 47  2.9  
15 [0.25] 
(13–18) 
 
70 [0.25] 
(63–80) 
 4.8 
(R)-258  CH(CH3)2  
 
 12  ND
i
    >10, <30 [0.5]  
>30, <100 
[0.5] 
  
(R)-99  C(CH3)3  H  13  ND
i
    
14 [0.25] 
(11–17) 
 
66 [0.25] 
(58–73) 
 4.7 
a 
The compounds were administered intraperitoneally to adult male NMRI mice under the auspices of UCB. ED50 and TD50 values are in mg/kg and were 
determined 30 min after ip administration. 
b
 The compounds were administered intraperitoneally to adult male albino CF-1 mice under the auspices of the NINDS 
ASP. ED50 and TD50 values are in mg/kg. A dose-response curve was generated for all compounds that displayed sufficient activity and the dose-effect data for 
these compounds was obtained at the “time of peak effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. 
c
 MES = 
maximal electroshock seizure test. 
d
 Tox = neurological toxicity. TD50 value determined from the rotorod test. 
e
 PI = protective index (TD50/ED50). 
f
 6 Hz (44 mA) 
ED50 = 58 mg/kg determined by UCB. 
g
 6 Hz (32 mA) ED50 = <30 mg/kg determined by the NINDS ASP. 
h
 MAD = minimal active dose. 
i
 ND = not determined.  
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3. Conclusions 
We evaluated more than 40 PAADs and analogs of PAADs in whole animal models 
of epilepsy and NP to optimize seizure protection and pain attenuation. We examined 4‟-N-
benzyl substituted C(3)-O-methoxy and C(2)-hydrocarbon PAADs using electron-
withdrawing substituents, electron-donating substituents, and chimeric substituents, and 
also evaluated analogs of N-benzyl 2-amino-3-methylbutanamide (R)-98 and N-benzyl 2-
aminobutanamide (R)-99. The SAR suggested that 4‟-N-benzyl substitution of C(3)-O-
methoxy PAADs ((R)-126, -240–242) moderately improves anticonvulsant activity in the 
MES test compared with the parent PAAD (R)-61, but the substitutions do not provide any 
advantage over the corresponding FAAs ((R)-123, -364–366) (Table 22). Correspondingly, 
4‟-N-benzyl substitution of C(2)-hydrocarbon PAADs with electron-withdrawing groups 
provided compounds with excellent activity (<30 mg/kg), but most 4‟-N-benzyl substituted 
C(2)-isopropyl and C(2)-tert-butyl PAADs did not provide an advantage over the 
unsubstituted parent compounds (R)-98 and (R)-99. We discovered that the 
pharmacological activities of C(2)-hydrocarbon PAADs was highly dependent upon the 
electronic properties of the 4‟-substitutent. This finding was unexpected since the 
anticonvulsant activity of 4‟-N-benzyl substituted FAAs was independent of electronic 
factors.102  
The 4‟-chimeric C(3)-O-methoxy PAAD (R)-255 and C(2)-isopropyl PAAD (R)-258 
displayed superb anticonvulsant activity (<15 mg/kg). This SAR pattern is unique to the 
PAADs because in the FAA series, C(2)-hydrocarbon 4‟-chimeric FAAs ((R)-370 and (R)-
371) are devoid of anticonvulsant (>300 mg/kg), while the C(3)-O-methoxy 4‟-chimeric FAAs 
((R)-367 and (R)-368) remain extremely active.103 Finally, we observed that C(2)-tert-butyl 
4‟-chimeric PAADs displayed only moderate activity (>30, <100 mg/kg). 
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We determined the SAR for C(2)-isopropyl analogs with successive N-methylation 
(SAAD (R)-269 and TAAD (R)-270), and found that the unmethylated derivative (PAAD (R)-
98) provided the greatest seizure protection (ED50 = 15 mg/kg).  
Next, we evaluated the importance of the PAAD structural backbone for bioactivity. 
Evaluation of N-benzyl 2-amino-3-methylbutanamide analogs at six sites (Sites A–F) 
concluded that the amide bond (Sites A and B) is necessary for anticonvulsant activity. 
However, changes in the length of the methylene linker between the amide bond and the 
aromatic ring (Site C), the position of substitution on the benzylamide ring (i.e., 2‟-, 3‟-, and 
4‟-substitution; Site D), reduction of the aromatic ring (Site E), and substitution for the C(2)-
amino group (Site F) all provided compounds that showed anticonvulsant activity, indicating 
that these structural units are important, but perhaps dispensable, for drug function. 
Consideration of anticonvulsant activity, neurotoxicity, and the protective index of these 
C(2)-isopropyl PAAD structural analogs indicated that the optimal activity occurred when the 
linker was n =1 or n = 2, there was benzylamide group, and where the ring was substituted 
either at the 2‟- or 3‟-positions. Of the other C(2)-groups investigated, the amino group was 
most active, but further analysis of the C(2)-methyl group ((R)-isomer) and other analogs 
should be conducted to show that the C(2)-amino group is not necessary for activity.  
When considering seizure protection, toxicity, the protective indices, and the amount 
of compound administered in µmol/kg, optimized PAADs (R)-255 and (R)-279 displayed 
superior anticonvulsant activity that may rival the therapeutic capabilities of (R)-28. The 
activity of (R)-255 (ED50 = 8.9 mg/kg) was noteworthy and is among the most active PAADs 
prepared. Using the conventional mg/kg dose it was 2-fold less active than (R)-28, but it 
exhibited nearly the same PI value as (R)-28 (PI: (R)-255, 5.4; (R)-28, 5.8). When the ED50 
values are converted to µmol/kg, the difference in activities between (R)-255 and (R)-28 
reduced to 1.4-fold (~30% increase). Similarly, the anticonvulsant activity of (R)-279 (ED50 = 
9.2 mg/kg) was 2-fold less potent than (R)-28 (ED50 = 4.5 mg/kg). However, there was an 
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approximate 2-fold decrease in neurotoxicity in mice (ip) (TD50 (mg/kg): (R)-279; 51; (R)-28; 
27), resulting in similar PI values ((R)-279, 5.5; (R)-28; 5.8). 
Collectively, this data, along with the finding that activity for hydrocarbon PAADs 
does not improve upon inclusion of a substituted heteroatom one atom removed from the 
C(2)-center, suggests that the C(2)-hydrocarbon PAADs have an unique SAR and possibly 
a pathway(s) of function that differ from FAAs and other PAADs. The sensitivity of the C(2)-
hydrocarbon PAADs to the electronic properties of the 4‟-N-benzyl substituent provides 
another difference in the SAR of this series of compounds compared with the findings 
reported for FAAs. We recognize that the PAADs and FAAs discussed here not only differ 
by the absence or presence of the N-terminal acetyl group, but also in the nature of the 
C(2)-substituent (e.g., hydrocarbon, CH2OCH3). 
 
4. Experimental 
4.1. General methods 
Melting points were determined in open capillary tubes using a Thomas-Hoover 
melting point apparatus and are uncorrected. IR were recorded on an ATI Mattson Genesis 
FT-IR spectrometer. Absorption values are expressed in wavenumbers (cm-1). Optical 
rotations were obtained on a Jasco P-1030 polarimeter at the sodium D line (589 nm) using 
a 1 dm path length cell. NMR spectra were recorded at 300 or 400 MHz (1H) and 75 or 100 
MHz (13C) using TMS as an internal standard. Chemical shifts (δ) are reported in ppm from 
TMS. LRMS were recorded with a BioToF-II-Bruker Daltonics spectrometer by Drs. M. 
Crowe and S. Habibi at the University of North Carolina Department of Chemistry. The 
HRMS were recorded on a Bruker Apex-Q 12 Telsa FTICR spectrometer by Drs. M. Crowe 
and S. Habibi. Microanalyses were performed by Atlantic Microlab, Inc. (Norcross, GA). 
Reactions were monitored by analytical TLC plates (Aldrich, catalog no. Z12272-6, or 
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Dynamic Adsorbents Inc., catalog no. 84111) and analyzed with 254 nm light. The reaction 
mixtures were purified by MPLC (CombiFlash Rf) with self-packed columns (silica gel from 
Dynamic Adsorbents Inc., catalog no. 02826-25) or by flash column chromatography using 
silica gel (Dynamic Adsorbents Inc., catalog no. 02826-25). All chemicals and solvents were 
reagent grade and used directly from commercial sources without further purification. THF 
was distilled from blue sodium benzophenone ketyl. Yields reported are for purified products 
and were not optimized. All compounds were checked by TLC, 1H and 13C NMR, MS, and 
elemental analyses. The analytical results are within 0.40% of the theoretical value. The 
TLC, NMR, and analytical data confirmed the purity of the products was ≥95%. 
 
General Procedure for the Preparation of N-Benzylamide Amino Acid Derivatives 
Using the Mixed Anhydride Coupling (MAC) Method (Method A). An anhydrous THF 
solution of carboxylic acid (0.5–2.0 M) was cooled to -78 ºC in a dry ice/acetone bath under 
an inert atmosphere (Ar or N2), and NMM (1.3–1.5 equiv) was added. After the mixture was 
stirred (2–10 min), IBCF (1.1–1.5 equiv) was added leading to the precipitation of a white 
solid. The reaction was allowed to proceed for an additional 15–25 min, and then 
benzylamine (1.05–1.36 equiv) was added at -78 ºC. The reaction mixture was allowed to 
stir at room temperature (1.5 h), and then the insoluble salts were filtered. The organic layer 
was concentrated in vacuo, and the product was purified by column chromatography (SiO2). 
 
General Procedure for PAAD Preparation Using TFA Deprotection (Method B). TFA (15 
equiv) was added to an anhydrous CH2Cl2 solution of the N-t-butoxycarbonyl protected N‟-
benzylamide PAAD (0.3 M) at room temperature. The solution was stirred (1 h) and then the 
solvent was evaporated in vacuo. The crude product was subjected either to an acidic 
workup or basic workup. Acidic: The crude product was diluted with CH2Cl2 and extracted 
with aqueous 1 M HCl (3x). The combined aqueous layers were washed with CH2Cl2 (2x), 
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basified (pH 10–12) with aqueous 4 M NaOH, and extracted with CH2Cl2 (3x). The combined 
organic layers were washed with brine (2x), dried (Na2SO4), evaporated in vacuo, and 
purified by column chromatography (SiO2). Basic: The crude product was diluted with 
CH2Cl2 and washed with aqueous 1 M Na2CO3 (3x). The aqueous layers were combined 
and washed with CH2Cl2 (2x). All of the CH2Cl2 layers were combined and successively 
washed with H2O (2x) and brine (2x), dried (Na2SO4), evaporated in vacuo, and purified by 
column chromatography (SiO2). 
 
4.2. Synthesis 
 
 
(R)-N-4’-(Fluoro)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-292). 
Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (4.00 
g, 18.42 mmol), NMM (2.63 mL, 23.95 mmol), IBCF (2.61 mL, 20.26 mmol), and 4-
fluorobenzylamine (2.20 mL, 19.34 mmol) in anhydrous THF (185 mL) gave the crude 
product that was purified by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) 
to give the desired compound (5.38 g, 90%) as a white solid: mp 129–130 ºC; [α]28D +10.1° 
(c 1.1, CHCl3); Rf 0.85 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2856 (br), 1690, 1644, 1520, 
1458, 1378, 1304, 1226, 1162, 1024, 928, 826, 693 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.92 
(d, J = 7.0 Hz, CH(CH3)CH3), 0.95 (d, J = 7.0 Hz, CH(CH3)CH3), 1.41 (s, C(CH3)3), 2.10–
2.20 (m, CH(CH3)2), 3.91 (dd, J = 6.6, 8.6 Hz, CH), 4.34–4.45 (m, NHCH2), 5.06–5.14 (br d, 
OC(O)NH), 6.50–6.56 (br t, NHCH2), 6.96–7.02 (m, 2 ArH), 7.21–7.24 (m, 2 ArH); 
13C NMR 
(100 MHz, CDCl3) δ 17.9 (CH(CH3)CH3), 19.4 (CH(CH3)CH3), 28.3 (C(CH3)3), 30.6 
(CH(CH3)2), 42.7 (NHCH2), 60.3 (CH), 80.0 (C(CH3)3), 115.5 (d, J = 20.9 Hz, C3), 129.3 (d, J 
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= 7.7 Hz, C2), 133.9 (d, J = 3.1 Hz, C1), 156.0 (OC(O)), 162.2 (d, J = 244.7 Hz, C4), 171.7 
(CC(O)); LRMS (ESI) 347.16 [M + Na+] (calcd for C17H25FN2O3Na
+ 347.16); Anal. Calcd for 
C17H25FN2O3: C, 62.94; H, 7.77; F, 5.86; N, 8.64. Found: C, 63.17; H, 7.87; F, 5.76; N, 8.62. 
 
 
(R)-N-4’-(Fluoro)benzyl 2-Amino-3-methylbutanamide ((R)-243). Utilizing Method B and 
using (R)-N-4‟-(fluoro)benzyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (4.50 g, 
13.88 mmol), TFA (15.47 mL, 0.21 mol), and CH2Cl2 (46 mL) gave the crude product after 
acidic workup and further purified by flash column chromatography (SiO2; 1:20 
EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired compound (2.73 g, 
87%) as a white solid: mp 86–87 ºC; [α]25D +32.9° (c 1.1, CHCl3); Rf 0.47 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 2724 (br), 1634, 1548, 1458, 1375, 1217, 1158, 1095, 1012, 
827, 720 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.82 (d, J = 6.8 Hz, CH(CH3)CH3), 0.99 (d, J = 
6.8 Hz, CH(CH3)CH3), 1.35 (s, NH2), 2.29–2.41 (m, CH(CH3)2), 3.27 (d, J = 3.2 Hz, CH), 
4.39 (dd, J = 6.0, 15.0 Hz, NHCHH‟), 4.45 (dd, J = 6.0, 14.8 Hz, NHCHH’), 6.97–7.03 (m, 2 
ArH), 7.23–7.27 (m, 2 ArH), 7.64–7.72 (br t, NH); 13C NMR (100 MHz, CDCl3) δ 16.0 
(CH(CH3)CH3), 19.7 (CH(CH3)CH3), 30.8 (CH(CH3)2), 42.4 (NHCH2), 60.1 (CH), 115.4 (d, J 
= 20.9 Hz, C3), 129.4 (d, J = 7.7 Hz, C2), 134.5 (d, J = 3.9 Hz, C1), 162.1 (d, J = 243.9 Hz, 
C4), 174.3 (C(O)); LRMS (ESI) 225.13 [M + H
+] (calcd for C12H17FN2OH
+ 225.13); Anal. 
Calcd for C12H17FN2O: C, 64.26; H, 7.64; F, 8.47; N, 12.49. Found: C, 64.37; H, 7.73; F, 
8.49; N, 12.47. 
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(R)-N-4’-(Chloro)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-293). 
Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (3.00 
g, 13.82 mmol), 4-methylmorpholine (1.97 mL, 17.96 mmol), isobutyl chloroformate (1.96 
mL, 15.20 mmol), and 4-chlorobenzylamine (1.76 mL, 14.51 mmol) in anhydrous THF (140 
mL) gave the crude product (3.43 g, 73%). The product was used immediately for the next 
step without further purification. 
 
 
(R)-N-4’-(Chloro)benzyl 2-Amino-3-methylbutanamide ((R)-244). Utilizing Method B and 
using (R)-N-4‟-(chloro)benzyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (2.86 g, 
8.41 mmol), TFA (6.09 mL, 82.02 mmol), and CH2Cl2 (18 mL) gave the crude product after 
acidic workup that was further purified by flash column chromatography (SiO2; 1:20–1:1 
EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired compound (1.52 g, 
76%) as a white solid: mp 72–73 ºC; [α]28.5D +26.7° (c 1.1, CHCl3); Rf 0.26 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 3116, 2732 (br), 1640, 1548, 1458, 1375, 1231, 1091, 1016, 
801, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.82 (d, J = 7.2 Hz, CH(CH3)CH3), 0.99 (d, J = 
6.4 Hz, CH(CH3)CH3), 1.30 (s, NH2), 2.28–2.37 (m, CH(CH3)2), 3.27 (d, J = 3.6 Hz, CH), 
4.37 (dd, J = 6.0, 14.8 Hz, NHCHH‟), 4.43 (dd, J = 6.0, 14.8 Hz, NHCHH’), 7.21 (d, J = 8.2 
Hz, 2 ArH), 7.28 (d, J = 8.2 Hz, 2 ArH), 7.72–7.80 (br t, NH); 13C NMR (100 MHz, CDCl3) δ 
16.0 (CH(CH3)CH3), 19.7 (CH(CH3)CH3), 30.8 (CH(CH3)2), 42.3 (NHCH2), 60.1 (CH), 128.7, 
129.1, 133.0, 137.3  (4 ArC), 174.4 (C(O)); LRMS (ESI) 241.12 [M + H+] (calcd for 
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C12H17ClN2OH
+ 241.12); Anal. Calcd for C12H17ClN2O: C, 59.87; H, 7.12; Cl, 14.73; N, 11.64. 
Found: C, 59.97; H, 7.17; Cl, 14.60; N, 11.58. 
 
 
(R)-N-4’-(Methyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-294). 
Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (4.00 
g, 18.42 mmol), NMM (2.63 mL, 23.95 mmol), IBCF (2.61 mL, 20.26 mmol), and 4-
methylbenzylamine (2.46 mL, 19.34 mmol) in anhydrous THF (185 mL) gave the crude 
product that was purified by recrystallization from hot EtOAc to give the desired compound 
(3.95 g, 67%) as a white solid: mp 139–140 ºC; [α]28.5D +5.2° (c 1.1, CHCl3); Rf 0.92 (1:1 
EtOAc/hexanes); IR (nujol mull) 3372, 3265, 3188, 2934 (br), 1654, 1458, 1374, 1161, 726 
cm-1; 1H NMR (400 MHz, CDCl3) δ 0.92 (d, J = 7.0 Hz, CH(CH3)CH3), 0.96 (d, J = 7.0 Hz, 
CH(CH3)CH3), 1.42 (s, (CH3)3), 2.10–2.20 (m, CH(CH3)2), 2.32 (s, CH3), 3.89–3.93 (m, CH), 
4.34 (dd, J = 6.0, 14.8 Hz, NHCHH‟), 4.42 (dd, J = 6.0, 14.8 Hz, NHCHH’), 5.07–5.14 (br d, 
OC(O)NH), 6.32–6.38 (br t, NHCH2), 7.11 (d, J = 8.2 Hz, 2 ArH), 7.15 (d, J = 8.2 Hz, 2 ArH); 
13C NMR (100 MHz, CDCl3) δ 17.8 (CH(CH3)CH3), 19.3 (CH(CH3)CH3), 21.1 (CH3),  28.3 
(C(CH3)3), 30.7 (CH(CH3)2), 43.2 (NHCH2), 60.2 (CH), 79.9 (C(CH3)3), 127.7, 129.3, 135.0, 
137.2 (C6H4), 155.9 (OC(O)), 171.5 (CC(O)); LRMS (ESI) 343.21 [M + Na
+] (calcd for 
C18H28N2O3Na
+ 343.21); Anal. Calcd for C18H28N2O3: C, 67.47; H, 8.81; N, 8.74. Found: C, 
67.26; H, 8.81; N, 8.78. 
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(R)-N-4’-(Methyl)benzyl 2-Amino-3-methylbutanamide ((R)-245). Utilizing Method B and 
using (R)-N-4‟-methylbenzyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (3.50 g, 
10.93 mmol), TFA (12.18 mL, 0.16 mol), and CH2Cl2 (36 mL) gave the crude product after 
acidic workup that was further purified by flash column chromatography (SiO2; 1:20 
EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired compound (1.70 g, 
71%) as a white solid: mp 67–68 ºC; [α]28.5D +26.7° (c 1.1, CHCl3); Rf 0.53 (1:10 
MeOH/CH2Cl2); IR (nujol mull) 3117, 3064, 2914, 2856, 1639, 1458, 1375, 1305, 1229, 
1162, 801, 723 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.83 (d, J = 7.0 Hz, CH(CH3)CH3), 0.99 
(d, J = 7.0 Hz, CH(CH3)CH3), 1.33 (s, NH2), 2.29–2.40 (m, CH(CH3)2), 2.33 (s, ArCH3), 3.27 
(d, J = 4.0 Hz, CH), 4.38 (dd, J = 6.0, 14.8 Hz, NHCHH‟), 4.44 (dd, J = 6.0, 14.8 Hz, 
NHCHH’), 7.13 (d, J = 8.4 Hz, 2 ArH), 7.17 (d, J = 8.4 Hz, 2 ArH), 7.54–7.62 (br t, NH); 13C 
NMR (100 MHz, CDCl3) δ 16.0 (CH(CH3)CH3), 19.8 (CH(CH3)CH3), 21.7 (ArCH3), 30.8 
(CH(CH3)2), 42.8 (NHCH2), 60.2 (CH), 127.8, 129.3, 135.6, 137.0 (C6H4), 174.2 (C(O)); 
HRMS (ESI) 221.1664 [M + H+] (calcd for C13H20N2OH
+ 221.1654); Anal. Calcd for 
C13H20N2O∙0.05H2O: C, 70.57; H, 9.16; N, 12.66. Found: C, 70.19; H, 9.17; N, 12.57. 
 
 
(R)-N-4’-(Trifluoromethyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide 
((R)-295). Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic 
acid (4.00 g, 18.42 mmol), NMM (2.63 mL, 23.95 mmol), IBCF (2.61 mL, 20.26 mmol), and 
4-(trifluoromethyl)benzylamine (2.76 mL, 19.34 mmol) in anhydrous THF (185 mL) gave the 
crude product that was purified by flash column chromatography (SiO2; 1:20–1:1 
EtOAc/hexanes) to give the desired product (4.40 g, 64%) as a white solid: mp 125–126 ºC; 
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[α]25D +8.5° (c 1.1, CHCl3); Rf 0.90 (1:1 EtOAc/hexanes); IR (nujol mull) 2859 (br), 1659, 
1528, 1458, 1375, 1332, 1247, 1166, 1120, 1070, 1021, 727 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 0.93 (d, J = 6.8 Hz, CH(CH3)CH3), 0.97 (d, J = 6.8 Hz, CH(CH3)CH3), 1.41 (s, 
CH(CH3)3), 2.15–2.20 (m, CH(CH3)2), 3.93 (dd, J = 6.6, 9.0 Hz, CH), 4.29–4.53 (m, NHCH2),  
5.12 (d, J = 7.6 Hz, OC(O)NH), 6.72–6.80 (br t, NHCH2), 7.36 (d, J = 8.2 Hz, 2 ArH), 7.65 (d, 
J = 8.2 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 17.9 (CH(CH3)CH3), 19.4 (CH(CH3)CH3), 
28.2 (C(CH3)3), 30.5 (CH(CH3)2), 42.8 (NHCH2), 60.3 (CH), 80.1 (C(CH3)3), 124.0 (q, J = 
270.2 Hz, CF3), 125.5 (q, J = 3.9 Hz, C3’), 127.7 (C2’), 129.7 (q, J = 31.8 Hz, C4’), 142.3 (C1’), 
156.0 (OC(O)), 174.6 (CC(O)); LRMS (ESI) 397.13 [M + Na+] (calcd for C18H25F3N2O3Na
+ 
397.13); Anal. Calcd for C18H25F3N2O3: C, 57.74; H, 6.73; F, 15.22; N, 7.48. Found: C, 
57.75; H, 6.78; F, 15.08; N, 7.62. 
 
 
(R)-N-4’-(Trifluoromethyl)benzyl 2-Amino-3-methylbutanamide ((R)-246). Utilizing 
Method B and using (R)-N-4‟-(trifluoromethyl)benzyl 2-N‟-(t-butoxycarbonyl)amino-3-
methylbutanamide (4.00 g, 10.69 mmol), TFA (11.91 mL, 0.16 mol), and CH2Cl2 (35 mL) 
gave the crude product after acidic workup that was further purified by flash column 
chromatography (SiO2; 1:10–1:1 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the 
desired compound (2.18 g, 75%) as a white solid: mp 86–87 ºC; [α]28.5D +26.0° (c 1.0, 
CHCl3); Rf 0.37 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3335, 2961, 1641, 1512, 1327, 1161, 
1107, 1067, 808 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.83 (d, J = 7.2 Hz, CH(CH3)CH3), 1.00 
(d, J = 7.2 Hz, CH(CH3)CH3), 1.32 (s, NH2), 2.30–2.41 (m, CH(CH3)2), 3.30 (d, J = 4.0 Hz, 
CH), 4.47 (dd, J = 6.0, 15.4 Hz, NHCHH‟), 4.53 (dd, J = 6.0, 15.4 Hz, NHCHH’), 7.39 (d, J = 
7.6 Hz, 2 ArH), 7.57 (d, J = 7.6 Hz, 2 ArH), 7.84–7.92 (br t, NH); 13C NMR (100 MHz, CDCl3) 
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δ 16.0 (CH(CH3)CH3), 19.7 (CH(CH3)CH3), 30.8 (CH(CH3)2), 42.6 (NHCH2), 60.2 (CH), 
124.2 (q, J = 270.6 Hz, CF3), 125.6 (q, J = 3.9 Hz, C3’), 127.9 (C2’), 129.6 (q, J = 31.8 Hz, 
C4’), 142.9 (C1’), 174.6 (C(O)); LRMS (ESI) 275.14 [M + H
+] (calcd for C13H17F3N2OH
+ 
275.14); Anal. Calcd for C13H17F3N2O: C, 56.93; H, 6.25; F, 20.78; N, 10.21. Found: C, 
57.06; H, 6.36; F, 20.61; N, 10.27. 
 
 
(R)-N-4’-(Methoxy)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-296). 
Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (4.00 
g, 18.42 mmol), NMM (2.63 mL, 23.95 mmol), IBCF (2.61 mL, 20.26 mmol), and 4-
methoxybenzylamine (2.51 mL, 19.34 mmol) in anhydrous THF (185 mL) gave the crude 
product that was purified by recrystallization from hot EtOAc/hexanes to give the desired 
compound (4.77 g, 77%) as pale yellow needles: mp 121–122 ºC; [α]28.5D +4.2° (c 1.0, 
CHCl3); Rf 0.88 (1:1 EtOAc/hexanes); IR (nujol mull) 3163, 2858 (br), 1653, 1458, 1375, 
1302, 1247, 1165, 1029, 726 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.91 (d, J = 6.8 Hz, 
CH(CH3)CH3), 0.94 (d, J = 6.8 Hz, CH(CH3)CH3), 1.40 (s, (CH3)3), 2.04–2.22 (m, CH(CH3)2), 
3.77 (OCH3), 3.93–3.97 (br t, CH), 4.28 (dd, J = 5.6, 14.4 Hz, NHCHH‟), 4.39 (dd, J = 5.6, 
15.0 Hz, NHCHH’), 5.27 (d, J = 8.8 Hz, OC(O)NH), 6.68–6.76 (br t, NHCH2), 6.82 (d, J = 8.6 
Hz, 2 ArH), 7.17 (d, J = 8.6 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH(CH3)CH3), 
19.3 (CH(CH3)CH3), 28.3 (C(CH3)3), 30.9 (CH(CH3)2), 42.8 (NHCH2), 55.2 (OCH3), 60.1 
(CH), 79.7 (C(CH3)3), 114.0, 129.0, 130.3 (3 ArC), 155.9 (OC(O)), 158.9 (1 ArC), 171.6 
(CC(O)); HRMS (ESI) 469.1108 [M + Cs+] (calcd for C18H28N2O4Cs
+ 469.1103); Anal. Calcd 
for C18H28N2O4∙0.08H2O: C, 64.00; H, 8.40; N, 8.29. Found: C, 63.63; H, 8.47; N, 8.13. 
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(R)-N-4’-(Methoxy)benzyl 2-Amino-3-methylbutanamide ((R)-247). Utilizing Method B 
and using (R)-N-4‟-methoxybenzyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (4.50 
g, 13.38 mmol), TFA (14.91 mL, 0.20 mol), and CH2Cl2 (45 mL) gave the crude product after 
acidic workup that was further purified by flash column chromatography (SiO2; 1:20 
EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired compound (3.04 g, 
96%) as a white solid: mp 81–82 ºC; [α]28.5D +25.5° (c 1.1, CHCl3); Rf 0.42 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 2728 (br), 1635, 1547, 1458, 1375, 1305, 1233, 1169, 1105, 
1022, 840, 722 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.83 (d, J = 7.0 Hz, CH(CH3)CH3), 0.99 
(d, J = 7.0 Hz, CH(CH3)CH3), 1.33 (s, NH2), 2.28–2.40 (m, CH(CH3)2), 3.26 (d, J = 3.6 Hz, 
CH), 3.79 (s, OCH3), 4.36 (dd, J = 5.6, 14.6 Hz, NHCHH‟), 4.41 (dd, J = 6.0, 14.6 Hz, 
NHCHH’), 6.86 (d, J = 8.6 Hz, 2 ArH), 7.21 (d, J = 8.6 Hz, 2 ArH), 7.52–7.58 (br t, NH); 13C 
NMR (100 MHz, CDCl3) δ 16.0 (CH(CH3)CH3), 19.7 (CH(CH3)CH3), 30.8 (CH(CH3)2), 42.5 
(NHCH2), 55.3 (OCH3), 60.2 (CH), 114.0, 129.1, 130.8. 158.9 (4 ArC), 174.1 (C(O)); LRMS 
(ESI) 237.17 [M + H+] (calcd for C13H20N2O2H
+ 237.17); Anal. Calcd for C13H20N2O2: C, 
66.07; H, 8.53; N, 11.85. Found: C, 65.94; H, 8.35; N, 11.60. 
 
 
(R)-N-4’-(Trifluoromethoxy)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide 
((R)-297). Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic 
acid (4.30 g, 19.80 mmol), NMM (2.83 mL, 25.75 mmol), IBCF (2.81 mL, 21.78 mmol), and 
4-(trifluoromethoxy)benzylamine (3.17 mL, 20.79 mmol) in anhydrous THF (200 mL) gave 
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the crude product that was purified by flash column chromatography (SiO2; 1:20–1:1 
EtOAc/hexanes) to give the desired product (5.17 g, 67%) as a white solid: mp 101–102 ºC; 
[α]25D +7.6° (c 1.0, CHCl3); Rf 0.94 (1:1 EtOAc/hexanes); IR (nujol mull) 2934 (br), 1652, 
1524, 1458, 1375, 1276, 1222, 1159, 1021, 923, 843, 721 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 0.93 (d, J = 6.8 Hz, CH(CH3)CH3), 0.97 (d, J = 6.8 Hz, CH(CH3)CH3), 1.41 (C(CH3)3), 
2.10–2.22 (m, CH(CH3)2), 3.91 (dd, J = 6.6, 8.6 Hz, CH), 4.43 (d, J = 5.6 Hz, NHCH2), 5.12–
5.22 (br d, NHCH), 6.56–6.62 (br t, NHCH2), 7.15 (d, J = 8.2 Hz, 2 ArH), 7.28 (d, J = 8.2 Hz, 
2 ArH); 13C NMR (100 MHz, CDCl3) δ 17.9 (CH(CH3)CH3), 19.4 (CH(CH3)CH3), 28.2 
(C(CH3)3), 30.4 (CH(CH3)2), 42.6 (NHCH2), 60.3 (CH), 80.1 (C(CH3)3), 120.4 (q, J = 255.6 
Hz, CF3), 121.1, 129.0, 136.9 (3 ArC), 148.5 (COCF3), 156.0 (OC(O)); 171.8 (CC(O)); LRMS 
(ESI) 413.12 [M + Na+] (calcd for C18H25F3N2O4Na
+ 413.12); Anal. calcd. for C18H25F3N2O4: 
C, 55.38; H, 6.45; F, 14.60; N, 7.18. Found: C, 55.45; H, 6.51; F, 14.65; N, 7.29. 
 
 
(R)-N-4’-(Trifluoromethoxy)benzyl 2-Amino-3-methylbutanamide ((R)-248). Utilizing 
Method B and using (R)-N-4‟-(trifluoromethoxy)benzyl 2-N‟-(t-butoxycarbonyl)amino-3-
methylbutanamide (3.20 g, 8.20 mmol), TFA (9.14 mL, 1.23 mol), and CH2Cl2 (27 mL) gave 
the crude product after acidic workup and further purified by flash column chromatography 
(SiO2; 1:20–1:1 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired 
compound (1.33 g, 56%) as a pale yellow solid: mp 63–64 ºC; [α]28.5D +26.6° (c 1.0, CHCl3); 
Rf 0.47 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2906 (br), 1638, 1510, 1459, 1373, 1269, 1141, 
1019, 889, 323, 728 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.83 (d, J = 7.2 Hz, CH(CH3)CH3), 
1.00 (d, J = 7.2 Hz, CH(CH3)CH3), 1.36 (s, NH2), 2.33–2.41 (m, CH(CH3)2), 3.30 (d, J = 3.2 
Hz, CH), 4.40–4.51 (m, NHCH2), 7.17 (d, J = 8.4 Hz, 2 ArH), 7.31 (d, J = 8.4 Hz, 2 ArH), 
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7.70–7.80 (br t, NH); 13C NMR (100 MHz, CDCl3) δ 15.9 (CH(CH3)CH3), 19.7 (CH(CH3)CH3), 
30.7 (CH(CH3)2), 42.3 (NHCH2), 60.1 (CH), 120.4 (q, J = 255.6 Hz, CF3), 121.1, 129.1, 137.5 
(3 ArC), 148.4 (COCF3), 174.4 (C(O)); LRMS (ESI) 291.15 [M + H
+] (calcd for 
C13H17F3N2O2H
+ 291.15); Anal. calcd. for C13H17F3N2O2: C, 53.79; H, 5.90; F, 19.63; N, 9.65. 
Found: C, 53.96; H, 5.92; F, 19.46; N, 9.66. 
 
 
(R)-N-(Biphenyl-4’-yl)methyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-
298). Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid 
(2.70 g, 12.44 mmol), NMM (1.78 mL, 16.17 mmol), IBCF (1.76 mL, 13.68 mmol), and 4-
(phenyl)benzylamine (2.39 g, 13.06 mmol) in anhydrous THF (125 mL) gave the crude 
product that was purified by flash column chromatography (SiO2; 1:10-1:1 EtOAc/hexanes) 
to give the desired compound (3.25 g, 68%) as a white solid: mp 144–145 ºC; [α]25D –5.1° (c 
1.2, CH2Cl2); Rf 0.81 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2911 (br), 1650, 1457, 1375, 
1162, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.93–0.95 (d, J = 6.6 Hz, CH(CH3)CH3), 0.98–
0.99 (d, J = 6.6 Hz, CH(CH3)CH3), 1.43 (s, C(CH3)3), 2.14–2.26 (m, CH(CH3)2), 3.91–3.94 
(dd, J = 6.4, 8.8 Hz, CH), 4.49–4.50 (d, J = 5.6 Hz, NHCH2), 5.02–5.09 (br d, OC(O)NH), 
6.30–6.39 (br t, NHCH2), 7.33–7.37 (m, 3 ArH), 7.41–7.45 (m, 2 ArH), 7.53–7.58 (m, 4 ArH); 
13C NMR (100 MHz, CDCl3) δ 18.0 (CH(CH3)CH3), 19.4 (CH(CH3)CH3), 28.3 (C(CH3)3), 30.8 
(CH(CH3)2), 43.1 (NHCH2), 60.2 (CH), 79.9 (C(CH3)3), 127.0, 127.3, 127.4, 128.1, 128.8, 
137.2, 140.4, 140.7 (8 ArC), 156.0 (OC(O)), 174.3 (CC(O)); HRMS (ESI) 515.1290 [M + Cs+] 
(calcd for C23H30N2O3Cs
+ 515.1311); Anal. Calcd for C23H30N2O3: C, 72.22; H, 7.91; N, 7.32. 
Found: C, 72.08; H, 7.94; N, 7.34.  
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(R)-N-(Biphenyl-4’-yl)methyl 2-Amino-3-methylbutanamide ((R)-249).234 Utilizing Method 
B and using (R)-N-(biphenyl-4‟-yl)methyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide 
(2.51 g, 6.57 mmol), TFA (7.32 mL, 98.50 mmol), and CH2Cl2 (22 mL) gave the crude 
product after basic workup that was further purified by flash column chromatography (SiO2; 
1:10–1:1 EtOAc/hexanes) to give the desired compound (1.81 g, 98%) as a white solid: mp 
96–97 ºC; [α]25D +16.5° (c 1.0, CH2Cl2); Rf 0.28 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3139, 
3089 (br), 2727, 1457, 1374, 1158, 1078, 963, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.85–
0.86 (d, J = 7.0 Hz, CH(CH3)CH3), 1.00–1.02 (d, J = 7.0 Hz, CH(CH3)CH3), 1.45 (s, NH2), 
2.33–2.42 (m, CH(CH3)2), 3.31–3.32 (d, J = 3.2 Hz, CH), 4.45–4.55 (m, NHCH2), 7.32–7.37 
(m, 3 ArH), 7.43 (m, 2 ArH), 7.56 (m, 4 ArH), 7.62–7.68 (br t, NH); 13C NMR (100 MHz, 
CDCl3) δ 16.0 (CH(CH3)CH3), 19.8 (CH(CH3)CH3), 30.8 (CH(CH3)2), 42.8 (NHCH2), 60.2 
(CH), 127.0, 127.3, 127.4, 128.2, 128.8, 137.6, 140.3, 140.8 (8 ArC), 174.3 (C(O)); HRMS 
(ESI) 283.1800 [M + H+] (calcd for C18H22N2OH
+ 283.1810); Anal. Calcd for 
C18H22N2O•0.07CH2Cl2: C, 75.18; H, 7.73; N, 9.70. Found: C, 75.08; H, 7.68; N, 9.61. 
 
 
(R)-N-4’-(Chloro)benzyl 2-N’-(t-Butoxycarbonyl)amino-3,3-dimethylbutanamide ((R)-
299). Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3,3-dimethylbutanoic 
acid (2.22 g, 9.60 mmol), NMM (1.37 mL, 12.49 mmol), IBCF (1.36 mL, 10.56 mmol), and 4-
chlorobenzylamine (1.23 mL, 10.08 mmol) in anhydrous THF (100 mL) gave the crude 
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product that was purified by flash column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) 
to give the desired compound (2.76 g, 81%) as a white solid: mp 83–84 ºC; [α]25D –7.3° (c 
1.2, CH2Cl2); Rf 0.21 (1:10 EtOAc/hexanes); IR (nujol mull) 2942 (br), 1658, 1458, 1373, 
1243, 1170, 1082, 1011, 911, 805, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.99 (s, 
CC(CH3)3), 1.40 (s, OC(CH3)3), 3.89 (d, J = 8.6 Hz, CH), 4.32 (dd, J = 6.0, 14.8 Hz, 
NHCHH‟), 4.42 (dd, J = 6.0, 14.8 Hz, NHCHH’), 5.31 (d, J = 8.6 Hz, OC(O)NH), 6.48–6.56 
(br t, NHCH2), 7.19 (d, J = 8.4 Hz, 2 ArH), 7.26 (d, J = 8.4 Hz, 2 ArH); 
13C NMR (100 MHz, 
CDCl3) δ 26.6 (CC(CH3)3), 28.3 (OC(CH3)3), 34.4 (CC(CH3)3), 42.7 (NHCH2), 62.4 (CH), 79.8 
(OC(CH3)3), 128.8, 129.1, 133.2, 136.6  (4 ArC), 156.0 (OC(O)), 171.1 (CC(O)); LRMS (ESI) 
377.10 [M + Na+] (calcd for C18H27ClN2O3Na
+ 377.10); Anal. Calcd for C18H27ClN2O3: C, 
60.92; H, 7.67; Cl, 9.99; N, 7.89. Found: C, 61.19; H, 7.70; Cl, 9.73; N, 7.78. 
 
 
(R)-N-4’-(Chloro)benzyl 2-Amino-3,3-dimethylbutanamide ((R)-250). Utilizing Method B 
and using (R)-N-4‟-(chloro)benzyl 2-N‟-(t-butoxycarbonyl)amino-3,3-dimethylbutanamide 
(2.50 g, 7.06 mmol), TFA (7.86 mL, 0.11 mol), and CH2Cl2 (23 mL) gave the crude product 
after acidic workup that was further purified by flash column chromatography (SiO2; 1:100–
1:10 MeOH/CH2Cl2) to give the desired compound (1.31 g, 73%) as a white solid: mp 78–79 
ºC; [α]25D +14.2° (c 1.0, CH2Cl2); Rf 0.23 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2934 (br), 
1457, 1374, 1160, 1082, 725 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.00  (s, C(CH3)3), 1.47 (s, 
NH2), 3.14 (s, CH), 4.36 (1/2 ABq, J = 17.6 Hz, NHCHH‟), 4.43 (1/2 ABq, J = 17.6 Hz, 
NHCHH’), 7.22 (d, J = 8.6 Hz, 2 ArH), 7.29 (d, J = 8.6 Hz, 2 ArH); 13C NMR (75 MHz, CDCl3) 
δ 27.0 (C(CH3)3), 34.4 (C(CH3)3), 42.6 (NHCH2), 64.6 (CH), 128.9, 129.4, 133.3, 137.4  (4 
ArC), 173.7 (C(O)); HRMS (ESI) 255.1256 [M + H+] (calcd for C13H19ClN2OH
+ 255.1264); 
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Anal. Calcd for C13H19ClN2O: C, 61.29; H, 7.52; Cl, 13.92; N, 11.00. Found: C, 61.35; H, 
7.58; Cl, 13.76; N, 10.90. 
 
 
(R)-N-4’-(Trifluoromethyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3,3-
dimethylbutanamide ((R)-300). Utilizing Method A and using (R)-2-N-(t-
butoxycarbonyl)amino-3,3-dimethylbutanoic acid (2.50 g, 10.82 mmol), NMM (1.55 mL, 
14.06 mmol), IBCF (1.53 mL, 11.90 mmol), and 4-(trifluoromethyl)benzylamine (1.62 mL, 
11.36 mmol) in anhydrous THF (110 mL) gave the crude product that was purified twice by 
flash column chromatography (SiO2; 1:1 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to 
give a ~4:1 mixture of (R)-N-4‟-(trifluoromethyl)benzyl 2-N‟-(t-butoxycarbonyl)amino-3,3-
dimethylbutanamide and N-4‟-(trifluoromethyl)benzyl (isobutoxycarbonyl)carbamate (2.77 g, 
66%) as a white solid. 
 
 
(R)-N-4’-(Trifluoromethyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3,3-
dimethylbutanamide ((R)-300): Rf 0.81 (1:1 EtOAc/hexanes);
 1H NMR (400 MHz, CDCl3) δ 
1.00 (s, CC(CH3)3), 1.37 (s, OC(CH3)3), 3.98 (d, J = 9.2 Hz, CH), 4.39 (dd, J = 5.8, 15.6 Hz, 
NHCHH‟), 4.48 (dd, J = 5.8, 15.6 Hz, NHCHH’), 5.38 (d, J = 9.2 Hz, OC(O)NH), 7.00–7.08 
(br t, NHCH2), 7.35 (d, J = 7.8 Hz, 2 ArH), 7.52 (d, J = 7.8 Hz, 2 ArH).
 13C NMR (100 MHz, 
CDCl3) δ 26.6 (CC(CH3)3), 28.2 (OC(CH3)3), 34.3 (CC(CH3)3), 42.8 (NHCH2), 62.3 (CH), 79.8 
(OC(CH3)3), 124.0 (q, J = 270.3 Hz, CF3), 125.4 (q, J = 3.1 Hz, C3’), 127.7 (C2’), 129.5 (q, J = 
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32.5 Hz, C4’), 142.3 (C1’), 156.1 (OC(O)), 171.5 (CC(O)); HRMS (ESI) 521.1028 [M + Cs
+] 
(calcd for C19H27F3N2O3Cs
+ 521.1044). 
 
 
N-4’-(Trifluoromethyl)benzyl (isobutoxycarbonyl)carbamate: Rf 0.85 (1:1 
EtOAc/hexanes).  1H NMR (400 MHz, CDCl3) δ 0.92 (d, J = 6.0 Hz, CH(CH3)2), 1.80–1.98 
(m, CH(CH3)2), 3.87 (d, J = 6.4 Hz, OCH2), 4.37–4.51 (m, NHCH2), 7.40 (d, J = 8.2 Hz, 2 
ArH), 7.58 (d, J = 8.2 Hz, 2 ArH). 13C NMR (100 MHz, CDCl3) δ 18.9 (CH(CH3)2), 28.0 
(CH(CH3)2), 44.4 (NHCH2), 71.3 (OCH2), 124.1 (q, J = 270.2 Hz, CF3), 125.5 (q, J = 3.9 Hz, 
C3’), 127.5 (C2’), 129.7 (q, J = 31.8 Hz, C4’), 142.9 (C1’), 156.9 (OC(O)). 
 
 
(R)-N-4’-(Trifluoromethyl)benzyl 2-Amino-3,3-dimethylbutanamide ((R)-251). Utilizing 
Method B and using (R)-N-4‟-(trifluoromethyl)benzyl 2-N‟-(t-butoxycarbonyl)amino-3,3-
dimethylbutanamide (2.50 g, 6.44 mmol), TFA (7.18 mL, 0.97 mol), and CH2Cl2 (21 mL) 
gave the crude product after acidic workup and further purified by flash column 
chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give the desired compound (0.68 g, 
37%) as a white solid: mp 90–91 ºC; [α]25D +17.2° (c 1.0, CH2Cl2); Rf 0.14 (1:1 
EtOAc/hexanes); IR (nujol mull) 3389, 3089, 2911 (br), 1648, 1557, 1459, 1373, 1335, 1264, 
1165, 1112, 1021, 946, 820, 767 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.01 (s, C(CH3)3), 1.49 
(s, NH2), 3.17 (s, CH), 4.44–4.54 (m, NHCH2), 7.29–7.37 (br t, NH), 7.40 (d, J = 7.6 Hz, 2 
ArH), 7.58 (d, J = 7.6 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 27.0 (C(CH3)3), 34.4 
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(C(CH3)3), 42.8 (NHCH2), 64.5 (CH), 124.3 (q, J = 271.0 Hz, CF3), 125.8 (q, J = 3.9 Hz, C3’), 
128.2 (C2’), 129.8 (q, J = 31.8 Hz, C4’), 143.0 (C1’), 173.9 (C(O)); HRMS (+ESI) 289.1515 
[M+H]+ (calcd. for C14H19F3N2OH
+ 289.1528). Anal. Calcd for C14H19F3N2O: C, 58.32; H, 
6.64; F, 19.77; N, 9.72. Found: C, 58.56; H, 6.57; F, 19.47; N, 9.73. 
 
 
(R)-N-4’-(Trifluoromethoxy)benzyl 2-N’-(t-Butoxycarbonyl)amino-3,3-
dimethylbutanamide ((R)-301). Utilizing Method A and using (R)-2-N-(t-
butoxycarbonyl)amino-3,3-dimethylbutanoic acid (2.00 g, 8.65 mmol), NMM (1.24 mL, 11.25 
mmol), IBCF (1.23 mL, 9.52 mmol), and 4-(trifluoromethoxy)benzylamine (1.39 mL, 9.09 
mmol) in anhydrous THF (90 mL) gave the crude product that was purified by flash column 
chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give the desired compound (1.40 g, 
40%) as a white solid: mp 62–63 ºC; [α]25D –4.9° (c 1.1, CH2Cl2); Rf 0.30 (1:10 
EtOAc/hexanes); IR (nujol mull) 2725 (br), 1670, 1457, 1374, 1262, 1168, 1073, 1012, 924, 
852, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.00 (s, CC(CH3)3), 1.37 (s, OC(CH3)3), 3.96 (d, 
J = 9.2 Hz, CH), 4.34 (dd, J = 5.4, 14.8 Hz, NHCHH‟), 4.45 (dd, J = 6.0, 14.8 Hz, NHCHH’), 
5.36 (d, J = 9.2 Hz, OC(O)NH), 6.86–6.92 (br t, NHCH2), 7.12 (d, J = 8.4 Hz, 2 ArH), 7.27 (d, 
J = 8.4 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 26.6 (CC(CH3)3), 28.2 (OC(CH3)3), 34.3 
(CC(CH3)3), 42.5 (NHCH2), 62.3 (CH), 79.7 (OC(CH3)3), 120.4 (q, J = 255.6 Hz, CF3), 121.0, 
129.0, 137.0 (3 ArC), 148.4 (COCF3), 156.0 (OC(O)), 171.3 (CC(O)); LRMS (ESI) 427.12 [M 
+ Na+] (calcd for C19H27F3N2O4Na
+ 427.12); Anal. Calcd for C19H27F3N2O4: C, 56.43; H, 6.73; 
F, 14.09; N, 6.93. Found: C, 56.54; H, 6.79; F, 14.06; N, 6.85. 
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(R)-N-4’-(Trifluoromethoxy)benzyl 2-Amino-3,3-dimethylbutanamide ((R)-252). Utilizing 
Method B and using (R)-N-4‟-(trifluoromethoxy)benzyl 2-N‟-(t-butoxycarbonyl)amino-3,3-
dimethylbutanamide (2.00 g, 4.95 mmol), TFA (5.51 mL, 74.22 mmol), and CH2Cl2 (16 mL) 
gave the crude product after acidic workup that was further purified by flash column 
chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give the desired compound (0.93 g, 
62%) as a white solid: mp 68–69 ºC; [α]25D +14.7° (c 1.1, CH2Cl2); Rf 0.29 (1:1 
EtOAc/hexanes); IR (nujol mull) 2860 (br), 1649, 1457, 1374, 1267, 1166, 1018, 926, 838, 
727 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.00 (s, C(CH3)3), 1.56 (s, NH2), 3.14 (s, CH), 4.43 
(d, J = 6.0 Hz, NHCH2), 7.17 (d, J = 8.6 Hz, 2 ArH), 7.23–7.29 (br s, NH), 7.31 (d, J = 8.6 
Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 26.8 (C(CH3)3), 34.3 (C(CH3)3), 42.4 (NHCH2), 
64.4 (CH), 120.5 (q, J = 255.6 Hz, CF3), 121.2, 129.2, 137.5 (3 ArC), 148.5 (COCF3), 173.6 
(C(O)); HRMS (ESI) 305.1463 [M + H+] (calcd for C14H19F3N2O2H
+ 305.1477); Anal. Calcd 
for C14H19F3N2O2: C, 55.26; H, 6.29; F, 18.73; N, 9.21. Found: C, 55.23; H, 6.14; F, 18.54; N, 
9.18. 
 
 
(R)-N-(Biphenyl-4’-yl)methyl 2-N’-(t-Butoxycarbonyl)amino-3,3-dimethylbutanamide 
((R)-302). Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3,3-
dimethylbutanoic acid (2.50 g, 10.82 mmol), 4-methylmorpholine (1.55 mL, 14.06 mmol), 
isobutyl chloroformate (1.53 mL, 11.90 mmol), and 4-phenylbenzylamine (2.08 g, 11.36 
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mmol) in anhydrous THF (110 mL) gave the crude product that was purified by flash column 
chromatography (SiO2; 5-50% EtOAc/hexanes) to give the desired compound (2.72 g, 63%) 
as a white solid: Rf 0.79 (1:1 EtOAc/hexanes);
 mp 125–126 ºC; IR (nujol mull) 2932 (br), 
1650, 1527, 1459, 1374, 1249, 1173, 1078, 1009, 918, 824, 758 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 1.02 (s, CC(CH3)3), 1.40 (s, OC(CH3)3), 3.93 (d, J = 8.5 Hz, CH), 4.40 (dd, J = 5.4, 
14.7 Hz, NHCHH‟), 4.50 (dd, J = 6.0, 14.7 Hz, NHCHH’), 5.37 (d, J = 8.5 Hz, OC(O)NH), 
6.50–6.58 (br t, NHCH2), 7.31–7.34 (m, 3 ArH), 7.40–7.44 (m, 2 ArH), 7.51–7.58 (m, 4 ArH); 
13C NMR (100 MHz, CDCl3) δ 26.6 (CC(CH3)3), 28.3 (OC(CH3)3), 34.5 (CC(CH3)3), 43.2 
(NHCH2), 62.4 (CH),  79.7 (OC(CH3)3), 127.0, 127.2, 127.3, 128.2, 128.5, 137.0, 140.4, 
140.7 (8 ArC), 156.0 (OC(O)), 171.1 (CC(O)); LRMS (ESI) 419.18 [M + Na+] (calcd for 
C24H32N2O3Na
+ 419.18); Anal. Calcd for C24H32N2O3: C, 72.70; H, 8.13; N, 7.06. Found: C, 
72.97; H, 7.94; N, 6.94. 
 
 
(R)-N-(Biphenyl-4’-yl)methyl 2-N’-Amino-3,3-dimethylbutanamide ((R)-253). Utilizing 
Method B and using (R)-N-(biphenyl-4‟-yl)methyl 2-N‟-(t-butoxycarbonyl)amino-3,3-
dimethylbutanamide (1.53 g, 3.86 mmol), TFA (4.30 mL, 57.92 mmol), and CH2Cl2 (13 mL) 
gave the crude product after basic workup that was further purified by flash column 
chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give the desired compound (0.76 g, 
67%) as a white solid: mp 75–76 ºC; [α]28.5D +14.4° (c 1.0, CH2Cl2); Rf 0.50 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 2858 (br), 1635, 1458, 1375, 1158, 1093, 1010, 823, 728 cm
-
1; 1H NMR (400 MHz, CDCl3) δ 1.03 (s, C(CH3)3), 1.50 (s, NH2), 3.16 (s, CH), 4.44–4.54 (m, 
NHCH2), 7.06–7.12 (br s, NH), 7.32–7.37 (m, 3 ArH), 7.42–7.45 (m, 2 ArH), 7.55–7.59 (m, 4 
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ArH); 13C NMR (100 MHz, CDCl3) δ 26.8 (C(CH3)3), 34.3 (C(CH3)3), 42.9 (NHCH2), 64.5 
(CH), 127.1, 127.3, 127.4, 128.3, 128.8, 137.6, 140.3, 140.7 (8 ArC), 173.5 (C(O)); LRMS 
(ESI) 297.20 [M + H+] (calcd for C19H24N2OH
+ 297.20); Anal. Calcd for C19H24N2O: C, 76.99; 
H, 8.16; N, 9.45. Found: C, 77.14; H, 8.28; N, 9.49. 
 
 
(R)-N-4’-((3’’-Fluoro)benzyloxy)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-
hydroxypropionamide ((R)-307).103 Utilizing Method A and using (R)-2-N-(t-
butoxycarbonyl)amino-3-hydroxypropionic acid (6.00 g, 29.25 mmol), NMM (4.18 mL, 38.03 
mmol), IBCF (4.15 mL, 32.18 mmol), and 4-((3-fluorobenzyloxy)benzylamine (7.09 g, 30.72 
mmol) in anhydrous THF (300 mL) gave the crude product that was purified by flash column 
chromatography (SiO2; 5–50% EtOAc/hexanes followed by 10% MeOH/CH2Cl2) to give the 
desired compound (3.74 g, 30%) as a pale yellow solid: mp 92–93 ºC (lit.103 mp 88–89 ºC); 
[α]25D +25.4° (c 0.7, CHCl3) (lit.
103 [α]25.8D +25.8° (c 1.0, CHCl3)); Rf 0.30 (1:1 
EtOAc/hexanes); IR (nujol mull) 3221, 3175, 3106, 2946 (br), 1660, 1526, 1458, 1376, 1304, 
1243, 1168, 1008, 866, 775, 726 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.40 (s, (CH3)3), 3.36–
3.48 (br m, CHH‟OH), 3.61–3.72 (br m, CHH’OH), 4.00–4.10 (br m, CH), 4.11–4.20 (br m, 
OH), 4.30–4.52 (m, NHCH2), 5.02 (s, OCH2), 5.65 (d, J = 7.2 Hz, NH), 6.87–6.91 (m, 2 ArH), 
6.98–7.12 (m,  1 ArH, NH), 7.16–7.18 (m, 4 ArH), 7.30–7.36 (m, 1 ArH); 13C NMR (100 MHz, 
CDCl3) δ 28.2 ((CH3)3), 42.8 (NHCH2), 54.9 (CH), 62.8 (CH2OH), 69.2 (CH2O), 80.6 
(C(CH3)3), 114.1 (d, J = 21.7 Hz, C4’’ or C2’’), 114.8 (d, J = 20.9 Hz, C2’’ or C4’’), 115.0 (C1), 
122.6 (d, J = 3.1 Hz, C6’’), 128.9 (ArC), 130.1 (d, J = 7.8 Hz, C5’’), 130.4 (ArC), 139.5 (d, J = 
6.9 Hz, C1’’), 156.3 (OC(O)), 157.9 (C4), 163.0 (d, J = 244.7 Hz, C3’’), 171.2 (CC(O)). 
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(R)-N-4’-((3’’-Fluoro)benzyloxy)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-
methoxypropionamide ((R)-314).103 Ag2O (9.00 g, 38.86 mmol) was added to a CH3CN 
solution (155 mL) of (R)-N-4‟-((3‟‟-fluoro)benzyloxy)benzyl 2-N‟-(t-butoxycarbonyl)amino-3-
hydroxypropionamide (3.25 g, 7.77 mmol), and CH3I (4.84 mL, 77.72 mmol) at room 
temperature under Ar. The reaction mixture was stirred (4 d), filtered, and the filtrate 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(SiO2; 5–50% EtOAc/hexanes) to give the desired compound (3.22 g, 96%) as a white solid: 
mp 70–71 ºC (lit.103 mp 68–70 ºC); [α]28.5D –15.9° (c 1.0, CHCl3) (lit.
103 [α]24.3D –16.6° (c 1.0, 
CHCl3)); : Rf 0.75 (1:1 EtOAc/hexanes); IR (nujol mull) 3307, 3255, 3157, 2929, 2858, 1647, 
1521, 1458, 1375, 1247, 1167, 1048, 917, 776, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.42 
(s, (CH3)3), 3.35 (s, OCH3), 3.49 (dd, J = 6.2, 9.1 Hz, CHH‟OCH3), 3.82 (dd, J = 4.0, 9.1 Hz, 
CHH’OCH3), 4.20–4.30 (br m, CH), 4.35–4.45 (m, NHCH2), 5.04 (s, OCH2), 5.38–5.42 (br d, 
OC(O)NH), 6.64–6.72 (br t, CC(O)NH),  6.91 (d, J = 8.8 Hz, 2 ArH), 6.98–7.02 (m, 1 ArH), 
7.13–7.20 (m, 4 ArH), 7.34 (q, J = 8.0 Hz, 1 ArH); 13C NMR (100 MHz, CDCl3) δ 28.2 
((CH3)3), 42.9 (NHCH2), 54.0 (CH), 59.1 (OCH3), 69.2 (CH2O), 72.1 (CH2OCH3), 80.3 
(C(CH3)3), 114.1 (d, J = 21.7 Hz, C4’’ or C2’’), 114.8 (d, J = 20.9 Hz, C2’’ or C4’’), 115.0 (C1), 
122.6 (d, J = 3.1 Hz, C6’’), 128.8 (ArC), 130.1 (d, J = 8.5 Hz, C5’’), 130.7 (ArC), 139.6 (d, J = 
7.7 Hz, C1’’), 155.5 (OC(O)), 157.9 (C4), 163.0 (d, J = 244.7 Hz, C3’’), 170.2 (CC(O)). 
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(R)-N-4’-((3’’-Fluoro)benzyloxy)benzyl 2-N’-Amino-3-methoxypropionamide ((R)-254). 
Utilizing Method B and using (R)-N-4‟-((3‟‟-fluoro)benzyloxy)benzyl 2-N‟-(t-
butoxycarbonyl)amino-3-methoxypropionamide (3.00 g, 6.94 mmol), TFA (7.73 mL, 0.10 
mol), and CH2Cl2 (23 mL) gave the crude product after basic workup that was further purified 
by flash column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 
MeOH/CH2Cl2) to give the desired product (2.05 g, 89%) as a pale yellow solid: mp 76–77 
ºC; [α]28.5D +7.9° (c 1.1, CHCl3); Rf 0.74 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3120, 2911 (br), 
1644, 1458, 1375, 1253, 1142, 1024, 781, 726 cm-1;  1H NMR (400 MHz, CDCl3) δ 1.67 (s, 
NH2), 3.36 (s, OCH3), 3.56–3.64 (m, CH2OCH3, CH), 4.33–4.44 (m, NHCH2), 5.04 (s, OCH2), 
6.91 (d, J = 8.4 Hz, 2 ArH), 6.98–7.02 (m, 1 ArH), 7.13–7.21 (m, 4 ArH), 7.34 (q, J = 8.0 Hz, 
1 ArH), 7.68–7.72 (br t, NH); 13C NMR (100 MHz, CDCl3) δ 42.6 (NHCH2), 54.9 (CH), 58.9 
(OCH3), 69.2 (CH2O), 74.5 (CH2OCH3), 114.2 (d, J = 21.7 Hz, C4’’ or C2’’), 114.8 (d, J = 21.7 
Hz, C2’’ or C4’’), 115.0 (C1), 122.7 (d, J = 2.3 Hz, C6’’), 129.0 (ArC), 130.1 (d, J = 8.5 Hz, C5’’), 
131.1 (ArC), 139.6 (d, J = 7.7 Hz, C1’’), 157.8 (C4), 163.0 (d, J = 244.7 Hz, C3’’), 172.5 
(C(O)); LRMS (ESI) 333.17 [M + H+] (calcd for C18H21FN2O3H
+ 333.17); Anal. Calcd for 
C18H21FN2O3: C, 65.05; H, 6.37; F, 5.72; N, 8.43. Found: C, 65.10; H, 6.39; F, 5.67; N, 8.34. 
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4’-((3’’-Fluoro)phenoxy)methyl)benzonitrile (321).103 A mixture of 4-cyanobenzyl bromide 
(10.00 g, 51.00 mmol), K2CO3 (29.66 g, 0.21 mol), and 3-fluorophenol (4.85 mL, 53.65 
mmol) were heated at reflux in acetone (215 mL) (18 h). The volatiles were evaporated in 
vacuo and the residue was dissolved in CH2Cl2 (100 mL). The organic layer was washed 
with H2O (2 x 100 mL), dried (Na2SO4), and evaporated in vacuo to give the desired product 
(11.61 g, 95%) as a white solid. The product was used for the next step without further 
purification: 1H NMR (400 MHz, CDCl3) δ 5.10 (s, CH2O), 6.65–6.75 (m, 3 ArH), 7.23 (q, J = 
8.0 Hz, 1 ArH), 7.53 (d, J = 7.6 Hz, 2 ArH), 7.68 (d, J = 8.4 Hz, 2 ArH); 13C NMR (100 MHz, 
CDCl3) δ 69.1 (CH2O), 102.7 (d, J = 25.5 Hz, C2’ or C4’), 108.3 (d, J = 21.0 Hz, C4’ or C2’), 
110.5 (d, J = 3.1 Hz, C6’), 111.9 (ArC), 118.6 (CN), 127.5 (ArC), 130.4 (d, J = 10.1 Hz, C5’), 
132.4, 141.9 (2 ArC), 159.5 (d, J = 10.8 Hz, C1’), 163.6 (d, J = 244.7 Hz, C3’). 
 
 
4’-((3’’-Fluoro)phenoxy)methyl)benzylamine Hydrochloride (306).103 To a LiAlH4 (5.02 g, 
132.12 mmol) suspension in THF (400 mL) was added dropwise at 0 ºC, a THF (30 mL) 
solution of 4‟-((3‟‟-fluoro)phenoxy)methyl)benzonitrile (10.00 g, 44.04 mmol). The mixture 
was stirred at room temperature (18 h). Then, H2O (4 mL) was added dropwise at 0 ºC 
followed by an aqueous NaOH solution (2 mL, 15% w/w) and H2O (4 mL). The mixture was 
stirred at room temperature (2 h), and the precipitate was filtered and the pad was washed 
with CH2Cl2, and the filtrate was concentrated in vacuo. The residue was solubilized in Et2O 
(30 mL), and then HCl in Et2O (1 M) was added dropwise at 0 ºC. The white precipitate was 
filtered to give the desired product (8.43 g, 72 %) as a white solid: mp 243–245 ºC (lit.103 mp 
240–245 ºC); Rf 0.00 (1:10 EtOAc/hexanes); IR (nujol mull) 3284, 2927, 2856, 1596, 1459, 
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1376, 1277, 1140, 1030, 964, 831, 771, 727 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 4.01 (s, 
CH2NH3), 5.14 (s, CH2O), 6.74–6.79 (m, 1 ArH), 6.85–6.92 (m, 2 ArH), 7.31 (q, J = 7.6 Hz, 1 
ArH), 7.47 (d, J = 8.2 Hz, 2 ArH), 7.55 (d, J = 8.2 Hz, 2 ArH), 8.50–8.71 (br s, NH3Cl); 
13C 
NMR (100 MHz, DMSO-d6) δ 42.2 (CH2NH3), 69.6 (CH2O), 102.8 (d, J = 24.8 Hz, C2’ or C4’), 
107.8 (d, J = 20.9 Hz, C4’ or C2’), 111.7 (d, J = 2.3 Hz, C6’), 128.3, 129.6 (2 ArC), 131.2 (d, J 
= 10.1 Hz, C5’), 134.3, 137.3 (2 ArC), 160.1 (d, J = 11.6 Hz, C1’), 163.4 (d, J = 241.6 Hz, 
C3’). 
 
 
(R)-N-4’-((3’’-Fluoro)phenoxy)methyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-
hydroxypropionamide ((R)-308).103 Utilizing Method A and using (R)-2-N-(t-
butoxycarbonyl)amino-3-hydroxypropionic acid (6.00 g, 29.25 mmol), NMM (8.04 mL, 73.14 
mmol), IBCF (4.15 mL, 32.18 mmol), and 4-((3-fluorophenoxy)methyl)benzylamine 
hydrochloride (8.20 g, 30.72 mmol) in anhydrous THF (300 mL) gave the crude product that 
was purified by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes followed by 
1:10 MeOH/CH2Cl2) to give the desired compound (3.47 g, 28%) as a pale yellow solid: mp 
85–86 ºC (lit.103 mp 85–86 ºC); [α]28.5D +25.3° (c 0.8, CHCl3) (lit.
103 [α]23.4D +27.9° (c 1.0, 
CHCl3)); Rf 0.46 (1:1 EtOAc/hexanes); IR (nujol mull) 3434, 3377, 3158, 2934 (br), 1652, 
1524, 1457, 1374, 1306, 1165, 1011, 961, 835, 727 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.41 
(s, (CH3)3), 3.30–3.40 (br m, CHH‟OH), 3.62–3.76 (br m, CHH’OH), 4.07–4.13 (m, CH), 
4.14–4.22 (br m, OH), 4.37–4.51 (m, NHCH2), 5.01 (s, OCH2), 5.65 (d, J = 6.8 Hz, NH), 
6.64–6.74 (m, 3 ArH), 7.10–7.22 (m, 1 ArH, NH), 7.27 (d, J = 8.2 Hz, 2 ArH), 7.36 (d, J = 8.2 
Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 28.2 ((CH3)3), 43.1 (NHCH2), 54.9 (CH), 62.8 
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(CH2OH), 69.8 (CH2O), 80.7 (C(CH3)3), 102.6 (d, J = 24.8 Hz, C4’’ or C2’’), 107.8 (d, J = 20.9 
Hz, C2’’ or C4’’), 110.5 (d, J = 3.1 Hz, C6’’), 127.7, 127.8 (2 ArC), 130.2 (d, J = 10.1 Hz, C5’’), 
135.8, 137.8 (2 ArC), 156.3 (OC(O)), 160.0 (d, J = 10.8 Hz, C1’’), 163.6 (d, J = 243.9 Hz, 
C3’’), 171.3 (CC(O)). 
 
 
(S)-N-4’-((3’’-Fluoro)phenoxy)methyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-
hydroxypropionamide ((S)-308). The previous procedure was repeated using (S)-2-N-(t-
butoxycarbonyl)amino-3-hydroxypropionic acid (2.50 g, 12.19 mmol), NMM (3.35 mL, 30.47 
mmol), IBCF (1.73 mL, 13.41 mmol), and 4-((3-fluorophenoxy)methyl)benzylamine 
hydrochloride (3.42 g, 12.80 mmol) in anhydrous THF (120 mL) to give the crude product 
that was purified by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) to give 
the desired compound (3.66 g, 72%) as a white solid: mp 89–90 ºC; [α]28D –24.0° (c 1.1, 
CHCl3) (lit.
103 (R): [α]23.4D +27.9° (c 1.0, CHCl3)); Rf 0.39 (1:1 EtOAc/hexanes); IR (nujol mull) 
2927 (br), 1652, 1527, 1458, 1375, 1276, 1166, 1012, 835, 768 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 1.41 (s, (CH3)3), 3.42–3.52 (br m, CHH‟OH), 3.62–3.74 (br m, CHH’OH), 4.06–4.10 
(m, CH), 4.16–4.24 (br m, OH), 4.33–4.50 (m, NHCH2), 5.00 (s, OCH2), 5.68 (d, J = 7.6 Hz, 
NH), 6.63–6.68 (m, 2 ArH), 6.72–6.74 (m, 1 ArH),  7.09–7.27 (m, 3 ArH, NH), 7.35 (d, J = 
7.6 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 28.2 ((CH3)3), 43.1 (NHCH2), 55.0 (CH), 62.8 
(CH2OH), 69.8 (CH2O), 80.6 (C(CH3)3), 102.6 (d, J = 24.8 Hz, C4’’ or C2’’), 107.7 (d, J = 20.9 
Hz, C2’’ or C4’’), 110.5 (d, J = 3.1 Hz, C6’’), 127.7, 127.8 (2 ArC), 130.2 (d, J = 10.1 Hz, C5’’), 
135.7, 137.7 (2 ArC), 156.3 (OC(O)), 160.0 (d, J = 10.9 Hz, C1’’), 163.6 (d, J = 243.9 Hz, 
C3’’), 171.3 (CC(O)); LRMS (ESI) 441.14 [M + Na
+] (calcd for C22H27FN2O5Na
+ 441.14); Anal. 
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Calcd for C22H27FN2O5: C, 63.14; H, 6.50; F, 4.54; N, 6.69. Found: C, 63.22; H, 6.66; F, 
4.29; N, 6.80. 
 
 
(R)-N-4’-((3’’-Fluoro)phenoxy)methyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-
methoxypropionamide ((R)-315).103 Ag2O (8.70 g, 37.54 mmol) was added to a CH3CN 
solution (150 mL) of (R)-N-4‟-((3‟‟-fluoro)phenoxy)methyl)benzyl 2-N‟-(t-
butoxycarbonyl)amino-3-hydroxypropionamide (3.14 g, 7.51 mmol), and CH3I (4.67 mL, 
75.09 mmol) at room temperature under Ar. The reaction mixture was stirred (4 d), filtered, 
and the filtrate concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2; 5–50% EtOAc/hexanes) to give the desired compound (2.80 g, 86%) 
as a white solid: Rf 0.72 (50% EtOAc/hexanes); mp 75–76 ºC (lit.
103 mp 77–79 ºC); [α]28.5D –
16.7° (c 1.1, CHCl3) (lit.
103 [α]26D –17.8° (c 1.0, CHCl3)); IR (nujol mull) 3409, 2927, 1689, 
1648, 1528, 1458, 1375, 1267, 1165, 1048, 961, 918, 825, 763, 726 cm-1; 1H NMR (400 
MHz, CDCl3) δ 1.43 (s, (CH3)3), 3.37 (s, OCH3), 3.50 (dd, J = 6.2, 9.2 Hz, CHH‟OCH3), 3.84 
(dd, J = 4.0, 9.2 Hz, CHH’OCH3), 4.24–4.30 (br s, CH), 4.44–4.48 (br d, NHCH2), 5.02 (s, 
OCH2), 5.36–5.44 (br m, OC(O)NH), 6.64–6.76 (m, 3 ArH, CC(O)NH), 7.21 (q, J = 8.4 Hz, 1 
ArH), 7.29 (d, J = 8.2 Hz, 2 ArH), 7.38 (d, J = 8.2 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 
28.2 ((CH3)3), 43.2 (NHCH2), 54.0 (CH), 59.1 (OCH3), 69.9 (CH2O), 72.0 (CH2OCH3), 80.4 
(C(CH3)3), 102.6 (d, J = 24.8 Hz, C4’’ or C2’’), 107.8 (d, J = 20.9 Hz, C2’’ or C4’’), 110.6 (d, J = 
2.3 Hz, C6’’), 127.7, 127.8 (2 ArC), 130.2 (d, J = 10.0 Hz, C5’’), 135.7, 138.0 (2 ArC), 155.5 
(OC(O)), 160.0 (d, J = 10.9 Hz, C1’’), 163.6 (d, J = 243.9 Hz, C3’’), 171.2 (CC(O)). 
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(S)-N-4’-((3’’-Fluoro)phenoxy)methyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-
methoxypropionamide ((S)-315). The previous procedure was repeated using (S)-N-4‟-
((3‟‟-fluoro)phenoxy)methyl)benzyl 2-N‟-(t-butoxycarbonyl)amino-3-hydroxypropionamide 
(3.14 g, 7.51 mmol), Ag2O (8.70 g, 37.54 mmol), CH3I (4.67 mL, 75.09 mmol), and CH3CN 
(140 mL) to give the crude product that was purified by flash column chromatography (SiO2; 
1:20–1:1 EtOAc/hexanes) to give the desired compound (2.68 g, 83%) as a white solid: mp 
83–84 ºC; [α]28D +16.0° (c 1.0, CHCl3) (lit.
103 (R): [α]26D –17.8° (c 1.0, CHCl3)); Rf 0.61 (1:1 
EtOAc/hexanes); IR (nujol mull) 2867 (br), 1647, 1529, 1458, 1375, 1322, 1264, 1165, 1047, 
960, 916, 823, 760 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.43 (s, (CH3)3), 3.37 (s, OCH3), 3.50 
(dd, J = 6.4, 9.1 Hz, CHH‟OCH3), 3.84 (dd, J = 3.8, 9.1 Hz, CHH’OCH3), 4.24–4.30 (br s, 
CH), 4.44–4.54 (br d, NHCH2), 5.02 (s, OCH2), 5.36–5.44 (br m, OC(O)NH), 6.64–6.69 (m, 2 
ArH), 6.73–6.78 (m, 1 ArH, CC(O)NH), 7.19–7.24 (m, 1 ArH), 7.29 (d, J = 8.0 Hz, 2 ArH), 
7.38 (d, J = 8.0 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 28.2 ((CH3)3), 43.2 (NHCH2), 54.0 
(CH), 59.1 (OCH3), 69.9 (CH2O), 72.0 (CH2OCH3), 80.4 (C(CH3)3), 102.6 (d, J = 24.8 Hz, C4’’ 
or C2’’), 107.8 (d, J = 21.6 Hz, C2’’ or C4’’), 110.5 (d, J = 2.4 Hz, C6’’), 127.7, 127.8 (2 ArC), 
130.2 (d, J = 10.0 Hz, C5’’), 135.7, 138.0 (2 ArC), 155.5 (OC(O)), 160.0 (d, J = 10.8 Hz, C1’’), 
163.6 (d, J = 243.9 Hz, C3’’), 171.3 (CC(O)); LRMS (ESI) 455.18 [M + Na
+] (calcd for 
C23H29FN2O5Na
+ 455.18); Anal. Calcd for C23H29FN2O5: C, 63.87; H, 6.76; F, 4.39; N, 6.48. 
Found: C, 64.14; H, 6.73; F, 4.44; N, 6.43. 
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(R)-N-4’-((3’’-Fluoro)phenoxy)methyl)benzyl 2-N’-Amino-3-methoxypropionamide ((R)-
255). Utilizing Method B and using (R)-N-4‟-((3‟‟-fluoro)phenoxy)methyl)benzyl 2-N‟-(t-
butoxycarbonyl)amino-3-methoxypropionamide (2.45 g, 5.67 mmol), TFA (6.32 mL, 85.03 
mol), and CH2Cl2 (19 mL) gave the crude product after basic workup that was further purified 
twice by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes followed by 1:10 
MeOH/CH2Cl2) followed by recrystallization from hot EtOAc/hexanes to give the desired 
product (1.30 g, 69%) as a pale yellow solid: mp 60–61 ºC; [α]25D +6.1° (c 1.1, CHCl3); Rf 
0.76 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3132, 2877 (br), 1651, 1457, 1375, 1270, 1130, 
1016, 774 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.63 (s, NH2), 3.38 (s, OCH3), 3.59–3.65 (m, 
CH, CH2OCH3),  4.42–4.52 (m, NHCH2), 5.03 (s, OCH2), 6.64–6.69 (m, 2 ArH), 6.75 (d, J = 
9.6 Hz, 1 ArH), 7.22 (q, J = 8.4 Hz, 1 ArH), 7.30 (d, J = 7.8 Hz, 2 ArH), 7.38 (d, J = 7.8 Hz, 2 
ArH), 7.74–7.83 (br t, NH); 13C NMR (100 MHz, CDCl3) δ 42.8 (NHCH2), 54.9 (CH), 58.9 
(OCH3), 69.9 (CH2O), 74.4 (CH2OCH3), 102.6 (d, J = 24.8 Hz, C4’’ or C2’’), 107.8 (d, J = 21.7 
Hz, C2’’ or C4’’), 110.6 (d, J = 2.3 Hz, C6’’), 127.8, 127.9 (2 ArC), 130.2 (d, J = 10.0 Hz, C5’’), 
135.6, 138.4 (2 ArC), 160.0 (d, J = 10.9 Hz, C1’’), 163.6 (d, J = 243.9 Hz, C3’’), 172.6 (C(O)); 
LRMS (ESI) 333.17 [M + H+] (calcd for C18H21FN2O3H
+ 333.17); Anal. Calcd for 
C18H21FN2O3: C, 65.05; H, 6.37; F, 5.72; N, 8.43. Found: C, 64.83; H, 6.39; F, 5.58; N, 8.50. 
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(S)-N-4’-((3’’-Fluoro)phenoxy)methyl)benzyl 2-N’-Amino-3-methoxypropionamide ((S)-
255). Utilizing Method B and using (S)-N-4‟-((3‟‟-fluoro)phenoxy)methyl)benzyl 2-N‟-(t-
butoxycarbonyl)amino-3-methoxypropionamide (2.71 g, 6.27 mmol), TFA (6.99 mL, 94.05 
mol), and CH2Cl2 (21 mL) gave the crude product after basic workup that was further purified 
by flash column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 
MeOH/CH2Cl2) to give a mixture of desired product and impurity as an orange oil. The crude 
oil obtained after the acid workup was then further purified by flash column chromatography 
(SiO2; 1:100–1:10 MeOH/CH2Cl2) to give the desired compound (0.27 g, 19%) as a pale 
yellow solid: mp 52–53 ºC; [α]25D - 6.8° (c 1.1, CHCl3); Rf 0.29 (1:20 MeOH/CH2Cl2); IR 
(nujol) 2938 (br), 1651, 1521, 1458, 1375, 1271, 1130, 1017, 964, 832, 774 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 1.68 (s, NH2), 3.38 (s, OCH3), 3.59-3.65 (m, CH, CH2OCH3), 4.42-4.52 
(m, NHCH2), 5.03 (s, OCH2), 6.64-6.70 (m, 2 ArH), 6.73-6.76 (m, 1 ArH), 7.19-7.26 (m, 1 
ArH), 7.30 (d, J = 8.0 Hz, 2 ArH), 7.38 (d, J = 8.0 Hz, 2 ArH), 7.76-7.84 (br t, NH); 13C NMR 
(100 MHz, CDCl3) δ 42.8 (NHCH2), 54.8 (CH), 58.9 (OCH3), 69.9 (CH2O), 74.5 (CH2OCH3), 
102.6 (d, J = 24.7 Hz, C4’’ or C2’’), 107.7 (d, J = 20.9 Hz, C2’’ or C4’’), 110.5 (d, J = 3.1 Hz, 
C6’’), 127.8, 127.9 (2 ArC), 130.2 (d, J = 10.0 Hz, C5’’), 135.6, 138.4 (2 ArC), 160.0 (d, J = 
10.9 Hz, C1’’), 163.6 (d, J = 243.9 Hz, C3’’), 172.6 (C(O)); LRMS (ESI) 333.12 [M + H
+] (calcd 
for C18H21FN2O3H
+ 333.12); Anal. Calcd for C18H21FN2O3: C, 65.05; H, 6.37; F, 5.72; N, 8.43. 
Found: C, 64.89; H, 6.39; F, 5.45; N, 8.21. 
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(R)-N-(4-(3-Fluoro)benzyloxy)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-
methylbutanamide ((R)-310). Utilizing Method A and using (R)-2-N-(t-
butoxycarbonyl)amino-3-methylbutanoic acid (3.07 g, 14.14 mmol), NMM (2.02 mL, 18.38 
mmol), IBCF (1.84 mL, 15.55 mmol), and 4-(3-fluoro)benzyloxybenzylamine (3.43 g, 14.85 
mmol) in anhydrous THF (15 mL) gave the crude product that was purified by flash column 
chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to give the desired compound (5.29 g, 
87%) as a pale yellow solid: mp 109–110 ºC; [α]25D +4.3° (c 1.1, CH2Cl2); Rf 0.21 (1:10 
EtOAc/hexanes); IR (nujol mull) 3298, 2947 (br), 1652, 1530, 1458, 1375, 1301, 1245, 1170, 
1017, 879, 777 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.91 (d, J = 6.8 Hz, CH(CH3)CH3), 0.95 
(d, J = 6.8 Hz, CH(CH3)CH3), 1.41 (s, C(CH3)3), 2.09–2.19 (m, CH(CH3)2), 3.86–3.92 (m, 
CH), 4.23–4.42 (m, NHCH2Ph), 5.04 (s, OCH2), 5.08–5.12 (br d, C(O)NH), 6.36 (t, J = 5.2 
Hz, NHCH2Ph), 6.88–6.93 (m, 2 ArH), 6.98–7.03 (m, 1 ArH), 7.12–7.22 (m, 4 ArH), 7.31–
7.36 (1 ArH); 13C NMR (100 MHz, CDCl3) δ 18.1 (CH(CH3)CH3), 19.6 (CH(CH3)CH3), 28.5 
(C(CH3)3), 30.9 (CH(CH3)2), 43.1 (NHCH2Ph), 60.4 (CH), 69.4 (OCH2), 80.1 (C(CH3)3), 114.4 
(d, J = 21.9 Hz, C4’ or C2’), 115.0 (d, J = 21.2 Hz, C2’ or C4’), 115.2 (C1), 122.9 (d, J = 2.6 Hz, 
C6’), 129.3 (ArC), 130.3 (d, J = 8.3 Hz, C5’), 130.9 (ArC), 139.8 (d, J = 7.1 Hz, C1’), 156.1 
(OC(O)), 158.1 (C4), 163.2 (d, J = 244.4 Hz, C3’), 171.7 (CC(O)); HRMS (ESI) 453.2178 [M + 
Na+] (calcd for C24H31FN2O4Na
+ 453.2166); Anal. Calcd for C24H31FN2O4: C, 66.96; H, 7.26; 
F, 4.41; N, 6.51. Found: C, 67.23; H, 7.22; F, 4.47; N, 6.28. 
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(R)-N-(4-(3-Fluoro)benzyloxy)benzyl 2-Amino-3-methylbutanamide ((R)-257). Utilizing 
Method B and using (R)-N-(4-(3-fluoro)benzyloxybenzyl 2-N‟-(t-butoxycarbonyl)amino-3-
methylbutanamide (2.00 g, 4.65 mmol), TFA (5.18 mL, 69.73 mmol), and CH2Cl2 (15 mL) 
gave the crude product after basic workup that was further purified by flash column 
chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to give the desired compound (481 mg, 
32%) as a white solid: mp 77–78 ºC; [α]25D +16.8° (c 1.0, CH2Cl2); Rf 0.57 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 3458, 3408, 3350, 3265, 2915, 2859, 1630, 1458, 1375, 
1251, 1137, 1032, 952, 831, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.83 (d, J = 6.8 Hz, 
CH(CH3)CH3), 0.99 (d, J = 7.2 Hz, CH(CH3)CH3), 1.31–1.58 (br s, NH2), 2.31–2.38 (m, 
CH(CH3)2), 3.26 (d, J = 2.8 Hz, CH), 4.33–4.44 (m, NHCH2Ph), 5.05 (s, OCH2), 6.91 (d, J = 
7.2 Hz, 2 ArH), 7.00 (t, J = 8.4 Hz, 1 ArH), 7.13–7.26 (m, 4 ArH), 7.31–7.39 (m, 1 ArH), 
7.51–7.59 (br t, NHCH2Ph); 
13C NMR (100 MHz, CDCl3) δ 16.2 (CH(CH3)CH3), 20.0 
(CH(CH3)CH3), 31.0 (CH(CH3)2), 42.7 (NHCH2Ph), 60.4 (CH), 69.4 (OCH2), 114.4 (d, J = 
21.9 Hz, C4’ or C2’), 115.0 (d, J = 21.2 Hz, C2’ or C4’), 115.2 (C1), 122.9 (d, J = 3.2 Hz, C6’), 
129.4 (ArC), 130.3 (d, J = 8.4 Hz, C5’), 131.6 (ArC), 139.8 (d, J = 7.0 Hz, C1’), 158.0 (C4), 
163.2 (d, J = 245.0 Hz, C3’), 174.4 (C(O)); HRMS (ESI) 331.1827 [M + H
+] (calcd for 
C19H23FN2O2H
+ 331.1822); Anal. Calcd for C19H23FN2O2: C, 69.07; H, 7.02; F, 5.75; N, 8.48. 
Found: C, 68.98; H, 6.90; F, 5.75; N, 8.32. 
 
 272 
 
 
(R)-N-4-((3-Fluoro)phenoxymethyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-
methylbutanamide ((R)-311). Utilizing Method A and using (R)-2-N-(t-
butoxycarbonyl)amino-3-methylbutanoic acid (2.25 g, 10.36 mmol), NMM (1.48 mL, 13.47 
mmol), IBCF (1.47 mL, 11.40 mmol), and 4-((3-fluorophenoxy)methyl)benzylamine (2.51 g, 
10.88 mmol) in anhydrous THF (10 mL) gave the crude product. The compound was purified 
by flash column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give the desired 
product (4.03 g, 90%) as a white solid: mp 115–116 ºC; [α]25D +2.6° (c 1.1, CH2Cl2); Rf 0.85 
(1:20 MeOH/CH2Cl2); IR (nujol mull) 3347, 2958, 1648, 1527, 1458, 1375, 1306, 1253, 1166, 
1045, 961, 826, 769, 724 cm-1; 1H NMR (300 MHz, CDCl3) δ 0.92 (d, J = 6.8 Hz, 
CH(CH3)CH3), 0.95 (d, J = 6.8 Hz, CH(CH3)CH3), 1.40 (s, C(CH3)3), 2.05–2.19 (m, 
CH(CH3)2), 3.94 (dd, J = 5.6, 10.0 Hz, CH), 4.34–4.49 (m, NHCH2Ph), 4.99 (s, OCH2), 5.23 
(d, J = 9.0 Hz, C(O)NH), 6.63–6.77 (m, 4 ArH), 7.11–7.39 (m, 4 ArH, NHCH2Ph); 
13C NMR 
(75 MHz, CDCl3) δ 18.1 (CH(CH3)CH3), 19.2 (CH(CH3)CH3), 28.5 (C(CH3)3), 30.9 
(CH(CH3)2), 43.3 (NHCH2Ph), 60.4 (CH), 70.1 (CH2O), 80.1 (C(CH3)3), 102.3 (d, J = 24.5 Hz, 
C4’ or C2’), 108.0 (d, J = 21.1 Hz, C2’ or C4’), 110.8 (d, J = 2.9 Hz, C6’), 128.0 (d, J = 10.9 Hz, 
C1’), 129.5 (ArC), 130.4 (d, J = 10.3 Hz, C5’), 135.9 (ArC), 138.3 (ArC), 156.2 (OC(O)), 160.2 
(d, J = 10.8 Hz, C4), 163.8 (d, J = 243.8 Hz, C3’), 172.0 (CC(O)); HRMS (ESI) 453.2172 [M + 
Na+] (calcd for C24H31FN2O4Na
+ 453.2166); Anal. Calcd for C24H31FN2O4: C, 66.96; H, 7.26; 
F, 4.41; N, 6.51. Found: C, 67.01; H, 7.41; F, 4.36; N, 6.38. 
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(S)-N-4-((3-Fluoro)phenoxymethyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-
methylbutanamide ((S)-311). The previous procedure was repeating using (S)-2-N-(t-
butoxycarbonyl)amino-3-methylbutanoic acid (2.50 g, 11.51 mmol), NMM (3.16 mL, 28.78 
mmol), IBCF (1.63 mL, 12.67 mmol), and 4-((3-fluorophenoxy)methyl)benzylamine 
hydrochloride (3.23 g, 12.09 mmol) in anhydrous THF (115 mL) to give the crude product 
that was purified by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) to give 
the desired compound (4.53 g, 91%) as a white solid: mp 115–116 ºC; [α]28D –2.6° (c 1.1, 
CH2Cl2); Rf 0.90 (1:1 EtOAc/hexanes); IR (nujol mull) 2911 (br), 1648, 1526, 1458, 1375, 
1305, 1252, 1166, 1044, 962, 826, 724 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.92 (d, J = 7.0 
Hz, CH(CH3)CH3), 0.96 (d, J = 7.0 Hz, CH(CH3)CH3), 1.41 (s, C(CH3)3), 2.10–2.20 (m, 
CH(CH3)2), 3.93 (dd, J = 6.4, 8.8 Hz, CH), 4.38–4.49 (m, NHCH2Ph), 5.01 (s, OCH2), 5.10–
5.15 (br d, C(O)NH), 6.55 (t, J = 5.6 Hz, NHCH2Ph), 6.64–6.75 (m, 3 ArH), 7.10–7.24 (m, 1 
ArH), 7.27 (d, J = 8.0 Hz, 2 ArH), 7.36 (d, J = 8.0 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 
17.9 (CH(CH3)CH3), 19.4 (CH(CH3)CH3), 28.3 (C(CH3)3), 30.6 (CH(CH3)2), 43.1 (NHCH2Ph), 
60.2 (CH), 69.9 (CH2O), 79.9 (C(CH3)3), 102.6 (d, J = 24.8 Hz, C4’ or C2’), 107.7 (d, J = 20.9 
Hz, C2’ or C4’), 110.7 (d, J = 3.1 Hz, C6’), 127.8 (d, J = 13.9 Hz, C1’), 129.3 (ArC), 130.2 (d, J 
= 10.0 Hz, C5’), 135.7 (ArC), 138.1 (ArC), 155.9 (OC(O)), 160.0 (d, J = 10.8 Hz, C4), 163.6 
(d, J = 243.9 Hz, C3’), 171.7 (CC(O)); LRMS (ESI) 563.10 [M + Cs
+] (calcd for 
C24H31FN2O4Cs
+ 563.10); Anal. Calcd for C24H31FN2O4: C, 66.96; H, 7.26; F, 4.41; N, 6.51. 
Found: C, 67.01; H, 7.33; F, 4.27; N, 6.43. 
 
 274 
 
 
(R)-N-4-((3-Fluoro)phenoxymethyl)benzyl 2-Amino-3-methylbutanamide ((R)-258). 
Utilizing Method B and using (R)-N-4-((3-fluoro)phenoxymethyl)benzyl 2-N‟-(t-
butoxycarbonyl)amino-3-methylbutanamide (3.00 g, 6.97 mmol), TFA (7.77 mL, 0.10 mol), 
and CH2Cl2 (23 mL) gave the crude product after basic workup that was further purified by 
flash column chromatography (SiO2; 1:100–1:10 MeOH/CH2Cl2) to give the desired 
compound (0.92 g, 40%) as a white solid: mp 78–79 ºC; [α]25D +17.5° (c 1.1, CH2Cl2); Rf 
0.50 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3418, 3222, 2919, 2861, 1641, 1459, 1375, 1268, 
1136, 1017, 960, 819, 776, 723 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.84 (d, J = 6.8 Hz, 
CH(CH3)CH3), 1.00 (d, J = 7.2 Hz, CH(CH3)CH3), 1.26–1.58 (br s, NH2), 2.33–2.41 (m, 
CH(CH3)2), 3.29 (d, J = 3.6 Hz, CH), 4.41–4.52 (m, NHCH2Ph), 5.03 (s, OCH2), 6.64–6.69 
(m, 2 ArH), 6.73–6.76 (m, 1 ArH), 7.12–7.39 (m, 5 ArH), 7.62–7.84 (br t, NHCH2Ph); 
13C 
NMR (100 MHz, CDCl3) δ 16.2 (CH(CH3)CH3), 20.0 (CH(CH3)CH3), 31.0 (CH(CH3)2), 43.0 
(NHCH2Ph), 60.4 (CH), 70.1 (CH2O), 102.8 (d, J = 24.4 Hz, C4’ or C2’), 108.0 (d, J = 21.2 Hz, 
C2’ or C4’), 110.8 (d, J = 2.6 Hz, C6’), 128.2 (d, J = 23.1 Hz, C1’), 129.5 (ArC), 130.4 (d, J = 
9.7 Hz, C5’), 135.8 (ArC), 138.9 (ArC), 160.2 (d, J = 11.0 Hz, C4), 163.8 (d, J = 243.7 Hz, 
C3’), 174.5 (C(O)); HRMS (ESI) 331.1828 [M + H
+] (calcd for C19H23FN2O2H
+ 331.1822); 
Anal. Calcd for C19H23FN2O2: C, 69.07; H, 7.02; F, 5.75; N, 8.48. Found: C, 68.77; H, 7.03; 
F, 5.48; N, 8.43. 
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(S)-N-4-((3-Fluoro)phenoxymethyl)benzyl 2-Amino-3-methylbutanamide ((S)-258). The 
previous procedure was repeated using (S)-N-4-((3-fluoro)phenoxymethyl)benzyl 2-N‟-(t-
butoxycarbonyl)amino-3-methylbutanamide (4.00 g, 9.30 mmol), TFA (10.36 mL, 0.14 mol), 
and CH2Cl2 (30 mL) to give the crude product after basic workup that was further purified by 
flash column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) 
to give the desired compound (2.67 g, 87%) as a white solid: mp 75–76 ºC; [α]28D –18.2° (c 
1.2, CH2Cl2); Rf 0.45 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2902 (br), 1640, 1522, 1459, 
1377, 1268, 1137, 1017, 958, 812, 778, 722 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.84 (d, J = 
7.0 Hz, CH(CH3)CH3), 0.99 (d, J = 7.0 Hz, CH(CH3)CH3), 1.20–1.52 (br s, NH2), 2.34–2.40 
(m, CH(CH3)2), 3.24–3.34 (br d, CH), 4.41–4.52 (m, NHCH2Ph), 5.02 (s, OCH2), 6.64–6.70 
(m, 2 ArH), 6.73–6.76 (m, 1 ArH), 7.12–7.25 (m, 1 ArH), 7.30 (d, J = 8.2 Hz, 2 ArH), 7.38 (d, 
J = 8.2 Hz, 2 ArH), 7.64–7.70 (br t, NHCH2Ph); 
13C NMR (100 MHz, CDCl3) δ 16.0 
(CH(CH3)CH3), 19.7 (CH(CH3)CH3), 30.8 (CH(CH3)2), 42.8 (NHCH2Ph), 60.1 (CH), 69.9 
(CH2O), 102.6 (d, J = 24.7 Hz, C4’ or C2’), 107.8 (d, J = 20.9 Hz, C2’ or C4’), 110.5 (d, J = 2.4 
Hz, C6’), 128.2 (d, J = 23.2 Hz, C1’), 129.3 (ArC), 130.2 (d, J = 10.0 Hz, C5’), 135.6 (ArC), 
138.6 (ArC), 160.0 (d, J = 10.8 Hz, C4), 163.6 (d, J = 243.9 Hz, C3’), 174.3 (C(O)); LRMS 
(ESI) 331.14 [M + H+] (calcd for C19H23FN2O2H
+ 331.14);  Anal. Calcd for C19H23FN2O2: C, 
69.07; H, 7.02; F, 5.75; N, 8.48. Found: C, 69.29; H, 7.06; F, 5.48; N, 8.60. 
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4-((5-(4-Chloro)phenyl)furan-2-carboxamido)benzyl O-(t-Butyl)carbamate (331). 5-(4-
Chloro)phenyl-2-furoic acid (2.00 g, 8.98 mmol) was dissolved in anhydrous CH2Cl2 (90 mL) 
and treated with oxalyl chloride (1.16 mL, 13.48 mmol) and DMF (0.20 mL, cat.). The 
reaction was stirred at room temperature (2 h) and the solvent evaporated in vacuo. The 
crude acid chloride was dissolved in anhydrous CH2Cl2 (18 mL) and treated with N-(t-
butoxycarbonyl) 4-(aminomethyl)aniline (2.00 g, 8.98 mmol) and Et3N (2.75 mL, 19.76 
mmol). The reaction was maintained at room temperature (2 h) before the solvent was 
evaporated in vacuo. The crude product was diluted with CH2Cl2 (30 mL) and successively 
washed with aqueous 1 M HCl (3 x 50 mL) and saturated aqueous brine (3 x 50 mL), dried 
(Na2SO4), and evaporated in vacuo to give the crude compound (3.66 mg, 96%) as an 
orange solid. The crude product was used for the next step without further purification: Rf 
0.84 (1:20 MeOH/CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 1.47  (s, C(CH3)3), 4.31 (d, J = 5.6 
Hz, NHCH2), 4.79–4.91 (br t, NHCH2), 6.79 (d, J = 3.2 Hz, 1 furanH), 7.29–7.32 (m, 1 
furanH, 2 ArH), 7.43 (d, J = 8.4 Hz, 2 ArH), 7.64 (d, J = 8.4 Hz, 2 ArH), 7.68 (d, J = 8.4 Hz, 2 
ArH), 8.05 (s, NH). 
 
 
4-((5-(4-Chloro)phenyl)furan-2-carboxamido)benzylamine (332). Utilizing Method B and 
using 4-((5-(4-Chloro)phenyl)furan-2-carboxamido)benzyl O-(t-butyl)carbamate (1.60 g, 3.75 
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mmol), TFA (4.18 mL, 56.32 mmol), and CH2Cl2 (13 mL) gave the crude product (1.11 g, 
91%) after basic workup as an orange solid. The crude product was used for the next step 
without further purification: Rf 0.34 (100% MeOH); 
1H NMR (400 MHz, DMSO-d6) δ 3.48–
3.67 (br s, NH2), 3.79 (s, CH2), 7.23 (d, J = 4.0 Hz, 1 furanH), 7.36 (d, J = 8.4 Hz, 2 ArH), 
7.42 (d, J = 4.0 Hz, 1 furanH), 7.57 (d, J = 8.4 Hz, 2 ArH), 7.71 (d, J = 8.4 Hz, 2 ArH), 8.02 
(d, J = 8.4 Hz, 2 ArH), 10.21 (s, NH); 13C NMR (100 MHz, DMSO-d6) δ 45.0 (CH2), 109.0 
(furan C3 or C4), 117.4 (furan C4 or C3), 121.0, 126.7, 128.0, 128.6, 129.4, 133.6, 137.3, 
138.3 (2 C6H4), 147.4 (furan C2), 154.4 (furan C5 or C(O)N), 156.3 (C(O)N or furan C5).  
 
 
(R)-4-((5-(4-Chloro)phenyl)furan-2-carboxamido)benzyl 2-N’-(t-Butoxycarbonyl)amino-
3-methylbutanamide ((R)-333). Utilizing Method A and using (R)-2-N-(t-
butoxycarbonyl)amino-3-methylbutanoic acid (0.70 g, 3.22 mmol), NMM (0.46 mL, 4.19 
mmol), IBCF (0.45 mL, 3.55 mmol), and 4-((5-(4-chloro)phenyl)furan-2-
carboxamido)benzylamine (1.10 g, 3.39 mmol) in anhydrous THF (40 mL) gave the crude 
product that was purified by recrystallization from hot EtOAc/hexanes to give the desired 
compound (0.87 g, 52%) as an orange solid: mp 204–206 ºC; [α]25D +10.7° (c 1.0, DMSO); 
Rf 0.56 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3194, 2897 (br), 1652, 1530, 1459, 1374, 1320, 
1242, 1164, 1097, 1027, 966, 808, 747, 673 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 0.83  (br 
s, CH(CH3)CH3), 0.85 (br s, CH(CH3)CH3), 1.40 (s, C(CH3)3), 1.92–1.97 (m, CH(CH3)2), 3.79 
(t, J = 7.6 Hz, CH), 4.28 (d, J = 7.2 Hz, NHCH2), 6.71 (d, J = 7.2 Hz, OC(O)NH), 7.23 (d, J = 
3.6 Hz, 1 furanH), 7.26 (d, J = 8.8 Hz, 2 ArH), 7.40 (d, J = 3.6 Hz, 1 furanH), 7.56–7.59 (m, 2 
ArH), 7.66 (d, J = 8.4 Hz, 2 ArH), 7.99–8.03 (m, 2 ArH), 8.33 (t, J = 6.0 Hz, NHCH2), 10.18 
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(s, NH); 13C NMR (100 MHz, DMSO-d6) δ 18.8 (CH(CH3)CH3), 19.7 (CH(CH3)CH3), 28.7 
(C(CH3)3), 30.6 (CH(CH3)2), 42.1 (NHCH2), 60.5 (CH), 78.4 (C(CH3)3), 109.0 (furan C3 or 
C4), 117.4 (furan C4 or C3), 121.0, 126.7, 127.9, 128.6, 129.5, 133.7, 135.4, 137.4 (2 C6H4), 
147.4 (furan C2), 154.4 (furan C5 or C(O)N), 156.0 (OC(O)N), 156.3 (C(O)N or furan C5), 
171.9 (CC(O)); HRMS (ESI) 658.1076 [M + Cs+] (calcd for C28H32ClN3O5Cs
+ 658.1085); 
Anal. Calcd for C28H32ClN3O5•0.09H2O: C, 63.74; H, 6.13; Cl, 6.74; N, 7.99. Found: C, 63.35; 
H, 6.18; Cl, 7.01; N, 7.88. 
 
 
(R)-4-((5-(4-Chloro)phenyl)furan-2-carboxamido)benzyl 2-Amino-3-methylbutanamide 
((R)-259). Utilizing Method B and using (R)-4-((5-(4-chloro)phenyl)furan-2-
carboxamido)benzyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (0.92 g, 1.75 mmol), 
TFA (1.95 mL, 26.28 mmol), and CH2Cl2 (6 mL) gave the crude product after basic workup 
that was further purified by flash column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes 
followed by 1:10 MeOH/CH2Cl2) to give the desired product (0.56 g, 75%) as an orange 
solid: mp 184–186 ºC; [α]25D –2.7° (c 1.0, DMSO); Rf 0.47 (100% MeOH); IR (nujol mull) 
2904 (br), 1644, 1601, 1542, 1458, 1375, 1166, 1090, 1030, 963, 791, 724 cm-1; 1H NMR 
(400 MHz, DMSO-d6) δ 0.80  (d, J = 6.8 Hz, CH(CH3)CH3), 0.88 (d, J = 6.8 Hz, 
CH(CH3)CH3), 1.85–2.01 (m, CH(CH3)2, NH2), 2.99–3.00 (m, CH), 4.28 (d, J = 4.8 Hz, 
NHCH2), 7.23 (d, J = 3.8 Hz, 1 furanH), 7.27 (d, J = 8.4 Hz, 2 ArH), 7.40 (d, J = 3.8 Hz, 1 
furanH), 7.57 (d, J = 8.4 Hz, 2 ArH), 7.68 (d, J = 8.4 Hz, 2 ArH), 8.01 (d, J = 8.4 Hz, 2 ArH), 
8.31 (t, J = 6.0 Hz, NHCH2), 10.18 (s, NH); 
13C NMR (100 MHz, DMSO-d6) δ 17.6 
(CH(CH3)CH3), 20.0 (CH(CH3)CH3), 32.1 (CH(CH3)2), 42.0 (NHCH2), 60.6 (CH), 109.0 (furan 
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C3 or C4), 117.4 (furan C4 or C3), 121.1, 126.7, 128.1, 128.6, 129.5, 133.6, 135.8, 137.4 (2 
C6H4), 147.4 (furan C2), 154.4 (furan C5 or C(O)N), 156.3 (C(O)N or furan C5), 175.0 
(CC(O)); HRMS (ESI) 558.0545 [M + Cs+] (calcd for C23H24ClN3O3Cs
+ 558.0560); Anal. 
Calcd for C23H24ClN3O3•0.03 EtOAc: C, 64.79; H, 5.70; Cl, 8.27; N, 9.80. Found: C, 64.41; 
H, 5.80; Cl, 8.03; N, 9.50. 
 
 
(R)-N-4’-((3’’-Fluoro)phenoxymethyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3,3-
dimethylbutanamide ((R)-313). Utilizing Method A and using (R)-2-N-(t-
butoxycarbonyl)amino-3,3-dimethylbutanoic acid (1.65 g, 7.14 mmol), NMM (1.02 mL, 9.28 
mmol), IBCF (1.01 mL, 7.85 mmol), and 4-((3-fluoro)phenoxymethyl)benzylamine (1.73 g, 
7.50 mmol) in anhydrous THF (65 mL) gave the crude product. The compound was purified 
by flash column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give a ~2:1 mixture of 
(R)-N-4‟-((3‟‟-fluoro)phenoxymethyl)benzyl 2-N‟-(t-butoxycarbonyl)amino-3,3-
dimethylbutanamide and N-4‟-((3‟‟-fluoro)phenoxymethyl)benzyl 
(isobutoxycarbonyl)carbamate (1.82 g, 57%) as a white solid. 
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(R)-N-4’-((3’’-Fluoro)phenoxymethyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-3,3-
dimethylbutanamide ((R)-313): Rf 0.88 (1:1 EtOAc/hexanes);
 1H NMR (400 MHz, CDCl3) δ 
1.00 (s, CC(CH3)3), 1.40 (s, OC(CH3)3), 3.87 (d, J = 7.6 Hz, CH), 4.36–4.40 (m, NHCHH‟), 
4.44–4.50 (m, NHCHH’), 5.01  (s, CH2O), 5.32 (d, J = 7.6 Hz, OC(O)NH), 6.42–6.48 (br t, 
NHCH2), 6.64–6.74 (m, 3 ArH), 7.18–7.49 (m, 5 ArH);
 13C NMR (100 MHz, CDCl3) δ 26.6 
(CC(CH3)3), 28.3 (OC(CH3)3), 34.4 (CC(CH3)3), 43.1 (NHCH2), 62.3 (CH), 69.9 (CH2O), 79.6 
(OC(CH3)3), 102.6 (d, J = 24.7 Hz, C4’’ or C2’’), 107.7 (d, J = 20.9 Hz, C2’’ or C4’’), 110.6 (d, J 
= 2.3 Hz, C6’’), 127.7, 127.8 (2 ArC), 130.2 (d, J = 9.3 Hz, C5’’), 135.4, 138.1 (2 ArC), 156.0 
(OC(O)), 160.0 (d, J = 10.8 Hz, C1’’), 163.6 (d, J = 243.9 Hz, C3’’), 171.2 (CC(O)); HRMS 
(ESI) 577.1479 [M + Cs+] (calcd for C25H33FN2O4Cs
+ 577.1595). 
 
 
N-4’-((3’’-Fluoro)phenoxymethyl)benzyl (Isobutoxycarbonyl)carbamate: Rf 0.92 
(1:1 EtOAc/hexanes).  1H NMR (400 MHz, CDCl3) δ 0.91 (d, J = 6.4 Hz, CH(CH3)2), 1.86–
1.95 (m, CH(CH3)2), 3.88–3.91 (br d, C(O)OCH2), 4.36–4.40 (m, NHCHH‟), 4.44–4.50 (m, 
NHCHH’), 5.02 (s, OCH2), 6.64–6.74 (m, 3 ArH), 7.18–7.49 (m, 5 ArH); 
13C NMR (100 MHz, 
CDCl3) δ 19.0 (CH(CH3)2), 28.0 (CH(CH3)2), 44.7 (NHCH2), 69.9, 71.2 (2 OCH2), 102.5 (d, J 
= 24.8 Hz, C4’’ or C2’’), 107.7 (d, J = 20.9 Hz, C2’’ or C4’’), 110.6 (d, J = 2.3 Hz, C6’’), 127.8, 
127.9 (2 ArC), 130.2 (d, J = 9.3 Hz, C5’’), 135.6, 138.8 (2 ArC), 156.9 (OC(O)), 160.0 (d, J = 
10.8 Hz, C1’’), 163.6 (d, J = 243.9 Hz, C3’’); HRMS (ESI) 464.0638 [M + Cs
+] (calcd for 
C19H22FNO3Cs
+ 464.0690). 
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(R)-N-4’-((3’’-Fluoro)phenoxymethyl)benzyl 2-Amino-3,3-dimethylbutanamide ((R)-
261). Utilizing Method B and using (R)-N-4‟-((3‟‟-fluoro)phenoxymethyl)benzyl 2-N‟-(t-
butoxycarbonyl)amino-3,3-dimethylbutanamide (1.82 g, 4.10 mmol), TFA (4.56 mL, 61.45 
mmol), and CH2Cl2 (14 mL) gave the crude product after basic workup that was further 
purified by flash column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give the 
desired compound (1.03 g, 73%) as a white solid: mp 59–60 ºC; [α]25D +9.3° (c 1.1, CH2Cl2); 
Rf 0.30 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2732 (br), 1648, 1604, 1552, 1458, 1375, 1306, 
1132, 1031, 961, 841, 726 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.01 (s, C(CH3)3), 1.50 (s, 
NH2), 3.14 (s, CH), 4.45–4.46 (d, J = 4.2 Hz, NHCH2Ph), 5.03 (s, OCH2), 6.65–6.69 (m, 2 
ArH), 6.74–6.76 (d, J = 6.0 Hz, 1 ArH), 7.02–7.14 (br t, NHCH2), 7.19–7.25 (m, 1 ArH), 7.31–
7.32 (d, J = 5.3 Hz, 2 ArH), 7.38–7.40 (d, J = 5.3 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 
26.8 (C(CH3)3), 34.2 (C(CH3)3), 42.8 (NHCH2), 64.4 (CH), 69.9 (CH2O), 102.6 (d, J = 24.8 
Hz, C4’’ or C2’’), 107.8 (d, J = 20.9 Hz, C2’’ or C4’’), 110.6 (d, J = 3.1 Hz, C6’’), 127.8, 128.2 (2 
ArC), 130.2 (d, J = 10.1 Hz, C5’’), 135.6, 138.6 (2 ArC), 160.0 (d, J = 10.8 Hz, C1’’), 164.8 (d, 
J = 243.9 Hz, C3’’), 173.4 (C(O)); HRMS (ESI) 345.1977 [M + H
+] (calcd for C20H25FN2O2H
+ 
345.1978); Anal. Calcd for C20H25FN2O2: C, 69.74; H, 7.32; F, 5.52; N, 8.13. Found: C, 
69.76; H, 7.37; F, 5.39; N, 8.14. 
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tert-Butyl N-(4-Aminobenzyl)carbamate (323).221 Boc2O (10.59 g, 48.53 mmol) was added 
to a THF solution (55 mL) of 4-aminobenzylamine (5.00 mL, 44.12 mmol) at room 
temperature. The reaction was continued at room temperature (2 h) and then the solvent 
was evaporated in vacuo to give the crude product that was purified by column 
chromatography (SiO2; 1:10–1:0 EtOAc/hexanes) to give the desired compound (6.60 g, 
67%) as a yellow solid: mp 79–81 ºC (lit.221 mp 74–75 ºC); Rf 0.39 (1:20 MeOH/CH2Cl2); IR 
(nujol mull) 2667 (br), 1690, 1619, 1521, 1457, 1371, 1289, 1174, 1045, 1048, 946, 818, 
726 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.45 (s, C(CH3)3), 3.68 (s, NH2), 4.16 (d, J = 5.4 Hz, 
NHCH2), 4.80–4.92 (br t, NH), 6.59–6.63 (m, 2 ArH), 7.04 (d, J = 8.1 Hz, 2 ArH); 
13C NMR 
(75 MHz, CDCl3) δ 28.5 (C(CH3)3), 44.4 (NHCH2), 79.3 (C(CH3)3), 115.2, 128.8, 128.9, 145.9 
(C6H4), 156.0 (C(O)); LRMS (ESI) 245.13 [M + Na
+] (calcd for C12H18N2O2Na
+ 245.13); 
HRMS (ESI) 355.0429 [M + Cs+] (calcd for C12H18N2O2Cs
+ 355.0423). 
 
 
tert-Butyl N-(((4-(3-Fluorophenyl)sulfonamido)benzyl)carbamate (325). tert-Butyl N-(4-
aminobenzyl)carbamate (2.00 g, 9.00 mmol) was dissolved in anhydrous pyridine (18 mL) 
and cooled to 0 ºC before 3-fluorobenzenesulfonyl chloride (1.44 mL, 10.80 mmol) was 
added dropwise. The reaction was warmed to room temperature (18 h) and then cooled to 0 
ºC before neutralizing with aqueous 1 M HCl. The solution was diluted with H2O (10 mL) and 
extracted with CH2Cl2 (3 x 20 mL). The organic layers were combined and successively 
washed with H2O (2 x 50 mL) and brine (2 x 50 mL), dried (Na2SO4), evaporated in vacuo, 
and purified by column chromatography (SiO2; 1:101:1 EtOAc/hexanes) to give the desired 
product (2.93 g, 86%) as a pale yellow solid. mp 147–150 ºC; Rf 0.64 (1:20 MeOH/CH2Cl2); 
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IR (nujol mull) 3328, 3116, 2988, 2927, 2839, 1689, 1457, 1374, 1158, 725 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 1.44 (s, C(CH3)3), 4.18–4.28 (m, NHCH2), 4.82–4.92 (br t, NHCH2), 7.03 
(d, J = 8.4 Hz, 2 ArH), 7.14 (d, J = 8.4 Hz, 2 ArH), 7.20–7.56 (m, 6 ArH, NH). 13C NMR (100 
MHz, CDCl3) δ 28.3 (C(CH3)3), 43.9 (NHCH2), 79.7 (C(CH3)3), 114.6 (d, J =  24.8 Hz, C2’ or 
C4’), 120.2 (d, J = 21.0 Hz, C4’ or C2’), 122.1 (ArC), 122.9 (d, J = 3.1 Hz, C6’), 128.3 (ArC), 
130.8 (d, J = 7.7 Hz, C5’), 135.1, 136.5 (2 ArC), 141.0 (d, J = 7.0 Hz, C1’), 156.0 (C(O)), 
162.3 (d, J = 250.9 Hz, C3’), two aromatic peaks were not detected and are believed to 
overlap with nearby signals; HRMS (ESI) 513.0255 [M + Cs+] (calcd for C18H21FN2O4SCs
+ 
513.0260). 
 
 
(4-((-3-Fluorophenyl)sulfonamido)phenyl)benzylamine Trifluoroacetate (326). tert-Butyl 
N-(((4-(3-fluorophenyl)sulfonamido)benzyl)carbamate (2.75 g, 7.23 mmol) was dissolved in 
anhydrous CH2Cl2 (70 mL) and cooled to 0 ºC before TFA (8.06 mL, 0.11 mol) was added 
dropwise. The reaction was maintained at 0 ºC (1.5 h) and then the solvent was evaporated 
in vacuo to give the desired product (2.73 g, 96%) as a pale yellow solid. The product was 
used in the next step without further purification: mp 209–211 ºC; Rf 0.00 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 3416, 3308, 2858 (br), 1659, 1516, 1458, 1380, 1332, 1196, 
1145, 924, 849, 794, 723 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 3.34–3.46 (br s, NH), 3.92 
(s, NHCH2), 7.14 (d, J = 8.8 Hz, 2 ArH), 7.33 (d, J = 8.8, 2 ArH), 7.47–7.64 (m, 4 ArH), 8.06–
8.21 (br s, NH3); 
13C NMR (100 MHz, DMSO-d6) δ 41.6 (CH2), 113.6 (d, J =  24.1 Hz, C2’ or 
C4’), 119.9 (ArC), 120.2 (d, J = 20.9 Hz, C4’ or C2’), 122.9 (d, J = 3.1 Hz, C6’), 129.7, 129.9 (2 
ArC), 131.7 (d, J = 7.8 Hz, C5’), 137.4 (ArC), 141.3 (d, J = 7.0 Hz, C1’), 161.5 (d, J = 247.8 
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Hz, C3’), two aromatic peaks were not detected and are believed to overlap with nearby 
signals. 
 
 
(R)-N-(4-((-3-Fluorophenyl)sulfonamido)phenyl)benzyl 2-N’-(t-Butoxycarbonyl)amino-
3,3-dimethylbutanamide ((R)-327). Utilizing Method A and using (R)-2-N-(t-
butoxycarbonyl)amino-3,3-dimethylbutanoic acid (1.40 g, 6.06 mmol), NMM (1.41 mL, 15.48 
mmol), IBCF (0.56 mL, 6.66 mmol), and (4-((-3-
fluorophenyl)sulfonamido)phenyl)benzylamine trifluroracetate (2.50 g, 7.61 mmol) in 
anhydrous THF (75 mL) gave the crude product that was purified by flash column 
chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give the desired compound (1.91 g, 
64%) as a pale yellow solid with minor impurities: 1H NMR (400 MHz, CDCl3) δ 1.00 (s, 
CC(CH3)3), 1.39 (s, OC(CH3)3), 4.09–4.15 (m, CH), 4.27–4.44 (m, NHCH2), 5.18 (s, NHSO2), 
5.70 (d, J = 9.6 Hz OC(O)NH), 6.93–7.63 (m, 8 ArH, NHCH2). 
 
 
(R)-N-(4-((-3-Fluorophenyl)sulfonamido)phenyl)benzyl 2-Amino-3,3-
dimethylbutanamide ((R)-262). Utilizing Method B and using (R)-N-(4-((-3-
fluorophenyl)sulfonamido)phenyl)benzyl 2-N‟-(t-butoxycarbonyl)amino-3,3-
dimethylbutanamide (1.80 g, 3.65 mmol), TFA (4.07 mL, 54.75 mol), and CH2Cl2 (12 mL) 
gave the crude product after basic workup as a yellow oil: 1H NMR (400 MHz, CDCl3) δ 0.84 
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(s, C(CH3)3), 3.71 (d, J = 6.8 Hz, CH), 4.04–4.17 (m, NHCH2), 6.90–7.56 (m, 8 ArH, NHSO2), 
8.09 (t, J = 5.6 Hz, NHCH2); The 
1H NMR spectrum showed a small amount of EtOAc along 
with other minor impurities. 
 
 
(R)-N,N-Dimethylamino-3-methylbutanoic acid ((R)-334).220 D-Valine (10.00 g, 85.41 
mmol) was dissolved in H2O (450 mL) and formaldehyde (37% w/w, 13.86 mL, 0.17 mol) 
and 10% Pd-C (10.00 g) were added. The mixture was hydrogenated (1 atm) at room 
temperature (5 d), and then heated to reflux (10 min). The mixture was filtered through a 
bed of Celite® (3x) and the filtrate was evaporated in vacuo. The crude solid was dissolved 
in a 7:1 mixture of EtOH/H2O and then evaporated in vacuo (5x) and then recrystallized from 
hot EtOH/acetone to give the desired product (11.89 g, 96%) as a white solid: mp 187–188 
ºC (lit.219 (S): mp 154 ºC); [α]28D –33.6° (c 2.1, EtOH); (lit.
219 (S): [α]16D +40.1° (c 2.02, 
EtOH)); IR (nujol mull) 2947 (br), 1726, 1459, 1373, 1196, 994, 884, 737 cm-1; 1H NMR (400 
MHz, DMSO-d6) δ 0.96 (d, J = 6.8 Hz, CH(CH3)CH3), 1.08 (d, J = 6.8 Hz, CH(CH3)CH3), 
2.31–2.42 (m, CH(CH3)2), 2.80 (s, N(CH3)2), 3.91 (d, J = 4.8 Hz, CH); 
13C NMR (400 MHz, 
DMSO-d6) δ 17.5 (CH(CH3)CH3), 20.7 (CH(CH3)CH3), 26.6 (CH(CH3)2), 41.7 (N(CH3)2), 71.9 
(CH), 168.7 (C(O)); LRMS (ESI) 146.11 [M + H+] (calcd for C7H15NO2H
+ 146.11). 
 
 
(R)-N-Benzyl N,N-Dimethylamino-3-methylbutanamide ((R)-270). (R)-N,N-
Dimethylamino-3-methylbutanoic acid (2.28 g, 15.71 mmol) and benzylamine (2.06 mL, 
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18.86 mmol) were added to anhydrous THF (160 mL) at room temperature. The mixture 
stirred (15 min) and then DMTMM (5.22 g, 18.86 mmol) was added in one portion. The 
reaction continued at room temperature overnight (18 h) and then the insoluble salts were 
filtered, evaporated in vacuo, and purified by flash column chromatography (SiO2; 2:1 
EtOAc/CH2Cl2 followed by 10% MeOH/CH2Cl2) to give the desired product (0.38 g, 10%) as 
a white solid: mp 78–79 ºC; [α]28D –11.2° (c 0.5, CHCl3); Rf 0.55 (1:20 MeOH/CH2Cl2); IR 
(nujol mull) 2850 (br), 1635, 1555, 1458, 1375, 1234, 1034, 747, 700 cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.89 (d, J = 6.6 Hz, CH(CH3)CH3), 1.03 (d, J = 6.6 Hz, CH(CH3)CH3), 2.04–
2.17 (m, CH(CH3)2), 2.25 (s, N(CH3)2), 2.48 (d, J = 6.0 Hz, CH), 4.42–4.51 (m, NHCH2Ph), 
6.58–6.65 (br t, NH), 7.25–7.35 (m, C6H5); 
13C NMR (100 MHz, CDCl3) δ 17.5 
(CH(CH3)CH3), 20.2 (CH(CH3)CH3), 27.7 (CH(CH3)2), 43.0, 43.1 (NHCH2Ph, N(CH3)2), 76.3 
(CH), 127.4, 128.0, 128.6, 138.5 (C6H5), 171.3 (C(O)); LRMS (ESI) 235.17 [M + H
+] (calcd 
for C14H22N2OH
+ 235.17); Anal. Calcd for C14H22N2O: C, 71.76; H, 9.46; N, 11.95. Found: C, 
71.50; H, 9.29; N, 11.94. 
 
 
(R)-N-Benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutane-thioamide ((R)-335). (R)-N-
Benzyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (4.00 g, 13.06 mmol) was 
dissolved in anhydrous THF (130 mL) and Lawesson‟s reagent (5.81 g, 14.37 mmol) was 
added at room temperature. The reaction was heated at reflux (4 h) and a second portion of 
Lawesson‟s reagent (5.81 g, 14.37 mmol) was added. The reaction was continued at reflux 
(18 h) before the solvent was evaproated in vacuo. The crude product was purified twice by 
flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes followed by 1:10 
MeOH/CH2Cl2) to give the desired compound (3.18 g, 76%) as a pale yellow oil with minor 
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impurities: Rf 0.28 (1:10 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 0.94 (d, J = 6.4 Hz, 
CH(CH3)2), 1.37 (s, C(CH3)3), 2.20–2.38 (br m, CH(CH3)2), 4.14 (t, J = 7.2 Hz, CH), 4.78 (dd, 
J = 5.2, 14.8 Hz, NHCHH‟), 4.90 (dd, J = 5.2, 14.8 Hz, NHCHH’), 5.18–5.38 (br d, C(O)NH), 
7.24–7.35 (m, C6H5), 8.38–8.48 (br t, C(S)NH); 
13C NMR (100 MHz, CDCl3) δ 18.1 
(CH(CH3)CH3), 19.7 (CH(CH3)CH3), 28.3 (C(CH3)3), 33.2 (CH(CH3)2), 49.7 (NHCH2), 66.9 
(CH), 80.2 (C(CH3)3), 128.0, 128.2, 128.9, 136.0 (C6H5), 155.9 (C(O)), 204.4 (C(S)); HRMS 
(ESI) 455.0786 [M + Cs+] (calcd for C17H26N2O2SCs
+ 455.0769). 
 
 
(R)-N-Benzyl 2-Amino-3-methylbutane-thioamide ((R)-271). Utilizing Method B and using 
(R)-N-benzyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutane-thioamide (1.72 g, 5.34 mmol), 
TFA (5.95 mL, 80.08 mmol), and CH2Cl2 (18 mL) gave the crude product after acidic workup 
and further purified by flash column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 
1:10 MeOH/CH2Cl2) to give the desired compound (0.89 g, 76%) as a yellow oil: [α]
28.5
D 
+43.7° (c 1.0, CHCl3); Rf 0.50 (1:1 EtOAc/hexanes); IR (neat) 3253, 3201, 3035, 2959, 
2873, 1601, 1520, 1456, 1382, 1327, 1362, 1181, 1068, 960, 740, 701 cm-1;  1H NMR (400 
MHz, CDCl3) δ 0.72 (d, J = 6.8 Hz, CH(CH3)CH3), 1.07 (d, J = 6.8 Hz, CH(CH3)CH3), 1.36 (s, 
NH2), 2.75–2.87 (m, CH(CH3)2), 3.78 (d, J = 2.8 Hz, CH), 4.84 (dd, J = 4.6, 15.0 Hz, 
NHCHH‟), 4.91 (dd, J = 5.0, 15.0 Hz, NHCHH’), 7.29–7.38 (m, C6H5), 9.75–9.95 (br s, NH); 
13C NMR (100 MHz, CDCl3) δ 14.4 (CH(CH3)CH3), 20.6 (CH(CH3)CH3), 32.9 (CH(CH3)2), 
49.2 (NHCH2), 66.6 (CH), 127.9, 128.2, 128.8, 136.5 (C6H5), 205.0 (C(S)); LRMS (ESI) 
223.13 [M + H+] (calcd for C12H18N2SH
+ 223.14); Anal. Calcd for C12H18N2S: C, 64.82; H, 
8.16; N, 12.60. Found: C, 64.71; H, 8.24; N, 12.45. 
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(R)-1-N-Benzylamino-2-amino-3-methylbutane ((R)-272).196 (R)-N-Benzyl 2-amino-3-
methylbutanamide (3.38 g, 16.40 mmol) was dissolved in anhydrous THF (65 mL) and 
cooled to 0 ºC. BH3•THF (1 M, 49.19 mL, 49.19 mmol) was added dropwise and the mixture 
was heated to reflux (18 h). The mixture was cooled to 0 ºC and aqueous 0.5 M HCl (100 
mL) was slowly added. The THF was evaporated in vacuo and Et2O (100 mL) was added to 
the acidic aqueous solution. The aqueous layer was separated and the organic layer was 
extracted with aqueous 0.5 M HCl (3 x 50 mL). All of the aqueous layers were combined and 
washed with Et2O (2 x 100 mL). The aqueous layer was basified to pH 10–12 using aqueous 
4 M NaOH and extracted with CH2Cl2 (3 x 100 mL). The CH2Cl2 layers were combined and 
were successively washed with a 1:1 mixture of EtOH/H2O (2 x 100 mL) and saturated 
aqueous brine (2 x 100 mL), dried (Na2SO4), evaporated in vacuo, and purified three times 
by flash column chromatography (SiO2; 1:100 MeOH/CH2Cl2) to give the desired product 
(0.53 g, 17%) as a pale yellow oil: [α]28D –31.4° (c 0.51, CH2Cl2) (lit.
196 [α]20D –30.4° (c 0.55, 
CH2Cl2)), [α]
28
D –31.4° (c 1.9, CHCl3) (lit.
235 (S): [α]25.4D +33.4° (c 1.80, CHCl3)); Rf 0.53 (1:20 
MeOH/CH2Cl2); IR (neat) 3318, 3210, 3062, 2958, 2877, 1595, 1458, 1368, 1114, 1028, 
851, 740, 701 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.90 (d, J = 6.8 Hz, CH(CH3)2), 1.58–1.69 
(m, CH(CH3)2), 2.42–2.48 (m, CHH‟NH, NH2), 2.64–2.69 (m, CH), 2.74 (dd, J = 3.2, 12.0 Hz, 
CHH’NH), 3.78 (1/2 ABq, J = 13.4 Hz, CHH‟Ph), 3.84 (1/2 ABq, J = 13.4 Hz, CHH’Ph), 7.22–
7.35 (m, C6H5); 
13C NMR (100 MHz, CDCl3) δ 18.0, 19.2 (CH(CH3)2), 32.0 (CH(CH3)2), 52.6, 
53.8, 56.5 (CH, CH2NHCH2), 127.0, 128.2, 128.4, 140.0 (C6H5); HRMS (ESI) 193.1705 [M + 
H+] (calcd for C12H20N2H
+ 193.1695); Anal. Calcd for C12H20N2•H2O: C, 68.53; H, 10.54; N, 
13.32. Found: C, 68.13; H, 10.97; N, 12.92. 
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(R)-N-Methyl-N-methoxy 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-
337).236 (R)-2-N-(t-Butoxycarbonyl)amino-3-methylbutanoic acid (5.00 g, 23.03 mmol) was 
dissolved in anhydrous THF (75 mL) and then 2-chloro-4,6-dimethoxy-1,3,5-triazine (4.85 g, 
27.63 mmol) and NMM (7.60 mL, 69.08 mmol) were successively added leading to the 
precipitation of a white solid. The mixture stirred at room temperature (30 min) and then 
N,O-dimethylhydroxylamine hydrochloride (2.25 g, 23.03 mmol) was added. The mixture 
stirred at room temperature (18 h) and then the reaction was quenched with H2O (75 mL) 
and extracted with Et2O (3 x 75 mL). All of the organic layers were combined and were 
successively washed with saturated aqueous Na2CO3 (2 x 100 mL), aqueous 1 M HCl (2 x 
100 mL), and saturated aqueous brine (2 x 100 mL). The organic layer was dried (Na2SO4) 
and evaporated in vacuo to give the desired product (5.89 g, 98%) as a white solid. The 
product was used for the next step without further purification: Rf 0.25 (1:10 
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 0.91 (d, J = 6.8 Hz, CH(CH3)CH3), 0.96 (d, J 
= 6.8 Hz, CH(CH3)CH3), 1.44 (s, C(CH3)3), 1.94–2.05 (m, CH(CH3)2), 3.22 (s, NCH3), 3.78 (s, 
OCH3), 4.52–4.64 (br m, CH), 5.16 (d, J = 8.8 Hz, NH); 
13C NMR (100 MHz, CDCl3) δ 17.4 
(CH(CH3)CH3), 19.3 (CH(CH3)CH3), 28.3 (C(CH3)3), 31.3, 31.8 (CH(CH3)2, NCH3), 54.9 
(CH), 61.5 (OCH3), 79.3 (C(CH3)3), 155.8 (OC(O)), 172.9 (CC(O)); LRMS (ESI) 283.15 [M + 
Na+] (calcd for C12H24N2O2Na
+ 283.15). 
 
 
(R)-4-N-(t-Butoxycarbonyl)amino-5-methyl-1-phenyl-3-hexanone ((R)-336).237,238 To 
anhydrous Et2O (130 mL) was added magnesium turnings (1.69 g, 69.42 mmol) and 2-
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(bromoethyl)benzene (8.97 mL, 65.45 mmol) in a 3 neck round bottom flask that was fitted 
with a thermometer and a condensor. An ice bath was applied when the reaction reached 40 
ºC (5 min) and was removed when the reaction cooled to 20 ºC. The reaction was continued 
at room temperature (1.5 h) and then an anhydrous Et2O solution (50 mL) of (R)-N-methyl-
N-methoxy 2-N’-(t-butoxycarbonyl)amino-3-methylbutanamide (5.16 g, 19.83 mmol) was 
added to the reaction via a cannula. An ice bath was applied when the reaction reached 40 
ºC (10 min) and was removed when the reaction cooled to 20 ºC. The reaction was 
continued at room temperature (1.5 h) and then was quenched with aqueous 1 M HCl (100 
mL). The organic layer was separated and washed with saturated aqueous brine (2 x 100 
mL), dried (Na2SO4), evaporated in vacuo, and purified by flash column chromatography 
(SiO2; 1:20 EtOAc/hexanes) to give the desired product (4.32 g, 71%) as a colorless oil: 
[α]28D –40.7° (c 2.2, CHCl3); Rf 0.52 (1:10 EtOAc/hexanes); IR (neat) 3342, 2970, 1709, 
1501, 1368, 1308, 1244, 1169, 1079, 1021, 872, 748, 701 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 0.70 (d, J = 6.8 Hz, CH(CH3)CH3), 0.96 (d, J = 6.8 Hz, CH(CH3)CH3), 1.44 (s, C(CH3)3), 
2.07–2.15 (m, CH(CH3)2), 2.74–2.95 (m, CH2CH2Ph), 4.26 (dd, J = 4.2, 8.5 Hz, CH), 5.11 (d, 
J = 8.5 Hz, NH), 7.15–7.29 (m, C6H5); 
13C NMR (100 MHz, CDCl3) δ 16.6 (CH(CH3)CH3), 
19.9 (CH(CH3)CH3), 28.3 (C(CH3)3), 29.4 (CH2CH2Ph), 30.1 (CH(CH3)2), 42.4 (CH2CH2Ph), 
64.0 (CH), 79.6 (C(CH3)3), 126.2, 128.3, 128.5, 140.8 (C6H5), 155.9 (OC(O)), 208.7 (CC(O)); 
HRMS (ESI) 438.1025 [M + Cs+] (calcd for C18H27NO3Cs
+ 438.1045). 
 
 
(R)-4-Amino-2-methyl-6-phenyl-4-hexanone Hydrochloride ((R)-273). (R)-4-N-(t-
Butoxycarbonyl)amino-5-methyl-1-phenyl-3-hexanone (3.04 g, 9.96 mmol) was dissolved in 
MeOH (50 mL) and aqueous concentrated HCl (4.92 mL, 0.20 mol) was added. The reaction 
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was heated at reflux (1 h) and then cooled to room temperature before evaporating the 
solvent in vacuo to give a crude oil. The crude product was triturated with hexanes (3x) to 
give the desired product (0.60 g, 25%) as a white solid: mp 123–124 ºC; [α]28D –59.7° (c 1.1, 
CHCl3); Rf 0.49 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2919 (br), 1716, 1590, 1458, 1375, 
1284, 1078, 980, 926, 751, 703 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.97 (d, J = 7.0 Hz, 
CH(CH3)CH3), 1.17 (d, J = 7.0 Hz, CH(CH3)CH3), 2.34–2.44 (br m, CH(CH3)2), 2.56–2.98 (m, 
CH2CH2Ph), 4.18–4.26 (br d, CH), 7.16–7.24 (m, C6H5), 8.57 (br s, NH3); 
13C NMR (100 
MHz, CDCl3) δ 17.1 (CH(CH3)CH3), 19.3 (CH(CH3)CH3), 29.0, 29.1 (CH(CH3)2, CH2CH2Ph), 
42.4 (CH2CH2Ph), 64.2 (CH), 126.3, 128.4, 128.5, 140.3 (C6H5), 204.7 (C(O)); LRMS (ESI) 
206.13 [M - Cl-] (calcd for C13H20NO 206.13); Anal. Calcd for C13H20ClNO: C, 64.59; H, 8.34; 
Cl, 14.66; N, 5.79. Found: C, 64.53; H, 8.47; Cl, 14.44; N, 5.78. 
 
 
(R)-O-Benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanoate ((R)-338).228,239 Et3N 
(2.38 mL, 17.13 mmol) was added to a solution of (R)-2-N-(t-butoxycarbonyl)amino-3-
methylbutanoic acid (3.72 g, 17.13 mmol) in anhydrous CH2Cl2 (60 mL) at 0 ºC. After the 
reaction was stirred at 0 ºC (10 min), benzyl chloroformate (2.41 mL, 17.13 mmol) was 
added dropwise. The reaction was continued at 0 ºC (10 min) and DMAP (0.21 g, 1.71 
mmol) was added. The reaction was continued at 0 ºC (30 min) and then the solution was 
diluted with CH2Cl2 (40 mL), successively washed with saturated NaHCO3 (2 x 100 mL), 
aqueous 0.1 M HCl (2 x 100 mL), and saturated aqueous brine (2 x 100 mL), dried 
(Na2SO4), and evaporated in vacuo. The crude product was purified by flash column 
chromatography (SiO2; 1:20 EtOAc/hexanes) to give the desired product (2.65 g, 50%) as a 
colorless oil: [α]28.5D +27.8° (c 1.1, MeOH) (lit.
239 [α]20D +32.1° (c 1.08, MeOH)); Rf 0.53 (1:10 
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EtOAc/hexanes); IR (neat) 2970, 1716, 1504, 1368, 1251, 1166, 1090, 1011, 747, 699 cm-1; 
1H NMR (400 MHz, CDCl3) δ 0.85 (d, J = 6.4 Hz, CH(CH3)CH3), 0.94 (d, J = 6.4 Hz, 
CH(CH3)CH3), 1.44 (s, C(CH3)3), 2.10–2.19 (m, CH(CH3)2), 4.27 (dd, J = 4.6, 8.8 Hz, CH), 
5.03 (d, J = 8.8 Hz, NH), 5.11–5.22 (m, OCH2), 7.32–7.36 (m, C6H5); 
13C NMR (100 MHz, 
CDCl3) δ 17.4 (CH(CH3)CH3), 19.0 (CH(CH3)CH3), 28.3 (C(CH3)3), 31.3 (CH(CH3)2), 58.5 
(CH), 66.8 (OCH2), 79.7 (C(CH3)3), 128.3, 128.4, 128.5, 135.4 (C6H5), 155.6 (OC(O)), 172.2 
(CC(O)). 
 
 
(R)-O-Benzyl 2-Amino-3-methylbutanoate ((R)-274).240 1 M HCl in Et2O (165 mL) was 
added to a Et2O solution (10 mL) of  (R)-O-benzyl 2-N‟-(t-butoxycarbonyl)amino-3-
methylbutanoate (2.02 g, 6.58 mmol) at 0 ºC. The reaction was stirred at room temperature 
(18 h) to give a cloudy white solution. The solution was filtered but no substantial filtrate was 
collected. The solvent was evaporated in vacuo to give a crude oil that was then redissolved 
in CH2Cl2 (10 mL). The organic layer was extracted with aqueous 1 M HCl (3 x 10 mL). The 
aqueous layers were combined and washed with CH2Cl2 (2 x 30 mL). The aqueous layer 
was basified to pH 10–12 with aqueous 4 M NaOH and extracted with CH2Cl2 (3 x 50 mL). 
The second set of organic layers were combined and washed with saturated aqueous brine 
(2 x 150 mL), dried (Na2SO4), and evaporated in vacuo. The crude product was purified by 
flash column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) 
to give the desired product (0.99 g, 72%) as a pale yellow oil: [α]28.5D –10.2° (c 1.1, CHCl3); 
Rf 0.39 (1:1 EtOAc/hexanes); IR (neat) 2962, 1602, 1460, 1378, 1163, 984, 912, 819, 747, 
700 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.88 (d, J = 7.0 Hz, CH(CH3)CH3), 0.96 (d, J = 7.0 
Hz, CH(CH3)CH3), 1.44 (s, NH2), 1.99–2.10 (m, CH(CH3)2), 3.34 (d, J = Hz, CH), 5.14 (1/2 
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ABq, J = 12.2 Hz, OCHH‟), 5.18 (1/2 ABq, J = 12.2 Hz, OCHH’), 7.30–7.39 (m, C6H5); 
13C 
NMR (100 MHz, CDCl3) δ 17.1 (CH(CH3)CH3), 19.3 (CH(CH3)CH3), 32.1 (CH(CH3)2), 59.9 
(CH), 66.5 (OCH2), 128.3, 128.4, 128.5, 135.8 (C6H5), 175.4 (C(O)); LRMS (ESI) 208.15 [M 
+ H+] (calcd for C12H17NO2H
+ 208.15); Anal. Calcd for C12H17NO2: C, 69.54; H, 8.27; N, 6.76. 
Found: C, 69.28; H, 8.44; N, 6.80. 
 
 
(R)-N-Phenyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-343).241 Utilizing 
Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (2.42 g, 11.15 
mmol), NMM (1.59 mL, 14.49 mmol), IBCF (1.58 mL, 12.26 mmol), and aniline (1.07 mL, 
11.70 mmol) in anhydrous THF (110 mL) gave the crude product that was purified by flash 
column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give the desired product (2.17 
g, 67%) as a pale orange solid: mp 178–179 ºC; [α]25D +37.0° (c 1.1, CH2Cl2); Rf 0.24 (1:10 
EtOAc/hexanes); IR (nujol mull) 3264, 3185, 2725 (br), 1677, 1606, 1457, 1375, 1297, 1167, 
726 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.01  (d, J = 6.8 Hz, CH(CH3)CH3), 1.04 (d, J = 6.8 
Hz, CH(CH3)CH3), 1.44 (s, C(CH3)3), 2.18–2.22 (m, CH(CH3)2), 4.09 (t, J = 6.4 Hz, 
CHCH(CH3)2), 5.36–5.38 (br d, OC(O)NH), 7.06 (br t, 1 ArH), 7.25 (d, J = 7.8 Hz, 2 ArH), 
7.48 (d, J = 7.8 Hz, 2 ArH), 8.38–8.49 (br s, NHPh); 13C NMR (100 MHz, CDCl3) δ 18.4 
(CH(CH3)CH3), 19.4 (CH(CH3)CH3), 28.3 (C(CH3)3), 30.9 (CH(CH3)2),  61.0 (CH), 80.1 
(C(CH3)3), 120.0, 124.2, 128.8, 137.7 (C6H5), 156.5 (OC(O)), 170.7 (CC(O)); HRMS (ESI) 
315.1685 [M + Na+] (calcd for C16H24N2O3Na
+ 315.1685); Anal. Calcd for C16H24N2O3: C, 
65.73; H, 8.27; N, 9.58. Found: C, 65.47; H, 8.32; N, 9.71. 
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(R)-N-Phenyl 2-Amino-3-methylbutanamide ((R)-275).242 Utilizing Method B and using 
(R)-N-phenyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (1.75 g, 5.99 mmol), TFA 
(6.67 mL, 89.84 mmol), and CH2Cl2 (20 mL) gave the crude product after acidic workup and 
was further purified by flash column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes 
followed by 1:10 MeOH/CH2Cl2) to give the desired compound (0.94 g, 82%) as a pale 
orange oil: [α]25D +82.5° (c 1.6, CH2Cl2); Rf 0.34 (1:1 EtOAc/hexanes); IR (neat) 3059, 2878 
(br), 1662, 1599, 1515, 1444, 1382, 1312, 1246, 1173, 1049, 1030, 982, 882, 753, 699 cm-1; 
1H NMR (400 MHz, CDCl3) δ 0.87  (d, J = 7.2 Hz, CH(CH3)CH3), 1.04 (d, J = 7.2 Hz, 
CH(CH3)CH3), 1.46 (s, NH2), 2.40–2.48 (m, CH(CH3)2), 3.37 (d, J = 3.6 Hz, CH), 7.09 (t, J = 
7.2 Hz, 1 ArH), 7.32 (t, J = 8.2 Hz, 2 ArH), 7.60 (d, J = 8.2 Hz, 2 ArH), 9.46–9.56 (br s, NH); 
13C NMR (100 MHz, CDCl3) δ 16.0 (CH(CH3)CH3), 19.8 (CH(CH3)CH3), 30.8 (CH(CH3)2),  
60.4 (CH), 119.4, 124.0, 128.9, 137.8 (C6H5), 172.6 (C(O)); HRMS (ESI) 193.1343 [M + H
+] 
(calcd for C11H16N2OH
+ 193.1341); Anal. Calcd for C11H16N2O•0.01H2O: C, 68.65; H, 8.39; N, 
14.56. Found: C, 68.27; H, 8.41; N, 14.32. 
 
 
(R)-N-Phenethyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-344). Utilizing 
Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (2.40 g, 11.05 
mmol), NMM (1.58 mL, 14.37 mmol), IBCF (1.57 mL, 12.16 mmol), and phenylethylamine 
(1.46 mL, 11.61 mmol) in anhydrous THF (110 mL) gave the crude product that was purified 
by flash column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes) to give the desired 
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compound (1.87 g, 53%) as a white solid: mp 121–122 ºC; [α]25D +10.7° (c 1.0, CH2Cl2); Rf 
0.77 (1:1 EtOAc/hexanes); IR (nujol mull) 2728 (br), 1653, 1457, 1375, 1162, 725 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 0.86  (d, J = 7.0 Hz, CH(CH3)CH3), 0.91 (d, J = 7.0 Hz, 
CH(CH3)CH3), 1.43 (s, C(CH3)3), 2.01–2.16 (m, CH(CH3)2), 2.81 (t, J = 6.8 Hz, CH2Ph), 
3.44–3.52 (m, NHCHH‟), 3.54–3.63 (m, NHCHH’), 3.81 (dd, J = 6.4, 8.8 Hz, CH), 4.98–5.14 
(br d, NH), 5.88–5.61 (br t, NH), 7.18–7.32 (m, C6H5); 
13C NMR (100 MHz, CDCl3) δ 17.8 
(CH(CH3)CH3), 19.2 (CH(CH3)CH3), 28.3 (C(CH3)3), 30.8 (CH(CH3)2), 35.8 (CH2Ph), 40.6 
(NHCH2), 60.1 (CH), 79.8 (C(CH3)3), 126.5, 128.6, 128.7, 138.7 (C6H5), 155.9 (OC(O)), 
171.5 (CC(O)); HRMS (ESI) 453.1151 [M + Cs+] (calcd for C18H28N2O3Cs
+ 453.1154); Anal. 
Calcd for C18H28N2O3•0.01H2O: C, 67.43; H, 8.81; N, 8.74. Found: C, 67.04; H, 8.93; N, 
8.97.  
 
 
(R)-N-Phenethyl 2-Amino-3-methylbutanamide ((R)-276). Utilizing Method B and using 
(R)-N-phenethyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (1.37 g, 4.28 mmol), 
TFA (4.77 mL, 64.18 mmol), and CH2Cl2 (15 mL) gave the crude product after acidic workup 
and further purified by flash column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes 
followed by 1:10 MeOH/CH2Cl2) to give the desired compound (873 mg, 93%) as a pale 
yellow solid: mp 36–37 ºC; [α]25D +32.9° (c 1.0, CH2Cl2); Rf 0.19 (1:20 MeOH/CH2Cl2); IR 
(nujol mull) 3199 (br), 1656, 1524, 1458, 1371, 1243, 1085, 1035, 895, 745, 700 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 0.77  (d, J = 7.2 Hz, CH(CH3)CH3), 0.96 (d, J = 7.2 Hz, 
CH(CH3)CH3), 1.20–1.26 (s, NH2), 2.22–2.33 (m, CH(CH3)2), 2.77–2.88 (m, CH2Ph), 3.19 (d, 
J = 4.0 Hz, CH), 3.46–3.62 (m, NHCH2), 7.20–7.32 (m, C6H5); 
13C NMR (100 MHz, CDCl3) δ 
15.9 (CH(CH3)CH3), 19.7 (CH(CH3)CH3), 30.7 (CH(CH3)2), 35.9 (CH2Ph), 40.1 (NHCH2), 
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60.2 (CH), 126.4, 128.5, 128.7, 130.6 (C6H5), 174.2 (C(O)); HRMS (ESI) 221.1643 [M + H
+] 
(calcd for C13H20N2OH
+ 221.1654); Anal. Calcd for C13H20N2O: C, 70.87; H, 9.15; N, 12.72. 
Found: C, 70.65; H, 9.15; N, 12.72. 
 
 
(R)-N-Phenylpropyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-345). 
Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (4.00 
g, 18.42 mmol), NMM (2.63 mL, 23.95 mmol), IBCF (2.61 mL, 20.26 mmol), and 3-phenyl-1-
propylamine (2.76 mL, 19.34 mmol) in anhydrous THF (185 mL) gave the crude product that 
was purified by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) to give the 
desired compound (6.08 g, 99%) as a white solid: mp 77–78 ºC; [α]28.5D +11.1° (c 1.1, 
CHCl3); Rf 0.88 (1:1 EtOAc/hexanes); IR (nujol mull) 3137, 2726 (br), 1681, 1527, 1457, 
1373, 1304, 1247, 1169, 1021, 929, 733 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.91 (d, J = 7.2 
Hz, CH(CH3)CH3), 0.95 (d, J = 6.4 Hz, CH(CH3)CH3), 1.43 (s, C(CH3)3), 1.79–1.86 (m, 
NHCH2CH2), 2.04–2.14 (m, CH(CH3)2), 2.63 (t, J = 8.0 Hz, CH2Ph), 3.20–3.35 (m, NHCH2),  
3.86 (dd, J = 7.0, 8.5 Hz, CH),  5.16 (d, J = 8.5 Hz, OC(O)NH), 6.32 (br t, CC(O)NH), 7.15–
7.20 (m, 3 ArH), 7.25–7.29 (m, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH(CH3)CH3), 
19.3 (CH(CH3)CH3), 28.3 (C(CH3)3), 30.8 (CH(CH3)2), 31.2 (NHCH2CH2), 33.2 (CH2Ph), 39.0 
(NHCH2), 60.2 (CH), 79.8 (C(CH3)3), 126.0, 128.3, 128.4, 141.4 (C6H5), 156.0 (OC(O)), 
171.6 (CC(O)); LRMS (ESI) 357.23 [M + Na+] (calcd for C19H30N2O3Na
+ 357.23); Anal. Calcd 
for C19H30N2O3: C, 68.23; H, 9.04; N, 8.38. Found: C, 68.51; H, 9.14; N, 8.24. 
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(R)-N-Phenylpropyl 2-Amino-3-methylbutanamide ((R)-277). Utilizing Method B and 
using (R)-N-phenylpropyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (5.00 g, 14.96 
mmol), TFA (16.67 mL, 0.22 mol), and CH2Cl2 (50 mL) gave the crude product after acidic 
workup and further purified by flash column chromatography (SiO2; 1:20 EtOAc/hexanes 
followed by 1:10 MeOH/CH2Cl2) to give the desired compound (3.02 g, 86%) as a pale 
yellow oil: [α]28.5D +30.1° (c 1.2, CHCl3); Rf 0.21 (1:1 EtOAc/hexanes); IR (neat) 3138, 2953 
(br), 2870, 1953, 1878, 1806, 1651, 1533, 1457, 1369, 1303, 1240, 1188, 1092, 1036, 898, 
746, 700 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.81 (d, J = 7.2 Hz, CH(CH3)CH3), 0.98 (d, J = 
7.2 Hz, CH(CH3)CH3), 1.30 (s, NH2), 1.79–1.90 (m, NHCH2CH2), 2.23–2.34 (m, CH(CH3)2), 
2.65 (t, J = 8.4 Hz, CH2Ph), 3.19 (d, J = 4.0 Hz, CH), 3.22–3.37 (m, NHCH2), 7.16–7.20 (m, 
3 ArH), 7.26–7.35 (m, 2 ArH, NH); 13C NMR (100 MHz, CDCl3) δ 16.0 (CH(CH3)CH3), 19.7 
(CH(CH3)CH3),  30.8 (CH(CH3)2), 31.3 (NHCH2CH2), 33.4 (CH2Ph), 38.6 (NHCH2), 60.2 
(CH), 125.9, 128.4, 128.4, 141.6 (C6H5), 174.3 (C(O)); HRMS (ESI) 235.1818 [M + H
+] 
(calcd for C14H22N2OH
+ 235.1810); Anal. Calcd for C14H22N2O•0.16H2O: C, 70.87; H, 9.48; N, 
11.81. Found: C, 70.48; H, 9.60; N, 11.72. 
 
 
(R)-N-Phenylbutyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-346). 
Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (4.24 
g, 19.53 mmol), NMM (2.79 mL, 25.39 mmol), IBCF (2.77 mL, 21.48 mmol), and 4-
phenylbutylamine (3.24 mL, 20.50 mmol) in anhydrous THF (195 mL) gave the crude 
product that was purified by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) 
to give the desired compound (3.75 g, 55%) as a white solid: mp 73–74 ºC; [α]28.5D +12.8° (c 
1.0, CHCl3); Rf 0.89 (1:1 EtOAc/hexanes); IR (nujol mull) 3139, 2917 (br), 1650, 1530, 1458, 
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1374, 1303, 1250, 1171, 1023, 926, 744, 697 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.91 (d, J = 
7.0 Hz, CH(CH3)CH3), 0.94 (d, J = 7.0 Hz, CH(CH3)CH3), 1.42 (s, C(CH3)3), 1.48–1.58 (m, 
NHCH2CH2 or CH2CH2Ph), 1.59–1.68 (m, CH2CH2Ph or NHCH2CH2), 2.04–2.14 (CH(CH3)2), 
2.62 (t, J = 7.6 Hz, CH2Ph), 3.19–3.34 (m, NHCH2), 3.84 (dd, J = 6.4, 8.8 Hz, CH), 5.10–
5.12 (br d, OC(O)NH), 6.10–6.16 (br t, CC(O)NH), 7.14–7.19 (m, 3 ArH), 7.25–7.28 (m, 2 
ArH); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH(CH3)CH3), 19.3 (CH(CH3)CH3), 28.3 
(C(CH3)3), 28.6 (CH2CH2Ph or NHCH2CH2), 29.2 (NHCH2CH2 or CH2CH2Ph), 30.8 
(CH(CH3)2), 35.4 (CH2Ph), 39.2 (NHCH2), 60.2 (CH), 79.8 (C(CH3)3), 125.8, 128.3, 128.4, 
142.0 (C6H5), 155.9 (OC(O)), 171.6 (CC(O)); LRMS (ESI) 371.24 [M + Na
+] (calcd for 
C20H32N2O3Na
+ 371.24); Anal. Calcd for C20H32N2O3: C, 68.93; H, 9.26; N, 8.04. Found: C, 
68.94; H, 9.44; N, 8.14. 
 
 
(R)-N-Phenylbutyl 2-Amino-3-methylbutanamide ((R)-278). Utilizing Method B and using 
(R)-N-phenylbutyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (3.18 g, 9.13 mmol), 
TFA (10.17 mL, 0.14 mol), and CH2Cl2 (30 mL) gave the crude product after basic workup 
that was further purified by flash column chromatography (SiO2; 1:20 EtOAc/hexanes 
followed by 1:10 MeOH/CH2Cl2) to give the desired compound (2.16 g, 96%) as a pale 
yellow oil: [α]28.5D +29.9° (c 1.0, CHCl3); Rf 0.53 (1:20 MeOH/CH2Cl2); IR (neat) 3126, 3005, 
2817 (br), 1652, 1530, 1458, 1371, 1302, 1240, 1180, 1091, 744, 700  cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.81 (d, J = 6.8 Hz, CH(CH3)CH3), 0.97 (d, J = 6.8 Hz, CH(CH3)CH3), 1.51–
1.59 (m, NHCH2CH2 or CH2CH2Ph, NH2), 1.62–1.70 (m, CH2CH2Ph or NHCH2CH2), 2.22–
2.34 (m, CH(CH3)2), 2.63 (t, J = 8.0 Hz, CH2CH2Ph), 3.20 (d, J = 4.0 Hz, CH), 3.22–3.44 (m, 
NHCH2), 7.15–7.19 (m, 3 ArH), 7.25–7.36 (m, 2 ArH, NH); 
13C NMR (100 MHz, CDCl3) δ 
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16.0 (CH(CH3)CH3), 19.7 (CH(CH3)CH3), 28.7 (CH2CH2Ph or NHCH2CH2), 29.3 (NHCH2CH2 
or CH2CH2Ph), 30.8 (CH(CH3)2), 35.5 (CH2Ph), 38.8 (NHCH2), 60.2 (CH), 125.8, 128.3, 
128.4, 142.2 (C6H5), 174.3 (C(O)); HRMS (ESI) 249.1954 [M + H
+] (calcd for C15H24N2OH
+ 
249.1967); Anal. Calcd for C15H24N2O•0.0.6CH2Cl2: C, 71.29; H, 9.58; N, 11.04. Found: C, 
71.01; H, 9.75; N, 10.88. 
 
 
(R)-N-2’-(Trifluoromethoxy)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide 
((R)-349). Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic 
acid (4.00 g, 18.42 mmol), NMM (2.63 mL, 23.95 mmol), IBCF (2.61 mL, 20.26 mmol), and 
2-(trifluoromethoxy)benzylamine (2.91 mL, 19.34 mmol) in anhydrous THF (185 mL) gave 
the crude product that was purified by flash column chromatography (SiO2; 1:20–1:1 
EtOAc/hexanes) to give the desired compound (6.20 g, 86%) as a white solid: mp 133–134 
ºC; [α]28.5D +11.1° (c 1.1, CHCl3); Rf 0.91 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2918 (br), 
1657, 1526, 1458, 1375, 1162, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.90 (d, J = 6.6 Hz, 
CH(CH3)CH3), 0.95 (d, J = 6.6 Hz, CH(CH3)CH3), 1.42 (s, C(CH3)3), 2.12–2.22 (m, 
CH(CH3)2), 3.89 (dd, J = 6.4, 8.8 Hz, CH), 4.53 (d, J = 6.0 Hz, NHCH2), 4.94–5.04 (br d, 
OC(O)NH), 6.24–6.36 (br t, CC(O)NH), 7.23–7.34 (m, 3 ArH), 7.40–7.42 (m, 1 ArH); 13C 
NMR (100 MHz, CDCl3) δ 17.7 (C(CH3)CH3), 19.3 (C(CH3)CH3), 28.3 (C(CH3)3), 30.5 
(CH(CH3)2), 38.1 (NHCH2), 60.3 (CH), 80.1 (C(CH3)3), 120.5 (1 ArC), 120.6 (q, J = 257.1 Hz, 
OCF3), 127.1, 129.0, 130.2, 130.5 (4 ArC), 147.3 (COCF3), 155.9 (OC(O)), 171.7 (CC(O)); 
LRMS (ESI) 413.15 [M + Na+] (calcd for C18H25F3N2O4Na
+ 413.15); Anal. Calcd for 
C18H25F3N2O4: C, 55.38; H, 6.45; F, 14.60; N, 7.18. Found: C, 55.31; H, 6.52; F, 14.51; N, 
7.15. 
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(R)-N-2’-(Trifluoromethoxy)benzyl 2-Amino-3-methylbutanamide ((R)-279). Utilizing 
Method B and using (R)-N-2‟-(trifluoromethoxy)benzyl 2-N‟-(t-butoxycarbonyl)amino-3-
methylbutanamide (6.00 g, 15.38 mmol), TFA (17.13 mL, 0.23 mol), and CH2Cl2 (50 mL) 
gave the crude product after acidic workup that was further purified by flash column 
chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the 
desired compound (3.70 g, 83%) as a pale yellow solid: mp 54–55 ºC; [α]28.5D +28.0° (c 1.0, 
CHCl3); Rf 0.59 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2954 (br), 1638, 1458, 1373, 1257, 
1160, 897, 727 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.81 (d, J = 6.8 Hz, CH(CH3)CH3), 0.98 
(d, J = 6.8 Hz, CH(CH3)CH3), 1.34 (s, NH2), 2.28–2.39 (m, CH(CH3)2), 3.27 (d, J = 4.0 Hz, 
CH), 4.48–4.57 (m, NHCH2), 7.22–7.33 (m, 3 ArH), 7.41–7.43 (m, 1 ArH), 7.71–7.79 (br t, 
NH); 13C NMR (100 MHz, CDCl3) δ 15.9 (C(CH3)CH3), 19.7 (C(CH3)CH3), 30.8 (CH(CH3)2), 
37.7 (NHCH2), 60.2 (CH), 120.5 (ArC), 120.6 (q, J = 256.4 Hz, OCF3), 127.1, 128.8, 130.3, 
131.2 (4 ArC), 147.4 (COCF3), 174.5 (C(O)); LRMS (ESI) 291.12 [M + H
+] (calcd for 
C13H17F3N2O2H
+ 291.12); Anal. Calcd for C13H17F3N2O2: C, 53.79; H, 5.90; F, 19.63; N, 9.65. 
Found: C, 53.80; H, 5.83; F, 19.37; N, 9.45. 
 
 
(R)-N-3’-(Trifluoromethoxy)benzyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide 
((R)-350). Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic 
acid (2.20 g, 10.13 mmol), NMM (1.45 mL, 13.17 mmol), IBCF (1.43 mL, 11.15 mmol), and 
3-(trifluoromethoxy)benzylamine (1.60 mL, 10.64 mmol) in anhydrous THF (100 mL) gave 
the crude product that was purified by flash column chromatography (SiO2; 1:20–1:1 
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EtOAc/hexanes) to give the desired compound (3.26 g, 82%) as a white solid: mp 103–104 
ºC; [α]28.5D +12.9° (c 1.0, CHCl3); Rf 0.88 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2917 (br), 
1646, 1458, 1375, 1166, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.93 (d, J = 7.0 Hz, 
CH(CH3)CH3), 0.96 (d, J = 7.0 Hz, CH(CH3)CH3), 1.41 (s, C(CH3)3), 2.09–2.22 (m, 
CH(CH3)2), 3.94 (dd, J = 6.9, 9.0 Hz, CH), 4.41 (dd, J = 6.0, 15.2 Hz, NHCHH‟), 4.52 (dd, J = 
6.0, 15.2 Hz, NHCHH’), 5.13 (d, J = 6.9 Hz, OC(O)NH), 6.72–6.78 (br t, CC(O)NH), 7.10–
7.11 (m, 2 ArH), 7.18–7.20 (m, 1 ArH), 7.30–7.34 (m, 1 ArH); 13C NMR (100 MHz, CDCl3) δ 
17.9 (CH(CH3)CH3), 19.4 (CH(CH3)CH3), 28.3 (C(CH3)3), 30.6 (CH(CH3)2), 42.7 (NHCH2), 
60.3 (CH), 80.1 (C(CH3)3), 119.8 (1 ArC), 120.4 (q, J = 255.6 Hz, OCF3), 120.0, 125.9, 
130.0, 140.7 (4 ArC), 149.5 (COCF3), 156.1 (OC(O)), 172.0 (CC(O)); LRMS (ESI) 413.14 [M 
+ Na+] (calcd for C18H25F3N2O4Na
+ 413.14); Anal. Calcd for C18H25F3N2O4: C, 55.38; H, 6.45; 
F, 14.60; N, 7.18. Found: C, 55.31; H, 6.46; F, 14.77; N, 7.08. 
 
 
(R)-N-3’-(Trifluoromethoxy)benzyl 2-Amino-3-methylbutanamide ((R)-280). Utilizing 
Method B and using (R)-N-3‟-(trifluoromethoxy)benzyl 2-N‟-(t-butoxycarbonyl)amino-3-
methylbutanamide (3.00 g, 7.69 mmol), TFA (8.57 mL, 0.12 mol), and CH2Cl2 (25 mL) gave 
the crude product after acidic workup that was further purified by flash column 
chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the 
desired compound (1.81 g, 81%) as a pale yellow oil: [α]28.5D +20.6° (c 1.3, CHCl3); Rf 0.47 
(1:20 MeOH/CH2Cl2); IR (neat) 3325, 3077, 2963, 2471, 1657, 1253, 1454, 1358, 1261, 
1166, 1088, 1025, 964, 874, 794, 699 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.83 (d, J = 7.0 Hz, 
CH(CH3)CH3), 1.00 (d, J = 7.0 Hz, CH(CH3)CH3), 1.38 (s, NH2), 2.31–2.40 (m, CH(CH3)2), 
3.30 (d, J = 4.0 Hz, CH), 4.43 (dd, J = 6.2, 15.0 Hz, NHCHH‟), 4.51 (dd, J = 6.6, 15.0 Hz, 
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NHCHH’), 7.10–7.13 (m, 2 ArH), 7.21–7.22 (m, 1 ArH), 7.34 (t, J = 8.0 Hz, 1 ArH), 7.78–
7.86 (br t, NH); 13C NMR (100 MHz, CDCl3) δ 16.0 (C(CH3)CH3), 19.7 (C(CH3)CH3), 30.8 
(CH(CH3)2), 42.5 (NHCH2), 60.2 (CH), 119.7, 120.0 (2 ArC), 120.5 (q, J = 256.3 Hz, OCF3), 
126.0, 130.0, 141.3 (3 ArC), 149.5 (COCF3), 174.6 (C(O)); LRMS (ESI) 291.11 [M + H
+] 
(calcd for C13H17F3N2O2H
+ 291.11); Anal. Calcd for C13H17F3N2O4: C, 53.79; H, 5.90; F, 
19.63; N, 9.65. Found: C, 53.55; H, 6.11; F, 19.63; N, 9.66. 
 
 
(R)-N-Cyclohexylmethyl 2-N’-(t-Butoxycarbonyl)amino-3-methylbutanamide ((R)-352). 
Utilizing Method A and using (R)-2-N-(t-butoxycarbonyl)amino-3-methylbutanoic acid (4.00 
g, 18.42 mmol), NMM (2.63 mL, 23.95 mmol), IBCF (2.61 mL, 20.26 mmol), and 
cyclohexylmethylamine (2.52 mL, 19.34 mmol) in anhydrous THF (185 mL) gave the crude 
product that was purified by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) 
to give the desired compound (5.01 g, 87%) as a white solid: mp 141–142 ºC; [α]28D +18.2° 
(c 1.1, CHCl3); Rf 0.88 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2919 (br), 1651, 1529, 1458, 
1375, 1307, 1249, 1170 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.87–0.97 (m, 2 cyclohexyl H), 
0.92 (d, J = 7.0 Hz, CH(CH3)CH3), 0.96 (d, J = 7.0 Hz, CH(CH3)CH3), 1.09–1.28 (m, 3 
cyclohexyl H), 1.44 (s, C(CH3)3), 1.64–1.74 (m, 6 cyclohexyl H), 2.06–2.20 (m, CH(CH3)2), 
3.05–3.16 (m, NHCH2), 3.83 (dd, J = 6.4, 8.8 Hz, NHCH), 5.04–5.10 (br d, OC(O)NH), 5.98–
6.08 (br t, NHCH2); 
13C NMR (100 MHz, CDCl3) δ 17.9 (CH(CH3)CH3), 19.4 (CH(CH3)CH3), 
25.8, 26.4 (2 cyclohexyl C), 28.3 (C(CH3)3), 30.6, 30.8 (CH(CH3)2, cyclohexyl C), 37.9 
(cyclohexyl C), 45.7 (NHCH2), 60.4 (CH), 79.9 (C(CH3)3), 155.9 (OC(O)), 171.6 (CC(O)); 
LRMS (ESI) 335.21 [M + Na+] (calcd for C17H32N2O3Na
+ 335.21); Anal. Calcd for 
C17H32N2O3: C, 65.35; H, 10.32; N, 8.97. Found: C, 65.39; H, 10.35; N, 8.84. 
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(R)-N-Cyclohexylmethyl 2-Amino-3-methylbutanamide ((R)-281). Utilizing Method B and 
using (R)-N-cyclohexylmethyl 2-N‟-(t-butoxycarbonyl)amino-3-methylbutanamide (3.60 g, 
11.53 mmol), TFA (12.84 mL, 0.17 mol), and CH2Cl2 (38 mL) gave the crude product after 
acidic workup that was further purified by flash column chromatography (SiO2; 1:20 
EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired compound (2.34 g, 
96%) as a white solid: mp 85–86 ºC; [α]25D +38.1° (c 1.1, CHCl3); Rf 0.59 (1:20 
MeOH/CH2Cl2); IR (nujol mull) 2934 (br), 1635, 1555, 1458, 1375, 1305, 1227, 1152, 1075, 
982, 720 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.82 (d, J = 7.0 Hz, CH(CH3)CH3), 0.89–0.99 
(m, 2 cyclohexyl H), 0.99 (d, J = 7.0 Hz, CH(CH3)CH3), 1.10–1.28 (m, 3 cyclohexyl H), 1.36 
(s, NH2), 1.41–1.52 (m, 1 cyclohexyl H), 1.65–1.74 (m, 5 cyclohexyl H), 2.26–2.37 (m, 
CH(CH3)2), 3.03–3.18 (m, NHCH2), 3.23 (d, J = 3.6 Hz, NHCH), 7.30–7.40 (br t, NH); 
13C 
NMR (100 MHz, CDCl3) δ 16.0 (CH(CH3)CH3), 19.8 (CH(CH3)CH3), 25.8, 26.4 (2 cyclohexyl 
C), 30.8, 30.9 (CH(CH3)2, cyclohexyl C), 38.0 (cyclohexyl C), 45.2 (NHCH2), 60.3 (CH), 
174.2 (C(O)); LRMS (ESI) 213.18 [M + H+] (calcd for C12H24N2OH
+ 213.18); Anal. Calcd for 
C12H24N2O: C, 67.88; H, 11.39; N, 13.19. Found: C, 67.88; H, 11.50; N, 13.02. 
 
 
N-Benzyl Butanamide (282).194,243 Utilizing Method A and using n-butanoic acid (2.00 mL, 
21.88 mmol), NMM (3.13 mL, 28.45 mmol), IBCF (3.10 mL, 24.07 mmol), and benzylamine 
(2.51 mL, 22.98 mmol) gave the crude product that was recrystallized from hot 
EtOAc/hexanes to give the desired compound (1.18 g, 30%) as a white solid: mp 54–55 C 
(lit.7 mp 36.9–38 ºC); Rf 0.67 (1:20 MeOH/CH2Cl2); IR (nujol mull) 3140, 2856 (br), 1457, 
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1375, 726 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.96 (t, J = 7.6 Hz, CH3), 1.65–1.74 (m, 
CH3CH2), 2.20 (t, J = 8.0 Hz, CH2CH2CH3), 4.45 (d, J = 5.6 Hz, NHCH2), 5.66–5.78 (br s, 
NH), 7.26–7.35 (m, C6H5); 
13C NMR (100 MHz, CDCl3) δ 13.8 (CH3), 19.2 (CH2CH3), 38.7 
(CH2CH2CH3), 43.6 (NHCH2), 127.5, 127.8, 128.7, 138.4 (C6H5), 172.7 (C(O)); HRMS (ESI) 
178.1238 [M + H+] (calcd for C11H15NOH
+ 178.1232); Anal. Calcd for C11H15NO•0.06H2O: C, 
74.06; H, 8.55; N, 7.85. Found: C, 73.72; H, 8.60; N, 7.93. 
 
 
Methyl (S)- 3-(Tetrahydro-2-pyranyloxy)-2-methylpropionate ((S)-359).230 (S)-3-Hydroxy-
2-methylpropionate (4.50 mL, 40.80 mmol) was dissolved in anhydrous Et2O (40 mL) and 
then dihydropyran (4.47 mL, 48.96 mmol) and p-toluenesulfonic acid (0.78 g, 4.08 mmol) 
were added at room temperature. The reaction was continued at room temperature (18 h) 
and then the solution was washed with saturated aqueous NaHCO3 (2 x 40 mL), dried 
(Na2SO4), and evaporated in vacuo to give a crude oil that was purified by flash column 
chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) to give the desired product (7.40 g, 90%) 
as an ~1:1 diastereomeric mixture (A,B) as a colorless oil: [α]28D +14.7° (c 3.9, Et2O) (lit.
230 
[α]25D +16.3° (c 3.9, Et2O)); Rf 0.58 (1:10 EtOAc/hexanes); IR (neat) 2944, 2875, 1739, 
1454, 1358, 1260, 1199, 1129, 1032, 974, 818 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.18 (d, J 
= 3.0 Hz) and 1.20 (d, J = 3.0 Hz) (CHCH3; A,B), 1.49–1.89 (m, OCH2CH2CH2CH2; A + B), 
2.73–2.81 (m, CHCH3; A + B), 3.42–3.62 (m, CHH‟OCHOCHH‟; A + B), 3.69 (s) and 3.70 
(s) (OCH3; A,B), 3.74–3.93 (m, CHH’OCHOCHH’; A + B), 4.60 (app t, J = 3.4 Hz) and 4.62 
(app. t, J = 3.4 Hz) (CHO; A,B); 13C NMR (100 MHz, CDCl3) δ 13.8, 13.9 (CHCH3), 19.0, 
19.2, 25.2, 30.3, 30.4 (OCH2CH2CH2CH2), 39.9, 40.1 (CHCH3), 51.5 (OCH3), 61.6, 61.9 
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(OCH2CH2), 68.9, 69.2 (OCH2CH), 98.3, 98.9 (OCHO), 175.1, 175.2 (C(O)), two peaks were 
not detected and are believed to overlap with nearby signals; LRMS (ESI) 214.11 [M + Na+] 
(calcd for C10H18O4Na
+ 214.11). 
 
 
(R)-2-Methyl-3-(tetrahydro-2-pyranyloxy)-propan-1-ol ((S)-360).230 Methyl (S)-3-
(tetrahydro-2-pyranyloxy)-2-methylpropionate (6.39 g, 31.61 mmol) was dissolved in 
anhydrous Et2O (30 mL) and added to a stirred solution of LiAlH4 (0.96 g, 25.30 mmol) in 
anhydrous Et2O (60 mL) at 0 ºC. The reaction was stirred at room temperature (18 h) and 
then cooled to 0 ºC. H2O (6.4 mL) was added to the mixture, followed by aqueous 15% 
NaOH (6.4 mL) and H2O (19.2 mL). The resulting mixture was filtered through Celite
® and 
the filtrate was evaporated in vacuo. The crude product was purified by flash column 
chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) to give the desired product (3.81 g, 98%) 
as an ~1:1 diastereomeric mixture (A,B) as a colorless oil: [α]28D +0.8° (c 1.5, Et2O) (lit.
230 
[α]25D +1.2° (c 1.5, Et2O)); Rf 0.48 (1:10 EtOAc/hexanes); IR (neat) 3225, 2944, 1457, 1356, 
1667, 1128, 1031, 902, 812 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.91 (d, J = 4.2 Hz) and 0.92 
(d, J = 4.2 Hz) (CHCH3; A,B), 1.48–2.08 (m, OCH2CH2CH2CH2, OH; A + B), 2.93–3.00 (br s, 
CHCH3; A + B), 3.34–3.47 (m, OCHH‟CH; A + B), 3.49–3.55 (m, CHH‟OCH; A + B), 3.58–
3.64 (m, CH2OH; A + B), 3.66–3.82 (m, OCHH’CH; A + B); 3.83–3.90 (m, CHH’OCH; A + 
B); 4.58 (app. t, J = 4.4 Hz, CHO; A + B); 13C NMR (100 MHz, CDCl3) δ 13.5, 13.6 (CHCH3), 
19.5, 25.2, 25.3, 30.4, 30.5 (OCH2CH2CH2CH2), 35.4, 35.6 (CHCH3), 62.3, 62.4 (OCH2CH2), 
66.7, 66.8 (CH2OH), 71.6, 71.7 (OCH2CH), 99.0, 99.2 (OCHO), one peak was not detected 
and is believed to overlap with nearby signals; LRMS (ESI) 197.10 [M + Na+] (calcd for 
C9H18O3Na
+ 197.10). 
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(S)-2-Methyl-3-(tetrahydro-2-pyranyloxy)-propyl-p-toluenesulfonate ((S)-361).230 (R)-2-
Methyl-3-(tetrahydro-2-pyranyloxy)-propan-1-ol (3.40 g, 19.53 mmol) was dissolved in 
anhydrous pyridine (25 mL) and cooled to 0 ºC and TsCl (4.84 g, 25.38 mmol) was added. 
The reaction was maintained at 5 ºC overnight (18 h) and then H2O (10 mL) was added. The 
aqueous layer was extracted with Et2O (3 x 10 mL). The Et2O layers were combined and 
successively washed with aqueous 10% citric acid (3 x 30 mL), saturated NaHCO3 (2 x 30 
mL), and saturated aqueous brine (2 x 30 mL), dried (Na2SO4), and evaporated in vacuo. 
The crude product was purified by flash column chromatography (SiO2; 1:20–1:1 
EtOAc/hexanes) to give the desired product (5.72 g, 89%) as an ~1:1 diastereomeric 
mixture (A,B) as a colorless oil: [α]28D –24.4° (c 7.1, Et2O) (lit.
230 [α]25D +6.8° (c 7.01, Et2O)); 
Rf 0.41 (1:10 EtOAc/hexanes); IR (neat) 2947, 2873, 1600, 1459, 1360, 1180, 1129, 1031, 
970, 820 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.93 (d, J = 2.4 Hz) and 0.95 (d, J = 2.4 Hz) 
(CHCH3; A,B), 1.42–1.78 (m, OCH2CH2CH2CH2, A + B), 2.05–2.15 (m, CHCH3; A + B), 2.44 
(s, PhCH3; A + B), 3.17–3.28 (m, OCHH‟CH; A + B), 3.43–3.48 (m, CHH‟OCH; A + B), 
3.56–3.64 (m, OCHH’CH; A + B), 3.71–3.78 (m, CHH’OCH; A + B), 3.93–4.14 (m, 
CH2OSO2), 4.44 (app. t, J = 3.8 Hz) and 4.47 (app. t, J = 3.8 Hz) (CHO; A,B), 7.34 (d, J = 
8.2 Hz, 2 ArH), 7.79 (d, J = 8.2 Hz, 2 ArH); 13C NMR (100 MHz, CDCl3) δ 13.5, 13.6 
(CHCH3), 19.2, 19.3, 25.3, 30.3, 30.4 (OCH2CH2CH2CH2), 21.5 (PhCH3), 33.4, 33.6 
(CHCH3), 61.9, 62.1 (OCH2CH2), 67.8, 68.3 (CH2OSO2); 72.2, 72.3 (OCH2CH), 98.5, 99.0 
(OCHO), 132.9, 133.0, 127.8, 129.7, 132.9, 133.0, 144.6 (C6H4), three peaks were not 
detected and are believed to overlap with nearby signals; LRMS (ESI) 351.11 [M + Na+] 
(calcd for C16H24O5SNa
+ 351.11). 
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(S)-1-Iodo-2-methyl-3-(tetrahydro-2-pyranyloxy)propane ((S)-363).244 A 3-neck round 
bottom flask was charged with magnesium turnings (0.17 g, 6.86 mmol) fitted with a 
thermometer and a condenser. Anhydrous Et2O (7 mL) was added and the mixture was 
cooled to 0 ºC in an ice bath before MeI (0.43 mL, 6.86 mmol) was added. The mixture was 
allowed to warm to room temperature and was maintained between 20–25 ºC by 
intermittently applying an ice bath. After all of the magnesium turning had disappeared (1 h), 
the solution was transferred via cannula to a -78 ºC THF solution (14 mL) of (S)-2-methyl-3-
(tetrahydro-2-pyranyloxy)-propyl-p-toluenesulfonate  (0.45 g, 1.37 mmol). The mixture was 
stirred (5 min) and then LiCuCl4 (0.1 M in THF, 0.27 mL) was added at -78 ºC. The mixture 
was allowed to warm to room temperature (18 h) and then washed with aqueous saturated 
NH4Cl (2 x 25 mL). The aqueous layers were combined and washed with Et2O (2 x 50 mL). 
All of the organic layers were combined and washed with H2O (2 x 50 mL), dried (Na2SO4), 
and purified by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) to give the 
starting material (0.02 g, 4%) and (S)-1-iodo-2-methyl-3-(tetrahydro-2-pyranyloxy)propane 
(0.23 g, 58%) as an ~1:1 diastereomeric mixture (A,B) as a pale yellow oil: Rf 0.61 (1:10 
EtOAc/hexanes); IR (neat) 3330, 3059 (br), 1456, 1353, 1267, 1194, 1129, 1033, 973, 903, 
813 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.99 (d, J = 6.8 Hz) and 1.02 (d, J = 6.8 Hz) (CHCH3; 
A,B), 1.51–1.86 (m, OCH2CH2CH2CH2, CHCH3; A + B), 3.17–3.38 (m, CH2I, OCHH‟CHCH3; 
A + B), 3.49–3.68 (m, OCHH’CHCH3, OCHH‟CH2; A + B), 3.66–3.82 (m, OCHH’CH2; A + 
B); 4.60 (app. t, J = 4.0 Hz, CHO; A + B); 13C NMR (100 MHz, CDCl3) δ 13.5, 14.0 (CH2I), 
17.6, 17.8 (CHCH3), 19.2, 19.5, 25.4, 30.5, 30.6 (OCH2CH2CH2CH2), 35.1, 35.3 (CHCH3), 
62.0, 62.3 (OCH2CH2), 71.0, 71.4 (OCH2CH), 98.0, 99.2 (OCHO), one peak was not 
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detected and is believed to overlap with nearby signals; HRMS (ESI) 307.0156 [M + Na+] 
(calcd for C9H17IO2Na
+ 307.0171). 
 
 
(S)-N-Benzyl 2-Methylbutanamide ((S)-283).245 Utilizing Method A and using (S)-2-
methylbutanoic acid (0.90 mL, 8.27 mmol), NMM (1.18 mL, 10.75 mmol), IBCF (1.17 mL, 
9.10 mmol), and benzylamine (0.95 mL, 8.62 mmol) gave the crude product that was 
purified twice by flash column chromatography (SiO2; 1:20 EtOAc/hexanes) to give the 
desired compound (1.01 g, 64%) as a white solid: mp 55–56 ºC; [α]28D +15.5° (c 1.0, 
acetone) (lit.245 [α]D +16.96° (c 1.0, acetone)); Rf 0.80 (1:1 EtOAc/hexanes); IR (nujol mull) 
2861 (br), 1644, 1550, 1458, 1374, 1245, 1107, 1024, 732 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 0.91 (t, J = 7.6 Hz, CH2CH3), 1.16 (d, J = 7.6 Hz, CHCH3), 1.40–1.50 (m, CHH‟CH3), 1.65–
1.75 (m, CHH’CH3), 2.09–2.18 (m, CH), 4.39–4.49 (m, NHCH2Ph), 5.80–5.88 (br s, NH), 
7.25–7.35 (m, C6H5); 
13C NMR (100 MHz, CDCl3) δ 11.9 (CH2CH3), 17.5 (CHCH3), 27.3 
(CH2CH3), 43.2, 43.4 (CH, NHCH2), 127.4, 127.7, 128.6, 138.6 (C6H5), 176.3 (C(O)); LRMS 
(ESI) 193.16 [M + H+] (calcd for C12H17NOH
+ 193.16); Anal. Calcd for C12H17NO: C, 75.35; 
H, 8.96; N, 7.32. Found: C, 75.21; H, 8.96; N, 7.36. 
 
 
(R,S)-N-Benzyl 2-Methylbutanamide ((R,S)-283).246 Utilizing Method A and using DL-2-
methylbutanoic acid (2.00 mL, 18.33 mmol), NMM (2.62 mL, 23.83 mmol), IBCF (2.60 mL, 
20.16 mmol), and benzylamine (2.10 mL, 19.25 mmol) gave the crude product that was 
purified twice by flash column chromatography (SiO2; 1:20 EtOAc/hexanes) to give the 
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desired compound (2.32 g, 66%) as a white solid: mp 54–55 ºC (lit.8 mp 47.5–48.5 ºC); Rf 
0.80 (1:1 EtOAc/hexanes); IR (nujol mull) 2967 (br), 1645. 1550. 1458. 1374, 1245, 1107, 
1024, 732 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.91 (t, J = 7.2 Hz, CH2CH3), 1.15 (d, J = 6.2 
Hz, CHCH3), 1.39–1.50 (m, CHH‟CH3), 1.64–1.75 (m, CHH’CH3), 2.09–2.17 (m, CH), 4.39–
4.49 (m, NHCH2Ph), 5.79–5.89 (br s, NH), 7.26–7.35 (m, C6H5); 
13C NMR (100 MHz, CDCl3) 
δ 12.1 (CH2CH3), 17.7 (CHCH3), 27.5 (CH2CH3), 43.4, 43.6 (CH, NHCH2), 127.6, 127.9, 
128.9, 138.8 (C6H5), 176.5 (CO); HRMS (ESI) 214.1199 [M + Na
+] (calcd for C12H17NOH
+ 
214.1208); Anal. Calcd for C12H17NO: C, 75.35; H, 8.96; N, 7.32. Found: C, 75.23; H, 8.91; 
N, 7.27. 
 
 
(R)-N-Benzyl 2-(Isobutoxycarbonyl)oxybutanamide ((R)-356). Utilizing Method A and 
using (R)-2-hydroxybutanoic acid (2.00 g, 19.21 mmol), NMM (2.75 mL, 24.98 mmol), IBCF 
(2.73 mL, 21.13 mmol), and 4-(trifluoromethoxy)benzylamine (2.20 mL, 20.17 mmol) in 
anhydrous THF (190 mL) gave the crude product that was purified by flash column 
chromatography (SiO2; 1:20–1:1 EtOAc/hexanes) to give the desired compound (1.96 g, 
35%) as a white solid: mp 67–68 ºC; Rf 0.89 (1:20 MeOH/CH2Cl2);  IR (nujol mull) 2849 (br), 
1750, 1658, 1556, 1458, 1375, 1243, 1128, 1041, 963, 789, 740 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 0.92 (s, CH(CH3)CH3‟), 0.94 (s, CH(CH3)CH3‟), 0.97 (t, J = 7.6 Hz, CH2CH3), 1.90–
2.04 (m, CH(CH3)2, CH2CH3), 3.90–3.98 (m, OCH2), 4.23–4.53 (m, NHCH2), 5.09 (dd, J = 
4.6, 6.6 Hz, CH), 6.49–6.56 (br t, NH), 7.26–7.36 (m, C6H5);  
13C NMR (100 MHz, CDCl3) δ 
8.9 (CH2CH3), 18.8 (CH(CH3)2), 25.3 (CH2CH3), 27.7 (CH(CH3)2), 43.1 (NHCH2), 74.7 
(OCH2), 78.4 (CH), 127.6, 127.7, 128.8, 137.8 (C6H5), 154.2 (OC(O)), 169.3 (C(O)); HRMS 
(ESI) 426.0667 [M + Cs+] (calcd for C16H23NO4Cs
+ 426.0681). 
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(R)-N-Benzyl 2-Hydroxybutanamide ((R)-284). To anhydrous toluene (80 mL) was added 
(R)-2-hydroxybutanoic acid (1.70 g, 16.33 mmol), benzylamine (1.78 mL, 16.33 mmol), and 
3,5-bis(trifluoromethyl)benzene boronic acid (0.42 g, 1.63 mmol). A pressure equalizing 
dropping funnel containing a cotton plug was filled 1/3 of the way with 3 Å molecular sieves 
that were oven dried (120 ºC) and a condenser was placed above the dropping funnel. The 
mixture was heated at reflux (18 h) before cooling to room temperature and then the solvent 
was evaporated in vacuo. The crude product was purified by flash column chromatography 
(SiO2; 1:20–1:1 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) followed by recrystallization 
from hot EtOAc/hexanes to give the desired compound (1.05 g, 33%) as a white solid: mp 
63–64 ºC; [α]28.5D +28.3° (c 2.2, CHCl3); Rf 0.56 (1:20 MeOH/CH2Cl2); IR (nujol mull) 2929 
(br), 1625, 1530, 1458, 1375, 1302, 1241, 1092, 1038, 985, 724 cm-1;  1H NMR (400 MHz, 
CDCl3) δ 0.96  (t, J = 7.6 Hz, CH3), 1.63–1.74 (m, CHH‟CH3), 1.82–1.92 (m, CHH’CH3), 3.32 
(d, J = 4.8 Hz, OH), 4.07–4.11 (m, CH), 4.38–4.48 (m, NHCH2), 6.95–7.20 (br t, NH), 7.24–
7.34 (m, C6H5); 
13C NMR (100 MHz, CDCl3) δ 9.1 (CH3), 27.9 (CH2CH3), 43.1 (NHCH2), 73.1 
(CH), 127.6, 127.7, 128.7, 138.0 (C6H5), 173.9 (C(O)); LRMS (ESI) 216.12 [M + Na
+] (calcd 
for C11H15NO2Na
+ 216.12); Anal. Calcd for C11H15NO2: C, 68.37; H, 7.82; N, 7.25. Found: C, 
68.36; H, 7.95; N, 7.36.  
 
4.3. Pharmacology 
Compounds (R)-126, (R)-240–242, (R)-255–258, and (R)-269 were screened under 
the auspices of UCB Pharma (Braine L‟Alleud, Belgium) following the procedures described 
in Chapter 2, Section 4.3.1. Compounds (R)-243–253, (R)-254, (R)- and (S)-255, (R)- and 
(S)-258, (R)-259–261, (R)-270–281, 282, (S)- and (R,S)-283, and (R)-284 were screened 
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under the auspices of the NINDS ASP (Rockville, MD) following the procedures described in 
Chapter 2, Section 4.3.2. Pharmacological evaluation by UCB Pharma consisted of four 
assays: the 6 Hz test and the MES test to assess anticonvulsant activity, the formalin test to 
assess neuropathic pain protection, and the rotorod test to assess neurological toxicity. 
Initial pharmacological evaluation by the NINDS ASP consisted of the MES test and the 
subcutaneous pentylenetetrazol (Metrazol®) (scMET) (mice and rats) seizure threshold test 
to assess anticonvulsant activity, the rotorod test to assess neurological toxicity (mice), and 
the positional sense test or gait and stance test to assess behavioral toxicity (rats). The 
effective dose (50%) (ED50) values were obtained in quantitative screenings for compounds 
that showed significant activity. The median doses for neurological impairment (50%) (TD50) 
in mice using the rotorod test, and the behavioral toxicity effects observed in rats were 
reported, when applicable. TD50 values were determined for those compounds that 
demonstrated significant activity in the MES test.  
 CHAPTER 4. Exploring the Mechanism of Action of 
PAADs
  
1. Introduction 
Our initial objective was to develop a class of compounds that could selectively 
target PNS sites, thereby reducing neurological toxicities typically associated with CNS 
active drugs. We proposed that PAADs represented an ideal class of compounds that may 
be able to achieve PNS selectivity because the presence of the protonated primary amine at 
physiological pH would allow both greater diversity of hydrophilic substituents at the C(2) 
and N-benzylamide sites, and prevent the transport of PAADs across the predominantly 
negatively charged BBB. We have demonstrated that several unsubstituted and substituted 
C(3)-O-methoxy and C(2)-hydrocarbon PAADs attenuate pain ((R)-95, (R)-96, (R)-98, (R)-
99, (R)-255, (R)-258), possibly by interaction with PNS targets, but these PAADs also 
possess significant anticonvulsant activity. The observed anticonvulsant activities indicate 
that PAADs readily penetrate the BBB, demonstrating that PAADs do not selectively target 
the PNS, but rather possibly exert their mechanism of action through a combination of 
interactions within the CNS and PNS. The brain:plasma ratio quantification of (R)-61, (R)-65, 
and (R)-77 (Table 4) confirmed that PAADs indeed penetrate the CNS. Therefore, we 
amend our original hypothesis and no longer propose that PAADs are PNS-selective 
agents. 
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Comparison of the PAADs with their corresponding FAAs suggests that the PAADs 
could be exerting their mechanism of action by one of three pathways: (1) interaction with 
receptor binding sites that are involved in FAA function; (2) interaction with receptor binding 
sites that are not involved with FAA function; or (3) a combination of both.  
The C(3)-alkoxy PAADs possibly follow scenario one and interact with similar 
receptor binding sites as the C(3)-alkoxy FAAs. We found that these PAADs followed the 
C(3)-alkoxy SAR trends of the corresponding C(3)-alkoxy FAAs, but the PAADs were 10-fold 
less effective in seizure prevention (Table 6). Several factors may account for this decrease 
in anticonvulsant activity. These include the binding affinity of the drug candidate with their 
cognate receptors, the susceptibility of the PAAD to metabolism, and the CNS concentration 
levels. Without specific information concerning the target(s) of PAAD function, we are not 
able to speculate if the PAADs bind weaker to molecular targets responsible for 
anticonvulsant activity. It is difficult to attribute the reduced PAAD potency solely to reduced 
levels in the CNS, since (R)-61 displayed a brain:plasma ratio of 1.2:1. Correspondingly, 
lacosamide ((R)-28) has ~100% bioavailability,247 but we recognize that the reported 
bioavailability does not provide information or the blood-to-plasma distribution.  A more likely 
cause for the 10-fold reduction in activity could be due to enhanced PAAD metabolism 
compared with its FAA counterpart. Lacosamide ((R)-28) undergoes negligible phase I 
metabolism.248 In proceeding from FAA (R)-28 to PAAD (R)-61, the terminal amide in the 
FAA has been converted to an amine. This structural change could permit phase I 
metabolism (e.g., deamination, hydroxylation) processes and/or phase II metabolism (e.g., 
methylation, sulphation, acetylation, glucuronidation).249 It is also feasible that PAADs may 
bind to serum proteins to a greater extent than their corresponding FAAs, resulting in a 
lower amount of PAAD available to bind to its receptor sites. (R)-28 has relatively low protein 
binding (<15%).247 If the C(3)-alkoxy PAADs do interact with similar targets as their 
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corresponding C(3)-alkoxy FAAs, then left unexplained is the pronounced loss of 
stereospecificity for the (R)-stereoisomer observed for the PAAD in comparison to the FAA. 
The C(2)-aromatic and C(2)-heteroaromatic PAADs pose a greater dilemma. Indeed, 
we do not consistently see evidence of key hallmarks of the FAA activity profile in the PAAD 
series. For example, inclusion of a heteroatom one atom removed from the C(2) site led, in 
some cases, to improved anticonvulsant activity ((R,S)-62 versus (R,S)-77). Nonetheless, 
notable exceptions were observed ((R,S)-62 versus (R,S)-94), and the improvement in 
anticonvulsant activity with heteroatom inclusion in the PAAD series was far less than in the 
FAA series.55-57 Also, confounding our interpretation of the data was the enhanced pain 
protection for several C(2)-heteroaromatic PAADs compared with their anticonvulsant 
activity. Therefore, the C(2)-heteroaromatic PAADs may be functioning by scenario three, 
since there was a preferred selectivity for pain attenuation over anticonvulsant activity.  
It is possible that the C(2)-hydrocarbon PAADs follow scenario two since they have a 
unique SAR. Most important, the FAA counterparts of the C(2)-hydrocarbon PAADs (e.g., 
FAA (R)-237 versus PAAD (R)-98; FAA (R)-238 versus PAAD (R)-99) displayed either 
minimal or no seizure protection in the MES test (Table 16), while the structurally similar 
PAADs showed excellent anticonvulsant activity. Further examination of Sites A–F of the 
C(2)-hydrocarbon PAADs revealed that a number of alterations to the PAAD structural 
backbone still produced pronounced pharmacological effects (Tables 30–35), while similar 
changes in the FAA structural backbone abolished activity. This structural flexibility with 
respect to pharmacology suggests that C(2)-hydrocarbon PAADs may interact with receptor 
binding sites not involved with FAA function. Furthermore, the observed SAR suggests that 
the receptor binding sites may not be size-limiting, but rather accommodates compounds of 
various sizes, and relies on both hydrogen bonding and hydrophobic interactions. 
Collectively, while PAADs may function at receptor sites not involved in FAA function, at this 
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time we cannot exclude the possibility of PAAD interaction with receptor sites involved in 
FAAs function.  
Lacosamide ((R)-28) did not significantly bind to more than 100 receptors in a variety 
of radioligand binding assays (<20% inhibition at 10 µM) or inhibit neurotransmission 
(norepinephrine, dopamine, 5-HT, GABA) (<20% inhibition at 10 µM), and only weak binding 
was observed at the site 2 of VGSCs (~25% at 10 µM).250 The molecular mode of action of 
(R)-28 remains elusive but recent electrophysiology studies suggests that (R)-28 selectively 
promotes the enhancement of sodium channels into the slow inactivated state (reviewed in 
Section 2.1.2).63,64 However, it is difficult to determine which receptors are involved in FAA 
function due to the lack of binding in the lacosamide target identification experiments.  
In this chapter, we continue our studies and focus on the C(3)-O-methoxy PAADs 
and the C(2)-hydrocarbon PAADs due to their excellent anticonvulsant activities in animal 
models. In an attempt to identify possible PAAD molecular target(s), we screened 17 PAADs 
in in vitro radioligand competition binding assays against 44 receptors, as well as in in vitro 
functional assays against 24 receptors, and one PAAD was subjected to an in vitro 
enzymatic assay.  
 
2. Results and discussion 
2.1. In vitro binding assays and functional receptor screens 
Receptor binding profiles were provided by the National Institute of Mental Health‟s 
Psychoactive Drug Screening Program (NIMH PDSP), directed by Dr. Bryan L. Roth at 
UNC-Chapel Hill. The primary radioligand competition binding assay included receptors 
known to be involved in seizure and nociceptive processes, including GABAA ([
3H]-baclofen) 
and benzodiazepine ([3H]-flunitrazepam).251,252 The PSDP assessed the affinity of PAADs for 
44 receptors (in quadruplicate at a concentration of 10 μM) to determine the percentage of 
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radioligand displacement (i.e., receptor binding). If displacement of the radioligand was 
greater than 50%, a secondary radioligand binding assay was performed to determine the 
binding affinity (Ki value) from a span of 11 dose points ranging from 10 pM to 10 μM. 
Functional activity using orphan 23 G-protein coupled receptors (GPCRs) and hERG was 
also screened (in triplicate at a concentration of 10 μM) by the PDSP. Another receptor of 
interest not currently available through the PDSP, the Na+ channel site 2 ([3H]-
batrachotoxin), was carried out by Cerep (Poitiers, France), a company that offers a range of 
pre-clinical drug discovery services. 
The 17 PAADs screened were categorized as either C(3)-O-methoxy-based ((R)-61, 
(S)-61), N-benzyl-safinamide-based ((R)-254, (R)-255, (S)-255, (R)-257, (R)-258, (S)-258), 
or C(2)-hydrocarbon-based ((R)-98, (S)-98, (R)-246, (R)-248, (R)-276, (R)-277, (R)-280, (S)-
283, (R,S)-283). The radioligand binding assays looked at an array of receptor classes, 
including serotonin receptors, adrenergic receptors, dopamine receptors, GABA receptors, 
histamine receptors, muscarinic receptors, opioid receptors, amine transporters, sigma 
receptors, and site 2 of VGSCs. The functional assays looked at 22 orphan GPCRs and the 
Kv11.1 potassium ion channel encoded by the human ether-a-go-go related gene (hERG).  
The GABA receptors, GABAA and benzodiazepine, as well as VGSCs, are known to 
play a role in epilepsy, and recently, VGSCs have been implicated in the pathology of NP 
(reviewed in Chapter 1).28-33,75,253 Serotonin receptors, dopamine receptors, muscarinic 
receptors, and amine transporters play a central role in the regulation of neurotransmission 
and dysregulation can result in a range of neurological disorders, including, but not limited 
to, addiction, alcoholism, anxiety, attention deficit hyperactivity disorder, bipolar disorder, 
depression, and Parkinson‟s disease.254-257 Adrenergic receptors generally cause a 
sympathetic response (i.e., fight-or-flight response)258 and histamine receptors cause 
allergic and inflammatory responses.259 Opioid receptors and sigma receptors, once thought 
to be a opioid receptor subtype due to their antitussive properties, are associated with CNS 
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disorders, such as pain, schizophrenia, and memory deficits.260,261 Finally, hERG potassium 
channels are essential for normal electrical activity in the heart, and mutations of hERG 
channels can result in life-threatening arrhythmias. Therefore, hERG serves as an important 
anti-target in drug development.262  
 
2.1.1. C(3)-O-Methoxy-based PAADs 
Analysis of the whole animal pharmacological trends observed in the C(3)-alkoxy 
PAADs and the C(2)-hydrocarbon PAADs suggested that different molecular pathways may 
be responsible for their overall pharmacological function. The primary radioligand binding 
profile of C(3)-O-methoxy PAADs (R)-61 and (S)-61 did not reveal any substantial (>50%) 
binding partners at 10 µM (Table 37), including receptors known to be involved in seizures 
and nociceptive processes (e.g., GABAA, BZP, Na
+ channel site 2).263 This result was not 
unexpected, as lacosamide ((R)-28) did not significantly (>50% at 10 µM) bind to either 
GABAA or BZP, and only weakly interacted with the Na
+ channel site 2 (~25% at 10 µM). 
The binding profile of the C(2)-isopropyl PAAD (R)-98 showed 76% inhibition of the 
dopamine transporter (DAT) at 10 µM (Table 37). Inhibition of DAT could also be 
stereospecific, as (S)-98 displayed only 4.7% inhibition. The (S)-isomer also inhibited the 
histamine receptor H1 (51%) and sigma 2 (88%) at 10 µM, and the binding affinities were 
determined to be 3.5 µM and 4.9 µM, respectively (Table 45). The determination of the 
binding affinity of (R)-98 for DAT is in progress. We would have expected that the binding 
affinity of (S)-98 for sigma 2 would be greater (a lower numerical value) than H1 due to their 
primary inhibition values. However, the primary radioligand competition assay has been 
designed for preliminary screening purposes and quantitative comparisons should be made 
using the Ki values determined from the secondary radioligand competition assay. 
Therefore, we will also determine the binding affinity of (S)-98 for DAT to definitively 
establish if the interaction of the C(2)-isopropyl PAAD is indeed stereospecific. Comparison 
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of the primary radioligand binding profile of C(3)-O-methoxy PAAD enantiomers ((R)-61 and 
(S)-61) with the C(2)-isopropyl PAAD enantiomers ((R)-98 and (S)-98) revealed one 
potential receptor, DAT, that may contribute to the unique SAR of the C(2)-hydrocarbon 
PAADs. DAT is important in maintaining neurotransmitter balance by removing dopamine 
from the synapse, and dysregulation in DAT expression can result in a range of neurological 
disorders, including Parkinson‟s disease, attention deficit hyperactivity disorder, bipolar 
disorder, depression, and alcoholism.256 Recently, positron emission tomography (PET) 
scans revealed reduced DAT binding in patients with juvenile myoclonic epilepsy,255,264 but 
further investigation needs to be conducted to determine the connection between DAT and 
seizure disorders. Lastly, neither (R)-61, (S)-61, (R)-98, nor (S)-98 significantly diminished 
the functional activity of either the orphan GPCRs or hERG (Table 38). 
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Table 37. Primary radioligand binding profile of PAADs (R)-61, (S)-61, (R)-98, and (S)-
98: Percentage of inhibition at 10 µM. Comparison of parent C(3)-O-methoxy PAADs 
versus C(2)-hydrocarbon PAADs 
 
 
 
R (R)-CH2OCH3 (S)-CH2OCH3 (R)-CH(CH3)2 (S)-CH(CH3)2 
Receptor Class Receptor Compound 
  
(R)-61 (S)-61 (R)-98 (S)-98 
Serotonin
a
 
5ht1a 5.3 11 -13 -17 
5ht1b 9.6 17 -12 -7.6 
5ht1d 4.0 7.3 19 14 
5ht1e 8.9 0.7 -4.8 3.5 
5ht2a -0.9 -4.9 -2.8 5.3 
5ht2b -7.1 -11 17 9.9 
5ht2c 11 8.2 26 26 
5ht3 9.8 11 23 29 
5ht5a 1.7 -17 18 15 
5ht6 -2.1 -4.9 0.8 3.3 
5ht7 -15 -14 -10 0.1 
Adrenergic
a
 
Alpha 1A 0.9 10 8.3 -7.8 
Alpha 1B 7.4 -1.2 26 30 
Alpha 1D -2.3 -0.2 13 -4.6 
Alpha 2A 34 25 -16 9.0 
Alpha 2B -3.0 -8.8 -3.5 -4.4 
Alpha 2C 25 22 17 -1.1 
Beta 1 34 24 2.1 8.7 
Beta 2 -0.4 -0.5 -4.7 19 
Beta 3 2.2 3.5 24 1.7 
Dopamine
a
 
D1 14 -3.1 -1.0 -0.3 
D2 22 20 -2.4 -0.5 
D3 -0.2 6.1 -0.2 5.0 
D4 0.9 -0.6 -2.7 -0.1 
D5 -1.7 -14 -0.4 1.3 
GABA
a
 
GABAA 31 -10 14 10 
BZP  30 32 23 23 
Histamine
a
 
H1 18 28 48 51
b
 
H2 19 25 21 20 
H3 15 12 31 28 
H4 29 12 23 27 
Muscarinic
a
 M1 -16 -17 -23 -17 
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M2 0.8 3.9 27 24 
M3 1.0 -5.8 -19 -15 
M4 38 24 -27 -16 
M5 3.9 26 -4.6 11 
Opioid
a
 
DOR 9.9 7.7 -17 -5.9 
KOR 32 21 -4.4 1.6 
MOR -12 -15 6.4 0.4 
Transporters
a
 
SERT 21 26 0 -2.1 
NET -5.7 13 -8.6 -0.7 
DAT 11 24 76
b
 4.7 
Misc
a
 
Sigma 1 -5.1 -3.4 30 48 
Sigma 2 -3.8 -0.1 48 88
b
 
Ion Channel
c
 Na+ Channel
d
 -11 -6.0 5.0 -8.0 
a
 The compounds were tested at 10 µM in quadruplicate under the auspices of the NIMH PDSP. % 
inhibition = 100% - % radioactivity bound. 
b
 Submitted for a secondary radioligand binding assay (Table 
45). 
c
 The compounds were tested at 10 µM in duplicate by the auspices of Cerep, Inc. % inhibition = 
100% - % radioactivity bound. 
d
 Site 2. 
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Table 38. Functional profile of PAADs (R)-61, (S)-61, (R)-98, and (S)-98: Percentage of 
inhibition at 10 µM. Comparison of parent C(3)-O-methoxy PAADs versus C(2)-
hydrocarbon PAADs 
 
 
R (R)-CH2OCH3 (S)-CH2OCH3 (R)-CH(CH3)2 (S)-CH(CH3)2 
Receptor
a
 Compound 
 
(R)-61 (S)-61 (R)-98 (S)-98 
GPR1 -0.2 -2.2 -11 -11 
GPR123 -0.6 1.8 3.6 6.0 
GPR132 13 -5.0 16 20 
GPR133 0.9 4.8 3 4.2 
GPR15 -1.1 -1.2 8.9 7.2 
GPR161 0.7 2.3 1.1 1.2 
GPR31 7.9 5.3 4.2 -0.2 
GPR39 4.5 -0.4 -0.2 4.5 
GPR4 1.4 2.9 2.2 0.5 
GPR41 -6.0 -4.7 -1.7 -1.8 
GPR43 -0.5 -2.9 1.5 5.0 
GPR45 2.3 1.9 4.0 10 
GPR55 3.4 2.0 1.1 -1.0 
GPR57 -2.1 0.1 -4.5 -5.5 
GPR58 2.8 4.0 2.4 4.2 
GPR62 -5.8 -2.5 -0.2 3.6 
GPR63 2.3 3.2 2.5 -1.6 
GPR68 0.2 -0.2 -1.6 0.9 
GPR83 -4.5 0.7 0.4 6.7 
GPR84 0.1 5.1 8.0 3.4 
GPR87 -3.8 -1.6 12 11 
GPR88 -10 0.8 -8.8 -3.5 
hERG 1.4 5.6 -0.3 7.7 
a
 The compounds were tested at 10 µM in quadruplicate under the auspices of the 
NIMH PDSP.  
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2.1.2. N-Benzyl safinamide-based PAADs 
A global comparison of the safinamide-like chimeric PAADs ((R)-254, (R)-255, (S)-
255, (R)-257, (R)-258, (S)-258) (Table 39) with the unsubstituted C(3)-O-methoxy PAADs 
((R)-61, (S)-61) and C(2)-isopropyl PAADs ((R)-98, (S)-98) (Table 38) revealed a greater 
number of receptor classes experiencing significant inhibition at 10 µM upon inclusion of 
either a benzyloxybenzyl unit or a phenoxymethylbenzyl unit at the 4‟-N-benzyl position. 
These include binding to serotonin receptors (5ht2a, 5ht2b, and 5ht2c), adrenergic receptors 
(alpha1A, alpha2A, alpha2B, and alpha2C), the dopamine receptor D5, histamine receptors 
(H1, H2, and H3), amine transporters (serotonin transporter (SERT), norepinephrine 
transporter (NET), and DAT), sigma 1 and 2, as well as the Na+ channel site 2. The 
considerable inhibition of sigma 1 and the Na+ channel site 2 was not unexpected, as 
safinamide (30) is known to interact with these receptors.77,212 Within the safinamide-based 
PAADs, the compounds can be further classified as chimeric C(3)-O-methoxy PAADs ((R)-
254, (R)-255, (S)-255) and chimeric C(2)-isopropyl PAADs ((R)-257, (R)-258, (S)-258). 
Using this subclassification, we observed that the (R)-stereoisomer of chimeric C(2)-
isopropyl PAADs significantly inhibited (>50%) 4-fold more receptors than the (R)-
stereoisomer of chimeric C(3)-O-methoxy PAADs at 10 µM (chimeric C(2)-isopropyl PAAD 
(R)-stereoisomers: 5ht2a, 5ht2b, 5ht2c, alpha1A, alpha2A, D5, H3, NET, DAT, sigma 1, 
sigma 2, Na+ channel site 2;  chimeric C(3)-O-methoxy PAAD (R)-stereoisomers: 5ht2b, 
DAT, sigma 1). We also observed significant binding interactions for the corresponding (S)-
stereoisomers of these two different C(2)-substituted PAADs, where the C(3)-O-methoxy 
PAAD (S)-255 significantly inhibited 5ht2a, 5ht2b, 5ht7, alpha1A, alpha2A, alpha2C, H1, 
SERT, NET, sigma 1, and the Na+ channel site 2, and the C(2)-isopropyl PAAD (S)-258 
significantly inhibited 5ht2a, 5ht2b, 5ht2c, H1, H2, NET, sigma 1, sigma 2, and the Na+ 
channel site 2. In instances where we observed significant binding (>50% at 10 µM) for both 
the (R)- and (S)-isomers of PAADs 255 and 258, the binding affinities were in the low 
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micromolar range and were similar for both the (R)- and (S)-stereoisomers (PAAD 255 (R)-
stereoisomer Ki (µM) versus (S)-stereoisomer Ki (µM): 5ht2b, 3.4 versus 2.8) (PAAD 258 
(R)-stereoisomer Ki (µM) versus (S)-stereoisomer Ki (µM): 5ht2b, 1.2 versus 1.2; 5ht2c, 3.2 
versus 1.7) (Table 45). This finding suggested that the enhanced receptor binding for the 
C(2)-hydrocarbon and C(3)-O-methoxy safinamide-based PAADs was independent of C(2)-
stereochemistry, and binding was likely was attributed to the combined structural effects of 
the C(2)-substituent and the safinamide N-benzyl pharmacophore. If this notion is correct, 
then perhaps these binding interactions are not relevant for their seizure and/or NP 
activities, since seizure protection was greater in the (R)-stereoisomer versus the (S)-
stereoisomer. Correspondingly, the binding to various receptor classes may signal that 
these compounds could exhibit other pharmacological effects, provided binding was 
appreciable and functionally significant. There was not any obvious difference in receptor 
inhibition with respect to the orientation of the ether linkage (-OCH2- versus -CH2O-) in either 
the chimeric C(3)-O-methoxy PAADs or the chimeric C(2)-hydrocarbon PAADs. Secondary 
radioligand binding assays of the safinamide-based PAADs revealed modest binding 
affinities (2–10 µM) for most receptors, although high nanomolar binding affinities for sigma 
1 were observed (Ki (nM): (R)-254, 147; (R)-255, 92; (S)-255, 765; (R)-257, 896; (R)-258, 
367; (S)-258; 1112) (Table 45). Again, this result was not unexpected because safinamide 
has been shown to bind to sigma 1 with an affinity of 19 nM.212 However, the seizure 
protection afforded by safinamide is not thought to occur through the interaction with sigma 
1, but rather by modulating VGICs, including VGSCs.212 Alternatively, the affinity of the 4‟-
chimeric PAADs for sigma 1 may contribute to their toxicity profile (profile not determined) as 
sigma 1 receptors have been reported to be involved in behavioral psychosis.210 Finally, 
neither (R)-254, (R)-255, (S)-255, (R)-257, (R)-258, nor (S)-98 significantly diminished the 
functional activity of either the orphan GPCRs or hERG (Table 38). 
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Table 39. Primary radioligand binding profile of (R)-254, (R)-255, (S)-255, (R)-257, (R)-258, and (S)-258: Percentage of 
inhibition at 10 µM. The effect of the N-benzyl safinamide unit on C(3)-O-methoxy PAAD and C(2)-hydrocarbon PAAD 
activity 
 
 
 
R (R)-CH2OCH3 (R)-CH2OCH3 (S)-CH2OCH3 (R)-CH(CH3)2 (R)-CH(CH3)2 (S)-CH(CH3)2 
X O CH2 CH2 O CH2 CH2 
Y CH2 O O CH2 O O 
Receptor Class Receptor Compound 
  
(R)-254 (R)-255 (S)-255 (R)-257 (R)-258 (S)-258 
Serotonin
a
 
5ht1a 15 8.9 12 -12 14 8.4 
5ht1b 0.6 -12 -8.5 -11 -18 -20 
5ht1d 3.5 11 16 16 6.5 13 
5ht1e 2.4 -2.9 -6.8 -2.4 1.1 14 
5ht2a 34 43 52
b 
45 55
b
 59
b 
5ht2b 8.2 68
b
 57
b 
52
b
 81
b
 82
b 
5ht2c 48 37 43 60
b
 59
b
 61
b
 
5ht3 11 14 6.2 22 32 -14 
5ht5a -20 6.3 11 7.9 1.6 14 
5ht6 2.7 3.8 -8.5 -7.7 -11 -20 
5ht7 -19 22 56
b 
3.4 2.7 6.2 
Adrenergic
a
 
Alpha 1A 46 -7.4 6.1 89
b
 -1.5 5.8 
Alpha 1B 3.0 29 19 28 20 36 
Alpha 1D -0.3 -0.9 16 -1.5 -0.5 50 
  
 
3
2
6 
Alpha 2A 24 -15 >50
b 
57
b
 74
b
 20 
Alpha 2B -6.3 6.4 >50
b 
5.9 12 20 
Alpha 2C 36 20 >50
b 
34 37 44 
Beta 1 26 38 31 35 14 19 
Beta 2 -2.8 4.3 2.5 -16 -14 -1.3 
Beta 3 1.5 20 29 49 36 15 
Dopamine
a
 
D1 2.1 -8.9 45 3.8 -9.9 48 
D2 9.7 -4.1 -7.5 -5.9 -4.1 7.5 
D3 8.8 8.5 -0.9 11 6.4 7.3 
D4 27 30 -0.4 24 38 -19 
D5 -1.5 31 45 59
b
 62
b
 33 
GABA
a
 
GABAA -4.9 -1.3 10 -0.1 -0.9 5.7 
BZP  30 14 27 16 13 27 
Histamine
a
 
H1 37 17 67
b
 29 31 56
b
 
H2 20 22 37 33 35 50
b
 
H3 29 31 28 57
b
 73
b
 31 
H4 19 13 5 9.0 6.8 11 
Muscarinic
a
 
M1 -9.1 -17 -1.2 -17 -19 -7.1 
M2 14 13 20 8.9 16 6.7 
M3 5.6 -4.0 27 -15 -7.2 -7.7 
M4 14 4.6 16 -17 -7.2 12 
M5 35 6.4 17 8.4 -2.4 3.9 
Opioid
a
 
DOR 8.9 -7.3 1.0 -17 -18 10 
KOR 16 6.4 5.4 12 18 7.9 
MOR -12 15 -13 19 17 -16 
Transporters
a
 
SERT 34 23 50
b 
25 41 25 
NET 25 42 64
b 
46 60
b 
57
b 
DAT 53
b
 40 50
b 
94
b
 73
b
 49 
Misc
a
 
Sigma 1 72
b
 94
b
 87
b
 96
b
 96
b
 69
b
 
Sigma 2 46 31 41 79
b
 90
b
 82
b
 
  
 
3
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Ion Channel
c
 Na+ Channel
d
 48 69 64 71 73
f
 86 
a
 The compounds were tested at 10 µM in quadruplicate under the auspices of the NIMH PDSP. % inhibition = 100% - % radioactivity 
bound. 
b
 Submitted for a secondary radioligand binding assay (Table 45). 
c
 The compounds were tested at 10 µM in duplicate under the 
auspices of Cerep, Inc. % inhibition = 100% - % radioactivity bound. 
d
 Site 2. 
e
 ND = not determined. 
f 
Submitted for a secondary assay to 
determine the IC50 from a span of 5 dose points ranging from 0.1 µM to 0.1 mM. 
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Table 40. Functional profile of (R)-254, (R)-255, (S)-255, (R)-257, (R)-258, and (S)-258: Percentage of inhibition at 10 µM. The 
effect of the N-benzyl safinamide unit on C(3)-O-methoxy PAAD and C(2)-hydrocarbon PAAD activity 
 
 
R (R)-CH2OCH3 (R)-CH2OCH3 (S)-CH2OCH3 (R)-CH(CH3)2 (R)-CH(CH3)2 (S)-CH(CH3)2 
X O CH2 CH2 O CH2 CH2 
Y CH2 O O CH2 O O 
Receptor
a 
Compound 
 
(R)-254 (R)-255 (S)-255 (R)-257 (R)-258 (S)-258 
GPR1 4.5 12 13 -6.1 -3.5 18 
GPR123 0.3 -7.6 4.6 -12 2.3 5.6 
GPR132 7.5 4.6 -5.9 -0.3 26 8.9 
GPR133 5.9 -4.2 2.2 -6.5 5.4 1.1 
GPR15 -5.3 -12 -2.5 -33 4.1 4.3 
GPR161 -0.6 -0.5 -0.1 -1.9 1.3 1.2 
GPR31 1.1 -1.6 3.5 -3.7 4.8 2.5 
GPR39 6.4 -7.3 -4.6 -0.7 7.1 -7.1 
GPR4 -0.2 -4.2 4.0 -4.4 3.2 -1.4 
GPR41 -5.6 -10 25 -15 0.8 17 
GPR43 2.9 -6.3 7.6 -16 2.1 6.0 
GPR45 -5.1 -14 0.6 -17 7.8 4.0 
GPR55 3.0 1.3 1.5 -2.3 -1.2 1.4 
GPR57 -2.3 -18 12 -21 5.7 21 
GPR58 1.3 -6.9 0.8 -12 2.6 2.5 
GPR62 0.3 -6.7 16 -6.7 -1.6 6.3 
  
 
3
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GPR63 0.1 -6.9 5.5 -2.8 3.0 1.6 
GPR68 5.5 9.3 6.5 -1.8 4.1 13 
GPR83 8.1 3.7 5.4 -10 -2.5 8.0 
GPR84 -7.2 -12 -3.2 -24 0.8 16 
GPR87 2.0 -7.4 -6.6 -2.3 8.0 11 
GPR88 -4.4 -3.1 22 -12 -2.1 16 
hERG 5.7 13 11 13 6.7 11 
a
 The compounds were tested at 10 µM in quadruplicate under the auspices of the NIMH PDSP.  
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2.1.3. C(2)-Hydrocarbon-based PAADs 
The primary radioligand receptor screening of the electron-withdrawing N-benzyl 
substituted C(2)-isopropyl PAADs ((R)-246, (R)-248, and (R)-280) showed minimal binding 
at 10 µM to the 44 receptors tested (Table 41). (R)-246 inhibited radioligand binding in D1 
(60%), DAT (83%), sigma 1 (58%), and sigma 2 (66%). (R)-248 displayed a similar binding 
profile with inhibition of DAT (60%), sigma 1 (68%), and sigma 2 (84%). (R)-280 did not 
significantly (>50% at 10 µM) inhibit radioligand binding in the receptors tested. (R)-280 did 
not resemble the binding profiles of (R)-246 and (R)-248, which was surprising since the 
anticonvulsant activities of (R)-246, (R)-248, and (R)-280 were similar (ED50 (mg/kg): (R)-
246, 14; (R)-248, 16; and (R)-280, >3, <10). This suggests that either the 4‟-N-benzyl 
substituted PAADs function at different receptor site(s) compared with 3‟-N-benzyl 
substituted PAADs or that the receptors profiled are not involved in PAAD function. We 
suspect the latter case, which was also supported by the 4‟-chimeric primary radioligand 
binding profiles. More likely, the binding profiles may represent receptors involved in 
neurotoxicity. As seen in the 4‟-chimeric PAADs, the 4‟-N-benzyl substituted PAADs 
revealed high nanomolar binding affinities for sigma 1 (Ki (nM): (R)-246, 1858; (R)-248, 804) 
(Table 45). These collective findings suggest that there may be an inherent safety 
advantage in this series of PAADs for 3‟-N-benzyl substituted compounds compared with 
the corresponding 4‟-substituted isomers. It will be interesting to determine the receptor 
binding profile to the 2‟-susbtituted isomer (R)-279 (study in progress). Also in line with the 
previous PAADs profiled, (R)-246, (R)-248, and (R)-280 did not significantly diminish the 
functional activity of either the orphan GPCRs or hERG (Table 42). 
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Table 41. Primary radioligand binding profile of (R)-98, (R)-246, (R)-248, and (R)-280: 
Percentage of inhibition at 10 µM. Assessment of N-benzyl substitution in C(2)-
isopropyl PAADs 
 
 
X H 4‟-CF3 4‟-OCF3 3‟-OCF3 
Receptor Class Receptor Compound 
  
(R)-98 (R)-246 (R)-248 (R)-280 
Serotonin
a
 
5ht1a -13 2.7 -13 24 
5ht1b -12 -18 -15 -18 
5ht1d 19 -6.4 11 -7.5 
5ht1e -4.8 1.0 -3.8 -12 
5ht2a -2.8 -4.6 -1.9 -7.5 
5ht2b 17 6.7 23 6.7 
5ht2c 26 7.8 15 5.1 
5ht3 23 -9.4 29 -3.7 
5ht5a 18 13 -5.9 6.2 
5ht6 0.8 -11 -3.8 -6.1 
5ht7 -10 -4.9 2.9 -4.7 
Adrenergic
a
 
Alpha 1A 8.3 -2.0 -0.3 -0.3 
Alpha 1B 26 -2.9 3.7 14 
Alpha 1D 13 18 14 6.6 
Alpha 2A -16 -5.2 23 -1.1 
Alpha 2B -3.5 24 -5.4 2.9 
Alpha 2C 17 30 -3.1 15 
Beta 1 2.1 -1.0 11 10 
Beta 2 -4.7 -0.3 17 19 
Beta 3 24 5.0 -1.6 8.6 
Dopamine
a
 
D1 -1.0 60
b 
1.9 29 
D2 -2.4 4.0 -3.2 -2.6 
D3 -0.2 -5.4 9.9 -3.9 
D4 -2.7 -18 2.9 -2.0 
D5 -0.4 40 -1.0 20 
GABA
a
 
GABAA 14 28 13 17 
BZP  23 14 27 32 
Histamine
a
 
H1 48 15 49 21 
H2 21 31 18 25 
H3 31 12 23 2.1 
H4 23 -1.1 25 -0.6 
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Muscarinic
a
 
M1 -23 -9.7 -13 -8.4 
M2 27 -4.2 -0.1 5.1 
M3 -19 -4.4 -5.7 -4.0 
M4 -27 2.8 -19 -2.5 
M5 -4.6 -2.9 -8.7 14 
Opioid
a
 
DOR -17 -19 -6.0 -14 
KOR -4.4 -6.4 7.8 0.2 
MOR 6.4 -14 23 -19 
Transporters
a
 
SERT 0 18 23 25 
NET -8.6 -8.0 -2.6 3.7 
DAT 76
b
 83
b 
60
b
 -8.2 
Misc
a
 
Sigma 1 30 58
b
 68
b
 37 
Sigma 2 48 66
b 
84
b
 36 
Ion Channel
c
 Na+ Channel
d
 5.0 39 41 47 
a
 The compounds were tested at 10 µM in quadruplicate under the auspices of the NIMH PDSP. % 
inhibition = 100% - % radioactivity bound. 
b
 Submitted for a secondary radioligand binding assay (Table 
45). 
c
 The compounds were tested at 10 µM in duplicate by the auspices of Cerep, Inc. % inhibition = 
100% - % radioactivity bound. 
d
 Site 2. 
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Table 42. Functional profile of (R)-98, (R)-246, (R)-248, and (R)-280: Percentage of 
inhibition at 10 µM. Assessment of N-benzyl substitution in C(2)-isopropyl PAADs 
 
 
X H 4‟-CF3 4‟-OCF3 3‟-OCF3 
Receptor
a 
Compound 
 
(R)-98 (R)-246 (R)-248 (R)-280 
GPR1 -11 5.0 -11 15 
GPR123 3.6 1.3 7.5 -0.8 
GPR132 16 -14 -14 25 
GPR133 3.0 -3.0 -0.4 6.7 
GPR15 8.9 12 -0.1 9.1 
GPR161 1.1 -1.7 -0.7 5.0 
GPR31 4.2 -2.7 -3.4 2.4 
GPR39 -0.2 -1.4 3.9 -0.7 
GPR4 2.2 2.5 -4.5 0.5 
GPR41 -1.7 5.1 -6.1 24 
GPR43 1.5 -14 4.6 -0.2 
GPR45 4.0 1.1 -6.9 -4.7 
GPR55 1.1 -3.9 -0.6 5.3 
GPR57 -4.5 6.0 -5.8 28 
GPR58 2.4 -7.9 6.1 15 
GPR62 -0.2 -3.3 2.9 13 
GPR63 2.5 0.1 3.8 2.9 
GPR68 -1.6 -1.1 -2.8 4.3 
GPR83 0.4 1.9 4.4 3.5 
GPR84 8.0 -2.5 0.3 12 
GPR87 12 -5.0 7.9 8.2 
GPR88 -8.8 0.8 5.7 26 
hERG -0.3 -3.4 0 5.3 
a
 The compounds were tested at 10 µM in quadruplicate under the auspices of the 
NIMH PDSP.  
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Finally, we looked at the binding profile of PAADs with extended N-terminal linkages 
((R)-276 and (R)-277), as well as the C(2)-hydrocarbon-like PAADs (S)-283, (R,S)-283. Of 
the PAADs with the extended N-terminal linkages, both (R)-276 and (R)-277 showed 
minimal binding at 10 µM to the chosen panel of receptors. For (R)-276, 54% radioligand 
displacement was observed for the dopamine receptor, D5 (Table 43). No significant binding 
(>50% at 10 µM) was observed with either (S)-283 or (R,S)-283. Similarly, these PAADs did 
not affect the functional activity of either the orphan GPCRs or hERG (Table 44). We can 
still ascertain information from the lack of receptor binding. The C(2)-isopropyl PAADs with 
the extended N-terminal linkages afforded excellent seizure protection (ED50 (mg/kg): (R)-
276, 10; (R)-277, 16) and the absence of receptor binding may indicate that these PAADs 
do not exert their pharmacological function through these receptors. Additionally, the 
absence of receptor binding indicated that potential adverse interaction did not occur with 
extension of the N-terminal linkage. 
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Table 43. Primary radioligand binding profile of (R)-98, (R)-276, (R)-277, (S)-283, and (R,S)-283: Percentage of inhibition at 10 
µM. Effect of C(2)-substituent and N-terminal linkage size in a series of C(2)-hydrocarbon PAAD-like compounds 
 
 
 
R1 NH2 NH2 NH2 CH3 CH3 
 
R2 (R)-CH(CH3)2 (R)-CH(CH3)2 (R)-CH(CH3)2 (S)-CH2CH3 (R,S)-CH2CH3 
n 1 2 3 1 1 
Receptor Class Receptor Compound 
  
(R)-98 (R)-276 (R)-277 (S)-283 (R,S)-283 
Serotonin
a
 
5ht1a -13 4.2 6.9 -3.5 15 
5ht1b -12 -13 -15 -14 -20 
5ht1d 19 2.1 -6.9 -13 -1.6 
5ht1e -4.8 17 8.3 4.6 21 
5ht2a -2.8 -8.0 -15 -19 4.0 
5ht2b 17 9.7 12 0.1 1.5 
5ht2c 26 -0.5 8.9 36 -1.1 
5ht3 23 1.0 0.4 -1.1 2.7 
5ht5a 18 13 14 7.2 8.6 
5ht6 0.8 -4.2 13 -4.3 -8.4 
5ht7 -10 -9.3 -3.9 -12 -6.6 
Adrenergic
a
 
Alpha 1A 8.3 12 -1.2 -2.5 2.3 
Alpha 1B 26 -0.1 14 22 2.5 
Alpha 1D 13 33 16 35 28 
Alpha 2A -16 3.3 -1.1 0 -2.3 
Alpha 2B -3.5 -6.7 3.7 8.2 -2.9 
Alpha 2C 17 19 28 68
b 
21 
  
 
3
3
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Beta 1 2.1 8.8 9.2 28 4.3 
Beta 2 -4.7 -6.2 11 -0.6 17 
Beta 3 24 8.4 28 26 -1.2 
Dopamine
a
 
D1 -1.0 33 29 15 34 
D2 -2.4 8.1 0.4 -19 3.7 
D3 -0.2 -14 -6.2 -9.7 -12 
D4 -2.7 -20 -17 -20 -19 
D5 -0.4 54
b 
16 -5 38 
GABA
a
 
GABAA 14 39 20 4.3 31 
BZP 23 14 24 24 13 
Histamine
a
 
H1 48 -1.9 13 35 -2.7 
H2 21 35 27 27 19 
H3 31 -0.4 -0.9 7.9 1.1 
H4 23 -18 -6.8 8.7 -14 
Muscarinic
a
 
M1 -23 -8.5 -11 -11 -12 
M2 27 -0.2 -2.5 -1.6 -4.1 
M3 -19 -9.0 -10 -2.4 -1.7 
M4 -27 -0.6 -2.2 10 -4.7 
M5 -4.6 8.0 -0.3 7.2 4.0 
Opioid
a
 
DOR -17 -16 -18 -1.8 -16 
KOR -4.4 3.9 -18 -0.2 -16 
MOR 6.4 -6.3 -9.5 -20 -16 
Transporters
a
 
SERT 0 12 21 18 16 
NET -8.6 23 17 -10 -9.2 
DAT 76
b
 -1.5 6.4 11 0 
Misc
a
 
Sigma 1 30 21 43 7.9 14 
Sigma 2 48 -6.0 30 4.9 -11 
Ion Channel
c
 Na+ Channel
d
 5.0 10 29 -7.0 -4.0 
a
 The compounds were tested at 10 µM in quadruplicate under the auspices of the NIMH PDSP. % inhibition = 100% - % 
radioactivity bound. 
b
 Submitted for a secondary radioligand binding assay (Table 45). 
c
 The compounds were tested at 10 
µM in duplicate by the auspices of Cerep, Inc. % inhibition = 100% - % radioactivity bound. 
d
 Site 2. 
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Table 44. Functional profile of (R)-98, (R)-276, (R)-277, (S)-283, and (R,S)-283: 
Percentage of inhibition at 10 µM. Effect of C(2)-substituent and N-terminal linkage 
size in a series of C(2)-hydrocarbon PAAD-like compounds 
 
 
R1 NH2 NH2 NH2 CH3 CH3 
R2 (R)-CH(CH3)2 (R)-CH(CH3)2 (R)-CH(CH3)2 (S)-CH2CH3 (R,S)-CH2CH3 
n 1 2 3 1 1 
Receptor Compound 
 
(R)-98 (R)-276 (R)-277 (S)-283 (R,S)-283 
GPR1 -11 5.9 -5.6 11 0.6 
GPR123 3.6 1.1 -5.5 6.7 0.3 
GPR132 16 6.8 -1.1 21 -14 
GPR133 3.0 -3.0 -7.5 4.6 0.6 
GPR15 8.9 0.5 1.1 10 -1.6 
GPR161 1.1 0.5 -2.1 0.1 -3.5 
GPR31 4.2 -1.3 -5.0 -2.6 -6.0 
GPR39 -0.2 2.5 -2.3 3.4 8.1 
GPR4 2.2 -1.1 -3.0 2.7 -0.3 
GPR41 -1.7 16 5.8 20 8.9 
GPR43 1.5 6.4 -13 1.8 3.5 
GPR45 4.0 8.5 -16 -4.6 3.1 
GPR55 1.1 -0.8 -9.3 2.5 -2.4 
GPR57 -4.5 2.6 -4.1 26 2.8 
GPR58 2.4 0.2 -7.8 -2.9 -1.5 
GPR62 -0.2 3.8 -8.0 10 5.6 
GPR63 2.5 3.8 -0.6 -0.5 0.4 
GPR68 -1.6 1.2 -9.8 1.1 -3.0 
GPR83 0.4 4.1 -5.3 -3.4 1.0 
GPR84 8.0 10 -24 12 -1.9 
GPR87 12 -10 -16 1.1 -7.7 
GPR88 -8.8 6.7 -9.1 29 12 
hERG -0.3 -3.8 -2.9 5.1 -9.6 
a
 The compounds were tested at 10 µM in quadruplicate under the auspices of the NIMH PDSP.  
 339 
 
Table 45. Secondary radioligand binding profile: Binding affinity of PAADs 
Compound
a 
 Receptor  Ki (nM)  Compound
a 
 Receptor  Ki (nM) 
(R)-98
a
  DAT    (R)-257
a
  Alpha1A  >10,000 
(S)-98
a
  H1  3516 ± 349  (R)-257
a
  Alpha2A  >10,000 
(S)-98
a
  Sigma 2  4908 ± 521  (R)-257
a
  D5  >10,000 
(R)-246
a
  DAT    (R)-257
a
  H3  2482 ± 538 
(R)-246
a
  D1    (R)-257
a
  DAT   
(R)-246
a
  Sigma 1  1858 ± 118  (R)-257
a
  Sigma 1  147 ± 13 
(R)-246
a
  Sigma 2  1267 ± 233  (R)-257
a
  Sigma 2  896 ± 107 
(R)-248
a
  DAT    (R)-258
a
  5ht2a  2435 ± 200 
(R)-248
a
  Sigma 1  804 ± 68  (R)-258
a
  5ht2b  2081 ± 105 
(R)-248
a
  Sigma 2  2270 ± 220  (R)-258
a
  5ht2c  3245 ± 201 
(R)-254
a
  DAT  9948 ± 778  (R)-258
a
  Alpha2A  >10,000 
(R)-254
a
  Sigma 1  147 ± 13  (R)-258
a
  D5  >10,000 
(R)-255
a
  5ht2b  3369 ± 145  (R)-258
a
  H3  7736 ± 612 
(R)-255
a
  Sigma 1  92 ± 8  (R)-258
a
  DAT   
(S)-255
a
  5ht2a  6076 ± 650  (R)-258
a
  NET  4139 ± 463 
(S)-255
a
  5ht2b  2800 ± 323  (R)-258
a
  Sigma 1  367 ± 32 
(S)-255
a
  5ht7  3510 ± 474  (R)-258
a
  Sigma 2  407 ± 42 
(S)-255
a
  Alpha2A  >10,000  (R)-258
b
  Na
+ 
(Site 2)  1600
c 
(S)-255
a
  Alpha2B  5403 ± 1058  (S)-258
a
  5ht2a  2422 ± 256 
(S)-255
a
  Alpha2C  6025 ± 1173  (S)-258
a
  5ht2b  1153 ± 109 
(S)-255
a
  H1  >10,000  (S)-258
a
  5ht2c  1676 ± 131 
(S)-255
a
  DAT    (S)-258
a
  H1  >10,000 
(S)-255
a
  NET    (S)-258
a
  H2  4247 ± 277 
(S)-255
a
  SERT  >10,000  (S)-258
a
  NET  325 ± 49 
(S)-255
a
  Sigma 1  765 ± 36  (S)-258
a
  Sigma 1  1112 ± 73 
(R)-257
a
  5ht2b  5548 ± 254  (S)-258
a
  Sigma 2  83 ± 15 
(R)-257
a
  5ht2c  4465 ± 215  (S)-283
a
  Alpha2C  >10,000 
a
 The compounds were tested under the auspices of the NIMH PDSP. The IC50 was determined from a span of 
11 dose points ranging from 10 pM to 10 μM, and used to obtain the Ki value by applying the Cheng-Prusoff 
approximation (Ki = IC50 / (1 + [ligand]/KD), where [ligand] equals the assay radioligand concentration and KD 
equals the affinity constant of radioligand for the target receptor). 
b
 The compound was tested under the 
auspices of the Cerep, Inc. The IC50 was determined from a span of 5 dose points ranging from 0.1 μM to 0.1 
mM. 
c
 IC50 value. 
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2.2. In vitro MAOB enzymatic assay 
The isoenzymes, monoamine oxidase A and B (MAOA and MAOB), catalyze the 
oxidative deamination of monoamine neurotransmitters to form H2O2 and reactive oxygen 
species. Generally, MAOA deaminates serotonin (52), epinephrine (50), and norepinephrine 
(51), whereas MAOB deaminates phenylethylamine. Dopamine (49), epinephrine (50), and 
norepinephrine (51) are oxidized by both enzymes. Initially, inhibitors of MAO enzymes were 
developed as antidepressants, but their potential has been expanded to neurodegenerative 
disorders, such as Parkinson‟s disease and Alzheimer‟s disease.265 Safinamide (30), 
originally developed as an anticonvulsant agent due to its voltage-sensitive channel blocking 
activity, has demonstrated reversible MAOB inhibition.
212 This makes safinamide the only 
reversible MAOB inhibitor in clinical development, and has indications for Parkinson‟s 
disease, epilepsy, and restless leg syndrome.211,212 We have synthesized several 
safinamide-based PAADs that retained the benzyloxybenzyl pharmacophore ((R)-254, (R)-
256, (R)-257, and (R)-260). We also investigated the reversed ether linkage (-CH2O- versus 
-OCH2-) between the aryl moieties ((R)-255, (S)-255, (R)-258, (S)-258, (R)-261). The 
primary structural feature distinguishing our compounds from 30 is the order in which the 
structural units appear. In 30, the benzyloxybenzyl pharmacophore is directly attached to a 
substituted amine, while in our compounds this pharmacophore is attached to an amide. We 
chose to determine the MOAB enzymatic activity of (R)-257 due to its significant 
anticonvulsant activity and pain attenuation. The inhibition of MAOB activity was determined 
by the spectrophotometric detection of benzyaldehyde, oxidized from benzylamine (0.5 
mM), in human platelets at 10 μM (assessed in duplicate at Cerep, Inc). The lack of MOAB 
enzymatic inhibition (-3%) suggested that the safinamide-based PAADs do not possess 
MOAB enzymatic, as exemplified by (R)-257, a finding that likely resulted from the absence 
of the benzyloxybenzyl amine moiety. 
 
 341 
 
 
 
3. Conclusions 
Many PAADs possess excellent anticonvulsant activities and can attenuate pain. 
These pharmacological events led us to conclude that PAADs are not PNS-selective agents, 
but rather exert function at both PNS and CNS receptor sites. We screened 17 PAADs in a 
series of primary radioligand binding assays, follow-up secondary radioligand binding 
assays to determine the binding affinity (Ki) when the primary assay indicated a radioligand 
displacement of >50%, functional receptor assays, and an MAOB enzymatic assay. Overall 
assessment of the binding, functional, and enzymatic assays suggests that we have not 
identified potential receptor sites involved with anticonvulsant activity or NP function. Of the 
binding interactions that were identified, most were in the low micromolar range (2-10 µM) 
and could possibly indicate receptor sites involved in CNS toxicities, in particular the sigma 1 
receptor. Nonetheless, in most cases these binding affinities were modest, suggesting that 
these interactions were not predictors of adverse toxicity profiles. Our results are not 
discouraging, as binding partners for lacosamide ((R)-28) have not been identified by similar 
methods. Therefore, it remains that PAADs could be exerting their mechanism of action by 
interaction with receptor binding sites that are involved in FAA function, interaction with 
receptor binding sites that are not involved with FAA function, or a combination of both.  
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4. Experimental 
4.1. Primary radioligand receptor screen 
The protocols for the PDSP primary binding assays, secondary binding assays, and 
functional assays are available online at http://pdsp.med.unc.edu/UNC-
CH%20Protocol%20Book.pdf. The affinities of the PAADs for various receptors were 
assessed in quadruplicate at a concentration of 10 μM to determine the percentage of 
inhibition. Test compound (PAAD) and reference compound (positive control) were diluted to 
5X final assay concentration (50 μM for a final assay concentration of 10 μM) in the 
appropriate radioligand binding buffer (Table 46). Then, 50 μL aliquots of buffer (negative 
control), test compound, and reference compound were added in quadruplicate to a 96-well 
plate, each of which contains 50 μL of 5X radioligand (see Table 46 for final assay 
concentration for each radioligand) and 100 μL of buffer. Finally, receptor-containing crude 
membrane fractions were resuspended in buffer and dispensed (50 μL per well) into a 96-
well plate. Radioligand binding was allowed to equilibrate (typically for 1.5 h at room 
temperature), and then bound radioactivity was isolated by filtration onto 0.3% 
polyethyleneimine-treated, 96-well filter mats using a 96-well Filtermate harvester. The filter 
mats were dried, then scintillant was melted onto the filters and the radioactivity retained on 
the filters was counted in a Microbeta scintillation counter. Raw dpm data from the Microbeta 
counter was analyzed on the PDSP database. Total bound radioactivity was estimated from 
quadruplicate wells containing no test or reference compound and adjusted to 100%. Non-
specifically bound radioactivity was assessed from quadruplicate wells containing 10 μM of a 
suitable reference compound (Table 46) and adjusted to 0%. The average bound 
radioactivity in the presence of the test compound (10 μM final assay concentration, 
quadruplicate determinations) was then expressed on the percent scale. The percent 
inhibition of radioligand binding was calculated as 100% minus the percentage of 
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radioactivity bound. The PDSP on-line data entry and analysis system calculated the 
variance of the quadruplicate determinations (for the total, non-specific, and test compound 
binding values) and variances greater than 20% were flagged for further inspection, and 
assays were repeated if necessary. Additionally, percent inhibition values that were greater 
than the total binding (i.e., 100%) by at least 20% were also flagged for inspection, as such 
results could indicate allosteric modulation of radioligand binding. 
 
Table 46. Primary radioligand binding assay conditions 
Receptor  Radioligand  [Assay] (nM)  Reference 
5ht1a  [
3
H]-8-OH-DPAT  0.5  Methysergide 
5ht1b  [
3
H]-GR127543  0.3  Ergotamine 
5ht1d  [
3
H]-GR127543  0.3  Ergotamine 
5ht1e  [
3
H]-5-HT  3.0  5-HT 
5ht2a  [
3
H]-Ketanserin  0.5  Chlorpromazine 
5ht2b  [
3
H]-LSD  1.0  Methylsergide 
5ht2c  [
3
H]-Mesulergine  0.5  Chlorpromazine 
5ht3  [
3
H]-LY278584  0.3  LY278584 
5ht5a  [
3
H]-LSD  1.0  Ergotamine 
5ht6  [
3
H]-LSD  1.0  Chlorpromazine 
5ht7  [
3
H]-LSD  1.0  Chlorpromazine 
Alpha 1A  [
3
H]-Prazosin  0.7  Urapidil 
Alpha 1B  [
3
H]-Prazosin  0.7  Corynanthine 
Alpha 1D  [
3
H]- Prazosin  0.7  Corynanthine 
Alpha 2A  [
3
H] –Clonidine  1.0  Oxymetazoline 
Alpha 2B  [
3
H] –Clonidine  1.0  Prazosin 
Alpha 2C  [
3
H] -Clonidine  1.0  Prazosin 
Beta 1  [
3
H]-Iodopindolol  0.1  Atenolol 
Beta 2  [
3
H] –Iodopindolol  0.1  ICI118551 
Beta 3  [
3
H] -Iodopindolol  0.1  IC118551 
D1  [
3
H]-SCH233930  0.2  SKF38393 
D2  [
3
H]-N-methylspiperone  0.2  Haloperidol 
D3  [
3
H] -N-methylspiperone  0.2  Chlorpromazine 
D4  [
3
H] -N-methylspiperone  0.3  Chlorpromazine 
D5  [
3
H]-SCH233930  0.2  SKF38393 
GABAA  [
3
H]-Baclofen  20  GABA 
BZP   [
3
H]-Flunitrazepam  0.5  Diazepam 
H1  [
3
H]-Pyrilamine  0.9  Chlorpheniramine 
H2  [
3
H]-Tiotidine  3.0  Cimetidine 
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H3  [
3
H]-α-Methylhistamine  0.4  Histamine 
H4  [
3
H]-Histamine  5.0  Clozapine 
M1  [
3
H]-QNB  0.5  Atropine 
M2  [
3
H] –QNB  0.5  Atropine 
M3  [
3
H] –QNB  0.5  Atropine 
M4  [
3
H] –QNB  0.5  Atropine 
M5  [
3
H] –QNB  0.5  Atropine 
DOR  [
3
H]-DADLE  0.3  Naltrindole 
KOR  [
3
H]-U69593  0.3  Salvinorin A 
MOR  [
3
H]-DAMGO  0.3  DAMGO 
SERT  [
3
H]-Citalopram  0.5  Amitriptyline 
NET  [
3
H]-Nisoxetine  0.5  Despiramine 
DAT  [
3
H]-Vasopressin  1.0  Vasopressin 
Sigma 1  [
3
H]-Pentazocine  3.0  Haloperidol 
Sigma 2  [
3
H]-DTG  3.0  Haloperidol 
Na+ Channel
d
  [
3
H]-Batrachotoxin  10  Veratridine 
 
 
4.2. Secondary radioligand receptor screen 
A solution of the test compound (PAAD) and reference compound (positive control) 
was prepared as a 1 mg/mL stock in standard binding buffer, or DMSO, according to its 
solubility. Eleven dilutions of the test and reference compounds (see Table 46) were 
prepared in standard binding buffer by serial dilution at concentrations of 0.05 nM, 0.5 nM, 
1.5 nM, 5 nM, 15 nM, 50 nM, 150 nM, 500 nM, 1.5 μM, 5 μM, and 50 μM. The appropriate 
radioligand (see Table 46) was diluted to 5X the assay concentration in standard binding 
buffer. Aliquots (50 μL) of radioligand were dispensed in duplicate into the wells of a 96-well 
plate containing 100 μL of standard binding buffer. Finally, crude membrane fractions of 
cells expressing recombinant target were resuspended in 3 mL of chilled standard binding 
buffer, homogenized by several passages through a 26 gauge needle, then 50 μL was 
dispensed into each well. The 250 μL reactions were incubated at room temperature and 
shielded from light (to prevent photolysis of light-sensitive ligands) for 1.5 h, then harvested 
by rapid filtration onto Whatman GF/B glass fiber filters pre-soaked with 0.3% 
 345 
 
polyethyleneimine using a 96-well Brandel harvester. Four rapid 500 μL washes were 
performed with chilled standard binding buffer to reduce non-specific binding. Filters were 
placed in 6 mL scintillation tubes and allowed to dry overnight. Then, 4 mL of EcoScint 
scintillation cocktail (National Diagnostics) were added to each tube. The tubes were 
capped, labeled, and counted by liquid scintillation counting. Raw data (dpm) representing 
total radioligand binding (i.e., specific + non-specific binding) was plotted as a function of the 
logarithm of the molar concentration of the competitor (i.e., test or reference compound). 
Non-linear regression of the normalized (i.e., percent radioligand binding compared to that 
observed in the absence of test or reference compound) raw data was performed in Prism 
4.0 (GraphPad Software) using the built-in three parameter logistic model describing ligand 
competition binding to radioligand-labeled sites as “y = bottom + [(top-bottom)/(1 + 10x-
logIC50)],” where bottom equals the residual radioligand binding measured in the presence of 
10 μM reference compound (i.e., non-specific binding) and top equals the total radioligand 
binding observed in the absence of competitor. The log IC50 (i.e., the log of the ligand 
concentration that reduces radioligand binding by 50%) was then estimated from the data 
and used to obtain the Ki by applying the Cheng-Prusoff approximation (Ki = IC50/(1 + 
[ligand]/KD), where [ligand] equals the assay radioligand concentration and KD equals the 
affinity constant of the radioligand for the target receptor).266  
 
4.3. Functional receptor screen 
For orphan GPCRs, receptor-expressing cell lines were seeded in glass-bottom 96- 
or 384-well, poly-L-lysine-coated plates 48 h prior to the assay (40,000 cells per well or 
6,700 cells, respectively) in DMEM containing 5% dialyzed serum. Twenty hours prior to the 
assay, the medium was changed to serum-free DMEM. Then, the cells were preincubated in 
30 μL (96-well plates) or 20 μL (384-well plates) of calcium dye-containing assay buffer (the 
lyophilized dye is reconstituted with 15 mL of assay buffer) at 37 ºC for 75 min in a 
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humidified incubator. During that time, serial dilutions of the test compounds were made at 
2x assay concentration (10 μM final assay concentration). Just prior to the assay, the plates 
were allowed to cool to room temperature for 10 min, and then transferred to a FLIPR Tetra 
fluorescence image plate reader (Molecular Devices). Basal fluorescence (excitation 488 
nm, emission 510–570 nm) was measured for 20 sec, then test compound (2x assay 
concentration) was added (30 μL for 96-well plates, 20 μL for 384-well plates, in triplicate) 
and fluorescence was measured for 60 sec. The maximum fluorescence values were 
measured during the baseline and test compound addition phases.  
For hERG, a fluorescence-based membrane potential assay (Molecular Devices) 
was used. HEK293 cells stably expressing recombinant human HERG (provided by Dr. J. 
Overholt, Case Western Reserve University, Cleveland, OH; cells originally from Drs. A. 
Brown and E. Ficker, MetroHealth Medical Center, Cleveland, OH) were seeded in poly-L-
lysine-coated 96-well plates (45,000 cells/100 μL DMEM supplemented with 10% fetal 
bovine serum/well) one day prior to the assay. The next day, the medium was removed and 
replaced with 30 μL/well of assay buffer containing the membrane potential dye (Molecular 
Devices) (the lyophilized dye was reconstituted with 15 mL of assay buffer). After a 15 min 
incubation at 37 ºC, 30 μL/well of 2X dilutions of terfenadine (a known HERG blocker used 
as a reference compound) or test compound (10 μM final assay concentration) was added to 
the cells (each concentration assayed in triplicate). Baseline fluorescence (excitation 530 
nM, emission 565 nM) was measured over 15 min, then 140 μL of depolarization solution 
(143 mM KCl in distilled water) containing test or reference compound (1x) was added to the 
cells and fluorescence is recorded for 3 min. Raw fluorescence data was exported to 
GraphPad Prism 4.0 for further analysis. The last data value measured in each well (i.e., 3 
min after addition of depolarization solution) was used for analysis, after subtraction of the 
mean background value obtained in the first 30 sec before depolarization of the cells. For 
negative controls, the value obtained using assay buffer alone was defined as 0% hERG 
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blockade, and for positive controls, the value obtained using 10 μM terfenadine was defined 
as 100% hERG blockade. Negative and positive terfenadine controls were done on each 
plate. Data from test compounds are scaled as follows: percent hERG blockade for test 
compound = 100 x (value for test compound - value for negative control)/(value for 10 μM 
terfenadine - value for negative control). "Hits" (or "blockers") were defined as those 
compounds with 20% or greater hERG blockade. hERG "openers" were defined as those 
compounds with values for hERG blockade less than -20%. 
 
4.4. MAOB enzymatic assay 
Human platelets containing 0.5 mM benzylamine were incubated at 37 ºC for 45 min 
with 10 µM of (R)-257, or reference compound (deprenyl, IC50
 = 0.35 nM), and the amount of 
benzylaldehyde generated was detected by spectrophotometry (in duplicate).267 The IC50 
value was determined by non-linear regression analysis of the inhibition curve generated 
with mean replicative values using Hill equation curve fitting (y = d + [(a-d)/(1 + (c/c50) 
nH)], 
where y equals the specific activity, d equals the minimum specific activity, a equals the 
maximum specific activity, c equals the compound concentration, c50 equals the IC50, and nH 
equals the slope factor. Analysis was performed using software developed at Cerep, Inc (Hill 
software) and validated by comparison with data generated by the commercial software 
Sigmaplot® 4.0 for Windows® (© 1997 by SPSS, Inc). 
 
  CHAPTER 5. General Conclusions and Future 
Directions
  
1. Conclusions 
Epilepsy and NP are serious neurological disorders that result from dysregulations in 
neuronal function, and the lack of adequate therapeutic agents available to treat these 
disorders are compounded by issues including, but not limited to, pharmacoresistance, 
adverse CNS side effects, and a lack of efficacy. Therefore, there is a substantial market for 
the treatment of these neurological disorders and the need remains to develop compounds 
that possess a novel mechanism of action to address the shortcomings of current 
medications. Recently, the role of VGSCs has been implicated in the pathophysiological 
mechanisms of NP,28,75,76 while their role in epilepsy has been known for some time.72-74,77 
The FAA (R)-lacosamide ((R)-28) is an emerging AED that has been shown to selectively 
promote VGSCs into the slow inactivated state63,64 and has recently been approved by the 
EMEA and the US FDA under the trademark Vimpat® for the adjuvant treatment of partial-
onset seizures in adult patients with epilepsy.61 (R)-28 has also demonstrated clinical 
efficacy in treating painful diabetic neuropathy, but has yet to gain regulatory approval for 
this indication.66 Furthermore, the pharmaceutical industry has made advances in 
developing PNS-specific agents that target specific isoforms of VGSCs for the treatment of 
NP.28-32  
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Encouraged by the discovery of several PNS-selective agents, we combined the 
concept of PNS-selectivity with our knowledge of FAAs, and initially proposed that PAADs 
may be able to selectively target PNS sites for the treatment of NP, but we have since 
concluded that PAADs can access the CNS. Accordingly, we examined the effect of PAADs 
on CNS function due to the known excellent anticonvulsant activities of FAAs. We 
synthesized and evaluated over 50 PAADs in whole animal models of epilepsy and NP, and 
developed a SAR that defined the structural requirements for PAAD activity. The SAR 
revealed excellent anticonvulsant activity and pain attenuation for the C(2)-hydrocarbon 
PAADs. While these PAADs were slightly less active than (R)-28, many C(2)-hydrocarbon 
PAADs surpassed the MES activity observed for the traditional antiepileptic agent 
phenobarbital (ED50 = 22 mg/kg). Then, we synthesized 36 C(2)-hydrocarbon PAADs along 
with 7 C(3)-O-methoxy PAADs and determined that, in some cases, functionalization of the 
N-benzylamide moiety enhanced anticonvulsant activity and pain attenuation, while 
functionalization of the N-terminal amine reduced these effects. Additionally, a closer 
examination of the PAAD structural blueprint in the C(2)-hydrocarbon series revealed that at 
least four methylene units could be inserted between the amide bond and the aromatic ring 
without a loss of seizure protection. From our optimization studies, we discovered two 
PAADs ((R)-255 and (R)-279) that displayed superior anticonvulsant activity that may rival 
the therapeutic capabilities of (R)-28. Finally, evaluation of our most active PAADs in a 
series of binding and enzymatic assays did not reveal any potential binding targets of 
therapeutic relevance. 
 
2. Future directions 
The findings from this SAR project warrant further studies of the C(2)-hydrocarbon 
PAADs that could prove beneficial for the treatment of epilepsy and NP, including expanding 
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the SAR, attempting to prolong their duration of action, expanding target identification efforts 
(including, but not limited to, electrophysiology studies), metabolism studies, and toxicity 
studies. 
 
2.1. Expanding the SAR of C(2)-hydrocarbon PAADs 
The C(2)-hydrocarbon PAAD SAR revealed that at least four methylene units could 
be incorporated between the amide bond and the aromatic ring without a dramatic loss in 
anticonvulsant activity. Anticonvulsant activity for this series reached at maximum when the 
methylene linker was two (CH2CH2) (Table 32). Separately, we determined that substitution 
of the N-benzylamide moiety with an electron-withdrawing substituent improved seizure 
protection. Therefore, we intend to combine these two elements to synthesize a C(2)-
isopropyl phenethylamide bearing an electron-withdrawing substituent (372) in an attempt to 
increase seizure protection, and possibly pain attenuation. Ideally, we would like to 
synthesize the 2‟-, 3‟-, and 4‟-OCF3 derivatives, but limited availability of the corresponding 
substituted phenethyl reagents would extend the synthetic route. A suitable alternative 
would be to synthesize the 2‟-, 3‟-, and 4‟-fluoro derivatives because the corresponding 
substituted phenethyl reagents are readily available and the anticonvulsant activity of the 
parent 4‟-OCF3 ((R)-248) and 4‟-fluoro ((R)-243) PAADs were similar (ED50 (mg/kg): (R)-248, 
16; (R)-243, >10, <30).  
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2.2. Prolonging the duration of action of C(2)-hydrocarbon PAADs 
The C(2)-isopropyl PAAD (R)-98 possessed significant anticonvulsant activity (ED50 
= 15 mg/kg), but the time to peak effect occurred within the first 15 min of compound 
administration (4/4 mice protected). The number of mice protected reduced by half within 30 
min of compound administration (2/4 mice protected), and then no protection was observed 
1 h after administration (0/4 mice protected). By comparison, the time to peak effect for (R)-
28 in mice (ip) was 0.5 h.60 Following a report published by Greenwarld and coworkers,268 
we propose that the synthesis of a poly(ethylene)glycol (PEG) prodrug employing a 1,4-
elimination system (373) could prolong the duration of action of C(2)-hydrocarbon PAADs. 
Polymeric prodrugs are often designed to circumvent unfavorable pharmacokinetic 
properties, such as limited solubility, uncontrolled degradation, and a short plasma half-
life.269 This double-prodrug strategy first relies on enzymatic hydrolysis of a PEG “trigger”, 
followed by a classic 1,4-elimination reaction of the linker to release the amine (PAAD).   
 
 
 
 Synthesis of 373 can be achieved by convergent synthesis of the C(2)-isopropyl 
PAAD and the pegylated-linker 378 in the presence of DMAP (Scheme 36). The pegylated-
linker 378 can be prepared in three steps by first activating PEG with N,N-disuccinimidyl 
carbonate (374) in the presence of DMAP270 to give 375, followed by treatment with 4-
hydroxybenzyl alcohol (376) and in the presence of DMAP at reflux268 to give 377. Benzyl 
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alcohol 377 is then activated by N,N-disuccinimidyl carbonate268 (374) to provide 378, and 
then coupled with the PAAD of choice to generate prodrug 373. 
 
Scheme 36. Synthesis of C(2)-isopropyl PAAD prodrug 
 
 
2.3. Electrophysiology studies 
Recently, the Lees63 and Cummins64 laboratories have examined the mechanism of 
action of lacosamide ((R)-28) on VGSC function through a series of electrophysiological 
experiments (discussed in Section 2.1.2.2).63,64 We have formed a collaboration with the 
Khanna laboratory at the Indiana University School of Medicine to determine the current-
voltage (I-V) relationship of selected optimized PAADs on Na+ channels at various 
concentrations on the resting state, fast inactivated state, and slow inactivated state of Na+ 
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channels using whole-cell patch clamp techniques. Recruiting a particular conformational 
state can be achieved by either manipulating the holding potential or varying the prepulse 
duration of the voltage protocol (Figure 17). The voltage protocols are applied in the 
absence of compound to determine the amount of current evoked, and the protocol is 
repeated after the application of PAAD to determine the amount of current inhibition. To 
examine the resting state, neurons are held at a potential of -100 mV and are stimulated by 
a 500 msec test pulse in 10 mV increments from -120 mV to +60 mV (Figure 17A). To 
examine the fast inactivated state, neurons are held at a potential of -100 mV and currents 
are evoked by 500 msec prepulses between -120 mV and -20 mV in 10 mV increments, 
followed by a 30 msec test pulse to +10 mV (Figure 17B). To examine the slow inactivated 
state, neurons are held at a potential of -100 mV and currents are evoked by 5 sec 
prepulses between -120 mV and -10 mV in 10 mV increments, allowed to return to the 
holding potential for 1 sec (to allow recovery from fast inactivation), followed by the test 
pulse to -10 mV to analyze the fraction of channels available (Figure 17C). The prepulses in 
the fast inactivated and slow inactivated voltage protocols allow PAAD binding to reach its 
steady state before the test pulses. A dose-response curve of current inhibition can be 
constructed by repeating the voltage protocols at various PAAD concentrations and provide 
insight into whether the PAAD mechanism of action occurs on resting, fast inactivated, or 
slow inactivated Na+ channels.  
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Figure 17. Proposed pulse protocol to evoke the resting state, fast inactivated state, 
or slow inactivated state of VGSCs 
 
 
We are particularly anxious to compare the patch-clamp electrophysiological results 
for the C(3)-O-methoxy PAADs and the C(2)-hydrocarbon PAADs with those previously 
reported for (R)-28.63,64 The whole animal pharmacological data for the C(3)-O-methoxy 
PAADs suggested that they mirrored those of C(3)-alkoxy FAAs (Table 6), and thus, the 
C(3)-O-methoxy may facilitate Na+ channel entry into the slow inactivated state and show 
stereospecificity for function. Confirmation of this finding would strengthen our suspicion that 
these PAADs function similar to their FAA counterparts. Correspondingly, the SAR for the 
C(2)-hydrocarbon PAADs deviated from the blueprint established for the FAAs (Table 15). 
Moreover, the corresponding C(2)-hydrocarbon FAAs showed minimal or no anticonvulsant 
activity. These findings provide significant impetus for us to explore if the C(2)-hydrocarbon 
PAADs modulate sodium channel activity, and if so, how. 
 
2.4. Metabolism studies 
Metabolism is one of several components that influence drug pharmacokinetics 
(other parameters include adsorption, distribution, and excretion) and can have a dramatic 
effect on pharmacological activity. Minimal (4%) in vitro metabolism of (R)-28 was detected 
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after 4 h of incubation with human hepatocytes, and there was no evidence of phase II 
metabolites. The major phase I metabolites identified were the O-desmethyl metabolite (R)-
374 and the phenolic metabolites (R)-375.248 However, in vivo phase I metabolism of (R)-28 
was more notable in animal species. Plasma, urine, and feces samples were analyzed 1.5 h 
and 6 h following a single oral dose of [14C]-(R)-28 in mouse, rat, and dog, and the 
percentage of unchanged [14C]-(R)-28 ranged from 80–90% (1.5 h post dose) and 50–65% 
(6 h post dose). The major metabolites identified 6 h post dose were (R)-374 (40%) and (R)-
375 (5%).248 
 
 
 
Although, metabolism of (R)-28 is not thought to be responsible for its 
pharmacological activity, it is possible that PAAD metabolism could be responsible for the 
unique C(2)-hydrocarbon PAAD SAR. To rule out this option, it would be informative to 
determine the interaction(s) of PAADs with cytochrome P-450 using a hepatic microsomal 
assay. Previously, the Kohn laboratory has conducted similar work, which included 
metabolic studies of PAAD (R,S)-62, from which the phenolic PAAD (R,S)-376 was identified 
as the major metabolite (25% after 1 h).92 In a similar manner, C(2)-hydrocarbon PAADs are 
incubated with liver microsomes containing P-450 enzymes, in the absence and presence of 
NADPH (22 ºC, 0–60 min), and substrate disappearance is measured by high pressure 
liquid chromatography (HPLC). Metabolites can then be identified by LC-UV and MS/MS 
detection.  
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2.5. Toxicity studies 
Preclinical and clinical toxicology studies are time and resource intensive, but it is a 
critical component to the success or failure of a drug candidate. Types of toxicity evaluated 
include, but are not limited to, single dose toxicity, repeat dose toxicity, genotoxicity, 
carcinogenicity, cardiotoxicity, and reproductive toxicity, and are performed to identify the 
possible human risk associated with the administration of the drug candidate. It is critical to 
identify the risks associated with AEDs and NP agents because these classes of drugs treat 
chronic medical disorders and are intended for long term use.  
We have extensively studied the C(2)-hydrocarbon PAAD series and have optimized 
its anticonvulsant activity in the MES seizure model in rodents. The excellent anticonvulsant 
activity and pain attenuating properties of the C(2)-hydrocarbons PAADs, in conjunction with 
a possible novel mechanism of action, warrant acute toxicity studies. In the acute studies, 
we want to identify the dose at which toxic effects first appear and the highest dose where 
no adverse affects are observed. If the C(2)-hydrocarbon PAADs demonstrate an 
acceptable toxicological profile under acute conditions, that would provide preliminary 
assurance in the safety of this class of compounds and we could justify long term toxicity 
studies. 
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